Molecular diagnostics for public and environmental health by Rice, Jack
        
University of Bath
PHD








If you require this document in an alternative format, please contact:
openaccess@bath.ac.uk
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.




Molecular diagnostics for public and environmental health 















A thesis submitted for the degree of Doctor of Philosophy 
University of Bath 
Department of Chemistry 







Attention is drawn to the fact that copyright of this thesis/portfolio rests with the author and copyright 
of any previously published materials included may rest with third parties. A copy of this 
thesis/portfolio has been supplied on condition that anyone who consults it understands that they must 
not copy it or use material from it except as licenced, permitted by law or with the consent of the 
author or other copyright owners, as applicable. 
 
Restrictions on use and licensing 
Access to this thesis in print or electronically is restricted until:  
Signed on behalf of the Doctoral College: 
 
Declaration of any previous submission of the work 
The material presented here for examination for the award of a higher degree by research has been 
incorporated into a submission for another degree. Work presented in chapter two in the paper 
Stereochemistry of ephedrine and its environmental significance: Exposure and effects directed 
approach concerning the use of river water microcosms and ephedrine toxicity to D. Magna was used 
for the completion of the candidate’s final year masters projected completed May 2014 submitted to 
the University of Bath, where the candidate was awarded the degree Master of Chemistry in June 
2014.  
Candidate’s signature:  
Declaration of authorship 
I am the author of this thesis, and the work described therein was carried out by myself personally, 
with the exceptions of chapters two and three where work was carried out in collaboration with other 
researchers as described by the statement of authorship preceding each chapter. 






Table of contents 
Title page         Page 1 
Preliminary information        Pages 2 
Table of contents        Pages 3-6 
List of tables and figures       Pages 7-14 
Acknowledgments        Page 14 
Summary of thesis         Pages 15-24 
• Abstract       Pages 15-17 
• Overview and aims of the thesis     Pages 17-20 
• Abbreviations       Pages 20-23 
Chapter One: Water fingerprinting as a tool for drug policy assessment – 
 a UK perspective, J. Rice, A. Kannan, E. Castrignanò, K. Jagadeesan and  
B. Kasprzyk-Hordern (accepted)        Pages 25-96 
• Chapter introduction      Page 27 
• Abstract       Page 28 
• 1. Introduction      Pages 29-31 
• 2. Experimental      Pages 32-40 
 - 2.1 Materials     Pages 32-34 
 - 2.2 Sample collection, preparation and  
                      analysis     Pages 35-36 
 - 2.3 WBE back-calculations   Pages 36-38 
 - 2.4 Enantiomeric Fractions   Page 39 
 - 2.5 Statistical analysis    Page 39 
 -2.6 Prescription analysis   Page 40 
• 3. Results and discussion     Pages 41-54 
 - 3.1 Trends in average daily intake  Pages 41-49 
 - 3.2 The use of prescription data  Pages 49-51 
 - 3.3 A European perspective   Pages 51-53 
 - 3.4 UK specific trends in consumption  Pages 53-54 
• 4. Conclusion       Page 55 
• References       Pages 56-59 





Chapter Two: Stereochemistry of ephedrine and its environmental significance: 
 exposure and effects directed approach, J. Rice, K. Proctor, L. Lopardo, S.  
Evans and B. Kasprzyk-Hordern. (2018), J. Hazard. Mater., volume 348,  
p 39-46          Pages 97-156 
• Chapter introduction      Page 99 
• Abstract       Page 100 
• 1. Introduction      Pages 101-104 
• 2. Experimental      Pages 104-109 
- 2.1 Chemicals and materials   Page 104 
- 2.2 Sample preparation and analysis  Pages 104-105 
- 2.3 River simulating microcosms   Pages 105-106 
- 2.4 Human liver microsome metabolism  Page 107 
- 2.5 Retrospective analysis with UHPLC-QTOF –  
screening for precursors of 1S, 2R-(+)-ephedrine Page 107 
- 2.6 Toxicity testing    Pages 107-109 
• 3. Results and discussion      Pages 109-115 
- 3.1 Stereoselective degradation of a mixture  
of ephedrine stereoisomers in river simulating  
microcosms       Pages 109-112 
- 3.2 Single 1R, 2S-(-)-ephedrine or 1S, 2S- 
(+)-pseudoephedrine river simulating microcosms Pages 112-113 
- 3.3 Human liver microsome assays to verify  
human metabolism of 1R, 2S-(-)-ephedrine and  
1S, 2S-(+)-pseudoephedrine    Page 113 
- 3.4 Retrospective analysis for 1S, 2R-(+)- 
ephedrine precursors in river water   Page 113 
- 3.5 Ecotoxicity of ephedrine stereoisomers to 
Daphnia magna, Pseudokirchneriella subcapitata  
and Tetrahymena thermophila    Page 114-115 
• 4. Conclusion        Page 115 
• References        Pages 116-117 
• Supplementary information      Pages 118-149 





Chapter Three: A multi-residue supercritical fluid chromatography coupled  
with tandem mass spectrometry method for the analysis of chiral and non- 
chiral chemicals of emerging concern in environmental samples, J. Rice,  
A. Lubben and B. Kasprzyk-Hordern (submitted)     Pages 157-211 
• Chapter introduction      Page 158 
• Abstract       Page 159 
• 1. Introduction      Pages 160-161 
• 2. Materials and Methods     Pages 162-168 
       - 2.1 Materials     Page 162 
       - 2.2 Methods     Page 162-168 
• 3. Results and discussion     Pages 168-182 
- 3.1 Method development    Pages 168-169 
- 3.2 Method validation    Pages 169-178 
- 3.3 Environmental analysis   Pages 179-182 
• 4. Conclusion       Page 183 
• References       Pages 184-188 
• Supplementary information     Pages 189-211 
Chapter Four: A new paradigm in public health assessment: Water  
fingerprinting for protein markers of public health using mass spectrometry, 
 J. Rice and B. Kasprzyk-Hordern. (2019) TrAC, Volume 119.    Pages 212-238 
• Chapter introduction      Page 213 
• Abstract       Page 214 
• Introduction – Public health monitoring and its limitations Page 215 
• Molecular epidemiology in public health assessment  Pages 215-216 
• Clinical proteomics for individual health   Pages 216-217 
• Urban water fingerprinting for public health assessment:  
the role of mass spectrometry in water fingerprinting for  
small molecules       Pages 217-221 
• Urinary proteins as a public health biomarkers: the role  
of mass spectrometry in water fingerprinting for proteins  Pages 222-226 
• Conclusions       Page 226 
• References       Pages 227-235 





Chapter Five: Development of an enzymatic digest method for use in  
wastewater for the analysis of proteins of disease by hydrophilic interaction  
liquid chromatography coupled to triple quadrupole mass spectrometry  Pages 239-323 
 • Chapter introduction      Page 239 
 • Abstract       Page 240 
 • 1. Introduction      Pages 241-257 
  - 1.1 Public health monitoring   Pages 241-242 
  - 1.2 Literature analysis    Pages 243-252 
  - 1.3 Human proteins in wastewater  Pages 252-257 
 • 2. Experimental      Pages 258-266 
  - 2.1 Analytical instrumentation and materials Pages 258-260 
  - 2.2 Enzymes digestion development  Pages 260-262 
  - 2.3 Assessing digest robustness  Pages 262-263 
  - 2.4 Quantotypic peptides   Page 263 
  - 2.5 HILIC-MS method development  Pages 263-265 
  - 2.6 Analysis of wastewater samples  Pages 265-266 
 • 3. Results       Pages 267-293 
  - 3.1 Enzyme digestion development  Pages 267-268 
  - 3.2 Assessing digest robustness  Pages 269-271 
  - 3.3 HILIC method development  Pages 272-278 
  - 3.4 Preliminary method performance  Pages 279-280 
  - 3.5 Analysis of wastewater samples  Pages 280-293 
 • 4. Conclusions      Page 293 
 • References       Pages 294-299 
 • Supplementary information     Pages 300-323 
Thesis conclusion and future work      Pages 324-334 
 • Conclusion        Pages 324-327 
 • Novelty and contribution statement     Pages 327-328 
 • Future work        Pages 328-332 
 • Research outputs       Pages 332-334 







List of tables and figures 
Chapter one 
• Table 1 – Analytes selected in this study     Pages 32-33 
• Table 2 – Correction factors used for calculating daily consumption  Page 36 
• Figure 1 – Average PNDLs and DIs of illicit drugs (2014-18)    Page 42 
• Figure 2 – Average PNDLs, DIs and prescription of non-opioid  
pharmaceuticals (2014-18)       Page 43 
• Figure 3 – Average PNDLs of oxymorphone and hydrocodone (2014-18) Page 46 
• Figure 4 – Average PNDLs, DIs and prescription of opioid pharmaceuticals  
(2014-18)         Page 47 
• Figure 5 – Average PNDL in Europe of benzoylecgonine (BEG), amphetamine 
(AMP), methamphetamine (METH) and ecstasy (MDMA) (2011-2018)  Page 52 
• Table S1 – Selected analytes and their properties    Pages 60-61 
• Table S2 – Daily wastewater flows      Page 62 
• Table S3 – Daily PNDLs       Pages 62-65 
• Table S4 – Daily intake       Pages 65-66 




)  Page 67 




) Page 67 
• Figure S1 – Daily PNDLs       Page 68-86 
• Figure S2 – Daily intake       Pages 87-95 
• Figure S3 – Average PNDL and DI of (i) caffeine and its metabolite  
1,7-DMX, and (ii) nicotine and its metabolite cotinine    Pages 95-96 
Chapter two 
• Table 1 – Studied chemicals and their properties    Pages 101-102 
• Figure 1 – Mixed-compound river simulating microcosms – (±)-ephedrine  
degradation under dark abiotic (DAR), dark biotic (DAR), light abiotic  
(LAR)  and light biotic (LBR) conditions      Page 110 
• Figure 2 – Mixed-compound river simulating microcosms –  
(±)-pseudoephedrine degradation under dark abiotic (DAR),  
dark biotic (DAR), light abiotic (LAR) and light biotic (LBR) conditions  Page 111 
• Figure 3 – Mixed-compound river simulating microcosms – norephedrine  
degradation under dark abiotic (DAR), dark biotic (DAR), light abiotic (LAR) 
 and light biotic (LBR) conditions       Page 112 
• Table 2 – Toxicity of ephedrine stereoisomers to Daphnia magna,  





• Table S1 – Optimised MRM conditions for the analysis of ephedrines by  
LC/MS/MS by Evans et al.       Page 118 
• Table S2 – Method performance data for the method described by Evans et al. Page 118 
• Table S3 – Optimised MRM conditions for the analysis of ephedrines by  
LC-MS/MS by Castrignanò et al.      Page 119 
• Table S4 – Method performance data for the method described by  
Castrignanò et al.         Page 119 
• Table S5 – Human liver microsome experiment showing ephedrine concentration 
over time. Analyte blanks contain no microsomes, whilst HLM blanks contain 
microsomes but no analytes       Page 119 
• Figure S1 – Summary of river simulating microcosms    Page 120 
• Figure S2 – Mixed-compound river microcosms – temperature, dissolved  
oxygen (DO), pH, ammonium, nitrate, nitrite and chemical oxygen demand  
(COD)          Page 121 
• Figure S3 – Summary of single-compound river microcosms   Page 122 
• Figure S4 - Single-compound river microcosms – temperature, dissolved  
oxygen (DO), pH, ammonium, nitrate, nitrite and chemical oxygen demand  
(COD)          Page 123 
• Figure S5. Formation of (+)-(1S, 2R)-ephedrine in (-)-(1R, 2S)-ephedrine  
river simulating microcosm       Page 124 
• Figure S6. Single-compound river simulating microcosms – 1R, 2S-(-)- 
ephedrine and 1S, 2S-(+)-pseudoephedrine degradation under biotic dark  
(DBR) and light biotic (LBR) conditions     Page 124 
• Figure S7 – Toxicity of ephedrine stereoisomers to Daphnia magna,   
Selenastrum capricornutum and Tetrahymena thermophila.   Page 125 
• Figure S8 - % mortality of Daphnia magna exposed to 1S, 2R-(+)-ephedrine Page 126 
• Figure S9 - % mortality of Daphnia magna exposed to 1R, 2S-(-)-ephedrine Page 126 
• Figure S10 - % mortality of Daphnia magna exposed to 1S, 2S-(+)- 
pseudoephedrine        Page 127 
• Figure S11 - % mortality of Daphnia magna exposed to 1R, 2R-(-)- 
pseudoephedrine        Page 127 
• Table S6 –% mortality of Daphnia Magna at various concentrations after  
24 hours         Page 128 
• Table S7 – % mortality of Daphnia Magna at various concentrations after  





• Table S8 – Ephedrine EC50 determination for Daphnia Magna after 24  
hours exposure         Page 129 
• Table S9 – Ephedrine EC50 determination for Daphnia Magna after 48  
hours exposure         Page 129 
• Table S10 – Multi-compound microcosm experiment  
– Biotic Light microcosms       Page 130 
• Table S11 – Multi-compound microcosm experiment  
–Biotic Dark microcosms       Page 131 
• Table S12 – Multi-compound microcosm experiment  
–Abiotic Light microcosms       Page 132 
• Table S13 – Multi-compound microcosm experiment  
–Abiotic Dark microcosms       Page 133 
• Table S14 – 1R, 2S-(-)-Ephedrine range finding test  
– Tetrahymena thermophile       Pages 134-135  
• Table S15 – 1R, 2S-(-)-Ephedrine range definitive test  
– Tetrahymena thermophile       Pages 136-137 
• Table S16 – 1S, 2R-(+)-Ephedrine range definitive test  
– Tetrahymena thermophile       Pages 138-139 
• Table S17 – 1R, 2R-(-)-Pseudoephedrine range finding test  
– Tetrahymena thermophile       Pages 140-141 
• Table S18 – 1R, 2R-(-)-Pseudoephedrine definitive test  
– Tetrahymena thermophile       Pages 142-143 
• Table S19 – 1S, 2S-(+)-Pseudoephedrine definitive test  
– Tetrahymena thermophile       Pages 144-145 
• Table S20 – ‘Natural’ isomers (1S,2S-(+)-Pseudoephedrine and  
1R,2S-(-)-ephedrine) DF = 0.5 definitive test – Tetrahymena thermophila Pages 146-147 
• Table S21 – ‘All’ isomers EF = 0.5 and DF = 0.5 definitive test  
– Tetrahymena thermophila       Pages 148-149 
• Addendum table 1 – The risk quotient posed by ephedrine isomer to a range 
of river organisms        Page 151 
• Addendum figure 1 – Elution order of ephedrine in the Evans et al. method Page 152 
• Addendum figure 2 – Biotic Light microcosm one (BL1), showing decrease 
 in the relative abundance of 1R, 2S-(-)-ephedrine and 1S, 2S-(+)- 






• Addendum figure 3 – Biotic Light microcosm two (BL2), showing decrease 
 in the relative abundance of 1R, 2S-(-)-ephedrine and 1S, 2S-(+)- 
pseudoephedrine        Page 153 
• Addendum figure 4 – Biotic Dark microcosm one (BD1), showing decrease 
 in the relative abundance of 1R, 2S-(-)-ephedrine and 1S, 2S-(+)- 
pseudoephedrine        Page 153 
• Addendum figure 5 – Biotic Dark microcosm two (BD2), showing decrease 
 in the relative abundance of 1R, 2S-(-)-ephedrine and 1S, 2S-(+)- 
pseudoephedrine        Page 154 
• Addendum figure 6 – Abiotic Light microcosm one (AL1)   Page 154 
• Addendum figure 7 – Abiotic Light microcosm two (AL2)   Page 155 
• Addendum figure 8 – Abiotic Dark microcosm one (AD1)   Page 155 
• Addendum figure 9 – Abiotic Dark microcosm two (AD2)   Page 156 
Chapter three 
• Table 1 – Enantiomeric fraction and peak resolution for chiral analytes (n=12) Page 170 
• Table 2 – Average relative method recovery at three concentrations (n=9) and 
signal suppression (n=3) in river water and wastewater    Pages 170-172 
• Table 3 – Method limits f detection, quantification, method accuracy and  
method precision in river water (n=9)       Pages 173-174 
• Table 4– Method limits of detection, quantification, method accuracy and 
method precision in wastewater (n=9)      Pages 175-176 
• Table 5 – Method resolution of enantiomers and enantiomeric fractions (n=9) Pages 177 
• Table 6 – Analysis of environmental samples in river water, effluent and  
influent wastewater        Pages 179-181 
• Table 9 – Average enantiomeric fraction and separation of chiral analytes in 
matrix ± standard deviation       Page 181 
• Table S1 – Supplier information and CAS numbers for all analytes and  
internal standards used in this paper      Pages 189-191 
• Table S2 – Method conditions selected for chiral separation   Page 192 
• Table S3 – Matrix of method conditions used to analyse analytes  Page 192 
• Table S4 – Chiral separation using twelve different methods   Page 192 
• Figure S1 – Enantioselective separation of bisoprolol, temazepam (partial),  
metoprolol, atenolol and propranolol in method B2    Page 193 
• Table S5 – MRM conditions of analytes and isotopically labelled internal  
standards studied using the selected SFC-TQD method    Pages 194-196 





• Figure S2 – Extracted mass chromatograms for analytes in the PHARMA  
method using their MRM 1 transitions      Pages 199-200 
• Figure S3 – Extracted mass chromatograms for analytes in the DAC method 
using their MRM 1 transitions       Pages 201-202 
• Figure S4 – Mass chromatograms for analytes in the NEG method using their 
MRM 1 transitions        Page 203 
• Table S7 – Instrument linearity, range, instrument limits of detection and  
quantification and average relative retention time    Page 204-205 
• Table S8 – Average absolute recoveries (%) for all analytes in the method, 
even if not developed further (n=3)      Pages 206-208 
• Table S9 – Instrument accuracy and precision assessed over a period of one  
week          Pages 208-209 
• Table S10 – Average relative recoveries for all analytes analysed in the method, 
even if not developed further (n=3)      Pages 209-211 
Chapter four 
• Table 1 – Examples of urinary biomarkers     Page 216 
• Figure 1 – Water fingerprinting for public health assessment   Page 218 
• Table 2 – Available biomarkers and studies undertaken so far   Pages 219-221  
• Table 3 – Advantages and limitations of WBE     Page 221 
• Table 4 – Proteins as potential biomarkers in WBE    Page 224 
Chapter five 
• Figure 1 – An overview of the peptide production process   Page 243 
• Table 1 – Summary of literature digestion methods highlighting the variety 
of methods reported in literature       Pages 244-250 
• Table 2 – Specificity of tryptic peptides from biomarkers of disease, non- 
human specific peptides with asterisks (*) could be considered pseudo- 
specific, as discussed below the table      Pages 253-255 
• Table 3 – Chip LC gradient with enrichment prior to analytical separation Page 258 
• Table 4 – HILIC method gradient      Page 259 
• Figure 2 – Summary of digestion experiments with colour coding to show 
the steps that were used by each method      Page 262 
• Table 5 – BSA + biomarker digest sequence coverage and digest efficiency 
as determined by mascot       Page 270 





• Table 7 – Average retention times of tuned peptides using average peak  
top retention time for each daughter (MRM) ion     Page 273 
• Figure 6 – Two MRM transitions for the BSA peptide [LVT-K]
2+
 from 
infusion of 5 µM tuning solution      Page 273 
• Figure 7 – Three MRM transitions for the BSA peptide [LVN-K]
2+
 from 
infusion of 5 µM tuning solution      Page 274 
• Figure 8 – Two MRM transitions for the BSA peptide [LGE-R]
2+
 from 
infusion of 5 µM tuning solution      Page 274 
• Figure 9 – Two MRM transitions for the CRP peptide [APL-K] from  
infusion of 5 µM tuning solution      Page 275 
• Figure 10 – Three MRM transitions for the CRP peptide [GYS-K]
2+
 from 
infusion of 5 µM tuning solution      Page 275 
• Figure 11 – Two MRM transitions for the CRP peptides [ALK-P]
3+
 from 
infusion of 5 µM tuning solution      Page 276 
• Figure 12 – Two MRM transitions for the CRP peptide [YEV-P]
2+
 from 
infusion of 5 µM tuning solution      Page 276 
• Figure 13 – Three MRM transitions for the PSA peptide [SVI-R]
2+
from 
infusion of 5 µM tuning solution      Page 277 
• Figure 14 – One MRM transitions for the PSA peptide [IVG-K]
2+
 from 
infusion of 5 µM tuning solution      Page 277 
• Figure 15 – Four MRM transitions for the PSA peptide [LSE-K]
2+
 from 
infusion of 5 µM tuning solution      Page 278 
• Table 8 – Preliminary method performance results for BSA   Page 279 
• Figure 16 – Calibration curves for BSA peptides    Page 279 
• Table 9 – Wastewater pH throughout the digestion procedure established  
in 2.2.2          Page 280 
• Figure 17 – Two MRM transitions for the BSA peptides [LVT-K]
2+
 in a 
standard 500 nM buffer digest       Page 281 
•Figure 18 – Three MRM transitions for the BSA peptide [LVN-K]
2+
 in a 
standard 500 nM buffer digest       Page 282 
• Figure 19 – Two MRM transitions for the BSA peptide [LGE-R]
2+
 in a 
standard 500 nM buffer digest       Page 282 
• Figure 20 – Three MRM transitions for the PSA peptide [SVI-R]
2+
 in a 
500 nM buffer digest        Page 283 
• Figure 21 – Three MRM transitions for the CRP peptide [GYS-K]
2+
 in a 






• Figure 22 – Three MRM transitions for the CRP peptide [GYS-K]
2+ 
in a 
100 mL wastewater digest without addition of any proteins   Page 284 
• Figure 23 – Three MRM transitions for the CRP peptide [GYS-K]
2+
 in a 
100 mL wastewater digest with addition of BSA, CRP and PSA each to a  
final concentration of 500 nM       Page 284 
• Figure 24 – Two MRM transitions for the BSA peptide [LVT-K]
2+
 in a  
standard 500 nM digest        Page 286 
• Figure 25 – Two MRM transitions for the BSA peptides [LVT-K]
2+
 in a 
100 mL wastewater digest with addition of BSA, CRP and PSA each to a 
final concentration of 5 µM       Page 286 
• Figure 26 – Three MRM transitions for the CRP peptide [GYS-K]
2+
 in a 
standard 500 nM buffer digest       Page 287 
• Figure 27 – Three MRM transitions for the CRP peptide [GYS-K]
2+
 in a 
100 mL digest with addition of BSA only to a final concentration of 500 nM Page 287 
• Figure 28 – Three MRM transitions for the CRP peptide [GYS-K]
2+
 in a 
100 mL wastewater digest with addition of BSA, CRP and PSA each to a 
final concentration of 500nM       Page 288 
• Figure 29 – Three MRM transitions for the CRP peptide [GYS-K]
2+
 in a 
100 mL wastewater digest with addition of BSA, CRP and PSA each to a 
final concentration of 5 µM       Page 288 
• Figure 30 – Spectra showing the presence of the CRP peptide [GYS-K]
2+
 
in duplicate 100 mL wastewater digests under standard digest conditions  Page 290 
• Figure 31 – Spectra showing the presence of the CRP peptide [GYS-K]
2+
  
in 100 mL duplicate wastewater digests using 1 mL of 25 µg mL
-1
 trypsin Page 291 
• Figure 32 – Spectra showing the presence of the CRP peptide [GYS-K]
2+
 
in 500 mL duplicate wastewater digests, under standard digest conditions  Page 292 
• SI figure 1 – 30 nM concentration, enzyme only, PSA only digest  Page 300 
• SI figure 2 – 606 nM concentration, enzyme only, BSA only digest 1  Page 301 
• SI figure 3 - 606 nM concentration, enzyme only, BSA only digest 2  Page 302 
• SI figure 4 – 303 nM concentration, enzyme only, PSA only digest 1  Page 303 
• SI figure 5 – 303 nM concentration, enzyme only, PSA only digest 2  Page 303 
• SI figure 6 – 30 nM concentration, no surfactant, BSA only digest 1  Pages 304-305 
• SI figure 7 – 30 nM concentration, no surfactant, BSA only digest 2  Pages 306-307 
• SI figure 8 – 30 nM concentration, no surfactant, PSA only digest 1  Page 308 
• SI figure 9 – 30 nM concentration, no surfactant, PSA only digest 2  Page 309 





• SI figure 11 – 30 nM concentration, combined BSA & PSA digest 2  Pages 312-313 
• SI figure 12 – 500 nM concentration, combined BSA & CRP digest  
0.1 µL injection volume        Pages 314-315 
• SI figure 13 – 500 nM concentration, combined BSA & CRP digest  
0.3 µL injection volume        Pages 316-376 
• SI figure 14 – 500 nM concentration, combined BSA & IL-6 digest  
0.1 µL injection volume        Pages 318-319 
• SI figure 15 – 500 nM concentration, combined BSA & IL-8 digest  
0.1 µL injection volume        Page 320 
• SI figure 16 – 500 nM concentration, combined BSA & IL-8 digest  
0.3 µL injection volume        Pages 321-322 
• SI figure 17 – 500 nM concentration, BSA only digest 0.1 µL injection 
 volume         Page 323 
Acknowledgments 
I would like to thank my supervisory team, prof. Barbara Kasprzyk-Hordern and Dr. Anneke 
Lubben for their confidence and support during my PhD. I’d also like to thank my co-authors 
for their contributions to published work, the members of the environmental chemistry group 
at the University of Bath, past and present, for their camaraderie and willingness to go 
sampling at 6am on a weekend, my friends, family and partner Josie for their love, support 
and willingness to proof read at all hours, and the members of the University of Bath 
counselling and mental health team and BANES talking therapies for their continuing 
support.




Summary of thesis 
Abstract: 
Both human and environmental health are born out of extraordinarily complex systems and no thesis 
could ever satisfactorily explore both, instead the focus of this document lies in both trying to get the 
most out of existing analytical techniques and how to apply these techniques to study new challenges. 
Currently, information about public health is obtained by looking at the health of a few individuals 
and then building this up to an understanding of the whole population such as public health England’s 
health survey for England or the European Monitoring Centre for Drugs and Drug Abuse’s 
(EMCDDA) country drug report. The flaws in this technique are that it relies on obtaining a 
representative sample of individuals in order to understand the community as a whole. Wastewater 
based epidemiology (WBE) is a methodology that examines influent wastewater to explore what is 
being consumed by the population and uses this to build up a picture of public health, relying on the 
assumption that wastewater is equivalent to a pooled urine sample for a population. Likewise, analysis 
of river water can be used to gain an understanding of environmental health by measuring the 
concentration of anthropogenic compounds in the environment and assessing their environmental risk. 
However, current assessments of human and environmental health do not allow for the collection of 
all available data, as collected analytical measurements are either incomplete or are lacking in context. 
This thesis seeks to address these limitations by exploring new analytical methodologies and 
techniques for collecting more comprehensive data and was focused into three main areas of research: 
1) the uses of chirality in determining analyte origin and its impact on assessments of public and 
environmental health, 2) the development of new methodologies to maximise the information 
obtainable from current health biomarkers and 3) the exploration of proteins as potential new 
biomarkers of public health.  
The importance of assessing chirality was first demonstrated in chapter one, where chiral 
chromatography was used to measure changes in the concentration of several drugs of abuse and 
human pharmaceuticals in wastewater over a period of five years. By monitoring changes in the 
enantiomeric fraction (EF) of chiral analytes it was possible to identify that these biomarkers 
originated from human consumption due to stereospecific excretion. Additionally, the EF of 
methamphetamine changed throughout the study, which appeared to indicate a change in how and 
where it was manufactured. However, the main focus of chapter one was in how WBE can be used to 
assess public health strategies, including addressing a need for assessing the impact of drug policy on 
changes in drug consumption. The novel use of local pharmaceutical prescription data alongside 
wastewater analysis allowed for a more thorough assessment of consumption within the population, 
including the observation that prescription and wastewater data showed good agreement for 




painkillers that are at risk of being abused, suggesting that there was no significant illicit usage in 
contrast to expectations from ongoing opioid epidemics in other countries. Additionally, by 
comparing trends in UK drug consumption with trends in European drug consumption it was possible 
to identify UK specific trends, such as a rapid increase in cocaine consumption, and well as those that 
were European wide. Alongside this, the observation that mephedrone, a drug first banned in 2010, 
was no longer consumed after 2015 showed that WBE can be used to assess the efficacy of drug 
policy. Likewise, the identification of an increasing trend in UK drug consumption from 2016 
onwards were postulated to be related to significant changes in UK drug policy that occurred in 2016. 
Overall, a combination of chiral analysis and local prescription data were used to verify the source of 
analytes in wastewater, whilst comparison with long term trends in prescription rates and European 
wide trends lead to the identification of a trend of increasing illicit drug use in the UK, as well as a 
strong correlation between prescription and wastewater concentrations of painkillers that were at risk 
of being abused. 
In a similar vein, the importance of chiral analysis for the assessment of environmental health was 
explored in chapter two, where river simulating microcosms and ecotoxicity tests were used to assess 
the environmental risk posed by ephedrine. From microcosm testing two isomers of ephedrine were 
observed to decay significantly more, under environmental conditions, than the remaining isomers. 
Following this, the compounds with the greatest environmental persistence were also observed to be, 
generally, the most toxic to a range of important river organisms. River simulating microcosms also 
revealed that one of the less persistent and less toxic isomers of ephedrine could be converted under 
environmental conditions to a more persistent and toxic isomer. This observation was confirmed by a 
combination of retrospective data analysis and human liver microcosm experimentation to rule out 
other potential metabolic sources of the toxic isomer. What this showed was that it was important for 
environmental studies to consider individual isomers as discrete compounds when considering their 
environmental impact. Additionally, studies should also consider how human pharmaceuticals enter 
the environment, the initial composition of any isomers when they enter the environment, and how 
they are changed, or not, after excretion or by wastewater treatment. Chapter three showcased the 
utility of supercritical fluid chromatography (SFC) for developing new chiral methodologies for use in 
wastewater and river water for monitoring compounds of environmental concern (CECs). Initial 
method development was able to qualitatively analyse 140 CECs, with the final method being able to 
fully or semi-quantify 95 CECs and detect 75% of them in grab samples of influent wastewater, 
effluent wastewater or river water. Initial analysis of wastewater and river water showed that the 
enantiomeric fractions of several analytes changed depending on the matrix they were detected in, 
which highlighted the importance of assessing chirality in not just environmental samples but also in 
the sources of CECs. The power of SFC lies in its analytical efficiency compared to contemporary 
chiral liquid chromatography. By developing new chiral methods that can rapidly analyse CECs it 




becomes increasingly easier for routine environmental and public health monitoring to measure 
chirality without sacrificing analytical power or sample throughput.  
The need to explore new biomarkers was brought about by the realisation that most current WBE 
biomarkers are used to measure consumption, rather than directly measuring public health, although 
biomarkers of oxidative stress have begun to be explored. Chapter four lays out the current landscape 
of WBE analysis and showcases the range of biomarkers currently used, as well as an estimation of 
the population they’ve been used to study, which for drugs of abuse represented roughly 1.5 % of the 
total human population. The use of urinary proteomics for assessing individual health in clinical 
analysis was discussed and compared with how drugs of abuse were used 20 years previously before 
the development of WBE. The case was then made for using urinary disease proteins to assess public 
health via their analysis in wastewater and several potential urinary biomarkers were proposed based 
on a set of criteria outlined in the chapter, including: urinary excretion, a known disease-biomarker 
relationship and disease specificity. Chapter five then took the first tentative steps towards developing 
a method for the analysis of human protein biomarkers in wastewater, by developing an enzymatic 
digestion method for five potential biomarkers in buffer, which was then adapted to work in 
wastewater for the most promising two proteins. The chapter also built upon the biomarker selection 
criteria discussed in the previous chapter to include the selection of human specific peptides, the 
ability to include peptides shared with other primates as pseudo-human specific and efforts to estimate 
the wastewater concentration of proteins from their excreted urinary concentrations in healthy adults. 
Initial analysis indicated the possible detection of one peptide of the inflammation biomarker C-
reactive protein (CRP) in 100 mL wastewater digests using hydrophilic interaction liquid 
chromatography coupled with triple quadrupole mass spectrometry. This showed that protein 
biomarkers of disease could be detected in wastewater using largely the same techniques as current 
WBE analysis, which would enable its uptake by the larger WBE community as well as facilitating 
direct measurements of public health. 
Overview and aims:  
Broadly, the goal of the research can be summed up by a famous Galileo Galilei quote as an effort to 
“measure what is measurable and make measurable what is not so”. In this instance the overall 
objective was to explore the uses of chromatography and mass spectrometry to explore public and 
environmental health. As described in the abstract this very broad statement was refined into three 
mains areas concerning analyte chirality, improving the analysis of current biomarkers and developing 
new biomarkers of public health.  
Aim one: To explore the uses of chirality in determining analyte origin and its impact on assessments 
of public and environmental health 




Despite many pharmaceuticals containing a chiral centre, when they are examined in wastewater [1-4] 
or the environment [5] they are often only analysed achirally, as a sum of their constituent isomers, 
instead of as individual isomers. Human metabolism is often stereoselective preferentially 
metabolising one isomer of a parent molecule over another. This means that chirality can be used to 
confirm that analytes detected in wastewater or river water are being consumed by the population 
rather than simply being discharged into the system [6; 7]. Establishing the origins of an analyte is 
important when assessing both public and environmental health. For example, strategies to reduce 
public consumption of an environmentally toxic pharmaceutical may be misplaced if it originated 
from direct discharge into the environment rather than from human consumption. Chapter one 
concerns a five-year study of wastewater, which was carried out using chiral chromatography 
allowing for the confirmation that analytes present in wastewater were being consumed rather than 
disposed of via the sewage system. This was particularly important for monitoring MDMA, which has 
been previously detected in literature at high concentrations due to disposal [8]. Chirality can also be 
used to determine the method of manufacture of an analyte [9], which is particularly important for 
determining the supply route used to import drugs of abuse into the UK or Europe [10]. Where 
chapter one primarily focused on human health chapter two focused on the determining the 
environmental fate of ephedrine, a pharmaceutical with two chiral centres, by exploring the stability 
and toxicity of each isomer individually. River simulating microcosms containing all four ephedrine 
isomers were used to explore the degradation of ephedrine under light, dark, biotic and abiotic 
conditions and were followed up by individual isomer microcosms under the conditions that gave the 
greatest amount of degradation. Toxicity testing was performed by exposing Daphnia magna, 
Pseudokirchneriella subcapita and Tetrahymena thermophila to individual ephedrine isomers and 
determining the EC50. Additionally, human liver microcosms and retrospective analysis of river water 
samples were used to explore the potential for non-medicinal ephedrine isomers to enter the 
environment as a result of human metabolism of medicinal ephedrine isomers, or from metabolism of 
similar compounds such as cathinones. As was the case with using chirality to determine the source of 
analytes in wastewater, HLM was used to help gain a better understanding of human metabolism of 
ephedrine as many studies of ephedrine metabolism were performed in the previous century using 
achiral methodologies.  
Aim two: To develop new methodologies to maximise the information obtainable from currently 
utilised health biomarkers 
A key part of assessing public health is the context in which the results should be viewed. WBE is still 
a relatively new field and whilst, at time of writing, key biomarkers have been surveyed for fifteen 
years [11] the relationship between what is detected in wastewater and public health is still not fully 
understood. This is particularly important as WBE has a unique capability to provide feedback on 
how public health and other initiatives directly impact the public, which are otherwise difficult to 




measure. In particular, the UK drug policy commission (UKDPC) and advisory council on the misuse 
of drugs (AMCD) have highlighted the need for better methods of assessing the impact of UK drug 
policy [12; 13]. Likewise, many countries are currently experiencing an epidemic of opioid misuse, 
which is initially characterised by abuse of prescription painkillers that changes into abuse of illicit 
opioids like heroin [14-16]. There are also concerns surrounding the joint abuse of heroin and 
benzodiazepines [17]. In addition to expressing the importance of chirality, chapter one also compared 
trends in UK drug use with those of a larger, longer, European wide WBE study [2] to assess which 
trends were likely UK specific and which were shared across the continent. However, the main 
objective of the paper was to establish the power of comparing local prescription and wastewater data 
in order to identify and provide context for longer term trends in pharmaceutical consumption. This 
was used to compare the prescription of pharmaceuticals that are of risk of illicit abuse, such as 
painkillers, to their concentration in wastewater in order to identify any potential abuse that could 
relate to other opioid crises. This technique was also used to estimate heroin consumption by 
subtracting licit sources of morphine, like prescribed morphine and codeine, from wastewater 
concentrations of morphine in order to calculate the amount of morphine produced from heroin 
metabolism and hence the amount of heroin consumed. As well as being important for giving context 
to WBE, analysis of chirality is also important for monitoring environmental health, as many CEC 
enter the environment through discharge of treated wastewater [18], making it important to monitor 
not just environmental matrices but also wastewater. Despite this there is a lack of methods for chiral 
analysis of CECs. Chapter three explored the use of supercritical fluid chromatography (SFC) for the 
chiral analysis of CECs in wastewater and river water. SFC has several advantages over traditional 
liquid chromatography including more efficient analyte separation as a result of its compatibility with 
a wider range of stationary phases, including chiral stationary phases. Having previously highlighted 
the importance of chiral chromatography, chapter three detailed the steps required for developing and 
validate a quantitative method to analyse 95 CECs using chiral-SFC coupled to triple quadrupole 
mass spectrometry in influent wastewater, effluent wastewater and river water. Additional details of 
initial method development using a single quadrupole MS for qualitative analysis of 140 CECs was 
also reported in this chapter in order to highlight the range of analytes that can be analysed by SFC 
and to show the selectivity of different chiral SFC stationary phases to a range of chiral analytes.  
Aim three: The exploration of proteins as potential new biomarkers of public health  
Since its inception WBE has focussed primarily on drugs of abuse and pharmaceuticals [9; 19-21]. 
This has likely been because they are relatively easy to analyse using already established techniques 
such as reverse-phase liquid chromatography and triple quadrupole or quadrupole-time of flight mass 
spectrometry. However, these biomarkers are focused on measuring human consumption and relating 
that to public health instead of trying to measure public health directly. Where human health 
biomarkers have been analysed, they have been biomarkers of broad health conditions, such as 




biomarkers of oxidative stress [22; 23], rather than biomarkers of specific diseases. Therefore, there 
exists an opportunity to explore new biomarkers that focus on truly monitoring public heath, rather 
than monitoring public consumption. Chapter four highlights the possibility of using urinary proteins 
as biomarkers of public health, which is simplified because they are already analysed clinically using 
similar techniques and instrumentation to other WBE biomarkers [24]. The challenge that urinary 
proteins pose however is that they have generally only been used previously to assess individual 
health, and few attempts have been made to use them for monitoring public health [25]. Additionally, 
in order to analyse proteins in a similar fashion to other WBE biomarkers they must first be broken 
down into peptides using an enzyme. Chapter five outlines the initial development of a methodology 
to analyse proteins in wastewater using a trypsin enzyme digest to generate peptides, followed by 
peptide analysis using hydrophilic interaction liquid chromatography coupled to a triple quadrupole 
mass spectrometer. The digest was first developed in buffer and focussed on five different protein 
biomarkers identified in chapter four as being potential candidates for wastewater analysis, with 
further development expanding the digest for use in influent wastewater. In addition, chapter five also 
discussed the issue of ensuring biomarker specificity in wastewater where proteins can have non-
anthropogenic sources and detailed a calculation for estimating the wastewater concentration of a 
protein from its urinary concentration in healthy individuals, which is important when considering 
future biomarker candidates. 
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Chapter one introduction 
 
In the thesis introduction the three aims of the research were laid out and can be broadly summarised 
as follows: 1) to demonstrate the importance of analyte chirality, 2) to acquire better data using 
current health biomarkers and 3) to explore proteins as potential new biomarkers of human health. To 
this end, chapter one explores both the importance of measuring chirality for identifying the source of 
chiral analytes and the novel use of local prescription data to provide context to WBE data by 
reporting the results of a five year study of influent wastewater, which was undertaken from 2014-
2018, with wastewater being collected once a day for one week each year.  
 
The paper reports on the results of a study of wastewater performed for one week each march from 
2014-2018 and analysed using a chiral chromatography method. The paper aims to identify trends in 
the consumption of drugs of abuse and pharmaceuticals and uses a combination of local prescription 
data, European wastewater data and changes in enantiomeric fraction (EF) in order to give context to 
the results. 
 
The importance of using chiral chromatography for collecting chiral information will be demonstrated 
in how it allows for the confirmation that detected analytes were being consumed. It achieves this by a 
comparison between the EF of analytes in wastewater and the EF of analytes in urine, as reported in 
literature. Likewise, local prescription data represents an important source of data with regards to the 
supply for pharmaceuticals and would be expected to match with trends in wastewater concentration 
if a substance is being us as intended. This is particularly important for prescription pharmaceuticals 
at risk of being abused, which could be potentially identified by an increase in wastewater 
concentrations relative to the prescribed concentration. For illicit substances context is provided by 
comparison with the larger European study, where possible, in order to identify UK specific and UK 
non-specific trends in drug use. This will demonstrate the power of WBE in providing data on the 
efficacy of public health initiatives, such as the regulation of illicit substances, by measuring what is 
being consumed by the population and how that can change over time.
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Abstract: 
This paper reports the application of wastewater-based epidemiology (WBE) for the 
monitoring of one city in the UK in years 2014-2018 as a means of 1) exploring  relative 
temporal changes of illicit drug usage trends across 5 sampling weeks in 5 years, (2) assess 
policy impact in reducing drug consumption, focussing particularly on mephedrone, which 
was classified as a class B drug in the UK in 2010, and the effects of subsequent regulation 
such as the novel psychoactive substances (NPS) bill of 2016, (3) investigate temporal 
changes in consumption of prescription pharmaceuticals vs illicit drug usage,  and (4) 
compare consumption of prescription drugs with WBE to enable  more accurate verification 
of prescription drugs with abuse potential. Mephedrone was quantified only for the first two 
years of the study, 2014-2015, and remained undetected for the next three years of the study. 
This shows that given enough time changes in drug policy can have an effect on drug 
consumption. However, after the introduction of the 2016 NPS bill, between the third and 
fourth study years, there was an observable increase in the consumption of “classic” drugs of 
abuse such as cocaine, MDMA and ketamine suggesting a shift away from novel 
psychoactives. The unique prescription dataset allowed for a more accurate calculation of 
heroin consumption using morphine by examining other sources morphine. Additionally, for 
compounds with controlled prescription like methadone, trends in consumption estimated by 
wastewater and trends in prescription correlated. Wastewater-based epidemiology is a 
powerful tool for examining whole populations and determining the efficacy and direction of 
government actions on health, as it can, alongside prescription and wider monitoring data, 
provide a clear insight into what is being consumed by a population and what action is 
needed to meet required goals.  
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In 2017 the UK home office published its drug strategy and set out its aims of reducing illicit 
and other harmful drug use and increasing rates of recovery from drug dependence (Home 
Office 2017). This was to be achieved by focussing on reducing demand for, restricting 
supply of, building recovery from and global actions on drugs of abuse. However the efficacy 
of policies designed to achieve this are difficult to measure by traditional means, such as 
surveys, police seizures and hospital records. This was discussed in reports from the UK drug 
policy commission (UKDPC) (Reuter and Stevens 2007) and the advisory council on the 
misuse of drugs (ACMD) (Iversen, Gibbons et al. 2011). The UKDPC highlights concerns 
regarding underreporting the number of drug users, and hence the scope of drug use, is a 
problem with current survey-based methods of data collection. The ACMD further highlights 
the difficulty in obtaining an accurate picture on drug use, particularly for novel psychoactive 
substances, such as mephedrone, where users may not be aware what they are taking. The UK 
2017 drug strategy also aims to engage problematic drug users to encourage abstinence as 
part of reducing demand for, and increasing recovery from drugs of abuse. However, the 
UKDPC highlights that vulnerable drug users would not engage with social services, 
meaning that perhaps the most important group of drug users would not be captured by 
hospital or survey data. Lastly, whilst police seizures or festival amnesty bins can allow for 
an understanding of drug purity, drug supply and drug availability they cannot necessarily 
provide a complete picture of the drug market without seizing all the drugs on the market 
(Reuter and Stevens 2007). 
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Traditional data collection approaches rely on obtaining accurate information from 
incomplete data sources about individual behaviour and then extrapolating them to 
understand the whole community, which can be misleading. Instead of this bottom-up 
approach of understanding the community by understanding some of its members, 
wastewater-based epidemiology (WBE) allows for a top-down approach by examining the 
whole community using community-derived wastewater (Ort, van Nuijs et al. 2014, Baz-
Lomba, Salvatore et al. 2016, Castrignano, Yang et al. 2018, Gonzalez-Marino, Baz-Lomba 
et al. 2020). The advantage of WBE is that information can be rapidly collected and analysed 
to provide near real time monitoring of a community. As all individuals, whether they 
consume illicit drugs or not, contribute to the wastewater it allows for an understanding of the 
drugs used within the community from a single, representative, anonymous sample. This can 
be used to understand short- and long-term trends in drug use, and in combination with an 
understanding of drug metabolism and police seizure data, this would allow for an 
understanding of the whole drug market. In effect, WBE could provide information on what 
is consumed, whilst police seizures on what is not. A disadvantage of WBE is that it cannot 
provide information on drug purity or the number of drug users, without additional 
information such as dosage, frequency of use and metabolomics excretion data. However if 
the goal of policy is to reduce the number of users then that can be determined by a 
corresponding decrease in the amount of consumption using WBE. Additionally, WBE can 
be used to examine the consumption of pharmaceuticals and other licit drugs, which 
combined with additional data sources, like prescription data from the National Health 
Service (NHS). Prescriptions can also provide a valuable insight into the use of 
pharmaceuticals that have the potential to be abused, such as opioids. The European 
Monitoring Centre for Drugs and Drug Addiction (EMCDDA) UK drug report highlights that 
the number of heroin users is decreasing, but there are increasing concerns about abuse of 
prescription opioids and the numbers entering specialised treatment for heroin addiction have 
been static since 2014 (Addiction 2018). The use of additional non-wastewater data is 
necessary to help validate long term trends in WBE, particularly studies when trying to 
establish temporal trends across years from only a single week (Ort, Eppler et al. 2014, 
Goulding, Hickman et al. 2020). 
In January 2016 the psychoactive substances (NPS) bill was given royal assent and entered 
UK law in May 2016 (Home Office 2015). The NPS bill covered all psychoactive substances 
for human consumption that were not already controlled by the 1971 misuse of drugs act, or 
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otherwise exempted. This served to effectively ban all products by exception and supported 
the government’s stated aims of reducing the supply of illicit drugs by preventing the 
previously legal grey area surrounding the sale of psychoactive substances in head shops 
(Office 2015).  In 2018, the government carried out a review of the 2016 NPS act to assess its 
impacts on curbing the use of NPS (Office 2018). The report largely reasons that the act was 
a success, leading to a decrease in the availability of NPS through the restriction of supply 
and a cessation of the “open” selling of NPSs. However, the report highlights that a lot of this 
evidence is qualitative, as the supply of NPSs has shifted from head shops to more illicit 
sources including street dealing and the dark web. Additionally, whilst there has been a 
decrease in NPS usage, particularly amongst young people (16-24), there has been an 
increase in the usage of Class A drugs from 2016-2018, and new NPSs continue to be 
developed and appearing in the UK. The report suggests that due to the global nature of the 
illicit drug market it is difficult to say if this is due to the NPS act or to wider trends in the 
drug market.  
Therefore, there exists an opportunity to use WBE to better understand drug use in the UK. 
From 2014 to 2018 a large city in the South-West of the UK was surveyed for one week each 
year in order to contribute data on illicit drug use to a European project (EMCDDA 2019, 
Gonzalez-Marino, Baz-Lomba et al. 2020). Whilst this study was only interested in four 
analytes data was collected on a much greater number of analytes over a period that, 
fortuitously, included a major piece of legislation that sought to fundamentally change how 
licit and illicit substances were regulated – the 2016 NPS act. This paper seeks to understand 
the use of licit and illicit substances and how this may have changed in the light of significant 
legislation. 
This paper aims to estimate illicit and legal drug usage trends in one city in the UK from 
2014 to 2018 via application of wastewater-based epidemiology and pharmaceutical 
prescription data for the very same city and study time to: (1) explore  relative temporal 
changes of illicit drug usage trends across 5 sampling weeks in 5 years, (2) assess policy 
impact in reducing drug consumption, focussing particularly on mephedrone, which was 
classified as a class B drug in the UK in 2010, and the effects of subsequent regulation such 
as the novel psychoactive substances (NPS) bill of 2016, (3) investigate temporal changes in 
consumption of prescription pharmaceuticals vs illicit drug usage,  and (4) compare 
consumption of prescription drugs with WBE to enable  more accurate verification of 
prescription drugs with abuse potential. 





Over the five years of the study the following analytes were selected (Table 1): opioid 
analgesics, benzodiazepines, antidepressants, stimulants, hallucinogens, dissociative, designer 
drugs, PDE5 inhibitors, Z-drugs, lifestyle biomarkers. Table S1 shows all target analytes, 
their CAS number, molecular formula, molecular weight, and supplier information. 
Table 1. Analytes selected in this study. 
Analyte Class of compound Internal standard 
1,7-dimethylxanthine (1,7-DMX) Lifestyle biomarker/Metabolite (of caffeine) Cotinine-d3 
7-Aminonitrazepam (AMNITRA) Benzodiazepine/Metabolite (of nitrazepam) Nitrazepam-d5 
Amitriptyline (AMI) Antidepressant EDDP-d3 
Amphetamine (AMP) Stimulant Amphetamine-d5 
Anhydroecgonine methyl ester (AEME) Stimulant/Metabolite (of cocaine) Cocaine-d3 
Benzoylecgonine (BEG) Stimulant/Metabolite (of cocaine) Benzoylecgonine-d8 
Benzylpiperazine (BZP) Stimulant Phencyclidine-d5 
Caffeine (CAFE) Lifestyle biomarker Cotinine-d3 
Cocaethylene (CE) 
Stimulant/Metabolite (of cocaine & alcohol co-
consumption) 
Cocaethylene-d3 
Cocaine (COC) Stimulant Cocaine-d3 
Codeine (COD) Opioid Codeine-d6 
Cotinine (COT) Lifestyle biomarker/Metabolite (of nicotine) Cotinine-d3 
Creatinine (CREAT) Lifestyle biomarker Cotinine-d3 
Desmethylvenlafaxine (DMVENLA) Antidepressant/Metabolite (of venlafaxine) Methamphetamine-d5 
2-(3,4-Dihydroxyphenyl)-N-methylpropylamine (DHMA) Hallucinogen/Metabolite (of MDMA) Amphetamine-d5 
Desmethylvenlafaxine Antidepressant/metabolite (of Venlafaxine) Methamphetamine-d5 
Diazepam (DZP) Benzodiazepines Diazepam-d5 
Dihydrocodeine (DHCOD) Opioid/Metabolite (of codeine) Codeine-d6 
Dihydromorphine (DHMORPH) Opioid/Metabolite(of morphine) Morphine-d6 
2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) Opioid/Metabolite (of methadone) EDDP-d3 
Ephedrine (EPH) Stimulant/Drug precursor 1S,2R-(+)-ephedrine-d3 
Fluoxetine (FLOX) Antidepressant Fluoxetine-d5 
Heroin (HEROIN) Opioid Heroin-d9 
1,4-Hydroxy-3-methoxyampheamine (HMA) Hallucinogen/Metabolite (of MDMA) Amphetamine-d5 
1,4-Hydroxy-3-methoxymethamphetamine (HMMA) Hallucinogen/Metabolite (of MDMA) Methamphetamine-d5 
Hydrocodone (HYCDNE) Opioid Hydrocodone-d6 
Ketamine (KETA) Dissociative agent Ketamine-d4 
Lorazepam (LORAZE) Benzodiazepine Lorazepam-d4 
3,4-Methylene dioxyethyl amphetamine (MDA) Hallucinogen/Metabolite (of MDMA) MDA-d5 
3,4-Methylene dioxyethyl methamphetamine (MDMA) Hallucinogen MDMA-d5 
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3,4-Methylene dioxyethyl ethylamphetamine (MDEA) Hallucinogen MDEA-D5 
Mephedrone (DRONE) Stimulant Mephedrone-d3 
Methadone (MDONE) Opioid Methadone-d9 
Methamphetamine (METH) Stimulant Methamphetamine-d5 
Morphine (MORPH) Opioid Morphine-d6 
Morphine-3b-D-glucuronide Opioid/metabolite (of Morphine) Morphine-3b-D-glucuronide-d3 
Nicotine (NIC) Lifestyle biomarker Cotinine-d3 
Nitrazepam (NITRA) Benzodiazepine Nitrazepam-d5 
Norcodeine (NorCOD) Opioid/Metabolite (of codeine) Codeine-d6 
N-desmethyl-cis-tramadol (NDMTRAM) Opioid/metabolite (of tramadol) Codeine-d6 
Nordiazepam (NorDZP) Benzodiazepines/Metabolite (of diazepam) Nordiazepam-d5 
Norephedrine (NorEPH) Stimulant/Metabolite (of ephedrine) 1S,2R-(+)-ephedrine-d3 
Norfluoxetine (NorFLOX) Antidepressant/Metabolite (of fluoxetine) Fluoxetine-d5 
Norketamine (NorKETA) Dissociative agent/Metabolite (of ketamine) Norketamine-d4 
Normorphine (NorMORPH) Opioid/Metabolite (of morphine) Morphine-d6 
Noroxycodone (NorOXY) Opioid/Metabolite (of oxycodone) Oxycodone-d6 
Nortriptyline (NTRIP) Antidepressant EDDP-d3 
6-monoacetylmorphine (O-6-MAM) Opioid/Metabolite (of heroin) Codeine-d6 
O-desmethyltramadol (O-DMTRAM) Opioid/Metabolite (of tramadol) Codeine-d6 
Oxazepam (OXAZE) Benzodiazepine Oxazepam-d4 
Oxycodone (OXY) Opioid Oxycodone-d6 
Oxymorphone (OMP) Opioid Oxycodone-d6 
4-methoxyamphetamine (PMA) Psychedelic MDA-d5 
Pseudoephedrine (PSE) Decongestant/Stimulant/Precursor 1S,2R-(+)-ephedrine-d3 
Sildenafil (SILD) Phosphodiesterase Type 5 inhibitor EDDP-d3 
Temazepam (TEMAZE) Benzodiazepines Temazepam-d5 
Tramadol (TRAM) Opioid Methamphetamine-d5 
Vardenafil (VARDEN) Phosphodiesterase Type 5 inhibitor Methadone-d9 
Venlafaxine (VENLA) Antidepressant Methamphetamine-d5 
Zolpidem (ZOLP) Z-drugs E1-Zopiclone-d4 
Zopiclone (ZOPI) Z-drugs Zopiclone-d4 
 
Deuterated analogues of target analytes were used as internal standards (IS) as detailed in 
Table 1: amphetamine-d5, benzoylecgonine-d8, cocaine-d3, cocaethylene-d3, codeine-d6, 
cotinine-d3, diazepam-d5, ecgonine methyl ester-d3, EDDP-d3, 1S,2R-(+)-ephedrine-d3, 
heroin-d9, hydrocodone-d6, ketamine-d4, lorazepam-d4, MDA-d5, MDEA-d5, MDMA-d5, 
mephedrone-d3, methadone-d9, methamphetamine-d5, morphine-d6, morphine-3-D-
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glucuronide-d3, nordiazepam-d5, norketamine-d4, oxazepam-d4, oxycodone-d6, temazepam-
d5 and zopiclone-d4. 
The following analytes were purchased and used as racemates: (±)-mephedrone, (±)-4-
hydroxy-3-methoxymethamphetamine (HMMA), (±)-3,4-methylenedioxymethamphetamine 
(MDMA), (±)-4-hydroxy-3-methoxyamphetamine (HMA), (±)-methamphetamine,  
(±)-amphetamine, (±)-3,4-methylenedioxyamphetamine (MDA), (±)-tramadol,  
(±)-desmethylvenlafaxine, (±)-venlafaxine, (±)-3,4-methylenedioxy-N-ethyl-amphetamine 
(MDEA), (±)-ephedrine, (±)-pseudoephedrine, (±)-para-methoxyamphetamine (PMA), (±)-
norephedrine, (±)-norfluoxetine, (±)-zopiclone, (±)-fluoxetine, (±)-3,4-dihydroxy 
methamphetamine (DHMA), (±)-methadone, (±)-ketamine, (±)-norketamine,  
(±)-2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP), (±)-lorazepam, (±)-
temazepam, (±)-oxazepam.  
Enantiomerically pure standard solutions were used for the following analytes: 6-
monoacetylmorphine with five defined stereocentres, oxycodone ((−)-oxycodone), morphine-
3-d-glucuronide, hydrocodone, dihydromorphine, codeine ((−)-codeine), morphine (d-(−)-
morphine), normorphine, heroin, dihydrocodeine ((−)-dihydrocodeine), noroxycodone, 
oxymorphone ((−)-oxymorphone), cocaethylene, cocaine ((−)-cocaine), benzoylecgonine 
((−)-benzoylecgonine) and anhydroecgonine methyl ester (AEME). Compounds synthesised, 
prescribed or used as racemates were purchased as racemates, whilst those prescribed or used 
as a single enantiomer were purchased as a single isomer. All standards and internal 
standards were of the highest purity available (>97%). Stock and working solutions of 
standards were stored at −20
◦
C. Methanol, acetonitrile and ammonium acetate were 
purchased from Sigma–Aldrich, UK. Ultrapure water was obtained from MilliQ (EMD 
Millipore, UK). In order to prevent the adsorption of polar compounds to the hydroxyl sites 
on the glass surface it was treated with DMDCS to deactivate the glass. The process consisted 
of the following steps: rinsing of the glassware with 5% DMDCS once, with toluene twice 
and with methanol thrice with glassware left to dry between each rinse. 
These compounds were originally selected as they represented a mixture of classical drugs of 
abuse, new emerging drugs of abuse and substances with abuse potential (Castrignano, 
Lubben et al. 2016). 
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2.2.Sample collection, preparation and analysis 
24h composite, time proportional, wastewater influent samples were collected every day for 
one week each March from 2014-2018 in accordance with the procedure detailed in the 
following paper (Castrignano, Lubben et al. 2016). The WWTP sampled serves a large city in 
the South West of England equivalent to a population of 886,650 (UK city 1). The week each 
year selected for sampling was chosen so that it contained no significant events such as 
festivals, demonstrations, etc. in UK City 1, cultural events such as Saint Patrick’s Day or 
extraordinary weather events in the South-West of the UK in line with other WBE studies 
(Castiglioni, Bijlsma et al. 2016). This was carried out to ensure that as close to a normal 
week as possible was sampled each year as public holidays will affect rates of consumption 
(van Nuijs, Mougel et al. 2011). Sampling always began on a Wednesday and lasted for 
seven days, i.e. until the following Tuesday. Wastewater flows used to calculate daily drug 
loads are detailed in Table S2.  In brief triplicate samples of either 100 mL (2014) or 50 mL 
(2015-2018) aliquots of composite influent were taken and spiked with 50 µL of deuterated 
internal standard solution at a concentration of 1µg mL
-1
. The pH of wastewater was not 
corrected as this can negatively affect the stability of certain analytes (Castiglioni and Gracia 
Lor 2016) and needed to be left uncorrected for inclusion in a European wide survey of 
wastewater (Gonzalez-Marino et al., 2020), discussed in section 3.3. The spiked samples 
were then filtered through Whatman GF/F filters and loaded onto conditioned Oasis HLB 
SPE cartridges at a rate of 3 mL min
-1
. Cartridges were conditioned with 2 mL methanol 
followed by 2 mL water.  After loading samples, the cartridges washed with 3 mL of MilliQ 
water and then left to dry under vacuum for one hour. Cartridges were then wrapped in 
aluminium foil and stored at -20 
o
C, awaiting analysis, and typically samples were stored in 
this way for a period of up to one month. All samples for one week were defrosted together 
and eluted from cartridge with 4 mL of methanol. . After elution samples were evaporated to 
dryness using a Turbovap evaporator under a stream of N2 and then reconstituted in 0.5 mL 
of 85:15 % v/v 1  mM NH4OAc(aq):MeOH and filtered through 0.2 µM PTFE syringe filters 
directly into the vial for analysis.   
Samples were then analysed via chiral LC-MS/MS in positive electrospray ionisation (ESI+) 
using a ChiralPak CBH column coupled directly to a Waters Xevo TQD mass spectrometer 
using conditions described elsewhere (Castrignano, Lubben et al. 2016). To summarise 
chromatographic conditions were as follows: Isocratic mobile phase of 85:15 %v/v 1 mM 
NH4OAc(aq):MeOH at a flow rate of 0.1 mL min
-1
, a 100 mm x 1.0 mm, 1.7 µm ChiralPak 
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CBH column at 25.0 
o
C with a 0.2 µm PTFE pre-column filter attached. MS analysis was 
performed in multiple reaction monitoring mode. All samples for one year were analysed 
together in a single analytical run within two months of initial sample collection.  
2.3. WBE back-calculations 
Back calculations were performed in accordance with the procedure detailed elsewhere 
(Baker, Barron et al. 2014, Castrignano, Lubben et al. 2016). Briefly concentration values 
obtained from LC-MS analysis were used to calculate the daily load of analyte (eq. 1), the 
population normalised daily load (PNDL, eq. 2) and the daily intake (eq. 3). Where possible 
daily intake was used to compare results and where not possible PNDLs were used instead. 
The final two terms in equation 3, used to calculated daily intake from PNDL, are known as 
correction factors. Excretion and correction factors used are summarised in the table below 
(Table 2). 
Table 2. Correction factors used for calculating daily consumption 






Cocaine Benzoylecgonine  29 3.6 (Gonzalez-Marino, Baz-Lomba et al. 
2020) Amphetamine Amphetamine 36 2.8 
Methamphetamine Methamphetamine 41 2.4 
MDMA MDMA 22.5 4.4 
Mephedrone Mephedrone 15.4 6.5 (Castrignano, Yang et al. 2018) 
Pseudoephedrine Pseudoephedrine 88.0 1.1 
Ephedrine Ephedrine 76.9 1.3 
Heroin 
O-6-MAM 1.3 86.9 (Postigo, Lopez de Alda et al. 2011) 
Morphine 42 3.08 (Gracia-Lor, Zuccato et al. 2016) 
Morphine Morphine 77.7 1.29 (Khan and Nicell 2011) 
Codeine Codeine 29.0 3.45 (Thai, O’Brien et al. 2019) 
Methadone Methadone 22.0 4.55 
Ketamine Ketamine 30.0 3.3 (Yargeau, Taylor et al. 2014) 
Tramadol Tramadol 30.0 3.3 (Mackul’ak, Birosova et al. 2015) 
Temazepam Temazepam 74.5 1.34 (Baker, Barron et al. 2014) 
Venlafaxine Venlafaxine 5.0 20 
Dihydrocodeine Dihydrocodeine 54.0 1.85 
Caffeine 1,7-dimethylxanthine 4.6 23.42 (Gracia-Lor, Rousis et al. 2017) 
Nicotine Cotinine 32.0 3.125 (Mackie, Tscharke et al. 2019) 
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Drug target residue (DTR) refers to the molecule (either drug itself or its metabolite) used to 
calculate daily intake (consumption) and was generally the parent molecule, except where 
specified, e.g. amphetamine was the DTR used for calculating daily intake of amphetamine, 
whilst benzoylecgonine was used instead of cocaine to calculate daily intake of cocaine (see 
table 2 for details). The parent molecule was always used to calculate daily load and PNDL. 
 
𝐷𝑎𝑖𝑙𝑦 𝑙𝑜𝑎𝑑 (𝜇𝑔 𝑑𝑎𝑦−1) = 𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 (𝜇𝑔 𝐿−1) ∗ 𝑊𝑎𝑠𝑡𝑒𝑤𝑎𝑡𝑒𝑟 𝑣𝑜𝑙𝑢𝑚𝑒 (𝐿 𝐷𝑎𝑦−1) −  𝑒𝑞. 1 
𝑃𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝑛𝑜𝑟𝑚𝑎𝑙𝑖𝑠𝑒𝑑 𝑑𝑎𝑖𝑙𝑦 𝑙𝑜𝑎𝑑 (𝑚𝑔 𝑑𝑎𝑦−11000 𝑖𝑛ℎ−1) = 𝐷𝑎𝑖𝑙𝑦 𝑙𝑜𝑎𝑑 ∗ 10−3 ∗ (
1000
𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛
) −  𝑒𝑞. 2 






− 𝑒𝑞. 3 
The use of non-parent molecules as DTRs was necessary for some analytes in order to 
accurately assess the concentration of the parent molecule. The best example of this is the use 
of benzoylecgonine as the DTR of cocaine. Benzoylecgonine as it is the primary metabolite 
of cocaine, which is heavily metabolised before excretion (Zuccato, Chiabrando et al. 2005) 
Similarly, O-6-MAM is often used as the DTR of heroin (Zuccato, Chiabrando et al. 2008, 
Terzic, Senta et al. 2010). The metabolism of heroin and opioids in general is complex as 
many therapeutically used opioids are metabolites of each other (Smith 2009, Barakat, 
Atayee et al. 2012). Despite only a low percentage (<1.5%) of heroin being metabolised and 
excreted as O-6-MAM, it is used because it is a heroin specific metabolite (Postigo, Lopez de 
Alda et al. 2011, van Nuijs, Covaci et al. 2015). Alternatively morphine can be used (Du, 
Zhou et al. 2017), but requires additional information to discriminate between sources of 
morphine. The most comprehensive correction factor has variables include wastewater loads 
of morphine and codeine, the concentration and excretion rates of therapeutic codeine, 
morphine and the percentage of codeine and acetyl codeine in street heroin. A modified form 
of the back-calculation procedure used by Du et al. is used here. The basic principle of both 
approaches is to calculate heroin consumption from morphine by subtracting all other sources 





) from the amount of morphine attributed to heroin 
metabolism.  






 𝑒𝑞. 4 
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Where MORHER is the amount of morphine produced from heroin metabolism, which is 
calculated using equation 5 (eq. 5). ExcretionMOR-HER is the excretion rate of heroin as 
morphine (42 %) (Gracia-Lor, Zuccato et al. 2016) and when multiplied by the ratio of heroin 
and morphine’s molecular weights is equivalent to the correction factor (Correction factor = 
3.08). MORHER can be calculated using equation 5 (eq. 5) where licit morphine (i.e. morphine 
prescriptions) and morphine from codeine metabolism are subtracted from the average daily 
intake of morphine.  
𝑀𝑂𝑅𝐻𝐸𝑅 = 𝑀𝑂𝑅𝑊𝑊 − 𝑀𝑂𝑅𝑃𝑅𝐸𝑆 − (𝐶𝑂𝐷𝑊𝑊 ∗ 𝐸𝑥𝑐𝑟𝑒𝑡𝑖𝑜𝑛𝑀𝑂𝑅−𝐶𝑂𝐷) 𝑒𝑞. 5 
MORWW is the average daily intake of morphine, MORPRES is the average daily prescription 
rate of morphine, CODww is the average daily intake of codeine and ExcretionMOR-COD is the 
amount of morphine produced from codeine metabolism (6.51%) (Khan and Nicell 2011) . 
The original back-calculation procedure by Du et al. examined the contribution from 
therapeutic and illicit sources of codeine and used PNDL of codeine and morphine instead of 
the daily intake. Daily intake of codeine was used under the assumption that it would contain 
all codeine consumed from both licit and illicit sources. However, morphine prescription may 
not be able to adequately capture all licit prescription of morphine due to the data being 
limited to prescriptions from the study city. Therefore, it was possible that users consuming 
licit morphine, or any other prescribed pharmaceutical, that commute into the study city 
would contribute licit morphine into the wastewater supply that would then be misidentified 
as illicit morphine, resulting in an overestimation of heroin consumption. However, as 
morphine is a strong painkiller for treating severe or chronic pain the number of individuals 
contributing licit morphine from outside the catchment is expected to be low and within other 
sources of method error.  
Where MORHER was calculated as a negative value heroin daily intake was assumed to be 
<LOQ. 
Data on daily wastewater volumes and the population of our study city was obtained from the 
city’s wastewater service provider (Table S2).  




Enantiomeric fractions (EFs) were calculated with respect to either the (+)-enantiomer or the 
first eluting enantiomer, E1, where the isomer elution order is not known. For the compounds 
amphetamine, methamphetamine, MDMA, MDA, ephedrine and pseudoephedrine the elution 
order of the isomers is known and EF was calculated using the following equation (eq. 4) 
𝐸𝐹 =  
(+) − 𝑖𝑠𝑜𝑚𝑒𝑟 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛
(+) − 𝑖𝑠𝑜𝑚𝑒𝑟 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 + (−) − 𝑖𝑠𝑜𝑚𝑒𝑟 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛
− 𝑒𝑞. 4 
For all other chiral molecules an alternative equation (eq. 5) was used instead 
𝐸𝐹 =  
𝐸1 − 𝑖𝑠𝑜𝑚𝑒𝑟 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛
𝐸1 − 𝑖𝑠𝑜𝑚𝑒𝑟 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 + 𝐸2 − 𝑖𝑠𝑜𝑚𝑒𝑟 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛
− 𝑒𝑞. 5 
2.5.Statistical analysis 
Data is presented in the form of daily or yearly averages, which was calculated from the 
average from the daily averages for seven consecutive days. When comparing two averages a 
2-tailed t-test was performed and significance determined at a threshold of P≤0.05 and greater 
significance at P≤0.01. When comparing more than two averages ANOVA was performed, 
again at P≤0.05 and P≤0.01 significance thresholds. Most commonly ANOVA was used to 
examine if there was significant variation within a week or across multiple study years before 
t-tests were performed. T-tests were performed on sequential years only, i.e. 2014-2015 or 
2015-2016, to look for significance. T-tests on non-sequential years, i.e. 2014-2016, were 
only performed if ANOVA analysis showed significant variation, but sequential t-tests 
showed no significant variation between sequential years. Statistical analysis was performed 
using IBM SPSS. 
Where analyte concentrations were below limits of quantification (<LOQ) a value of 0.00 
was used for the purposes of ANOVA and non-sequential t-tests were used to compare years 
where the analyte was detected at a quantifiable concentration. Where analytes were not 
detected (<LOD) they were removed from ANOVA calculations.  
A common phenomenon in illicit drug consumption is the presence of a so called “weekend 
effect”, where consumption is significantly greater on the weekend than during the week. For 
the purposes of calculating this Friday-Monday is considered the weekend, whilst Tuesday-
Thursday is considered the weekday (EMCDDA 2020).  
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2.6. Prescription analysis 
 Mass of each compound prescribed in our study region from January 2014–November 2018 
was calculated using an interactive online tool, PrAna (Jagadeesan and Kasprzyk-Hordern, in 
preparation), which displays all primary care prescription data in England down to the 
individual practice level. The data source for PrAna is the monthly prescribing datasets 
published by NHS Digital (https://digital.nhs.uk/). These monthly datasets provide the 
number of items prescribed, the net ingredient cost, actual cost and quantity by 15-digit BNF 
code for each practice. The tool uses quantity, which represents the quantity of a drug 
dispensed and mass of each compound prescribed for each practice is calculated and 
displayed using open source statistical software R (Team R. C., 2013). Data was provided by 
month and further divided by GP surgery, although this higher level of data was not required 
for this study and analysed using the statistical methods in section 2.5 to look for variation 
between months and years. Only GP surgeries that fall within the geographical catchment of 
the sampled wastewater treatment facility were included for this study. For each compound 
included in the study, the monthly prescription data for the whole catchment area was used to 
calculate the average amount prescribed each day for that month (kg day
-1
). The daily 
averages for each month were then used to calculate the daily average for the whole year. The 
average daily prescription for each year was then used to calculate the population normalised 
daily prescription (PNDP) of compound X using equation six (eq. 6). 
𝑃𝑁𝐷𝑃𝑥(𝑚𝑔 𝑑𝑎𝑦
−11000 𝑖𝑛ℎ−1) =  (𝐷𝑎𝑖𝑙𝑦 𝑎𝑣𝑒𝑟𝑎𝑔𝑒)𝑥 ∗  
1000
𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛
∗ 106 𝑒𝑞. 6  
The PNDP of each compound was then comparable to the PNDL and daily intake of that 
compound calculated from wastewater. A limitation of this approach is that compares 
monthly prescription data to daily wastewater data, which may hid any short term changes in 
prescription rates that may be picked up in wastewater. Likewise, there is the assumption that 
everything is prescribed will be taken during the same period, which may not be true for 
medication like antihistamines or painkillers that are taken in response to an outside stimulus, 
like high pollen counts, rather than every day. An additional consideration is the assumption 
that prescriptions from GPs within the catchment will be consumed within the catchment, and 
vice-versa that only compounds prescribed from within the catchment will be consumed. As 
discussed with morphine in section 2.3 this could potentially result in an underestimation and 
an overestimation of consumption, respectively, but is not expected to be significant 
compared to other sources of error. 
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3. Results and discussion 
3.1 Trends in average daily intake 
The simplest way of viewing the results would be to examine the changes in average daily 
intake from 2014 to 2018 (Tables S3 and S4). Viewed this way four compounds had a 
significant decrease (P<0.01) in concentration (heroin, mephedrone, methadone and 
tramadol), two had no significant change in concentration (P>0.05) (amphetamine and 
codeine), and twelve had a significant increase (P<0.01) (cocaine, methamphetamine, 
MDMA, ketamine, hydrocodone, oxymorphone, morphine, temazepam, oxazepam, 
venlafaxine, ephedrine and pseudoephedrine). However, this simplistic view conceals a lot of 
important information on how daily intake changed over the study period.  
Firstly, cocaine was the only compound to have a significant (P<0.05) year on year increase 









 in 2018. Two other 
compounds had a similarly increased daily intake from 2014-2018, with significant increases 
only reported for some years: oxazepam and pseudoephedrine (Figure 2). Average daily 
intake of oxazepam only increased significantly (P<0.01) between 2016 and 2017, whilst for 
pseudoephedrine the only increase (P<0.05) came between 2014 and 2015. In contrast, the 
average daily intake of codeine increased significantly (P<0.05) from 2017-2018 despite no 
significant overall increase in consumption from 2014-2018 (P>0.05).  




Figure 1. Average PNDLs and DIs of illicit drugs (2014-18) (star indicates 2016 NPS bill) 
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Figure 2. Average PNDLs, DIs and prescription of non-opioid pharmaceuticals (2014-18) 
 
Chapter one: Results and discussion (Sections 3.1 and 3.2) 
44 
 
Cocaine exhibited a pronounced weekend effect each year, with significantly greater 
consumption (P<0.01) on weekend days (Friday-Monday) compared to weekday days 
(Tuesday-Thursday). Interestingly the increase in consumption between years was not 
necessarily equally divided across the week, with no significant increase (P>0.05) in weekday 
cocaine consumption between 2015 and 2016 despite an increase in average daily 
consumption between the two years. Only two others compounds also exhibited a 
pronounced weekend effect for the majority of years they were detected: ketamine and 
MDMA.  
The average daily intake of MDMA was more complicated to understand than cocaine’s, as 
despite significant increases (P<0.01) in average daily intake between 2014-2015 and 2017-
2018 there was also a significant decrease (P<0.01) from 2016-2017 and overall there was no 
significant variation between years according to ANOVA (P>0.05). This apparent 
contradiction in MDMA consumption can be explained by its significant (P<0.01) and large 
weekend effect, which meant the data was not normally distributed making ANOVA 
unsuitable for assessing variation between years. Instead the average weekday and weekend 
daily intake were used to determine trends in MDMA consumption. Weekend and weekday 
average daily intake of MDMA both increased significantly (P<0.01) from 2014-2015 and 
2017-2018, in line with the above observations. Additionally, there was then significant 
variation between years by ANOVA (P<0.05). From 2015-2016 however there was a 
significant decrease in weekday average daily intake (P<0.01), whilst weekend intake 
remained constant (P>0.05). This decrease was not previously captured when looking at 
MDMA consumption for the whole week. Similarly, from 2016-2017 there was a significant 
(P<0.01) decrease in weekend average daily intake and an insignificant (P>0.05) decrease in 
weekday average daily intake, resulting in the significant decrease in MDMA consumption 
detailed above. The overall increase in MDMA consumption from 2014-2018 was driven by 
a significant increase in the average daily weekend intake of MDMA, which increased from 








 in 2018 whilst the 
average daily weekday intake did not vary significantly (P>0.05).   
Meanwhile ketamine consumption was more similar to cocaine than MDMA, with a less 
pronounced weekend effect. Ketamine average daily intake increased each year from 2015-
2018 and each of these years also exhibited a significant weekend effect (P<0.05). However, 
like with cocaine, the year on year increase was not equally distributed between weekend and 
weekday consumption with no significant increase (P>0.05) in weekend consumption of 
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ketamine between 2016 and 2017 despite an overall increase in average daily intake. Unlike 
cocaine and MDMA, ketamine is used medicinally, so some of this consumption could be the 
result of licit consumption. However, the presence of a weekend effect in most years 
suggested that it was likely being used recreationally. 
The most common trend in average daily intake was exemplified by temazepam (Figure 2), 
which had a significant decrease (P<0.01) in year on year daily intake from 2015-2016, 
where it was <LOQ in 2016, and then significant increases (P<0.01) between 2016-2017 and 
2017-2018 and no weekend effect. Oxymorphone and hydrocodone (Figure 3) both had 
similar trends in average daily intake, with an initial significant decrease (P<0.05) in 
consumption from 2015-2016, below LOQ PNDLs in 2016 and then a significant increase in 
consumption from 2016-2018 (P<0.01), leading to an overall increase in average daily intake 
from 2014-2018. Temazepam and hydrocodone also had a significant increase (P<0.01) in 
average daily intake between 2017 and 2018. Hydrocodone is a metabolite of codeine 
(Barakat, Atayee et al. 2012) as well as a prescription opioid in its own right. As codeine and 
hydrocodone had different overall trends in PNDL this suggested that the hydrocodone being 
detected resulted from hydrocodone consumption rather than codeine metabolism. For all 
these compounds the trend in consumption suggested that they were overall becoming more 
widely used despite an initial period of decreasing or variable use. In contrast, morphine 
(Figure 4) and venlafaxine (Figure 2), which also had an overall increase in daily intake from 
2014-2018, behaved oppositely with an initial significant increase (P<0.01) in daily intake 
followed by a significant decrease (P<0.01). This suggested that usage of morphine and 
venlafaxine were then decreasing after an initial period of increased consumption.  
 




Figure 3. Average PNDLs of oxymorphone and hydrocodone (2014-18) 




Figure 4. Average PNDLs, DIs and prescription of opioid pharmaceuticals (2014-18) 
Tramadol had a pattern of alternating consumption with tramadol consumption significantly 
decreasing (P<0.01) from 2014-2018 and between every year except from 2016-2017. The 
EF of tramadol increased over the study period with a significant increase (P<0.01) from 
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2017-2018, despite a significant decrease from (P<0.01) 2015-2016, resulting in a racemic 
mixture of both enantiomers in 2018. Similar to tramadol, methadone exhibited an overall 
decrease with alternating trends in intake with a year decrease between 2015-2016 and a year 
on year increase from 2016-2017. Regrettably methadone’s deuterated internal standard was 
not detected in 2018 samples so methadone could not be quantified for this year of the study, 
although it was detected.  Despite an overall downwards trend in consumption across the 
study period, the alternating changes in daily intake suggested that consumption of these 
compounds was in a state of flux. Further monitoring and non-wastewater data sources would 
be necessary to see if this state of flux will continue or develop into broader trends. Heroin 
had a simpler pattern of consumption with average daily intake decreasing significantly 
(P<0.01) from 2014-2018 and between every year (P<0.05) except between 2014 and 2015 
where there was a significant increase (P<0.05) in average daily intake. This supports other 
observations that the number of injectable drug users was decreasing (EMCDDA 2018) to 
suggest heroin was becoming a less popular drug of abuse. Despite having a similar pattern of 
consumption as morphine, which was used along with codeine to calculate heroin 
consumption, the two compounds behaved different overall with morphine consumption 
increasing significantly (P<0.01) from 2014-2018 whilst heroin consumption decreased 
significantly (P<0.01) over the same period. In contrast, if heroin daily intake was calculated 
using O-6-MAM then the daily intake was observed to increase significantly (P<0.01) 
between 2014-2018 with an alternating pattern of consumption similar to temazepam, 
oxazepam and hydrocodone. In this case the calculation of heroin consumption using 
morphine and codeine is likely more accurate than the calculation using O-6-MAM, 
particularly as the greatest O-6-MAM PNDLs occurred in 2017-2018 when heroin 
consumption from morphine was at its lowest level. Furthermore, using O-6-MAM lead to 




 in 2017 and 2018, which is roughly 
140-300% greater than consumption of cocaine, amphetamine, methamphetamine and 
MDMA combined in the same year and is therefore extremely unlikely to be accurate, 
particularly as heroin is meant to be less popular than cocaine in the UK (EMCDDA 
2018).Therefore, further work is needed  to accurately determine heroin consumption as the 
use of O-6-MAM seems to lead to an overestimation, and the approach of using morphine 
and codeine prescription and wastewater data (Du, Zhou et al. 2017) is still relatively novel 
and requires further work to validate its suitability and robustness.  
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Overall there was no significant change in amphetamine consumption (P>0.05) between 2014 
and 2018, with the only significant change during the period being a significant decrease 
(P<0.01) in average daily intake between 2016 and 2017 and significant variation by 
ANOVA (P<0.01). The EF of amphetamine was similarly stable across the period of 2014-
2018, with a significant increase from 2014-2015 (P<0.05) and a significant decrease 
(P<0.05) from 2017-2018 resulting in no net change in EF. The only year with a significant 
weekend effect (P<0.01) was 2017, where the decrease in weekday average daily intake of 
amphetamine was greater than the decrease in weekend average daily intake. Therefore, 
amphetamine consumption seemed very stable across the study period. 
Lastly, the absence of mephedrone (Figure 1) from 2016 onwards and its static average daily 
intake from 2014-2015 suggested that it was no longer being widely consumed five years 
after first being regulated as a Class B drug of abuse. For the two years it was detected there 
was no significant change (P>0.05) in EF or any evidence of a weekend effect for 
mephedrone. The continued use of mephedrone after regulation was expected, as a survey of 
users said they were planning on continuing to use mephedrone (Winstock, Mitcheson et al. 
2010). In contrast, other NPS that were regulated in the same manner and at the same time as 
mephedrone, such as synthetic cannabinoids, usually disappeared relatively quickly and were 
replaced with a structural analogue (Bijlsma, Ibanez et al. 2017). Mephedrone can be viewed 
as evidence of successful, if delayed, drug policy and, although not successful with all drugs 
of abuse, showed that regulation can lead to a cessation of consumption.  
3.2 The use of prescription data 
NHS prescription data was available for roughly half of the analytes detected, which allowed 
for greater insight into the trends discussed above. This was particularly useful for assessing 
opioids as there were disparity in trends of average daily intake of heroin (decreasing) and 
morphine (increasing). Codeine displayed excellent agreement between wastewater and 
prescription data (Figure 4), whilst tramadol and methadone displayed similar trends of 
decreasing average daily intake in wastewater and decreasing prescription rates. In both cases 
the wastewater concentration of tramadol and methadone were lower than the prescription 
data would suggest. Whilst most commonly associated with the treatment of opioid addiction, 
methadone is also prescribed for treating chronic pain, as is tramadol and as such they may be 
taken in response to pain rather than continuously. This could result in a lower wastewater 
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concentration as not all the tramadol or methadone prescribed will be consumed if it is being 
used periodically as part of chronic pain management.  
In contrast venlafaxine and pseudoephedrine (Figure 2) had higher wastewater concentrations 
than would be expected from prescriptions, although both prescription and wastewater 
concentrations underwent the same trend of decreasing or stable consumption, respectively. 
Pseudoephedrine is available without a prescription or “over the counter” from a pharmacist 
and this may explain its relatively greater wastewater concentration. Alternatively, this could 
be evidence of the use of pseudoephedrine in clandestine manufacture of methamphetamine 
(Pal, Megharaj et al. 2012). However, this is unlikely as methamphetamine in Europe is not 
generally produced in the UK and methamphetamine is not a popular drug in the UK, which 
suggests low demand (EMCDDA 2019). As an antidepressant venlafaxine is not available in 
the UK without a prescription, however its availability online and associated abuse has been 
reported previously (Francesconi, Orsolini et al. 2015). Rates of antidepressant prescription 
were rising in the decades prior to the study period and were expected to continue increasing 
(Mars, Heron et al. 2017). The UK has been experiencing a period of political economic 
austerity since 2010 including across the period of 2014-2018, and under similar 
circumstances in other European countries this has led to an increase in prescriptions of 
antidepressants and other drugs to treat mental health (Thomaidis, Gago-Ferrero et al. 2016). 
In line with expectations venlafaxine prescription rates did increase significantly each year 
(P<0.01), although prescription rates of other antidepressants (amitriptyline and fluoxetine) 
did not change significantly (P>0.05) from 2014-2018 (Table S4). Increasing demand for 
antidepressants coupled with the online availability of venlafaxine and its relatively lower 
cost, compared to NHS prescriptions, could explain the mismatch between prescription and 
wastewater data. Ultimately, the reason behind the discrepancy in wastewater and 
prescription data is unclear, but what is important is that the trends in both of them are the 
same, which helps to provide important context to the results. 
Of greater concern were those compounds for which prescription rates were decreasing from 
2014-2018 but wastewater concentrations were increasing: morphine, temazepam and 
oxazepam. There was a significant difference between wastewater and prescription 
concentrations of morphine (P<0.01). However, this could have been the result of morphine 
production from opioid metabolism, such as codeine and heroin, although the discrepancy is 




. Prescription rates of diamorphine (figure 4) were low 
and stable throughout the study period in contrast to large decreases in the average daily 
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intake of heroin, but as it is a drug of abuse it was not surprising that diamorphine 
prescription would not match wastewater concentrations. Temazepam and oxazepam (Figure 
2) prescriptions rates were a lot lower than their wastewater concentrations. This was likely 
due to the interconversion of benzodiazepines during metabolism, where oxazepam is a 
metabolite of temazepam, which is in turn a metabolite of diazepam (Whirl-Carrillo, 
McDonagh et al. 2012). From prescription data diazepam also had significantly decreasing 
(P<0.01) rates of prescription. Additionally, prescription of nitrazepam and lorazepam also 
decreased significantly (P<0.01) across the study period suggesting that all benzodiazepines 
were being prescribed less not just those detected in wastewater. It is important to note that 
nitrazepam and lorazepam have a different metabolic pathway to the other benzodiazepines 
discussed here. Benzodiazepines can be purchased online, which would result in prescription 
data underestimating consumption, however a review of availability in Europe suggested that 
prescriptions were the main source of benzodiazepines for non-medical use in the UK 
(Lyphout, Yates et al. 2019). Overall this suggested that benzodiazepines were being abused 
in greater quantities from 2016-2018, but the magnitude and source of this abuse was difficult 
to quantify. Prescription data was not available for other opioids with similar trends 
(oxymorphone and hydromorphone).  
Whilst not detected above LOQ for most of the study period comments can be made about 
the use of Z-drugs and PDE-5 inhibitors from their prescription data. Prescription rates of 
sildenafil (Viagra) increased significantly (P<0.05) each year from 2014-2018, whilst 
prescription rates of the vardenafil (Levitra) decreased significantly each year (P<0.05), 
except from 2015-2016. Zopiclone prescription rates decreased each year and zolpidem 
prescription rates decreased between 2014-2015 and 2017-2018. As Z-drugs are 
pharmacologically similar to benzodiazepines it seemed logical that there would be similar 
trends in how they were prescribed. 
3.3 A European perspective 
A recent publication of European wastewater data covering the period of 2011-2017 provided 
crucial context for the result of this study (Gonzalez-Marino, Baz-Lomba et al. 2020), with 
additional data for 2018 available online from the EMCDDA. The European study reported 
the average daily intake of benzoylecgonine (cocaine), amphetamine, methamphetamine and 
MDMA over a period of one week for several European cities (Figure 5) with our UK city 
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contributing data from 2014-2018. In 2011 the most abundant drugs were amphetamine and 
cocaine, followed by methamphetamine and MDMA, which also had similar abundance.  
 
Figure 5. Average PNDL in Europe of benzoylecgonine (BEG), amphetamine (AMP), 
methamphetamine (METH) and ecstasy (MDMA) (2011-2018). All cities refers to all cities 
that contributed to the study that year, 5 year cities refers to cities that contributed to the 
study each year from 2014-2018, UK City 1 is the city studied in this manuscript. 
From 2011-2014 the sum total of all four analytes decreased by ≈60 % and the relative 
abundance of cocaine increased from ≈40% to ≈66% of the total drug load. From 2014-2018 
the total drug load and % BEG increased reaching a maximum in 2017 before decreasing 
slightly in 2018 to approximately the same levels as 2016. If only the cities that contributed 
every year from 2014-2018, excluding our study city, (5-year cities) are included then the 
total drug load and % BEG continued to increase in 2018. Overall the paper noted several 
trends exhibited in European drug use: 
1) Cocaine use increased year on year 
2) MDMA consumption increased intermittently over the period of 2014-2018 
3) Amphetamine use was only increasing in Northern Europe, Belgium and the 
Netherlands  
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This helped to provide context for illicit drug consumption in our study city. Firstly, whilst 
cocaine usage was increasing in Europe it was increasing faster in the UK, as evidenced by a 
much greater % BEG compared to the 5-year cities from 2015 onwards, despite a very similar 
% BEG in 2014. This suggested that there were UK specific factors driving the increase in 
cocaine consumption, causing it to increase at a greater rate than in Europe. Conversely 
sequential year t-tests of weekday and weekend MDMA consumption showed that there was 
a significant increase (P<0.01) in the use of MDMA in the UK across the study period, which 
agreed with European observations. Additionally the source of MDMA in the UK appeared to 
be from consumption rather than from disposal or manufacturing, which has been observed in 
Dutch cities, as the EFs of MDMA were consistent (P>0.05) and non-racemic (Emke, Evans 
et al. 2014). Additionally, UK drug consumption of amphetamine and methamphetamine 
matched expected spatial trends within Europe with amphetamine usage remaining constant, 
and low but increasing usage of methamphetamine, which was the least abundant of these 
four drugs of abuse.  
3.4 UK specific trends in consumption 
European data on cocaine, amphetamine, methamphetamine and MDMA usage showed that 
drug consumption was decreasing from 2011-2014 and then increased slowly before 
appearing to stabilise in 2018. However, for the UK the rate of total drug consumption 
increased significantly (P<0.01) over the period of 2014-2018 and continued increasing 
instead of stabilising. In 2016 the NPS bill was brought into force, banning the use of all 
novel psychoactive substance except those compounds either covered by existing regulations, 
such as medicines or drugs of abuse, or specifically exempted, like caffeine or nicotine. The 
majority of compounds analysed as part of this manuscript exhibited a decrease in average 
daily intake from 2014-2016, i.e. before the bill came into law, but then exhibited an increase 
in average daily intake from 2016-2018.  
Venlafaxine, pseudoephedrine, codeine, heroin, cocaine, amphetamine and MDMA did not 
exhibit a significant decrease (P<0.05) from 2014-2016, with all except amphetamine, 
codeine and heroin actually undergoing a significant increase (P<0.01) in consumption. Then 
from 2016-2018 only amphetamine, morphine, heroin and pseudoephedrine did not 
experience a significant increase (P<0.05) in average daily intake, with morphine, heroin and 
pseudoephedrine consumption decreasing significantly (P<0.01). The volume of wastewater 
used in the study did decrease from 100 mL to 50 mL between 2014 and 2015, and for some 
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compounds with low abundance, such as methamphetamine, this could explain their apparent 
decrease. However, this would still not explain why concentrations of so many analytes 
increased after 2016 when the population of our city had not changed.  
Whilst it is still too early to assess the impact of the 2016 NPS bill, particularly as this study 
did not try and analyse contemporary NPS such as synthetic cannabinoids, the observed 
increase in drug consumption was concerning. Heroin, methadone and mephedrone were the 
only compounds to have a significantly lower (P<0.01) average daily drug intake after 2016, 
whilst consumption of amphetamine and tramadol did not significantly change (P>0.05). 
None of the drugs of abuse included in this study were regulated any more heavily over the 
study period, so a potential reason for the increased consumption is that drug users migrated 
from NPS to more “popular” drugs of abuse such as cocaine and ketamine, both of which saw 
their average daily intake quadruple across the study period. This was also observed by the 
UK government in its review of the 2016 NPS bill and concluded that there was not enough 
data to support this (Home Office, 2018), although this review did not include an assessment 
of wastewater. Whilst no conclusive this report does support the observations that there has 
been an increase in Class A drug use. Further work would be necessary to determine if this 
effect was UK wide as previous studies of other countries have revealed differences in drug 
consumption depending on city size and socioeconomic factors (Been, Lai et al. 2016, Choi, 
Tscharke et al. 2019). 
The agreement between wastewater and prescription data concerning decreasing consumption 
of tramadol and largely unchanged consumption of codeine, were positive as, at time of 
writing, other countries, like the United States of America, were combatting an ongoing 
opioid epidemic centred on abuse of prescription opioids (Cicero, Ellis et al. 2015, 
Champagne-Langabeer, Madu et al. 2019, Cicero, Ellis et al. 2020). Likewise, decreasing 
consumption of methadone combined with decreasing consumption of heroin was positive. 
Available non-wastewater data from the EMCDDA showed that the number of heroin users, 
as well as the number of injectable drug users in general, was decreasing across the study 
period (EMCDDA 2018). Available data on heroin pricing and purity in Europe showed that 
both purity and cost had dropped by 13 % and 20 % respectively from 2007-2017 (European 
Monitoring Centre for Drugs and Drug Addiction and Europol 2019). Whilst this decrease in 
price could be expected to lead to an increase in heroin users, available data suggested that 
heroin was price inelastic (Olmstead, Alessi et al. 2015) and as such demand would not be 
expected to increase, which matched what was observed in wastewater.  




Consumption of illicit drugs of abuse has generally increased from 2014 to 2018 particularly 
for cocaine, methamphetamine and ketamine and this cannot purely be explained by either 
wider European drug trends, or increased prescription of licit forms of the drug. Likewise, 
increasing consumption of cocaine in the wake of the 2016 NPS bill could not be purely 
explained by increasing consumption across Europe.  
The benefits of combining unique prescription and wastewater data were shown by the ability 
of both to explain apparently misleading trends identified in one another. This was 
particularly beneficial for compounds with pharmaceutically active metabolites like opioids 
and for identifying sources of morphine to estimate heroin consumption. Additionally, for 
compounds with controlled prescription like methadone, trends in consumption by 
wastewater and trends in prescription correlated to show that there is a link between what is 
prescribed and what is consumed. This shows that wastewater-based epidemiology is a 
powerful tool for examining whole populations and determining the efficacy and direction of 
government actions on health, as it can, alongside prescription and wider monitoring data, 
provide a clear insight into what is being consumed by a population and what action is 
needed to meet required goals.  
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Table S1. Selected analytes and their properties 
Compound CAS Formula MW Supplier 
1,7-dimethylxanthine 611-59-6 C7H8N4O2 180.2 Sigma-Aldrich 
2-(3,4-Dihydroxyphenyl)- 
N-methylpropylamine (DHMA) 
15398-87-5 C10H15NO2 181.2 Kinesis 
2-ethylidene-1,5-dimethyl- 
3,3-diphenylpyrrolidine (EDDP) 
30223-73-5 C20H23N 277.4 LGC (Cerilliant product) 
3,4-methylenedioxy 
amphetamine (MDA) 
4764-17-4 C10H13NO2 179.2 LGC (Cerilliant product) 
3,4-methylenedioxy 
ethylamphetamine (MDEA) 
82801-81-8 C12H17NO2 207.3 LGC (Cerilliant product) 
3,4-methylenedioxy 
methamphetamine (MDMA) 
42542-10-9 C11H15NO2 193.2 LGC 
6-acetylmorphine 2784-73-8 C19H21NO4 327.4 
Sigma Aldrich 
(Cerilliant product) 
7-aminonitrazepam 4928-02-3 C15H13N3O 251.3 
Sigma Aldrich  
(Cerilliant product) 
Amitriptyline 549-18-8 C20H23N 277.4 Sigma-Aldrich 
Amphetamine 300-62-9 C9H13N 135.2 LGC (Cerilliant product) 
Anhydroecgonine  
methyl ester 
43021-26-7 C10H15NO2 181.2 
Sigma Aldrich  
(Cerilliant product) 
Benzoylecgonine 519-09-5 C16H19NO4 289.3 Sigma-Aldrich 
Benzylpiperazine 2759-28-6 C11H16N2 176.3 LGC 
Caffeine 58-08-2 C8H10N4O2 194.2 Sigma-Aldrich 
Cocaethylene 529-38-4 C18H23NO4 317.4 
Sigma Aldrich  
(Cerilliant product) 
Cocaine 50-36-2 C17H21NO4 303.4 LGC (Cerilliant product) 
Codeine 76-57-3 C18H21NO3 299.4 Sigma-Aldrich 
Cotinine 486-56-6 C10H12N2O 176.2 
Sigma Aldrich  
(Cerilliant product) 
Creatinine 60-27-5 C4H7N3O 113.1 Sigma-Aldrich 
d,l-4-Hydroxy-3-methoxy 
amphetamine (HMA) 
13062-61-8 C10H15NO2 181.2 Kinesis 
d,l-4-Hydroxy-3-methoxy 
methamphetamine (HMMA) 
438625-58-2 C11H17NO2 195.2 Kinesis 
Desmethylvenlafaxine 93413-62-8 C16H25NO2 263.4 Sigma-Aldrich 
Diazepam 439-14-5 C16H13ClN2O 284.7 
Sigma Aldrich  
(Cerilliant product) 
Dihydrocodeine 125-28-0 C18H23NO3 301.4 
Sigma Aldrich  
(Cerilliant product) 
Dihydromorphine 509-60-4 C17H21NO3 287.4 
Sigma Aldrich  
(Cerilliant product) 
Ephedrine 50-98-6 C10H15NO 165.2 Sigma-Aldrich 
Fluoxetine 59333-67-4 C17H18F3NO 309.3 LGC (Cerilliant product) 
Heroin 561-27-3 C21H23NO5 369.4 
Sigma Aldrich  
(Cerilliant product) 
Hydrocodone 125-29-1 C18H21NO3 299.4 
Sigma Aldrich  
(Cerilliant product) 
Ketamine 1867-66-9 C13H16ClNO 237.7 Sigma-Aldrich 
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Lorazepam 846-49-1 C15H10Cl2N2O2 321.2 
Sigma-Aldrich  
(Cerilliant product) 
Mephedrone 1189726-22-4 C11H15NO 177.7 
Sigma-Aldrich ( 
Cerilliant product) 
Methadone 76-99-3 C21H27NO 309.4 
Sigma Aldrich  
(Cerilliant product) 
Methamphetamine  4846-07-5 C10H15N 149.2 LGC (Cerilliant product) 
Morphine 57-27-2 C17H19NO3 285.3 
Sigma Aldrich  
(Cerilliant product) 
Morphine-3β-D-glucuronide 20290-09-9 C23H27NO9 461.5 
Sigma Aldrich  
(Cerilliant product) 
N-Desmethyltramadol 1018989-94-0 C15H23NO2 249.4 LGC 
Nicotine 54-11-5 C10H14N2 162.2 Sigma-Aldrich 
Nitrazepam 146-22-5 C15H11N3O3 281.3 LGC (Cerilliant product) 
Norcodeine 467-15-2 C17H19NO3 285.3 
Sigma Aldrich (Cerilliant 
product) 
Nordiazepam  1088-11-5 C15H11ClN2O 270.7 
Sigma Aldrich  
(Cerilliant product) 
Norephedrine 154-41-6 C9H13NO 151.2 Sigma-Aldrich 
Norfluoxetine 107674-50-0 C16H16F3NO 295.3 LGC (Cerilliant product) 
Norketamine  79499-59-5 C12H14ClNO 223.7 
Sigma Aldrich  
(Cerilliant product) 
Normorphine 466-97-7 C16H17NO3 271.3 
Sigma Aldrich  
(Cerilliant product) 
Noroxycodone 52446-25--0 C17H19NO4 301.2 
Sigma Aldrich  
(Cerilliant product) 
Nortriptyline 894-71-3 C19H21N 263.4 Sigma-Aldrich 
O-Desmethyltramadol 185453-02-5 C15H23NO2 249.4 LGC 
Oxazepam 604-75-1 C15H11ClN2O2 286.7 
Sigma-Aldrich  
(Cerilliant product) 
Oxycodone 76-42-6 C18H21NO4 315.4 
Sigma Aldrich  
(Cerilliant product) 
Oxymorphone 76-41-5 C17H19NO4 301.3 
Sigma Aldrich  
(Cerilliant product) 
PMA (Para-methoxyamphetamine) 3706-26-1 C10H15NO 165.0 LGC 
Pseudoephedrine 321-97-1 C10H15NO 165.2 Sigma-Aldrich 
Sildenafil 139755-83-2 C22H30N6O4S 474.6 
Sigma Aldrich  
(Cerilliant product) 
Temazepam 846-50-4 C16H13ClN2O2 300.7 
Sigma Aldrich  
(Cerilliant product) 





Sigma Aldrich  
(Cerilliant product) 




99294-93-6 C19H21N3O 307.4 
Sigma Aldrich  
(Cerilliant product) 
Zopiclone 43200-80-2 C17H17ClN6O6 388.8 LGC 
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Table S2. Daily wastewater flows 
Day 





2014 2015 2016 2017 2018 
Wednesday 214,229.0 198,950.0 215,806.5 292,715.1 231,919.2 
Thursday 208,782.0 197,523.0 307,513.8 284,589.0 227,280.6 
Friday 208,644.0 252,682.0 304,422.3 246,701.7 217,694.7 
Saturday 204,287.0 220,687.0 294,425.1 223,340.4 225,110.7 
Sunday 198,221.0 193,194.0 271,405.8 212,575.5 230,450.4 
Monday 199,012.0 197,493.0 249,774.3 208,015.2 218,876.4 
Tuesday 216,049.0 204,491.0 235,544.4 211,186.8 219,577.5 
 
Table S3. Daily PNDLs 
Compound 
Average PNDL (mg day/1000 inh) 
2014 2015 2016 2017 2018 
Benzoylecognine (BEG) 
Average 248.2973 306.303 390.4124 754.7391 969.2295 
+/- 21.33318 15.82813 14.82511 21.31492 28.63601 
Amphetamine (AMP) 
Average 83.06841 82.80847 93.6493 53.75748 121.0263 
+/- 8.268261 4.750731 7.140431 2.148553 16.24645 
Methamphetamine (METH) 
Average 2.104612 1.256922 0 41.36523 8.673653 
+/- 1.153871 0.875313 0 24.95339 1.134556 
3,4-methylenedeoxyamphetamine 
(MDA) 
Average 2.208702 1.947971 0 0.804672 0 
+/- 1.835686 0.466986 0 0.111187 0 
3,4-methylenedeoxy 
methamphetamine (MDMA) 
Average 31.46043 53.2289 51.71856 33.04484 46.9303 
+/- 2.010495 2.956396 2.781761 1.058683 0.948299 
4-hydroxy-3-methoxy 
methamphetamine (HMMA) 
Average 8.128021 15.44585 0 55.50796 0 
+/- 1.186781 0 0 2.843198 0 
Caffeine 
Average 38.58803 44.74016 41.99957 52.15982 52.77973 
+/- 1.94694 0.789701 2.378755 1.551367 3.208756 
1,7-dimethylxanthine (1,7-DMX) 
Average 24.51775 60.14676 83.10163 99.23699 112.7096 
+/- 4.425167 2.006441 6.309632 4.845674 6.683458 
Nicotine ((-)-NIC) 
Average 1.423007 1.696898 2.625194 5.550752 7.179193 
+/- 0.7798 0.111869 0.527135 2.109184 0.815735 
  




Average 0.506785 0.487587 0.413297 0.468155 0.54007 
+/- 0.093108 0.021205 0.018833 0.014314 0.022275 
Creatinine (CREAT) 
Average 0.088253 0.204459 0 0.180037 0.209353 
+/- 0.017113 0.029252 0 0.016912 0.019039 
Codeine (COD) 
Average 486.0118 460.5703 389.6839 456.3295 570.6245 
+/- 45.01354 30.59654 35.09607 21.8931 19.19197 
Norcodeine (NorCOD) 
Average 0 0 0 54.57926 0 
+/- 0 0 0 1.065644 0 
Noroxycodone (NorOXY) 
Average 5.83519 7.44451 0 56.87295 0 
+/- 3.021134 1.772931 0 0.531392 0 
Hydrocodone (HYCDNE) 
Average 3.525357 7.388551 0 137.968 268.6697 
+/- 5.438296 2.710745 0 23.21353 5.375476 
Oxymorphone (OXYMORPH) 
Average 4.854138 5.439319 0 45.70448 0 
+/- 2.702657 1.327378 0 0.406306 0 
Morphine (MORPH) 
Average 145.1919 290.368 260.9531 226.6823 225.8408 
+/- 9.629086 49.29619 9.004827 1.585444 2.498178 
Normorphine (NorMORPH) 
Average 36.83189 318.7468 0 239.9074 0 
+/- 9.958646 3.413121 0 9.857387 0 
Dihydromorphine (DHMORPH) 
Average 6.341436 0 0 3.922981 0 
+/- 1.574158 0 0 0.54557 0 
Dihydrocodeine (DHCOD) 
Average 98.76037 68.70265 45.37795 36.02608 0.056805 
+/- 11.1793 5.156476 6.060355 2.212172 0.00369 
Methadone (MDONE) 
Average 12.57207 13.79809 8.551855 11.55235 0 
+/- 1.137421 0.896985 0.790081 0.466848 0 
Tramadol (TRAM) 
Average 324.1231 225.9863 101.0895 228.4439 101.3231 
+/- 13.51263 16.94739 14.01864 13.76417 5.25227 
Temazepam (TEMAZE) 
Average 65.7856 25.14433 0 68.58208 714.7638 
+/- 25.32444 3.645201 0 8.840072 113.9894 
  




Average 24.13408 0 0 111.1557 86.65784 
+/- 25.33208 0 0 5.909581 10.02523 
Venlafaxine (VENLA) 
Average 45.20403 38.76657 81.1626 130.3215 85.206 
+/- 3.767817 3.665721 3.872556 7.28028 2.238418 
Ketamine (KETA) 
Average 62.13813 27.91556 102.5845 118.564 205.3144 
+/- 3.561798 1.800038 5.618439 3.207801 4.778964 
Vardenafil (VARDEN) 
Average 0.224454 0 0 59.25679 0 
+/- 0.288584 0 0 5.39497 0 
1S,2R-(-)-Ephedrine (EPH) 
Average 5.285351 0 0 0 31.79748 
+/- 1.059189 0 0 0 3.327085 
1R,2R-(+)-Pseudoephedrine 
(PSE) 
Average 39.15167 96.4653 109.3234 0 72.70608 
+/- 3.423638 19.22876 12.98509 0 7.374135 
Norephedrine (NorEPH) 
Average 0 3.416569 0 0 0 
+/- 0 0.924007 0 0 0 
Desmethyl venlafaxine 
(DSMVENLA) 
Average 120.658 0 0 337.7837 405.5399 
+/- 5.190345 0 0 33.68885 29.62472 
Para-methoxyamphetamine 
(PMA) 
Average 0 0 0 241.2251 0 
+/- 0 0 0 21.0044 0 
Cocaine (COC) 
Average 115.0255 160.2827 12.98584 445.4593 554.8532 
+/- 6.703992 6.474846 0.892027 11.50117 13.26825 
Cocaethylene (CE) 
Average 1.085241 7.556583 10.70124 15.22374 25.14734 
+/- 0.099369 0.967827 0.957959 0.526797 0.717654 
Anhydroecgonine methyl ester 
(AEME) 
Average 2.064846 3.326668 0 28.97084 0 
+/- 0.370081 0.758871 0 0.614639 0 
Heroin (HEROIN) 
Average 14.08867 0 0 4.016655 0 
+/- 16.09458 0 0 0 0 
6-monoacetly morphine (O-6-
MAM) 
Average 0.962679 0.855209 0 76.80896 66.12448 
+/- 0.766139 0 0 0.335485 1.824299 
  




Average 14.73284 25.70685 0 0 0 
+/- 3.028567 6.908809 0 0 0 
 
Table S4. Daily intake 
Compound 
Average daily intake (mg day/1000 inh) 
2014 2015 2016 2017 2018 
Cocaine 
(Using BEG PNDL) 
Average 578.53 713.69 909.66 1758.54 3489.23 
+/- 49.71 36.88 34.54 49.66 66.72 
Amphetamine 
(Using AMP PNDL) 
Average 274.13 273.27 309.04 177.40 338.87 
+/- 27.29 15.68 23.56 7.09 45.49 
Methamphetamine 
(Using METH PNDL) 
Average 4.84 2.89 0.00 95.14 20.82 
+/- 2.65 2.01 0.00 57.39 2.72 
3,4-methylenedeoxy 
methamphetamine 
(Using MDMA PNDL) 
Average 138.43 234.21 227.56 145.40 206.49 
+/- 8.85 13.01 12.24 4.66 4.17 
Caffeine 
(Using 1,7-DMX PNDL) 
Average 573.72 1407.43 1944.58 2322.15 2637.40 
+/- 103.55 46.95 147.65 113.39 156.39 
Nicotine 
(Using COT PNDL) 
Average 1.58 1.52 1.29 1.46 1.69 
+/- 0.29 0.07 0.06 0.04 0.07 
Codeine 
(Using COD PNDL) 
Average 1676.74 1588.97 1344.41 1574.34 1968.65 
+/- 155.30 105.56 121.08 75.53 66.21 
Dihydrocodeine 
(Using DHCOD PNDL) 
Average 182.71 127.10 83.95 66.65 0.11 
+/- 20.68 9.54 11.21 4.09 0.01 
Morphine  
(Using MORPH PNDL) 
Average 187.30 374.57 336.63 292.42 291.33 
+/- 12.42 63.59 11.62 2.05 3.22 
Methadone 
(Using MDONE PNDL) 
Average 57.20 62.78 38.91 52.56 0.00 
+/- 5.18 4.08 3.59 2.12 0.00 
Tramadol 
(Using TRAM PNDL) 
Average 1079.33 752.53 336.63 760.72 337.41 
+/- 45.00 56.43 46.68 45.83 17.49 




(Using VENLA PNDL) 
Average 904.08 775.33 1623.25 2606.43 1704.12 
+/- 75.36 73.31 77.45 145.61 44.77 
Ketamine 
(Using KETA PNDL) 
Average 205.06 92.12 338.53 391.26 677.54 
+/- 11.75 5.94 18.54 10.59 15.77 
1S,2R-(-)-Ephedrine 
(Using EPH PNDL) 
Average 6.87 0.00 0.00 0.00 41.34 
+/- 1.38 0.00 0.00 0.00 4.33 
1R,2R-(+)-Pseudoephedrine 
(Using PSE PNDL) 
Average 43.07 106.11 120.26 0.00 79.98 
+/- 3.77 21.15 14.28 0.00 8.11 
Heroin 
(Using O-6-MAM PNDL) 
Average 83.66 74.32 0.00 6674.70 5746.22 
+/- 66.58 0.00 0.00 29.15 158.53 
Heroin  
(Using MORPH AND 
CODEINE) 
Average 143.59 628.07 221.74 90.86 27.87 
+/- 40.81 179.42 53.40 25.70 13.54 
Mephedrone 
(Using DRONE PNDL) 
Average 95.76 167.09 0.00 0.00 0.00 
+/- 19.69 44.91 0.00 0.00 0.00 
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Diamorphine 1.52 0.24 1.35 0.52 0.67 0.14 0.52 0.07 0.52 0.16 










207.16 7.92 189.56 5.48 
Ephedrine 0.12 0.04 0.13 0.07 0.10 0.01 0.10 0.04 0.11 0.03 
Fluoxetine 150.01 6.74 153.43 5.74 154.16 6.48 156.37 6.00 156.22 4.06 
Lorazepam 1.39 0.07 1.31 0.08 1.21 0.08 1.10 0.05 1.04 0.04 
Methadone 73.31 3.19 76.16 4.01 79.58 3.18 77.52 3.18 77.98 3.22 
Morphine 174.78 7.74 178.66 8.21 181.95 6.94 172.64 5.77 161.95 3.84 
Nicotine 4.71 0.77 3.35 0.82 2.79 0.41 2.41 0.34 1.99 0.24 
Nitrazepam 3.06 0.19 2.52 0.15 2.26 0.09 2.03 0.14 1.76 0.06 
Oxazepam 1.23 0.12 1.12 0.15 1.03 0.23 0.85 0.12 0.65 0.09 
Oxycodone 35.47 2.12 36.30 1.63 38.75 2.23 40.43 2.41 40.40 1.58 
Pseudoephedrin
e 
5.27 0.97 4.23 0.81 3.59 0.63 2.82 0.62 1.73 0.57 
Sildenafil 22.92 4.54 38.03 3.69 45.77 2.81 49.86 2.38 52.73 1.61 
































Zolpidem 2.86 0.14 2.71 0.13 2.75 0.17 2.67 0.14 2.47 0.12 
Zopiclone 25.08 0.88 23.70 1.17 22.58 0.87 21.38 0.55 20.21 0.61 
 
Table S6. Average weekend and weekday PNDL (mg day-1 1000 inh-1) 
Year Day 
Cocaine PNDL MDMA PNDL Ketamine PNDL 
Average SD Average SD Average SD 
2014 
Weekday 192.52 18.36 17.27 4.43 61.58 5.91 
Weekend 290.13 70.21 85.00 10.90 62.56 3.84 
2015 
Weekday 238.43 14.95 21.66 4.10 25.69 2.65 
Weekend 358.04 95.54 76.91 34.62 29.53 4.37 
2016 
Weekday 254.62 93.29 15.39 8.56 89.14 39.48 
Weekend 491.12 150.24 75.91 53.46 114.61 23.79 
2017 
Weekday 549.85 109.80 13.70 1.60 112.69 14.11 
Weekend 908.40 190.53 47.55 22.59 122.97 20.80 
2018 
Weekday 744.93 118.18 16.90 1.26 174.50 20.65 
Weekend 1137.45 209.54 69.93 34.23 228.43 6.15 
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Caffeine PNDLs did not show much change over the study period only increasing 
significantly from 2014-2015 but caffeine was not consistently used across the week (Fig S1-
2), with weekly significant variation every year. Caffeine’s major urinary metabolite, 1,7-
dimethylxanthine (1,7-DMX), followed the same overall pattern of stable usage year on year, 
except from 2014-2015 where there was no significant change in PNDLs of 1,7-DMX. Like 
with caffeine there was no clear weekly pattern of excretion (Fig S3).  
Nicotine usage was similarly static across the study period with significant increase only 
between 2015 and 2016 and significant weekly variation observed for every year except 2014 
(Fig S3). Trends in PNDLs of cotinine, the main urinary nicotine metabolite, were broadly 
similar as could be expected of a metabolite. The only significant increase in loads of cotinine 
was between 2017 and 2018, and there was significant weekly variation for every year except 
2015. Significant public health initiatives are centred on reducing rates of smoking and data 
shows that the prevalence of smoking is decreasing [ONS report]. Between 2014 and 2017 
the percentage of adults who smoked in the United Kingdom decreased from 18.1% to 
15.1%, with our study city having a below average result of 11.1% in 2017. Similarly, the 









































2014 to 5.5% in 2017. Whilst smokers and e-cigarettes users are not mutually exclusive 
groups the increased use of e-cigarettes could explain why nicotine and cotinine loads are not 
decreasing despite the number of adults who smoke decreasing. This could potentially point 
to increasing rates of smoking among a decreasing population, but further data on consumer 
spending would be required to determine this as current data only asks if a participant smokes 
and not how much. Alternatively, as the amount of nicotine per dose/puff of an e-cigarette 
can be programmed, then users could potentially be consuming more nicotine and so 
contributing more to wastewater loads than a tobacco smoker. Again more data would be 
required to determine an exact cause of this discrepancy but in either case this highlights the 
power of WBE for understanding the reality of what is being consumed rather than the more 
abstract model of extrapolating individual trends to understand the whole population, which 
is important for determining if government health strategies are effective. 





Figure S3. Average PNDL and DI of (i) caffeine and its metabolite 1,7-DMX, and (ii) 
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Chapter two introduction 
In chapter one the was focus was on introducing the use of local prescription data for providing 
context to wastewater data and showcasing the importance of chirality in determining the source of 
drugs of abuse and confirming the human consumption of analytes. In chapter two the narrative 
changes from an examination of human health to investigating environmental health by investigating 
the environmental stability and toxicity of the four isomers of ephedrine. As such, chapter two directly 
explores the first aim of the thesis as laid out in the introduction, including an assessment of chirality 
for determining the source of an analyte. 
The objective of chapter two was to examine the stability of each isomer of ephedrine under 
environmental conditions and how this would impact assessments of its environmental toxicity, which 
currently only examines the diasteromers ephedrine and pseudoephedrine. Additionally, the paper 
explores an observation from literature that ephedrine isomers may interconvert to form different 
isomers. 
The initial intention of chapter two was to investigate both the environmental persistence and toxicity 
of each isomer of ephedrine and its metabolite nor-ephedrine, using a combination of river water 
microcosms and EC50 toxicity tests kits. A series of follow-up single isomer microcosm experiment 
were then performed to investigate if ephedrine isomers could interconvert under environmental 
conditions, which has been hypothesised to occur during wastewater treatment. The paper concludes 
by using human liver microsomes to check if ephedrine interconversion could occur during human 
metabolism, whilst a retrospective analysis of river water was used to investigate if ephedrine could 
be formed from other sources, such as the metabolism of cathinones. An additional interpretation 
section is provided at the end of the chapter (page 149), which includes statistical information 
surround ephedrine degradation that was not provided in the paper but is usefully in assessing the 
significance of the observations reported in the paper.
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Stereochemistry of ephedrine and its environmental 
significance: exposure and effects directed approach 
Jack Rice, Kathryn Proctor, Luigi Lopardo, Sian Evans, Barbara Kasprzyk-Hordern
1
 
Department of Chemistry, University of Bath, Bath BA2 7AY, UK 
ABSTRACT 
Analysis of drugs and pharmaceuticals in the environment is typically performed with non-chiral 
chromatographic techniques. The environmental risks posed by chiral compounds analysed in this 
way must therefore be assumed to be independent of chirality, meaning that each enantiomer is 
equally potent in toxicity and long-lived in stability. This manuscript examines the degradation of 
each of the four isomers of ephedrine in river simulating microcosms and links this to toxicity data 
obtained by exposing three different organisms (D. magna, P. subcapitata and T. thermophila) to 
each of the isomers individually. Microcosms showed that significant degradation only occurred in 
biotic conditions and that only two isomers (1R,2S-(-)-ephedrine, 1S,2S-(+)-pseudoephedrine) 
degraded significantly over a period of fourteen days. This is concerning because at least one of the 
non-degraded isomers (1S,2R-(+)-ephedrine) has been observed in wastewater effluent, which 
discharges directly into rivers, meaning these isomers could be persistent in the environment. We also 
observed formation of 1S,2R-(+)-ephedrine in single isomer 1R,2S-(-)-ephedrine river simulating 
microcosms. Human liver microsome assays and mass spectrometry based data mining revealed that 
1S,2R-(+)-ephedrine is not human derived but it could be formed as a results of microbial metabolic 
processes. Across all three organisms tested the persistent isomers (1S,2R-(+)-ephedrine and 1R,2R-(-
)-pseudoephedrine) were more toxic than those that undergo degradation; meaning that if these 
isomers are entering or formed in the environment they might represent a potentially hazardous 
contaminant. 
KEYWORDS: chiral, pharmaceuticals, wastewater, environment, river, enantiomeric profiling, 
enantiomeric fractions 
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Stereoselective degradation of 1R,2S-(-)-ephedrine (left) and 1S,2S-(+)-pseudoephedrine (right) under 
biotic conditions in river simulating microcosms.  
1. Introduction 
Ephedrine has two chiral centres and can therefore exist in the form of four stereoisomers: 1R,2S- 
(-)-ephedrine, 1S,2R-(+)-ephedrine, 1S,2S-(+)-pseudoephedrine and 1R,2R-(-)-pseudoephedrine 
(Table 1). However, only two stereoisomers: 1R,2S-(-)-ephedrine and 1S,2S-(+)-pseudoephedrine are 
believed to exist in natural sources such as ephedra. 1R,2S-(-)-ephedrine finds wide applications as a 
bronchodilator to treat bronchospasm associated with asthma, bronchitis and emphysema. It is also 
abused for its stimulant properties. 1S,2S-(+)-pseudoephedrine is used as a decongestant [1]. 
Table 1. Studied chemicals and their properties 































































Ephedrine has been detected previously in environmental matrices [2; 3] but with the usage of non-
enantioselective methodology, which did not allow for stereoisomeric profiling of ephedrine. As a 
result this did not allow for an accurate assessment of the possible effects ephedrine might have on the 
environment. Stereoisomeric profiling is of vital importance as different stereoisomers of ephedrine 
differ significantly in potency, 1R,2S-(-)-ephedrine has much higher stimulant properties than 1S,2S-
(+)-pseudoephedrine, and possibly also in toxicity to certain organisms.  
In our previous study [1], a verification of the enantiomer-specific fate of ephedrine isomers was 
undertaken in a full scale WWTP and in receiving waters. Of the two enantiomers of (±)-ephedrine 
only the natural 1R,2S-(-)-ephedrine enantiomer was frequently detected. However, ‘non-natural’ 
1S,2R-(+)-ephedrine was detected at low levels in only certain WWTPs throughout the sampling 
campaign, mainly in treated wastewater, which might suggest stereoselective processes occurring 
during treatment (e.g. chiral inversion although there is currently no experimental evidence to support 
this claim) leading to enrichment of ephedrine with 1S,2R-(+)-enantiomer. It is worth noting that the 
most prevalent formation of 1S,2R-(+)-ephedrine occurred during spring/summer time due to 
potentially higher activity of microorganisms. The possibility of chiral inversion occurring during 
treatment is of critical importance in understanding the fate of ephedrines in the environment and has 
to be studied further.  
The verification of cumulative concentrations of ephedrines in raw wastewater indicated that higher 
levels of these compounds were observed during winter time (reaching 180 g/day in February in all 
studied WWTPs) than during summer time (< 80 g/day in August) [1; 4]. Interestingly, the analysis of 
diastereomeric fractions (DFs) of natural 1R,2S-(-)-ephedrine and 1S,2S-(+)-pseudoephedrine in raw 
wastewater revealed that over the winter months ephedrines were enriched with 1S,2S-(+)-
pseudoephedrine. This is possibly due to higher usage of over-the-counter medications (containing 




1S,2S-(+)-pseudoephedrine) for the treatment of mild symptoms of cold. During the spring and 
summer months a reverse situation was observed as ephedrine was found to be enriched with a much 
more potent stimulant, 1R,2S-(-)-ephedrine. This is a very important finding indicating that non-
enantioselective measurement of ephedrines cannot be a reliable indicator of actual potency of 
ephedrines in the environment. Higher cumulative concentrations of ephedrines, which are enriched 
with less potent 1S,2S-(+)-pseudoephedrine (as was observed during winter time in this study) might 
be of lower environmental significance than lower concentrations of ephedrines enriched with much 
more potent 1R,2S-(-)-ephedrine (in summer in this study). Furthermore, wastewater treatment 
resulted in almost all cases in further enrichment of ephedrines in the aqueous phase with more potent 
1R,2S-(-)-ephedrine, with an average increase in DFs from 0.25 in raw wastewater to 0.35 in treated 
wastewater. Interestingly, the monitoring of receiving waters revealed that ephedrine was enriched 
with 1R,2S-(-)-ephedrine at the beginning of the course of the river and its DFs decreased over the 
course of the river indicating an increase of 1S,2S-(+)-pseudoephedrine (e.g. during the August 
sampling campaign DF of ephedrine denoted 0.93±0.03 at the beginning of the river course and 
decreased to 0.33±0.03 over 50 km downstream); a reverse situation to the one observed during 
wastewater treatment. This might indicate that different microbial communities are responsible for 
transformation of ephedrines during wastewater treatment and in the environment.  
The absence of 1S,2R-(+)-ephedrine in influent wastewater suggests that it is not formed by 
metabolism of ephedrine in humans. However previous research into human metabolism of ephedrine 
was not carried out in a stereoselective manner and is mostly limited to 1R,2S-(-)-ephedrine, rather 
than the more prescribed and environmentally abundant 1S,2S-(+)-pseudoephedrine. Metabolic data 
indicates that 1R,2S-(-)-ephedrine is excreted primarily unchanged, with norephedrine and other 
metabolites forming in smaller quantities [5; 6]. Whilst literature data was not available for the 
metabolism of other ephedrine isomers in humans, metabolism of 1S,2R-(+)-ephedrine in rabbits and 
rabbit liver microsomes was observed to be slower than metabolism of 1R,2S-(-)-ephedrine [7]. 
Whilst this shows that a metabolic preference for the naturally occurring isomer, which may be 
important for the formation of synthetic isomers in the environment, rabbit metabolism of ephedrine is 
different from human metabolism with only a small percentage of (±)-ephedrine excreted [7; 8] or 
isolated from rabbit liver microsomes [7]. 
Our previous research raises several questions undermining validity of widely accepted environmental 
risk assessment procedures for pharmacologically active compounds. This includes lack of 
appreciation of the phenomenon of chirality in environmental risk assessment (ERA) for human and 
veterinary medicines [9; 10]. This paper attempts to answer the most urgent questions regarding the 
significance of stereochemistry of pharmaceuticals (using stereoisomers of ephedrine as a model 
example) in the context of their environmental fate and effects. To the authors’ knowledge this is the




 first report tackling stereoselective transformation of ephedrines in river simulating microcosms and 
associated enantiomer-specific ecotoxicity. 
2. Experimental  
2.1. Chemicals and materials 
Reference standards: 1R,2S-(-)-ephedrine [(-)-Eph], 1S,2R-(+)-ephedrine [(+)-Eph], 1S,2S-(+)-
pseudoephedrine [(+)-Pse], 1R,2R-(-)-pseudoephedrine [(-)-Pse], 1R,2S-(-)-norephedrine [(-)-NorEph] 
and 1S,2R-(+)-norephedrine [(+)-NorEph] were of ≥98% purity and were purchased from Sigma-
Aldrich (Gillingham, UK). Surrogate/internal standards (SS/IS): 1S,2R-(+)-ephedrine-d3 (CAS No. 
285979-73-9) and R/S-(±)-methamphetamine-d5 (CAS No. 60124-88-1, were purchased from Sigma 
Aldrich (Gillingham, UK) and Toronto Research Chemicals (Canada) respectively (Table 1). All 
surrogate/internal standards were added to the samples before extraction and were also used for the 
quantification of the analytes.  
2.2. Sample preparation and analysis  
Chiral drugs were extracted from surface water (50 mL) using Solid-Phase Extraction (SPE)  and 
Oasis HLB cartridges (Waters, UK). All samples were spiked with 50 ng of each surrogate/internal 
standard and filtered with GF/F filters. Analytes were then eluted with 4 mL of MeOH and the 
extracts evaporated to dryness under nitrogen with a TurboVap evaporator (Caliper, UK, 40
o
C, N2, 5-
15 psi) and reconstituted in 0.5 mL of mobile phase.  
Waters ACQUITY UPLC
TM
 system (Waters, Manchester, UK) equipped with Chiral-CBH column, 
100x2mm, 5µm (Chromtech, Congleton, UK) and Chiral-CBH 10x2.0mm guard column (Chromtech, 
Congleton, UK) were used for the analysis of enantiomers of ephedrines. The separation of 
ephedrines was undertaken using two different methods depending on the experiment. Samples from 
river simulating microsom experiments were analysed using the method described by Evans et al. [11] 
. The elution order of the four ephedrine isomers was: 1S,2R-(+)-ephedrine, 1R,2R-(-)-
pseudoephedrine, 1R,2S-(-)-ephedrine, 1S,2S-(+)-pseudoephedrine. Samples from human liver 
microsome experiments were using the method described by Castrignanò et al. [12]. The elution order 
of the four ephedrine isomers was the same as in the previous method, but with co-elution of 1R,2S-(-
)-ephedrine and 1R,2R-(-)-pseudoephedrine. This co-elution was not considered a hindrance for the 
analysis undertaken in the human liver microsome experiments. An injection volume of 20 µL was 
used in both experiments. Method validation parameters for both methods are summarised in Tables 
S1-4. 
A XevoTQD (triple quadrupole) mass spectrometer (Waters, Manchester, UK) equipped with an 
electrospray ionisation source (ESI) was used for the quantification of ephedrines in both methods. 
The analyses were performed in ESI positive mode using multiple-reaction monitoring (MRM). 




Nitrogen was used as the nebulising gas at a flow rate of 500 L/Hr, supplied by a high-purity nitrogen 
generator (Waters, Manchester, UK). Argon (99.998%) was used as the collision gas and supplied by 
BOC cylinder. MassLynx 4.1 (Waters, UK) and TargetLynx (Waters, UK) software was used to 
collect and analyse the obtained data.  
The relative concentration of enantiomers of chiral drugs was expressed as the enantiomeric fraction 
(EF) and was calculated with the following equation:  
𝐸𝑞𝑢𝑎𝑡𝑖𝑜𝑛 1: 𝐸𝐹 =  
𝐶(+)−𝑒𝑛𝑎𝑛𝑡𝑖𝑜𝑚𝑒𝑟
𝐶(+)−𝑒𝑛𝑎𝑛𝑡𝑖𝑜𝑚𝑒𝑟 +  𝐶(−)−𝑒𝑛𝑎𝑛𝑡𝑖𝑜𝑚𝑒𝑟 
  
Where C-(+)-enantiomer and C-(-)-enantiomer are concentrations for the (+) and (-) enantiomers of 
(±)-ephedrine or (±)-pseudoephedrine. EF equals 1 or 0 in the case of single enantiomer form and 0.5 
in the case of racemate.  






) and chemical oxygen demand (COD) were 
quantified to assess environmental conditions at the time of sampling and for experimental 
monitoring. Commercially available testing kits (purchased from Merck) were used and 
concentrations determined photochemically utilising a Merck Spectroquant
®
 Pharo 300 
spectrophotometer. Collected surface water was tested before spiking with ephedrine and again after a 
two week testing period. 
2.3. River simulating microcosm experiments 
2.3.1. Mixed river simulating microcosms 
Mixed compound microcosm experiments were conducted to investigate the fate of ephedrines at an 
enantiomeric level due to biodegradation, photodegradation and other abiotic processes including 
sorption. River water for the microcosm bioreactor experiments was collected from a large river in the 
South-West of the UK in November.  
Degradation experiments were conducted with and without light, to study photochemical and physical 
processes, e.g. hydrolysis and sorption, and with or without sodium azide, as an inhibitor to biotic 
processes (see Figure S1). Eight conical flasks, made of borosilicate 3.3 glass with no visible light 
absorption and UV light cut-off at <275 nm, were used as bioreactors in all microcosm experiments 
and were autoclaved prior to use. All were subsequently spiked with 1μg/L each of 1S,2R-(+)-
ephedrine, 1R,2S-(-)-ephedrine, 1S,2S-(+)-pseudoephedrine, 1R,2R-(-)-pseudoephedrine, 1R,2S-(-)-
norephedrine and 1S,2R-(+)-norephedrine in methanol, which was allowed to evaporate. 
Norephedrine was tested alongside ephedrines as it is the primary metabolite of ephedrine [5]. 
Microcosms were then filled with 2L of unfiltered river water and four were spiked with sodium azide 
to a concentration of 1g/L to inhibit biotic processes (Abiotic Reactors). Four bioreactors remained 
un-spiked in order to allow biotic processes to occur (Biotic Reactors). Two biotic and two abiotic 




reactors were then wrapped in aluminium foil (Dark Reactors) and the remaining two biotic and two 
abiotic reactors left uncovered (Light Reactors). To limit outside contamination of the microcosms, all 
eight were plugged at the top with cotton wool, as this still allowed for the flow of air into the 
microcosm. Finally each reactor had a magnetic stirrer bar added and were placed onto unheated 
magnetic stirring pads at the lowest speed that allowed a vortex to form. 
Daylight conditions were simulated using an Osram400W powerstar® HGI®-BT daylight lamp, 
which was switched on for eight hours each day to mimic average sunlight conditions in the UK. The 




 per microamp of illumination at the 2L mark of a 2L conical flask, 





microamp of illumination at the bottom of a dry 2L conical flask, with the probe directly facing the 
light source. All light intensity measurements were made using a LI-250A light meter with a quantum 
sensor. In order to decrease the effect of heat generated by the lamp all the microcosms, including 
those in the dark, were cooled using fans to ensure a roughly equal temperature inside each 
microcosm.  
Samples were taken at regular intervals (once per day) over a fifteen-day sampling period and 
analysed as detailed by Evans et al. [11]. Other parameters analysed during the sampling period 
included dissolved oxygen (DO), pH, temperature, COD, ammonium, nitrate and nitrite (Figure S2). 
2.3.2. Single-isomer ephedrine river simulating microcosms 
Single ephedrine microcosms were carried out as an extension of the river water simulating 
microcosms described in 2.3.1, to examine the effects of chirality on ephedrine degradation. The 
microcosms were set up as described previously using river water collected from a large river in the 
South West of the UK in February and spiked with 1μg/L of either 1R,2S-(-)-ephedrine or 1S,2S-(+)-
pseudoephedrine, the naturally occurring isomers. Eight microcosms were prepared in total (see 
Figure S3) four containing 1R,2S-(-)-ephedrine and four containing 1S,2S-(+)-pseudoephedrine. For 
each set of four single ephedrine microcosms two were wrapped in foil (Dark Reactors) and the others 
left exposed to eight hours a day of simulated daylight (Light Reactors) from an Osram400W 
powerstar® HGI®-BT daylight lamp as described previously.  
Samples were taken at regular intervals (once per day) over a fifteen-day sampling period and 
analysed as detailed by Evans et al. [11]. Other parameters analysed during the sampling period 
included dissolved oxygen (DO), pH, temperature, COD, ammonium, nitrate and nitrite (Figure S4). 
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2.4. Human liver microsome metabolism 
Human liver microsomes (HLMs) were set-up in accordance to the method described by Lopardo et 
al. [13] and were performed in duplicate for both 1R,2S-(-)-ephedrine and 1S,2S-(+)-
pseudoephedrine, with each isomer examined in isolation. Metabolism studies were carried out to 
investigate if human metabolism of either ephedrine isomer lead to the formation of any other isomer. 
Currently available data on (±)-ephedrine metabolism in humans suggests that if metabolised 
ephedrine will primarily undergo hydroxylation or demethylation [5; 6]. The microsomes were 
incubated for a total of six hours as this matched the expected in vitro half-life of 1R,2S-(-)-ephedrine 
[5]. To determine absolute ephedrine and norephedrine isomer concentrations the samples were 
analysed as described by Castrignanò et al. [12].  
2.5. Retrospective analysis with UHPLC-QTOF – screening for precursors of 1S,2R-(+)-ephedrine 
River water samples collected during seven consecutive days in South-West England were analysed in 
accordance to the method described by Lopardo et al. [13]. Briefly, river water samples were filtered 
using GF/F  glass microfibre filter 0.75 µm (Fisher Scientific, UK) followed by a solid phase 
extraction (SPE) using HLB Oasis® cartridges Water, UK) and concentrated 400-fold. Extracts were 
then dried under nitrogen using a TurboVap evaporator (Caliper, UK, 40◦C). Dry extract was then 
reconstituted in 250 µL 80:20 H2O:MeOH, transferred to polypropylene vials. 
A Dionex Ultimate 3000 HPLC (Thermo Fisher UK Ltd.) coupled with a Bruker Maxis HD Q-TOF 
(Bruker) equipped with an electrospray ionization source was utilized for the analysis of extracts. ESI 
positive and negative mode acquisition was performed in broadbandCID acquisition mode. HyStar™ 
Bruker was used to coordinate the LC-MS system. Chromatographic separation and MS source 
conditions are described by Lopardo et al. [13]. 
After analysis, data extracted from the Bruker system were processed with MetID software 
(Advanced Chemistry Development, Inc., ACD/Labs, UK) in order to predict metabolite structures.  
2.6. Toxicity testing 
2.6.1. Daphnia magna toxicity tests 
The experiment was performed using Daphtoxkit F Magna (Laboratory for Biological Research in 
Aquatic Pollution, Ghent University, Belgium) in accordance with test procedures prescribed by 
national and international organizations (OECD test no. 202 [14]).  
24h to 48h EC50 (or LC50) bioassays were performed in multiwell test plates starting from neonates, 
uniform in size and in age, hatched from ephippia. In order to provide the neonates hatched from the 
ephippia with food prior to the test, a 2h “pre-feeding” was applied with a suspension of Spirulina 
micro-algae. Each ephedrine isomer was tested individually at the following concentrations 7.8, 15.6, 
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31.3, 62.4, 125, 250, 500, 1000 mg/L. These were prepared by serial dilution of an initial 1g/L 
ephedrines solution with standard fresh water [14]. For a statistically acceptable evaluation of the 
effects each test concentration, as well as the control, were assayed in four replicates of five neonates. 
Daphnia magna neonates were incubated at 20-22
o
C for 48 hours and the number of dead or 
immobilised organisms was counted after 24 and 48 hours. The EC50/LC50 is the concentration where 
50% of the Daphnia are dead or immobilised, determined by if they can swim freely after gently 
agitating the solution.  
2.6.2. Pseudokirchneriella subcapitata toxicity tests 
The experiment was performed using Algaltoxkit F (Laboratory for Biological Research in Aquatic 
Pollution, Ghent University, Belgium) in accordance with test procedures prescribed by national and 
international organizations (e.g. ‘Algal growth inhibition test’ (OECD Guideline 201 [15]) and the 
ISO "Water Quality - Freshwater Algal Growth Inhibition Tests with Unicellular Green Algae" (ISO 
Standard 8692). A 72h algal growth inhibition test was performed with Pseudokirchneriella 
subcapitata de-immobilized from algal beads. The test is based on the measurement of the optical 
density of algal cell suspensions (at 670 nm) in spectrophotometric cells of 10 cm path-length. Optical 
densities were then converted into algal numbers with the aid of the regression formula. The algae 
density was measured by photometry absorbance at 670 nm and it was diluted with culturing medium 
to achieve a density of 1.10
6
. Each ephedrine isomer was individually diluted to a concentration of 
500 mg L
-1
, 300 mg L
-1
, 160 mg L
-1
, 50 mg L
-1
, 5 mg L
-1
 and 0 mg L
-1
 with culturing medium.  Algae 




.  25 mL of this solution was placed in 
10 cm spectrophotometer cells, in triplicate.  The absorbance was measured every 24 hours after 
agitation to re-suspend the algae.  They were stored at 20 °C under cool white fluorescent lamps in a 
random order. The data was statistically analyzed using the Algaltox kit F Data treatment ErC50 
spreadsheet. 
2.6.3. Tetrahymena thermophila toxicity tests 
The 24 h protozoan growth inhibition bioassay was performed using Protoxkit F (Laboratory for 
Biological Research in Aquatic Pollution, Ghent University, Belgium). Tetrahymena thermophila 
were chosen for toxicity testing due to their sensitivity to a variety of emerging organic contaminants 
at environmentally relevant concentrations, as well as their position within the ecosystem and the 
potential for further bioaccumulation [16].  
The test was carried out in disposable spectrophotometric cells of 1 cm path-length to measure 
changes in optical density (OD) at 440nm. Each test cell contains T. thermophila ciliate inoculum 
(40uL), food substrate (40uL) and known concentration of the isomer or isomers being tested in 
synthetic freshwater (pH 7.75±0.19, 2mL). The OD measurements were taken at T0h and at T24h. At 
T0h the turbidity of the test cell will be high due to the food substrate. Over 24h the turbidity will 




drastically decrease as the uninhibited growth of the ciliates will consume the food substrate. The 
degree of inhibition can be calculated from the difference in OD between the control cells and the test 
cells after 24 hours.  
A preliminary investigation was carried out for 1R,2S-(-)-ephedrine and 1S,2S-(+)-pseudoephedrine 
to ascertain the approximate range between 100% inhibition and uninhibited growth across 4 orders of 
magnitude. Based on these results (see Supplementary Table 14 and 17), further definitive tests were 
carried out for each isomer between the lowest concentrations with a population growth inhibition of 
80-100% and the highest concentration with an inhibition between 0-20%. To ensure the tests were 
valid each concentration was examined in duplicate and the control had to reach 60% OD decrease 
after 24h. Some test required an extra 2-4 hours to reach the validation criteria, which was batch 
dependent and indicated a slightly slower growth of the ciliates. The EC50 values for this study were 
calculated using 28h results.  
3. Results and discussion 
3.1. Stereoselective degradation of a mixture of ephedrine stereoisomers in river simulating 
microcosms 
Degradation of a mixture of all four ephedrine stereoisomers and norephedrine enantiomers was 
studied in well-defined laboratory river water microcosm experiments. The following parameters 
were investigated: microbial degradation, photochemical reactions as well as other physicochemical 
processes such as sorption. 
As can be observed from Figure 1 during a 14-day period (±)-ephedrine degradation only occurs in 
biotic microcosms, which indicates that microbial metabolic processes are the main degradation 
pathway for this compound in the environment (under studied experimental conditions). It is worth 
noting that the rate of biodegradation is higher in dark biotic microcosms than in those exposed to 
light. This shows that ephedrine is photostable under the experimental conditions. Furthermore, biotic 
degradation of ephedrine shows high stereoselectivity favouring degradation of natural 1R,2S-(-)-
ephedrine and leading to enrichment of (±)-ephedrine with synthetic 1S,2R-(+)-enantiomer.  This 
process is much more pronounced in dark biotic microcosms.  







Figure 1. Mixed-compound river simulating microcosms – (±)-ephedrine degradation under dark abiotic 
(DAR), dark biotic (DBR), light abiotic (LAR) and light biotic (LBR) conditions (concentrations are represented 
by bars, enantiomeric fractions are represented by symbols). See tables S10-S13 for raw data. 
Pseudoephedrine was found to degrade in a similar manner to ephedrine (Figure 2). It shows high 
photostability in both biotic and abiotic microcosms and no changes in enantiomeric composition 
were observed in both light and dark abiotic microcosms, whilst microbial metabolic processes are 
effective in the degradation of pseudoephedrine. These processes show high stereoselectivity with 
preferential degradation of 1S,2S-(+)-pseudoephedrine and subsequent enrichment of 
pseudoephedrine with synthetic 1R,2R-(-)-enantiomer. Similarly to ephedrine, degradation of 
pseudoephedrine is faster and shows higher stereoselectivity in the absence of external light. The 
increased rate of 1R,2S-(-)-ephedrine and 1S,2S-(+)-pseudoephedrine degradation in the biotic dark 
microcosms compared to biotic light might be due to the growth of algae in the presence of light and 





























































































































































































































Figure 2. Mixed-compound river simulating microcosms – pseudoephedrine degradation under dark abiotic 
(DAR), dark biotic (DBR), light abiotic (LAR) and light biotic (LBR) conditions (concentrations are represented 
by bars, enantiomeric fractions are represented by symbols). See tables S10-S13 for raw data. 
 
Similar to ephedrine and pseudoephedrine, degradation of norephedrine was observed in the biotic 
microcosms only indicating an importance of microbial metabolic processes (Figure 3). (±)-
Norephedrine was examined in this experiment due to its potential importance as a breakdown 
product of (±)-ephedrine in animals and man [5-8], however significant (±)-norephedrine formation 
has not been observed in either of the biotic microcosms. Daily pH, temperature and dissolved oxygen 
(DO) measurements on each microcosms showed little variation between replicate samples (Figure 






































































































































































































Figure 3. Mixed-compound river simulating microcosms – norephedrine degradation under dark abiotic (DAR), 
dark biotic (DBR), light abiotic (LAR) and light biotic (LBR) conditions (concentrations are represented by 
bars, enantiomeric fractions are represented by symbols). See tables S10-S13 for raw data. 
 
3.2. Single 1R,2S-(-)-ephedrine or 1S,2S-(+)-pseudoephedrine river simulating microcosms 
In the light of the observed extensive biodegradation of naturally occurring 1R,2S-(-)-ephedrine and 
1S,2S-(+)-pseudoephedrine, single isomer 1R,2S-(-)-ephedrine or 1S,2S-(+)-pseudoephedrine river 
simulating microcosms were undertaken to verify if chiral inversion leading to the formation of non-
natural 1S,2R-(+)-ephedrine or 1R,2R-(-)-pseudoephedrine can occur in the aqueous environment 
(Figure S3). Formation of 1S,2R-(+)-ephedrine was observed in a single-isomer biotic-light 1R,2S- 
(-)-ephedrine microcosm (Figure S5). It is important to note that the river water used in the 
microcosm experiments did not contain any ephedrine isomers prior to the start of the experiment. 
The observed peak passed method identification criteria, including retention time and MRM transition 
ratios, and is possibly formed as a result of chiral inversion, albeit after long residence time of 14 days 
and despite limited degradation of 1R,2S-(-)-ephedrine (Figure S6). Whilst not completely definitive 
this is a very important result, as it matches the observation of Kasprzyk-Hordern and Baker [1] 
showing formation of 1S,2R-(+)-ephedrine after biological wastewater treatment. The limited 
















































































































































































































rainfall and low biomass content) has hindered the observation of metabolite formation within early 
stages of the experiment.  
3.3. Human liver microsome assays to verify human metabolism of 1R,2S-(-)-ephedrine and 1S,2S-
(+)-pseudoephedrine 
Kasprzyk-Hordern and Baker [1] observed formation of 1S,2R-(+)-ephedrine after biological 
wastewater treatment. Human liver microsomes assays were utilized to verify any human contribution 
to environmental occurrences of 1S,2R-(+)-ephedrine, via stereoselective metabolic processes of 
ephedrine isomers including chiral inversion.  
Across the six hours of incubation a sample was taken and quenched at 1, 3 and 6 hours after addition 
of HLMs. At each of these time points there was no significant change in the concentration of  1R,2S-
(-)-ephedrine relative to the control samples (Table S5), this is in line with literature data showing that 
1R,2S-(-)-ephedrine is generally excreted unchanged in humans [5; 6]. This is further supported by 
the absence of (±)-norephedrine or any other ephedrine isomer, which were expected to be the main 
metabolite [5; 6] if 1R,2S-(-)-ephedrine were metabolised. The concentration of 1S,2S-(+)-
pseudoephedrine however did decrease relative to the control sample, but no (±)-norephedrine or any 
other ephedrine isomers were observed. The HLM experiments for both compounds therefore 
supports the available literature data that ephedrines are mainly excreted un-metabolised and without 
chiral conversion. This also eliminates human metabolism of ephedrines as a source for the previous 
detection of 1S,2R-(+)-ephedrine in wastewater [1].  
3.4. Retrospective analysis for 1S,2R-(+)-ephedrine precursors in river water 
It is important to mention that there could be other sources of 1S,2R-(+)-ephedrine formation in water 
such as the reduction of R-(+)-methcathinone during human metabolism [17]. (±)-Methcathinone has 
been occasionally detected in wastewater influent [18; 19] but not in other environmental samples, 
and never with a focus on chirality. However as no ephedrine isomers were present in the river water 
used for microcosm experiments, and as relatively low percentages of methcathinone are excreted un-
metabolised [17], it is postulated that 1S,2R-(+)-ephedrine was formed as a result of microbial 
transformation of 1R,2S-(-)-ephedrine. Further work is needed to confirm this hypothesis, however 
retrospective analysis of river water collected in a week long sampling campaign in England, using 
the procedure detailed in [13], showed no evidence of methcathinone.  
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3.5. Ecotoxicity of ephedrine stereoisomers to Daphnia magna, Pseudokirchneriella subcapitata and 
Tetrahymena thermophila 
Ecotoxicity tests and obtained EC50 data for the non-natural isomers 1R,2R-(-)-pseudoephedrine and 
1S,2R-(+)-ephedrine revealed that these isomers are more toxic to Daphnia magna than their naturally 
occurring enantiomers (Table 2). Their EC50s after 48h exposure were as follows: 107 and 171 mg/L 
in the case of 1R,2R-(-)-pseudoephedrine and 1S,2R-(+)-ephedrine respectively. EC5048h for the 
natural isomers 1R,2S-(-)-ephedrine and 1S,2S-(+)-pseudoephedrine, being widely used as 
prescription and over-the-counter medications, were much higher: 253 and 274 g/L respectively. 
Table 2. Toxicity of ephedrine stereoisomers to Daphnia magna, Pseudokirchneriella subcapitata and 
Tetrahymena thermophila. Raw data is presented in figures S7-S11, tables S6-S9 and tables S14-S21. 
 
Similarly, non-natural 1R,2R-(-)-pseudoephedrine was found to be the most toxic isomer (<100 mg/L) 
for Pseudokirchneriella subcapitata after 72h exposure time. Interestingly, 1S,2R-(+)-ephedrine was 
found to be less toxic than its natural isomer 1R,2S-(-)-ephedrine and was found to be the least toxic 
isomer. 
The results show Tetrahymena thermophila are far more sensitive to the presence of the ephedrine 
isomers than the other organisms explored in this study. As with the other organisms 1R,2R-(-)-
pseudoephedrine is by far the most toxic and its enantiomer 1S,2S-(+)-pseudoephedrine the least: 4.6 
and 99.3 mg/L, respectively. The ephedrine enantiomers 1S,2R-(+)-ephedrine and 1R,2S-(-)-ephedrine 
are much more similar in toxicity: 42.6 and 36.0 mg/L, respectively. As with Pseudokirchneriella 
subcapitata 1R,2S-(-)-ephedrine was more toxic than 1S,2R-(+)-ephedrine, although with less 
disparity. 





Single isomers EC5024h EC5048h EC5072h EC5024h 
1S,2R-(+)-Ephedrine 373.1 170.8 754.5 42.6 
1R,2S-(-)-Ephedrine 408.6 253.7 259.1 36.0 
1S,2S-(+)-Pseudophedrine 528.3 274.3 417.9 99.3 
1R,2R-(-)-Pseudophedrine 128.2 107.2 44.8 4.6 
Mixtures     
Natural - - - 61.8 
All - - - 52.4 




The Tetrahymena thermophila EC5024h results for the ephedrine mixtures ‘natural’ (containing 1S,2S-
(+)-pseudoephedrine and 1R,2S-(-)-ephedrine, DF = 0.5) and ‘all’ (which contains all the isomers, all 
EF and DF = 0.5) are 61.8 and 52.4 mg/L respectively. These two mixtures are less toxic than all of 
the individual isomers apart from 1S,2S-(+)-pseudoephedrine, which is present in both mixtures, so it 
does not appear that there are any synergistic effects. All Tetrahymena thermophila EC5024h results 
are classified as harmful (< 100 mg/L), however 1R,2R-(-)-pseudoephedrine is toxic (1-10 mg/L) 
according to the classification made by OECD and Commission of the European Communities [20-
23]. For more detailed results please see Supplementary Tables 14-21. 
4. Conclusion 
To summarize, the high toxicity of 1S,2R-(+)-ephedrine is of significant environmental importance. 
Kasprzyk-Hordern and Baker [1] have detected 1S,2R-(+)-ephedrine in wastewater effluent, assumed 
to be formed during wastewater treatment, which is eventually discharged into the environment. HLM 
assays support previous literature evidence that human metabolism of ephedrines does not proceed 
with any conversion of chirality, so that 1S,2R-(+)-ephedrine formation is occurring after excretion or 
during wastewater treatment. Multi-compound microcosm experiments show that, if present, 1S,2R-
(+)-ephedrine is persistent within the environment, allowing it to become more widely spread. The 
detection of 1S,2R-(+)-ephedrine in single isomer microcosms containing only  
1R,2S-(-)-ephedrine suggests that chiral inversion from biological processes is possible, further 
increasing the risk of pseudo-persistent environmental exposure to 1S,2R-(+)-ephedrine and that 
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Table S1. Optimised MRM conditions for the analysis of ephedrines by LC/MS/MS by Evans et al. (CV-cone 








23/12 166.1 > 148.1 23/21 166.1 > 133.1 
1S,2S-(+)/1R,2R-(-)-Pseudophedrine 
1R,2S-(-)/1S,2R-(+)-Norephedrine 23/10 152.2 > 134.1 23/16 152.2 > 117.1 
R/S-(±)-Methamphetamine-d5 24/11 155.0 > 121.0 - - 
R/S-(±)-ephedrine-d3 23/12 169.2 > 148.1 23/21 169.2 > 133.1 
 











































































































































 - correlation coefficient 
c
 MDLcalc - calculated method detection limit 
d
 MQLcalc - calculated method quantification limit 
e
 Rs - chromatographic resolution of enantiomers 
f
 EF - enantiomeric fraction 
g

















23/12 166.1 > 148.1 23/21 166.1 > 133.1 
1S,2S-(+)/1R,2R-(-)-Pseudophedrine 
1R,2S-(-)/1S,2R-(+)-Norephedrine 23/10 152.2 > 134.1 23/16 152.2 > 117.1 
R/S-(±)-ephedrine-d3 23/18 169.2 > 151.0 - - 
 


















































































































a tr - retention time 
b R2 - correlation coefficient 
c MDLcalc - calculated method detection limit 
d MQLcalc - calculated method quantification limit 
e Rs - chromatographic resolution of enantiomers 
f EF - enantiomeric fraction 
g Rec - mean method (SPE) recovery (calculated for river water spiked with 25, 250 and 2500 µg L-1) 
 
Table S5. Human liver microsome experiment showing ephedrine concentrations over time. Analyte blanks 










Time 0 Analyte blank 25.25 ± 0.45 35.40 ± 0.40 
Time 1 Digest 1 33.90 ± 0.00 224.50 ± 2.60 
Time 1 Digest 2 38.45 ± 0.45 178.15 ± 0.35 
Time 1 Analyte blank 37.2 ± 0.20 159.40 ± 2.00 
Time 3 Digest 1 33.00 ± 0.60 88.45 ± 1.25 
Time 3 Digest 2 36.45 ± 0.35 74.30 ± 0.20 
Time 3 Analyte blank 35.15 ± 0.85 88.15 ± 0.85 
Time 6 Digest 1 28.75 ± 0.65 133.50 ± 3.10 
Time 6 Digest 2 32.00 ± 0.00 104.55 ± 0.75 
Time 6 Analyte blank 29.15 ± 0.35 143.70 ± 0.40 
Time 6 HLM blank <LOD, <LOD 15.00 ± 0.00 
% degradation (1R,2S)-(-)-ephedrine (1S,2S)-(+)-pseudoephedrine 
Time 1 % degradation 97.24 ± 1.66 126.30 ± 3.30 
Time 3 % degradation 98.79 ± 5.13 92.31 ± 2.44 
Time 6 % degradation 104.20 ± 3.61 82.83 ± 2.75 
 





Figure S1. Summary of river simulating microcosms 
  





Figure S2. Mixed-compound river microcosms - temperature, dissolved oxygen (DO), pH, ammonium, 





























































 mg/L COD mg/L O2 
0 River water No result No result No result No result 
14 
Dark Abiotic No result No result 0.7 176 
Dark Biotic No result No result 1.9 < 25 
Light Abiotic No result No result 1.8 213 
Light Biotic No result No result 3.2 < 25 





Figure S3. Summary of single-compound river microcosms 
  











 mg/L COD mg/L O2 




No result No result No result 90 
1R,2S-(-)-ephedrine 
 Biotic Dark 
No result No result No result 81 
1S,2S-(+)-pseudoephedrine  
Biotic Light 
No result No result No result 117 
1S,2S-(+)-pseudoephedrine  
Biotic Dark 
No result No result No result 344 
Figure S4. Single-compound river microcosms - temperature, dissolved oxygen (DO), pH, ammonium, 













(-)-ephedrine Biotic Light average pH
(-)-ephedrine Biotic Dark average pH
(+)-pseudoephedrine Biotic Light average pH
































































Figure S5. Formation of (+)-(1S,2R)-ephedrine (retention time, 19.97 minutes) in (-)-(1R,2S)-ephedrine river 
simulating microcosm (retention time, 22.43 minutes) 
 
 
Figure S6. Single-compound river simulating microcosms – 1R,2S-(-)-ephedrine  and 1S,2S-(+)-






























































Note: Replicate 2 for 1S,2S-(+)Pseudoephedrine in Selenastrum capricoruntum tests did not achieve the 
minimum growth inhibition required to validate the test, and therefore should be treated semi-quantitative. 
Figure S7 Toxicity of ephedrine stereoisomers to Daphnia magna, Selenastrum capricornutum and 
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Figure S8. % mortality of Daphnia Magna exposed to 1S,2R-(+)-ephedrine 
 

















1S,2R-(+)-ephedrine Daphnia Magna 
24 hours - replicate one 24 hours - replicate two
















1R,2S-(-)-ephedrine Daphnia Magna 
24 hours - replicate one 24 hours - replicate two
48 hours - replicate one 48 hours - replicate two





Figure S10. % mortality of Daphnia Magna exposed to 1S,2S-(+)-pseudoephedrine 
 






















1S,2S-(+)-pseudoephedrine Daphnia Magna 
24 hours - replicate one 24 hours - replicate two
















1R,2R-(-)-psuedoephedrine Daphnia Magna 
24 hours - replicate one 24 hours - replicate two 24 hours - replicate three
48 hours - replicate one 48 hours - replicate two 48 hours - replicate three



























A 90 70 25 30 0 5 0 0 




A 100 93 43 18 7 4 7 7 





A 80 30 30 25 0 0 0 0 




A 100 100 100 50 5 0 0 0 
B 100 100 100 25 0 0 0 0 
C 100 100 100 65 5 15 0 0 
 























A 100 100 60 40 20 5 0 0 




A 100 93 43 18 7 4 7 7 





A 100 95 45 35 15 0 5 5 




A 100 100 100 95 5 25 15 0 
B 100 100 95 35 0 10 0 5 
















Table S8. Ephedrine EC50 determination for Daphnia Magna after 24 hours exposure 
Compound Replicate M C EC 50 (mg/L) Average (mg/L) 
1S,2R-(+)-
ephedrine 
A 149.5 -33.5 367.4 
373.1 
B 83.0 -164.1 378.9 
1R,2S-(-)-
ephedrine 
A 142.4 -323.5 420.4 
408.6 




A 166.1 -418.3 659.7 
528.3 




A 157.8 -279.2 122.0 
128.2 B 249.1 -497.4 157.5 
C 199.3 -353.0 105.1 
 
Table S9. Ephedrine EC50 determination for Daphnia Magna after 48 hours exposure 
Compound Replicate M C EC 50 (mg/L) Average (mg/L) 
1S,2R-(+)-
ephedrine 
A 66.4 -99.3 176.8 
170.8 
B 83.0 -134.14 164.9 
1R,2S-(-)-
ephedrine 
A 166.1 -355.4 276.0 
253.7 




A 166.1 -353.3 267.9 
274.3 




A 299.0 -531.9 88.4 
107.2 B 199.3 -383.0 148.6 
C 265.8 -462.3 84.6 
  




























0 0.74 0.84 0.45 0.48 0.86 0.47 N/A N/A N/A 
Biotic Light 
1 
1 0.83 0.82 0.54 0.51 1.02 0.48 8.78 27.7 6.75 
Biotic Light 
1 
4 0.68 0.66 0.43 0.44 0.99 0.38 8.62 28.6 6.46 
Biotic Light 
1 
5 0.69 0.63 0.42 0.47 0.82 0.31 8.84 29 6.33 
Biotic Light 
1 
6 0.62 0.00 0.00 0.33 0.47 0.23 8.94 30.2 7.29 
Biotic Light 
1 
7 0.65 0.46 0.29 0.36 0.58 0.20 8.69 29.4 7.55 
Biotic Light 
1 
8 0.71 0.46 0.23 0.39 0.74 0.22 8.51 29.3 7.48 
Biotic Light 
1 
11 0.69 0.27 0.13 0.44 0.61 0.20 8.39 28.1 7.62 
Biotic Light 
1 
12 0.70 0.21 0.07 0.31 0.45 0.18 8.36 29 6.72 
Biotic Light 
1 
13 0.61 0.16 0.07 0.36 0.42 0.17 8.38 29.3 6.73 
Biotic Light 
1 
14 0.61 0.15 0.04 0.32 0.41 0.16 8.15 29.2 6.74 
Biotic Light 
2 
0 0.76 0.83 0.39 0.41 0.59 0.37 N/A N/A N/A 
Biotic Light 
2 
1 0.75 0.74 0.36 0.36 0.60 0.27 8.8 27.3 6.86 
Biotic Light 
2 
4 0.69 0.73 0.35 0.35 0.53 0.19 8.58 28.1 6.63 
Biotic Light 
2 
5 0.68 0.64 0.36 0.37 0.55 0.19 8.62 28.6 6.45 
Biotic Light 
2 
6 0.74 0.69 0.37 0.45 0.61 0.18 8.55 29.5 7.53 
Biotic Light 
2 
7 0.70 0.63 0.34 0.37 0.61 0.19 8.46 29 7.71 
Biotic Light 
2 
8 0.70 0.56 0.29 0.37 0.61 0.20 8.43 28.7 7.59 
Biotic Light 
2 
11 0.71 0.44 0.25 0.37 0.56 0.20 8.4 27.7 7.77 
Biotic Light 
2 
12 0.74 0.41 0.18 0.33 0.57 0.19 8.37 28.6 6.96 
Biotic Light 
2 
13 0.69 0.40 0.21 0.38 0.51 0.19 8.43 29 6.81 
Biotic Light 
2 
14 0.70 0.38 0.19 0.35 0.42 0.18 8.15 28.8 6.85 
 
  




























0 1.23 1.40 0.90 0.87 1.42 0.68 N/A N/A N/A 
Biotic Dark 
1 
1 0.73 0.78 0.42 0.42 0.80 0.37 8.81 27.7 6.72 
Biotic Dark 
1 
4 0.70 0.62 0.36 0.45 0.87 0.27 8.44 29 6.35 
Biotic Dark 
1 
5 0.76 0.55 0.33 0.51 0.91 0.26 8.51 29.3 6.26 
Biotic Dark 
1 
6 0.70 0.23 0.09 0.42 0.72 0.18 8.47 31 7.07 
Biotic Dark 
1 
7 0.83 0.09 0.12 0.45 0.92 0.18 8.51 30.4 7.3 
Biotic Dark 
1 
8 0.80 0.00 0.00 0.47 0.90 0.18 8.52 29.7 7.53 
Biotic Dark 
1 
11 0.66 0.00 0.00 0.46 0.64 0.17 8.52 29.2 7.26 
Biotic Dark 
1 
12 0.73 0.00 0.02 0.35 0.43 0.15 8.5 29.5 6.89 
Biotic Dark 
1 
13 0.52 0.00 0.00 0.31 0.40 0.14 8.48 30.5 6.67 
Biotic Dark 
1 
14 0.60 0.00 0.00 0.32 0.51 0.15 8.26 30.2 6.5 
Biotic Dark 
2 
0 0.62 0.72 0.32 0.34 0.57 0.36 N/A N/A N/A 
Biotic Dark 
2 
1 0.66 0.73 0.30 0.29 0.54 0.28 8.81 27.3 6.84 
Biotic Dark 
2 
4 0.68 0.58 0.18 0.28 0.58 0.21 8.45 28.6 6.46 
Biotic Dark 
2 
5 0.86 0.56 0.20 0.34 0.67 0.19 9.43 29.1 6.3 
Biotic Dark 
2 
6 0.62 0.17 0.05 0.31 0.43 0.15 8.45 30.2 7.31 
Biotic Dark 
2 
7 0.70 0.00 0.00 0.36 0.62 0.15 8.5 29.5 7.53 
Biotic Dark 
2 
8 0.65 0.00 0.00 0.36 0.54 0.15 8.52 29.3 7.2 
Biotic Dark 
2 
11 0.58 0.00 0.00 0.30 0.41 0.15 8.51 28.4 7.53 
Biotic Dark 
2 
12 0.62 0.00 0.00 0.33 0.46 0.15 8.51 29.1 6.86 
Biotic Dark 
2 
13 0.56 0.00 0.00 0.32 0.37 0.15 8.49 29.4 6.94 
Biotic Dark 
2 
14 0.60 0.00 0.22 0.35 0.37 0.14 8.25 29.2 7.11 
 
  




























0 0.64 0.75 0.30 0.35 0.51 0.34 N/A N/A N/A 
Abiotic 
Light 1 
1 0.70 0.78 0.34 0.36 0.54 0.37 8.86 27.1 6.92 
Abiotic 
Light 1 
4 0.69 0.79 0.29 0.33 0.66 0.40 8.56 28.3 6.56 
Abiotic 
Light 1 
5 0.62 0.76 0.41 0.41 0.70 0.42 8.54 28.8 6.41 
Abiotic 
Light 1 
6 0.58 0.70 0.29 0.35 0.60 0.38 8.51 30 7.35 
Abiotic 
Light 1 
7 0.74 0.84 0.29 0.35 0.79 0.44 8.54 29.3 7.6 
Abiotic 
Light 1 
8 0.66 0.70 0.28 0.28 0.66 0.38 8.55 28.9 7.45 
Abiotic 
Light 1 
11 0.56 0.66 0.26 0.28 0.57 0.36 8.55 28.1 7.62 
Abiotic 
Light 1 
12 0.77 0.75 0.42 0.40 0.84 0.44 8.53 28.4 6.97 
Abiotic 
Light 1 
13 0.69 0.73 0.32 0.35 0.80 0.45 8.53 29.3 6.72 
Abiotic 
Light 1 
14 0.64 0.68 0.35 0.37 0.74 0.43 8.3 28.9 6.82 
Abiotic 
Light 2 
0 0.72 0.86 0.43 0.34 0.80 0.46 N/A N/A N/A 
Abiotic 
Light 2 
1 0.73 0.74 0.39 0.38 0.64 0.39 8.84 27 6.93 
Abiotic 
Light 2 
5 0.88 0.99 0.34 0.38 0.93 0.49 8.47 28.9 6.38 
Abiotic 
Light 2 
6 0.69 0.79 0.38 0.36 0.69 0.42 8.46 30 7.34 
Abiotic 
Light 2 
7 0.69 0.73 0.33 0.32 0.81 0.46 8.51 29.3 7.57 
Abiotic 
Light 2 
8 0.62 0.67 0.37 0.36 0.57 0.39 8.53 28.9 7.34 
Abiotic 
Light 2 
11 0.67 0.78 0.36 0.40 1.04 0.52 8.54 28.2 7.61 
Abiotic 
Light 2 
12 0.77 0.73 0.47 0.45 0.93 0.52 8.52 28.8 6.97 
Abiotic 
Light 2 
13 0.73 0.72 0.48 0.44 1.06 0.56 8.52 29.4 6.68 
Abiotic 
Light 2 
14 0.79 0.83 0.50 0.52 1.23 0.59 8.29 29.1 6.75 
 
  




























0 0.79 1.15 0.39 0.40 0.81 0.47 N/A N/A N/A 
Abiotic 
Dark 1 
1 0.60 0.71 0.30 0.34 0.50 0.36 8.86 27.5 6.83 
Abiotic 
Dark 1 
4 0.67 0.68 0.34 0.31 0.62 0.38 8.46 29.3 6.29 
Abiotic 
Dark 1 
5 0.74 0.80 0.37 0.34 0.65 0.41 8.51 27.8 6.7 
Abiotic 
Dark 1 
6 0.86 0.91 0.36 0.35 0.83 0.50 8.54 29.1 7.48 
Abiotic 
Dark 1 
7 0.90 0.89 0.37 0.36 0.71 0.44 8.55 28.8 7.76 
Abiotic 
Dark 1 
8 0.75 0.57 0.32 0.31 0.65 0.40 8.55 27.9 7.62 
Abiotic 
Dark 1 
11 0.75 0.70 0.43 0.43 0.78 0.43 8.51 27.6 7.37 
Abiotic 
Dark 1 
12 0.69 0.57 0.37 0.40 0.77 0.39 8.52 27.6 7.35 
Abiotic 
Dark 1 
13 0.67 0.37 0.34 0.36 0.81 0.32 8.51 28.9 6.84 
Abiotic 
Dark 1 
14 0.66 0.00 0.46 0.44 0.63 0.17 8.68 25.2 7.77 
Abiotic 
Dark 2 
0 0.63 0.76 0.53 0.49 0.53 0.35 N/A N/A N/A 
Abiotic 
Dark 2 
1 0.91 1.07 0.48 0.55 0.89 0.48 8.85 27.6 6.78 
Abiotic 
Dark 2 
4 0.57 0.62 0.31 0.34 0.55 0.35 8.48 27.9 6.7 
Abiotic 
Dark 2 
5 0.67 0.69 0.36 0.36 0.56 0.38 8.51 27.5 6.81 
Abiotic 
Dark 2 
6 0.60 0.69 0.29 0.32 0.58 0.38 8.53 29.2 7.41 
Abiotic 
Dark 2 
7 0.65 0.70 0.34 0.34 0.52 0.36 8.56 28.6 7.93 
Abiotic 
Dark 2 
8 0.66 0.69 0.30 0.36 0.54 0.36 8.56 27.6 7.69 
Abiotic 
Dark 2 
11 0.68 0.70 0.29 0.35 0.64 0.39 8.56 27 7.62 
Abiotic 
Dark 2 
12 0.66 0.70 0.32 0.35 0.61 0.38 8.55 27.2 7.36 
Abiotic 
Dark 2 
13 0.74 0.76 0.30 0.38 0.65 0.40 8.52 28.5 7.32 
Abiotic 
Dark 2 
14 0.71 0.80 0.36 0.38 0.58 0.40 8.85 26.4 7.22 
 
  




Table S14. 1R,2S-(-)-Ephedrine range finding test - Tetrahymena thermophile 
Results – Optical Density 
Conc. Time Replicate Mean Std. dev. CV% 
  
1 2 
   
 
t0 0.711 0.811 0.761 0.071 9.29% 
Control t24 0.192 0.281 0.237 0.063 26.61% 
 
t0 0.777 0.755 0.766 0.016 2.03% 
0.500 t24 0.409 0.347 0.378 0.044 11.60% 
 
t0 0.777 0.765 0.771 0.008 1.10% 
2.500 t24 0.419 0.353 0.386 0.047 12.09% 
 
t0 0.770 0.775 0.773 0.004 0.46% 
5.000 t24 0.405 0.376 0.391 0.021 5.25% 
 
t0 0.778 0.766 0.772 0.008 1.10% 
25.000 t24 0.424 0.428 0.426 0.003 0.66% 
 
t0 0.765 0.767 0.766 0.001 0.18% 
50.000 t24 0.579 0.590 0.585 0.008 1.33% 
 
t0 0.770 0.766 0.768 0.003 0.37% 
250.000 t24 0.597 0.610 0.604 0.009 1.52% 
 
t0 0.775 0.766 0.771 0.006 0.83% 
500.000 t24 0.540 0.550 0.545 0.007 1.30% 
 
Summary of Results 
Conc. Statistics Time (hours) 
  
0 24 
Control Mean 0.761 0.237 
 
CV% 9.29% 26.61% 
0.500 Mean 0.766 0.378 
 
CV% 2.03% 11.60% 
2.500 Mean 0.771 0.386 
 
CV% 1.10% 12.09% 
5.000 Mean 0.773 0.391 
 
CV% 0.46% 5.25% 
25.000 Mean 0.772 0.426 
 
CV% 1.10% 0.66% 
50.000 Mean 0.766 0.585 
 
CV% 0.18% 1.33% 
250.000 Mean 0.768 0.604 
 
CV% 0.37% 1.52% 
500.000 Mean 0.771 0.545 
 
CV% 0.83% 1.30% 
 
Percentage Inhibition Computation 
Conc. 0  100% % I 
















































Concentration vs. Percent Inhibition 
Log Conc. I% Conc. 
-0.301 26.02 0.500 
0.398 26.60 2.500 
0.699 27.17 5.000 
1.398 34.03 25.000 
1.699 65.40 50.000 
2.398 68.64 250.000 
2.699 57.01 500.000 
 
Effect Concentration Results 
log x =  -0.925 
  24hEC10 =  0.119 
  log x = -0.266 
  24hEC20 =  0.542 
  log x = 1.709 
  24hEC50 =  50.919 
  log x =  3.026 
  24hEC70 =  1052.423 Lower 95% Upper 95% 
log x = 4.342 6.622 41.470 




       Multiple R 0.853 
       R Square 0.728 
       Adjusted R Square 0.673 
       Standard Error 11.051 
       Observations 7 
       
         ANOVA 
        
 
df SS MS F 
Significance 
F 
   Regression 1 1630.479 1630.479 13.350 0.015 
   Residual 5 610.658 122.132 
     Total 6 2241.136 
      




Error t Stat 
P-







Intercept 24.046 6.778 3.547 0.016 6.622 41.470 6.622 41.470 











Table S15. 1R,2S-(-)-Ephedrine definitive test - Tetrahymena thermophila 
Results – Optical Density 
Conc. Time Replicate Mean Std. dev. CV% 
  
1 2 
   
 
t0 0.751 0.720 0.736 0.022 2.98% 
0.000 t24 0.200 0.237 0.219 0.026 11.97% 
 
t0 0.754 0.753 0.754 0.001 0.09% 
5.100 t24 0.324 0.409 0.367 0.060 16.40% 
 
t0 0.744 0.745 0.745 0.001 0.09% 
15.200 t24 0.375 0.402 0.389 0.019 4.91% 
 
t0 0.738 0.744 0.741 0.004 0.57% 
50.600 t24 0.460 0.567 0.514 0.076 14.73% 
 
t0 0.749 0.755 0.752 0.004 0.56% 
101.100 t24 0.646 0.659 0.653 0.009 1.41% 
 
t0 0.741 0.735 0.738 0.004 0.57% 
161.800 t24 0.599 0.599 0.599 0.000 0.00% 
 
t0 0.740 0.740 0.740 0.000 0.00% 
252.800 t24 0.600 0.594 0.597 0.004 0.71% 
 
t0 0.738 0.734 0.736 0.003 0.38% 
505.600 t24 0.550 0.556 0.553 0.004 0.77% 
 
Summary of Results 
Conc. Statistics Time (hours) 
  
0 24 
0.00 Mean 0.736 0.219 
 
CV% 2.98% 11.97% 
5.100 Mean 0.754 0.367 
 
CV% 0.09% 16.40% 
15.200 Mean 0.745 0.389 
 
CV% 0.09% 4.91% 
50.600 Mean 0.741 0.514 
 
CV% 0.57% 14.73% 
101.100 Mean 0.752 0.653 
 
CV% 0.56% 1.41% 
161.800 Mean 0.738 0.599 
 
CV% 0.57% 0.00% 
252.800 Mean 0.740 0.597 
 
CV% 0.00% 0.71% 
505.600 Mean 0.736 0.553 
 
CV% 0.38% 0.77% 
 
Percentage Inhibition Computation 
Conc. 0 100% % I 

















































Concentration vs. Percent Inhibition 
Log Conc. I% Conc. 
0.708 25.15 5.100 
1.182 31.14 15.200 
1.704 56.00 50.600 
2.005 80.75 101.100 
2.209 73.11 161.800 
2.403 72.34 252.800 
2.704 64.60 505.600 
 
Effect Concentration Results 
log x =  0.045 
  24hEC10 =  1.110 
  log x = 0.423 
  24hEC20 =  2.648 
  log x = 1.558 
  24hEC50 =  35.995 
  log x =  2.314 
  24hEC70 =  205.001 Lower 95% Upper 95% 
log x = 3.071 -26.498 44.105 
24hEC90 =  1167.546 
   
Summary Output 
Regression Statistics 
       Multiple R 0.860 
       R Square 0.739 
       Adjusted R Square 0.687 
       Standard Error 12.079 
       Observations 7 
       
         ANOVA 
        
  df SS MS F 
Significance 
F 
   Regression 1 2069.623 2069.623 14.186 0.013 
   Residual 5 729.479 145.896 
     Total 6 2799.102      
   
         
  Coefficients 
Standard 
Error t Stat 
P-







Intercept 8.803 13.733 0.641 0.550 -26.498 44.105 -26.498 44.105 











Table S16. 1S,2R-(+)-Ephedrine definitive test - Tetrahymena thermophila 
Results – Optical Density 
Conc. Time Replicate Mean Std. dev. CV% 
  
1 2 
   
 
t0 0.777 0.756 0.767 0.015 1.94% 
Control t24 0.245 0.290 0.268 0.032 11.90% 
 
t0 0.771 0.781 0.776 0.007 0.91% 
5.024 t24 0.446 0.454 0.450 0.006 1.26% 
 
t0 0.760 0.763 0.762 0.002 0.28% 
15.072 t24 0.429 0.415 0.422 0.010 2.35% 
 
t0 0.764 0.756 0.760 0.006 0.74% 
50.240 t24 0.484 0.500 0.492 0.011 2.30% 
 
t0 0.771 0.761 0.766 0.007 0.92% 
100.480 t24 0.593 0.563 0.578 0.021 3.67% 
 
t0 0.778 0.773 0.776 0.004 0.46% 
160.768 t24 0.615 0.614 0.615 0.001 0.12% 
 
t0 0.756 0.774 0.765 0.013 1.66% 
251.200 t24 0.607 0.622 0.615 0.011 1.73% 
 
t0 0.759 0.752 0.756 0.005 0.66% 
502.400 t24 0.614 0.600 0.607 0.010 1.63% 
 
Summary of Results 
Conc. Statistics            Time (hours) 
  
  0 24  
Control Mean 0.767 0.268 
  CV% 1.94% 11.90% 
5.024  Mean 0.776 0.450 
  CV% 0.91% 1.26% 
15.072  Mean 0.762 0.422 
  CV% 0.28% 2.35% 
50.240  Mean 0.760 0.492 
  CV% 0.74% 2.30% 
100.480  Mean 0.766 0.578 
  CV% 0.92% 3.67% 
160.768  Mean 0.776 0.615 
  CV% 0.46% 0.12% 
251.200  Mean 0.765 0.615 
  CV% 1.66% 1.73% 
502.400  Mean 0.756 0.607 
  CV% 0.66% 1.63% 
 
Percentage Inhibition Computation 
Conc. 0 100% % I 
















































Concentration vs. Percent Inhibition 
Log Conc. I% Conc. 
0.701 34.67 5.024 
1.178 31.96 15.072 
1.701 46.29 50.240 
2.002 62.32 100.480 
2.206 67.74 160.768 
2.400 69.84 251.200 
2.701 70.24 502.400 
 
Effect Concentration Results 
log x =  -0.144 
  24hEC10 =  0.718 
  log x = 0.300 
  24hEC20 =  1.993 
  log x = 1.632 
  24hEC50 =  42.642 
  log x =  2.520 
  24hEC70 =  328.646 Lower 95% Upper 95% 
log x = 3.407 -4.269 30.761 
24hEC90 =  2532.922 
   
Summary Output 
Regression Statistics 
       Multiple R 0.945 
       R Square 0.893 
       Adjusted R Square 0.872 
       Standard Error 6.012 
       Observations 7 
       
         ANOVA 
        
  df SS MS F 
Significance 
F 
   Regression 1 1506.905 1506.905 41.695 0.001 
   Residual 5 180.707 36.141 
     Total 6 1687.612      
   
         
  Coefficients 
Standard 







Intercept 13.246 6.814 1.944 0.109 -4.269 30.761 -4.269 30.761 











Table S17. 1R,2R-(-)-Pseudoephedrine range finding test - Tetrahymena thermophila 
Results – Optical Density 
Conc. Time Replicate Mean Std. dev. CV% 
  
1 2 
   
 
t0 0.757 0.746 0.752 0.008 1.04% 
0.000 t24 0.272 0.251 0.262 0.015 5.68% 
 
t0 0.751 0.748 0.750 0.002 0.28% 
0.005 t24 0.297 0.311 0.304 0.010 3.26% 
 
t0 0.737 0.742 0.740 0.004 0.48% 
0.050 t24 0.342 0.357 0.350 0.011 3.03% 
 
t0 0.734 0.745 0.740 0.008 1.05% 
0.502 t24 0.300 0.348 0.324 0.034 10.48% 
 
t0 0.758 0.748 0.753 0.007 0.94% 
5.024 t24 0.364 0.302 0.333 0.044 13.17% 
 
t0 0.741 0.686 0.714 0.039 5.45% 
50.240 t24 0.554 0.538 0.546 0.011 2.07% 
 
t0 0.733 0.742 0.738 0.006 0.86% 
251.200 t24 0.606 0.612 0.609 0.004 0.70% 
 
t0 0.737 0.720 0.729 0.012 1.65% 
502.400 t24 0.529 0.569 0.549 0.028 5.15% 
 
Summary of Results 
Conc. Statistics Time (hours) 
  
0 24 
0.00 Mean 0.752 0.262 
 
CV% 1.04% 5.68% 
0.005 Mean 0.750 0.304 
 
CV% 0.28% 3.26% 
0.050 Mean 0.740 0.350 
 
CV% 0.48% 3.03% 
0.502 Mean 0.740 0.324 
 
CV% 1.05% 10.48% 
5.024 Mean 0.753 0.333 
 
CV% 0.94% 13.17% 
50.240 Mean 0.714 0.546 
 
CV% 5.45% 2.07% 
251.200 Mean 0.738 0.609 
 
CV% 0.86% 0.70% 
502.400 Mean 0.729 0.549 
 
CV% 1.65% 5.15% 
 
Percentage Inhibition Computation 
Conc. 0 100% % I 

















































Concentration vs. Percent Inhibition 
Log Conc. I% Conc. 
-2.299 9.08 0.005 
-1.299 20.41 0.050 
-0.299 15.20 0.502 
0.701 14.29 5.024 
1.701 65.82 50.240 
2.400 73.78 251.200 
2.701 63.37 502.400 
 
Effect Concentration Results 
log x =  -1.580 
  24hEC10 =  0.026 
  log x = -0.816 
  24hEC20 =  0.153 
  log x = 1.476 
  24hEC50 =  29.829 
  log x =  3.004 
  24hEC70 =  1002.068 Lower 95% Upper 95% 
log x = 4.532 14.899 46.453 
24hEC90 =  33663.146 
   
Summary Output 
Regression Statistics 
       Multiple R 0.868 
       R Square 0.753 
       Adjusted R Square 0.704 
       Standard Error 15.583 
       Observations 7 
       
         ANOVA 
        
  df SS MS F 
Significance 
F 
   Regression 1 3708.343 3708.343 15.271 0.011 
   Residual 5 1214.204 242.841 
     Total 6 4922.547      
   
         
  Coefficients 
Standard 







Intercept 30.676 6.138 4.998 0.004 14.899 46.453 14.899 46.453 












Table S18. 1R,2R-(-)-Pseudoephedrine definitive test - Tetrahymena thermophila 
Results – Optical Density 
Conc. Time Replicate Mean Std. dev. CV% 
  
1 2 
   
 
t0 0.773 0.787 0.780 0.010 1.27% 
0.000 t24 0.283 0.256 0.270 0.019 7.08% 
 
t0 0.772 0.775 0.774 0.002 0.27% 
0.050 t24 0.392 0.496 0.444 0.074 16.56% 
 
t0 0.783 0.766 0.775 0.012 1.55% 
5.020 t24 0.350 0.467 0.409 0.083 20.25% 
 
t0 0.764 0.778 0.771 0.010 1.28% 
12.550 t24 0.375 0.364 0.370 0.008 2.11% 
 
t0 0.774 0.767 0.771 0.005 0.64% 
25.100 t24 0.662 0.640 0.651 0.016 2.39% 
 
t0 0.751 0.774 0.763 0.016 2.13% 
32.630 t24 0.660 0.679 0.670 0.013 2.01% 
 
t0 0.772 0.764 0.768 0.006 0.74% 
50.200 t24 0.664 0.661 0.663 0.002 0.32% 
 
t0 0.767 0.763 0.765 0.003 0.37% 
251.000 t24 0.557 0.579 0.568 0.016 2.74% 
 
Summary of Results  
Conc. Statistics Time (hours) 
  
0 24 
0.00 Mean 0.780 0.270 
 
CV% 1.27% 7.08% 
0.050 Mean 0.774 0.444 
 
CV% 0.27% 16.56% 
5.020 Mean 0.775 0.409 
 
CV% 1.55% 20.25% 
12.550 Mean 0.771 0.370 
 
CV% 1.28% 2.11% 
25.100 Mean 0.771 0.651 
 
CV% 0.64% 2.39% 
32.630 Mean 0.763 0.670 
 
CV% 2.13% 2.01% 
50.200 Mean 0.768 0.663 
 
CV% 0.74% 0.32% 
251.000 Mean 0.765 0.568 
 
CV% 0.37% 2.74% 
 
Percentage Inhibition Computation 
Conc. 0 100% % I 
















































Concentration vs. Percent Inhibition 
Log 
Conc. I% Conc. 
-1.299 35.46 0.050 
0.701 28.31 5.020 
1.099 21.35 12.550 
1.400 76.59 25.100 
1.514 81.78 32.630 
1.701 79.33 50.200 
2.400 61.41 251.000 
 
Effect Concentration Results 
log x =  -2.690 
  24hEC10 =  0.002 
  log x = -1.852 
  24hEC20 =  0.014 
  log x = 0.663 
  24hEC50 =  4.599 
  log x =  2.340 
  24hEC70 =  217.511 Lower 95% Upper 95% 
log x = 4.017 9.304 74.869 
24hEC90 =  10286.829 
   
Summary Output 
Regression Statistics 
       Multiple R 0.538 
       R Square 0.289 
       Adjusted R 
Square 0.147 
       Standard Error 23.973 
       Observations 7 
       
         ANOVA 
        
  df SS MS F 
Significance 
F 
   Regression 1 1169.863 1169.863 2.036 0.213 
   Residual 5 2873.586 574.717 
     Total 6 4043.449      
   
         
  Coefficients 
Standard 
Error t Stat 
P-







Intercept 42.086 12.753 3.300 0.021 9.304 74.869 9.304 74.869 











Table S19. 1S,2S-(+)-Pseudoephedrine definitive test - Tetrahymena thermophila 
Results – Optical Density 
Conc. Time Replicate Mean Std. dev. CV% 
  
1 2 
   
 
t0 0.750 0.760 0.755 0.007 0.94% 
0.000 t24 0.233 0.253 0.243 0.014 5.82% 
 
t0 0.750 0.753 0.752 0.002 0.28% 
6.200 t24 0.401 0.397 0.399 0.003 0.71% 
 
t0 0.763 0.762 0.763 0.001 0.09% 
18.500 t24 0.402 0.400 0.401 0.001 0.35% 
 
t0 0.755 0.766 0.761 0.008 1.02% 
61.500 t24 0.363 0.433 0.398 0.049 12.44% 
 
t0 0.753 0.753 0.753 0.000 0.00% 
123.000 t24 0.405 0.550 0.478 0.103 21.47% 
 
t0 0.761 0.764 0.763 0.002 0.28% 
196.800 t24 0.593 0.578 0.586 0.011 1.81% 
 
t0 0.748 0.752 0.750 0.003 0.38% 
307.500 t24 0.592 0.594 0.593 0.001 0.24% 
 
t0 0.753 0.753 0.753 0.000 0.00% 
615.000 t24 0.563 0.615 0.589 0.037 6.24% 
 
Summary of Results 
Conc. Statistics Time (hours) 
  
0 24 
0.00 Mean 0.755 0.243 
 
CV% 0.94% 5.82% 
6.200 Mean 0.752 0.399 
 
CV% 0.28% 0.71% 
18.500 Mean 0.763 0.401 
 
CV% 0.09% 0.35% 
61.500 Mean 0.761 0.398 
 
CV% 1.02% 12.44% 
123.000 Mean 0.753 0.478 
 
CV% 0.00% 21.47% 
196.800 Mean 0.763 0.586 
 
CV% 0.28% 1.81% 
307.500 Mean 0.750 0.593 
 
CV% 0.38% 0.24% 
615.000 Mean 0.753 0.589 
 
CV% 0.00% 6.24% 
 
Percentage Inhibition Computation 
Conc. 0 100% % I 
















































Concentration vs. Percent Inhibition 
Log Conc. I% Conc. 
0.792 31.15 6.200 
1.267 29.39 18.500 
1.789 29.20 61.500 
2.090 46.19 123.000 
2.294 65.43 196.800 
2.488 69.34 307.500 
2.789 67.97 615.000 
 
Effect Concentration Results 
log x =  0.289  
  24hEC10 =  1.945  
  log x = 0.717  
  24hEC20 =  5.200  
  log x = 1.999  
  24hEC50 =  99.265  
  log x =  2.854  
  24hEC70 =  709.061  Lower 95% Upper 95% 
log x = 3.709  -27.890 34.351 
24hEC90 =  5064.911  
   
Summary Output 
Regression Statistics 
       Multiple R 0.869 
       R Square 0.756 
       Adjusted R 
Square 0.707 
       Standard Error 10.228 
       Observations 7 
       
         ANOVA 
        
  df SS MS F 
Significance 
F 
   Regression 1 1620.413 1620.413 15.489 0.011 
   Residual 5 523.082 104.616 
     Total 6 2143.495      
   
         
  Coefficients 
Standard 
Error t Stat 
P-







Intercept 3.231 12.106 0.267 0.800 -27.890 34.351 -27.890 34.351 










Table S20. ‘Natural’ isomers (1S,2S-(+)-Pseudoephedrine and 1R,2S-(-)-ephedrine) DF = 0.5 definitive test - 
Tetrahymena thermophila 
Results – Optical Density 
Conc. Time Replicate Mean Std. dev. CV% 
  
1 2 
   
 
t0 0.758 0.774 0.766 0.011 1.48% 
0.000 t24 0.223 0.222 0.223 0.001 0.32% 
 
t0 0.750 0.765 0.758 0.011 1.40% 
4.978 t24 0.156 0.119 0.138 0.026 19.03% 
 
t0 0.753 0.755 0.754 0.001 0.19% 
14.933 t24 0.206 0.184 0.195 0.016 7.98% 
 
t0 0.767 0.753 0.760 0.010 1.30% 
49.775 t24 0.592 0.485 0.539 0.076 14.05% 
 
t0 0.752 0.755 0.754 0.002 0.28% 
99.550 t24 0.681 0.566 0.624 0.081 13.04% 
 
t0 0.744 0.746 0.745 0.001 0.19% 
159.280 t24 0.645 0.633 0.639 0.008 1.33% 
 
t0 0.747 0.753 0.750 0.004 0.57% 
248.875 t24 0.660 0.634 0.647 0.018 2.84% 
 
t0 0.751 0.757 0.754 0.004 0.56% 
497.750 t24 0.592 0.785 0.689 0.136 19.82% 
 
Summary of Results 
Conc. Statistics Time (hours) 
  
0 24 
0.00 Mean 0.766 0.223 
 
CV% 1.48% 0.32% 
4.978 Mean 0.758 0.138 
 
CV% 1.40% 19.03% 
14.933 Mean 0.754 0.195 
 
CV% 0.19% 7.98% 
49.775 Mean 0.760 0.539 
 
CV% 1.30% 14.05% 
99.550 Mean 0.754 0.624 
 
CV% 0.28% 13.04% 
159.280 Mean 0.745 0.639 
 
CV% 0.19% 1.33% 
248.875 Mean 0.750 0.647 
 
CV% 0.57% 2.84% 
497.750 Mean 0.754 0.689 
 
CV% 0.56% 19.82% 
 
Percentage Inhibition Computation 
Conc. 0 100% % I 





































Natural ( 1S2S-(+)-P and 1R,2S-(-)-E; 
DF=0.5) Definitive 









Concentration vs. Percent Inhibition 
Log Conc. I% Conc. 
0.697 -14.08 4.978 
1.174 -2.85 14.933 
1.697 59.25 49.775 
1.998 76.08 99.550 
2.202 80.50 159.280 
2.396 81.05 248.875 
2.697 87.95 497.750 
 
Effect Concentration Results 
log x =  1.103  
  24hEC10 =  12.640  
  log x = 1.276  
  24hEC20 =  18.798  
  log x = 1.793  
  24hEC50 =  61.832  
  log x =  2.138  
  24hEC70 =  136.757  Lower 95% Upper 95% 
log x = 2.483  -94.616 -13.219 
24hEC90 =  302.474  
   
Summary Output 
Regression Statistics 
       Multiple R 0.954 
       R Square 0.911 
       Adjusted R Square 0.893 
       Standard Error 13.996 
       Observations 7 
       
         ANOVA 
        
  df SS MS F 
Significance 
F 
   Regression 1 9973.600 9973.600 50.911 0.001 
   Residual 5 979.509 195.902 
     Total 6 10953.109      
   
         
  Coefficients 
Standard 
Error t Stat 
P-







Intercept -53.917 15.832 -3.406 0.019 -94.616 -13.219 -94.616 
-
13.219 










Table S21. ‘All’ isomers EF = 0.5 and DF = 0.5 definitive test - Tetrahymena thermophila 
Results – Optical Density 
Conc. Time Replicate Mean Std. dev. CV% 
  
1 2 
   
 
t0 0.759 0.761 0.760 0.001 0.19% 
0.000 t24 0.165 0.162 0.164 0.002 1.30% 
 
t0 0.747 0.749 0.748 0.001 0.19% 
4.981 t24 0.120 0.161 0.141 0.029 20.63% 
 
t0 0.760 0.754 0.757 0.004 0.56% 
14.944 t24 0.225 0.166 0.196 0.042 21.34% 
 
t0 0.762 0.763 0.763 0.001 0.09% 
49.813 t24 0.534 0.615 0.575 0.057 9.97% 
 
t0 0.746 0.758 0.752 0.008 1.13% 
99.625 t24 0.644 0.666 0.655 0.016 2.38% 
 
t0 0.758 0.761 0.760 0.002 0.28% 
159.400 t24 0.632 0.629 0.631 0.002 0.34% 
 
t0 0.760 0.755 0.758 0.004 0.47% 
249.063 t24 0.664 0.622 0.643 0.030 4.62% 
 
t0 0.754 0.754 0.754 0.000 0.00% 
498.125 t24 0.594 0.586 0.590 0.006 0.96% 
 
Summary of Results 
Conc. Statistics Time (hours) 
  
0 24 
0.00 Mean 0.760 0.164 
 
CV% 0.19% 1.30% 
4.981 Mean 0.748 0.141 
 
CV% 0.19% 20.63% 
14.944 Mean 0.757 0.196 
 
CV% 0.56% 21.34% 
49.813 Mean 0.763 0.575 
 
CV% 0.09% 9.97% 
99.625 Mean 0.752 0.655 
 
CV% 1.13% 2.38% 
159.400 Mean 0.760 0.631 
 
CV% 0.28% 0.34% 
249.063 Mean 0.758 0.643 
 
CV% 0.47% 4.62% 
498.125 Mean 0.754 0.590 
 
CV% 0.00% 0.96% 
 
Percentage Inhibition Computation 
Conc. 0 100% % I 












































All (Eph; EF=0.5, PEph; EF=0.5) Definitive 





Concentration vs. Percent Inhibition 
Log Conc. I% Conc. 
0.697 -1.84 4.981 
1.174 5.87 14.944 
1.697 68.48 49.813 
1.998 83.74 99.625 
2.202 78.37 159.400 
2.396 80.80 249.063 
2.697 72.51 498.125 
 
Effect Concentration Results 
log x =  0.861  
  24hEC10 =  7.246  
  log x = 1.076  
  24hEC20 =  11.882  
  log x = 1.721  
  24hEC50 =  52.387  
  log x =  2.151  
  24hEC70 =  140.856  Lower 95% Upper 95% 
log x = 2.581  -84.400 24.306 
24hEC90 =  378.727  
   
Summary Output 
Regression Statistics 
       Multiple R 0.887 
       R Square 0.786 
       Adjusted R 
Square 0.743 
       Standard Error 18.690 
       Observations 7 
       
         ANOVA 
        
  df SS MS F 
Significance 
F 
   Regression 1 6423.891 6423.891 18.391 0.008 
   Residual 5 1746.505 349.301 
     Total 6 8170.396      
   
         
  Coefficients 
Standard 
Error t Stat 
P-







Intercept -30.047 21.144 -1.421 0.215 -84.400 24.306 -84.400 24.306 









Additional data interpretation 
Firstly, whilst a large portion of the introductory portion of the paper is rightly dedicated to a 
discussion of ephedrine’s metabolism in mammals there was no discussion of its pharmacology. 
Ephedrine is a direct and indirect sympathomimetic amine [24], meaning it binds directly to alpha and 
beta adrenergic receptors (direct) whilst also inhibiting neuronal norepinephrine reuptake and 
displacing norepinephrine from storage vesicles (in-direct), which allows norepinephrine to bind to 
alpha and beta receptors [25]. Whilst this has no readily apparent bearing on ephedrine’s metabolism, 
it is important to consider that its activity within humans may be related to its activity and subsequent 
toxicity to the species investigated in the paper: D. magna, P. subcapitata and T. thermophila. 
The degradation of ephedrine isomers in the first river simulating microcosms was interpreted only by 
visual examination of the changes in EF and isomer concentration (as shown in figures 1 and 2). 
Whilst this was sufficient for the dark biotic reactors where (-)-1R, 2S-ephedrine and (+)-1S, 2S-
pseudoephedrine were not detected at the end of the experiment, the changes in the other reactors 
would benefit from statistical analysis. To this end, a 2-tailed t-tail test was used to compare the 
average concentration in each pair of reactors, i.e. biotic dark 1 and biotic dark 2, on days 0-1 with the 
average concentration on days 11-14, using data presented in supplementary table S10-S13. For 
1R,2S-(-)-ephedrine and 1S,2S-(+)-pseudoephedrine the concentration of both isomers decreased 
significantly (<0.01) in the biotic light and biotic dark microcosms, with no significant (P>0.05) 
change in concentration in the abiotic microcosms. For 1S,2R-(+)-ephedrine there was a significantly 
(P<0.01) decrease in concentration in the biotic light and (P<0.05) in the biotic dark microcosms 
(respectively), but no significant change in concentration in the abiotic microcosms. Likewise, there 
was a significant (P<0.05) decrease in the concentration of 1R,2R-(-)-pseudoephedrine in the biotic 
light microcosm only. What this showed was that even the more persistent isomers were still degraded 
under environmental conditions. Interestingly, the synthetic isomers were more significantly degraded 
in the biotic light microcosms than the biotic dark microcosms, whereas the naturally occurring 
isomers where more heavily degraded in the biotic dark microcosms. This suggested that different 
microorganisms may have been present in the biotic light and biotic dark microcosms. The changes in 
EF fraction were also evaluated and showed that there was a significant (P<0.01) decrease in the EF 
of (±)-ephedrine, showing enrichment with 1S,2R-(+)-ephedrine, in the biotic light and dark 
microcosms but no significant change (P>0.05) in the abiotic microcosms. Likewise, there was a 
significant (P<0.01) increase in the EF of (±)-pseudoephedrine, showing enrichment with 1R,2R-(-)-
pseudoephedrine, in both of the biotic microcosms, but no change in the EF in the abiotic 
microcosms. 
Additionally, the formation of (+)-1S, 2R-ephedrine was not accompanied by a discussion of how 
other anthropogenic compounds degrade in river water and wastewater, both of which are potential 




sources of the isomer.  Other examples of analyte degradation in wastewater are present with the 
literature [26; 27] including the degradation of amphetamine-like compounds in wastewater and river 
water [27], which also observed differences in how compounds degraded between the two matrices 
and suggested it could be due to different bacterial communities. The presence of different bacterial 
communities could explain why (+)-1S, 2R-ephedrine was not detected in all treated wastewater and 
only during the second set of (-)-1R, 2S-ephedrine containing microcosms. 
Lastly, whilst much is made of the environmental risk posed by (+)-1S, 2R-ephedrine due to its 
comparatively high stability and toxicity it is important to put this risk in context. This can be done by 
using risk quotients (RQs), which are used by the US environmental protection agency (EPA) to 
assess the ecological risk of pesticides [28]. RQ can be calculated by dividing the estimated 
environmental concentration of an analyte by its lowest LC50 or EC50. As no isomer of ephedrine was 
detected in river water the Evans method’s limits of detection were used instead to determine the 
maximum possible RQ, alongside the EC50’s summarised in table 2. For natural and all isomer 
toxicity the highest limit of detection was used to generate the maximum possible RQ. The RQs in 
addendum table 1 showed that there was no significant risk posed by ephedrine, with even the highest 
RQ far below the acute toxicity level of concern, which is equivalent to an RQ of 0.5.  














































Natural 1.83 - - 2.96 x 10
-5 
All 1.83 - - 3.49 x 10
-5 




Additionally, the chromatographic separation of the isomers was never shown in the publication. 
Addendum figure 1 shows a chromatogram from the mixed isomer, biotic light 1 microcosm, which 
was analysed via the Evans et al method. The elution order is as follows: 1S, 2R-(+)-epehdrine,  
1R, 2R-(-)-pseudoephedrine, 1R, 2S-(-)-ephedrine and 1S, 2S-(+)-pseudoephedrine 
Addendum figure 1. Elution order of ephedrine in the Evans et al. method 
The following figures show the change in relative abundance of each isomer in the various mixed 
isomer microcosms on day 0 (D0) and day 14 (D14). 
Addendum figure 2. Biotic Light microcosm one (BL1), showing decrease in the relative abundance of 1R, 2S-
(-)-ephedrine and 1S, 2S-(+)-pseudoephedrine 




Addendum figure 3. Biotic Light microcosm two (BL2), showing decrease in the relative abundance of 1R, 2S-
(-)-ephedrine and 1S, 2S-(+)-pseudoephedrine 
Addendum figure 4. Biotic Dark microcosm one (BD1), showing decrease in the relative abundance of 1R, 2S-
(-)-ephedrine and 1S, 2S-(+)-pseudoephedrine 




Addendum figure 5. Biotic Dark microcosm two (BL2), showing decrease in the relative abundance of 1R, 2S-
(-)-ephedrine and 1S, 2S-(+)-pseudoephedrine 
Addendum figure 6. Abiotic Light microcosm one (AL1) 




Addendum figure 7. Abiotic Light microcosm two (AL2) 
Addendum figure 8. Abiotic Dark microcosm one (AD1) 




Addendum figure 9. Abiotic Dark microcosm two (AD2)
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Chapter three introduction 
In chapter one there was a focus on exploring both chirality and local prescription data for 
better interpretation of human health data, whilst chapter two was more explicitly focussed on 
exploring chirality for determining environmental toxicity. Chapter three is likewise focussed 
on chiral environmental analysis by developing a new analytical method using chiral 
supercritical fluid chromatography, but also lends itself to the analysis of public health due to 
its ability to analyse both CEC and WBE biomarkers in wastewater and river water.  
Despite the attention on chirality in method development chapter three is primarily about 
developing a new method for rapidly and chirally analysing CEC in waste and environmental 
water. The assessment of wastewater is important for environmental health as many CECs 
will enter rivers from wastewater treatment. By showcasing the analytical power of SFC the 
chapter also seeks to make chiral analysis easier to perform, thereby, hopefully, increase the 
amount of research carried out using chiral chromatography and therefore increasing the 
amount of chiral information available to researchers assessing public and environmental 
health. 
The initial work in the paper explores a range of different chiral analytical methodologies for 
analysing 140 potential CECs, including antibiotics, beta-blockers, drugs of abuse, pesticides 
and UV-filters. This was carried out using a single quadrupole MS instrument and was used 
to help establish chiral analyte separation and retention times for all analytes. For quantitative 
method development a triple quadrupole instrument was used instead, with the analytes 
divided into three groups to facilitate easier method development and sufficient analytical 
power. The final method was then used to analyse grab samples of influent and effluent 
wastewater and river water to assess the method’s suitability for environmental analysis.   
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A multi-residue method by supercritical fluid chromatography coupled with tandem 
mass spectrometry method for the analysis of chiral and non-chiral chemicals of 
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Abstract 
This manuscript presents the development, validation and application of a multi-residue 
supercritical fluid chromatography coupled with tandem mass spectrometry method for the 
analysis of 140 chiral and non-chiral chemicals of emerging concern in environmental 
samples with 81 compounds being fully quantitative, 14 semi-quantitative and 45 qualitative, 
validated according to European Medicine Agency (EMA) guidelines [1]. One unified LC-
MS method was used to analyse all analytes, which were split into three injection methods to 
ensure sufficient peak resolution. The unified method provided an average of 113 % accuracy 
and 4.5 % precision across the analyte range. Limits of detection were in the range of 35 pg 
L
-1
 - 0.7 µg L
-1
, in both river water and wastewater, with an average LOD of 33 ng L
-1
. The 
method was combined with solid-phase extraction and applied in environmental samples, 
showing very good accuracy and precision, as well as excellent chromatographic resolution 
of a range of chiral enantiomers including beta blockers, benzodiazepines and 
antidepressants. The method resulted in quantification of 75 % of analytes in at least two 
matrices, and 56 % in the trio of environmental matrices of river water, effluent wastewater 
and influent wastewater, enabling its use in monitoring compounds of environmental 
concern, from their sources of origin through to their discharge into the environment.   
Keywords: Supercritical fluid chromatography, environment, mass spectrometry, chiral 
chromatography, chemicals of emerging concern 
  





In 2000 the European Union (EU) set out its first Water Framework Directive (WFD) [1], 
which aimed to maintain and restore water quality across the EU by adopting a unified 
approach to discharge and emissions into surface waters. Thirty-three priority substances 
were identified and regulations were set-up to reduce their discharge into the environment. 
These initial priority substances were mainly metals, flame retardants and biocides. 
Additional compounds were prioritised by a new directive in 2012 [2]. As part of this 
expansion the NSAID diclofenac and the synthetic estrogens 7β-estradiol (E2) and 17α-
ethinylestradiol (EE2) were proposed as potential priority substances. In 2019 the publication 
of the EU’s ‘strategic approach to pharmaceuticals in the environment’ [3] mapped out the 
EU’s objectives for how to monitor and reduce the usage of pharmaceuticals, promote 
‘greener’ manufacturing, improve environmental risk assessments (ERAs) for 
pharmaceuticals, and support monitoring of these compounds in fresh and coastal waters. 
However, despite this focus on pharmaceutical as chemicals of emerging concern (CECs) in 
the environment, there has been no assessment on the effect of chirality. The effects of 
chirality in pharmaceuticals for human consumption are well documented, particularly in the 
wake of the thalidomide disaster, however the effect of chirality on environmental toxicity is 
still not as well understood. Both new and existing ERAs currently do not require any 
examination of the effect of chirality on their environmental toxicity [4; 5]. The main reason 
for not acknowledging chirality in ERAs is a lack of published knowledge on the relative 
effects of enantiomers, as well as lack of methods enabling research in this area. New, 
sensitive, multi-residue methods enabling identification and quantification of chiral and non-
chiral CECs within one analytical method are therefore urgently needed.  
Methods have already been developed for the monitoring of CECs in surface waters [6-18] 
and their effect on the aquatic environment [19-21]. However, many of these methods are not 
performed using chiral discrimination as separation at enantiomeric level poses an analytical 
challenge. Enantiomers cannot be separated by conventional reversed-phase chromatography 
utilising C18 stationary phases. Instead specific chiral chromatography methods must be 
developed utilising expensive chromatography columns. The types of chiral selectors used 
range from small molecules like modified benzenes to macrocycles and proteins. The 
difficulty of chiral chromatography is that the biological nature of many chiral selectors 
restricts the range of solvents and other modifiers which can be used in the methods [6; 22]. 
This generally also restricts the ability to develop LC methods with mobile phase gradients, 




thus increasing analytical runtimes. Chiral columns usually operate within inefficient HPLC 
modes due to large silica particle sizes being used. 
Supercritical fluid chromatography (SFC) is an increasingly popular analytical technique that 
is of great interest for chiral analysis [23; 24]. As with other chiral chromatography, chiral-
SFC requires a stationary phase containing a chiral selector, but unlike reversed-phase (RP) 
chiral-LC this chiral selector is a small chiral molecule, rather than a biomolecule, enabling 
the use of a wider range of solvents. Additionally, these columns can tolerate higher 
backpressures and have shorter equilibration times making the use of mobile phase gradients 
possible using SFC. SFC generally uses CO2 as its primary mobile phase [25] with an organic 
co-solvent for elution such as n-heptane, isopropyl alcohol or methanol. This makes SFC a 
“greener” analytical technique compared to traditional chromatography because of the use of 
renewable CO2 as a mobile phase. Acidic or basic modifiers, such as formic acid or 
ammonium hydroxide, are also commonly added to help limit unwanted analyte-stationary 
phase interactions, such as those with uncapped silanols on unmodified silica stationary 
phases. The main requirement for using SFC is that analytes have to be soluble in either the 
supercritical CO2 or the organic co-solvent. Fortunately, most CECs are soluble in common 
organic solvents like methanol or acetonitrile [14; 24; 26].  
(Stereoselective) analysis of trace levels of CECs is also required in wastewater-based 
epidemiology (WBE). Large public health monitoring studies have become increasingly wide 
spread, both in terms of the size of the populations studied [27-31] and the range of analytes 
that have been detected are often those of interest as environmental micropollutants [27; 32-
40]. However, despite many of these analytes having at least one chiral centre, most 
published WBE analytical methods do not include enantiomer separations. Whilst sometimes 
desirable, this trend can be limiting as it effectively excludes analytical approaches that 
require long sample preparation or analysis times, like chiral HPLC. Therefore, perhaps the 
greatest benefit of SFC is that it could be used for the analysis of both public and 
environmental health determinants. Hence, this manuscript aims to deliver a rapid method 
with sensitive and selective multi-residue measurements of structurally variable groups of 
CECs.  
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2. Materials and Methods 
2.1.Materials 
High purity (≥99.97 %), food grade, gaseous CO2 was supplied to the system from an 
unheated cylinder without a dip tube. All solvents, except water, were of MS-grade and 
purchased from VWR. Ultrapure water was obtained from a MilliQ purification system 
(Merck Millipore, UK). Mobile modifiers trifluroacetic acid (TFA), formic acid (FA), 
ammonium hydroxide, ammonium formate and ammonium acetate were all purchased from 
Sigma Aldrich UK. A full list of analytes and internal standards, and their associated supplier 
information, is provided in the supplementary materials section (Table S1). All glassware 
used was silanised with dimethylchlorosilane (DMDCS in toluene, Sigma-Alrich) prior to use 
to limit adsorption of basic analytes to silanol sites on the surface of the glassware. Solid-
phase extraction cartridges used for validation were Oasis, 60 mg, 3 cc, HLB SPE cartridges 
(Waters, UK). Sample evaporation was performed using a turbovap LV concentration 
workstation (Caliper, UK). Whatman GF/F filter papers were used for all water sample 
filtrations. 
2.2 Methods 
A Waters Acquity UltraPerformance Covergence Chromatography (UPC
2
) instrument 
coupled with either a Waters Acquity QDa single quadrupole mass detector or a Waters Xevo 
TQD triple quadrupole mass spectrometer was used for method development. Three Waters 
chromatography columns were tested: (i) Waters Trefoil 2.1x50 mm, 2.5 µm amylose based 
column modified with 3,5-dimethylphenylcarbamate (AMY1) Waters Trefoil 2.1x50 mm, 2.5 
µm cellulose based column modified 3,5-dimethylphenylcarbamate (CEL1), (iii) Waters 
Trefoil 2.1x50 mm, 2.5 µm cellulose based column modified with 3-chloro-4-
methylphenylcarbamate (CEL2) 
2.2.1 UPC2-MS method development 
2.2.1.1. Initial screening 
Initial screening used conditions outlined in the Waters chiral method development strategy 
for optimal path screening [41]. A range of analytes were selected for this initial screening 
including both chiral and achiral compounds, with a full listing provided in the 
supplementary materials section (Table S1). The following four methods were trialled:  
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(i) AMY1 (column) with A: 100 % CO2 and B: 1:1:1 (v/v) EtOH:IPA:MeCN with 20 mM 
NH4OAc 
(ii) CEL1 (column) with A: 100 % CO2, and B: 1:1 (v/v) MeOH:IPA with 0.2 % (v/v) TFA  
(iii) CEL2 (column) with A: 100 % CO2, and B: 1:1 (v/v) EtOH/MeCN with 0.2 % (v/v) TFA  
(iv) AMY1 with A: 100 % CO2, and B: 1:1 (v/v) EtOH:IPA with 0.2 % (v/v) TFA  
All columns were 2.1x50 mm Trefoil chiral columns with a particle size of 2.5 µm. Initial 
conditions were 3 % B mobile phase at a flow rate of 1.2 mL min
-1
, a column temperature of 
40 
o
C ± 5 
o
C, an automatic backpressure regulator pressure of 3,200 psi, and a sample 
injection volume of 2µL. All samples were dissolved in methanol. The QDa detector was set 
to alternating positive and negative ESI mode and collected data in both modes for a mass 
range of 150-650 m/z. A mobile phase gradient was applied in all methods and consisted of 
holding the initial 3 % B mobile phase conditions for 0.5 minutes, before increasing the % B 
mobile phase to 60 % B over 1.5 minutes and then holding at 60 % B for 0.5 minutes. After 
this, initial conditions were restored by decreasing the mobile phase B % to 3 % B over 0.5 
minutes, and holding at this level for 0.5 minutes before starting the next run. The total cycle 
time for each sample was 3.5 minutes, with MS data collected for 3.0 minutes. The make-up 
solvent used was 9:1 (% v:v) MeOH:H2O with 1 % formic acid and a flowrate of 0.45 mL 
min
-1
.  Analyte detection was performed using single quadrupole MS in ESI+ and ESI- 
scanning mode using the following conditions: ESI+ and ESI- scan conditions used a centroid 
data format and scanned between 120-650 m/z over 3.5 minutes with a cone voltage of 15 V. 
ESI+ capillary voltage was 1.5 kV, ESI- capillary voltage was 0.8 kV. The initial optimal 
screening path was used to identify column chemistries and mobile phases that could resulted 
in at least partial separation of chiral analytes, as well as the detection of both chiral and 
achiral analytes.  
2.2.1.2. Selection of mobile phases 
Following initial screening four mobile phase compositions (A-D) were selected and tested 
with three different columns (see Tables S2 and S3 for details). Analytes were detected using 
the QDa single quadrupole MS using a targeted ESI+ MS method rather than a scanning 
method. Using these methods the following chiral analytes were analysed at a concentration 
of 100 µg L
-1
: atenolol, bisoprolol, ketamine, metoprolol, propranolol, temazepam, zolpidem, 
amitriptyline, MDMA, methamphetamine, amphetamine, PMA, mephedrone, venlafaxine, 
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desmethylvenlafaxine, cocaine, benzoylecognine, methadone, EDDP, fluoxetine, 
chloramphenicol and tramadol.   
2.2.2 Solid-phase extraction 
To enable the sensitive analysis of environmental samples a solid phase extraction (SPE) 
method was developed for use with influent wastewater, effluent wastewater and river water. 
Prior to extraction samples were homogenised by inverting their storage containers to 
resuspend settled sediment. 50 mL of each sample solution was then taken and 25 µL of a 2 
mg L
-1
 internal standard stock solution was added. The sample was then filtered through 
Whatman GF/F filter paper and stored on ice before extraction. Waters Oasis HLB cartridges 
were used to extract samples and were conditioned according to the manufacture’s 
guidelines, using 2 mL of methanol followed by 2 mL of ultrapure water. Samples were 
loaded onto the SPE cartridges under vacuum at a rate of 3 mL min
-1
 before washing with 3 
mL of ultrapure water. Samples were then left to dry under vacuum for 30 minutes. Once 
dried, samples were eluted or directly stored at -20 
o
C for future analysis. Samples were 
eluted using 4 mL of MeOH into silanised glass tubes before being placed in a water bath at 
30 
o
C and evaporated in a turbovap evaporator under a gentle stream of N2. Once completely 
evaporated, samples were reconstituted to a final volume of 500 µL in 100 % MeOH.  
2.2.3 Method performance  
Validation was carried out in accordance with recommendations set by the European 
Medicines Agency (EMA) [42; 43]. Method validation was performed in 100 % methanol, in 
influent wastewater and in river water. The following parameters were evaluated: instrument 
and method accuracy, precision, linearity and range, limits of detection and quantification 
recovery, and signal suppression.  
A mixture of all available analytes was prepared from stock solutions at a concentration of 2 
mg L
-1
 of each analyte in methanol, and was used to create all working solutions, spiked 
samples and quality controls as described below. Another mixture of deuterated compounds 
was also prepared at the same concentration (2 mg L
-1
 of each in methanol) and is described 
in the text as internal standards or internal standard mixture. The internal standard mixture 
was used to create all working solutions, spiked samples and quality controls as described 
below. 
  






-TQD instrument method performance 
The instrument linearity and concentration range over which an analyte could be detected 
were determined using a seventeen point calibration curve ranging from 0.0-1000 µg L
-1
 for 
achiral analytes and 0.0-500 µg L
-1
 for individual chiral isomers such that the concentration 
of the sum of both isomers covered a range of 0.0-1000 µg/L. Calibrant concentrations used 
are as follows, with chiral concentrations in brackets: 0 (0) µg L
-1





, 0.1 (0.05) µg L
-1
, 0.5 (0.25) µg L
-1
, 1 (0.5) µg L
-1
, 5 (2.5) µg L
-1
, 10 (5) µg L
-
1
, 25 (12.5) µg L
-1
, 50 (25) µg L
-1
, 100 (50) µg L
-1
, 200 (100) µg L
-1





, 800 (400) µg L
-1
  and 1000 (500) µg L
-1
. 100 µg L
-1
 of internal standard was 
included in each calibrant sample. Instrument linearity was determined using the R
2
 of a 
linear line of best fit, as determined by the data analysis software used (MassLynx V4.1). The 
linear range was the calibrant concentration range over which the linearity was calculated. 2 
µL of each calibrant sample were injected three times for the determination of linearity.  
Instrument limits of detection (iLOD) and quantification (iLOQ) were determined using the 
calibration curve. iLOD was determined as the lowest measured calibrant concentration with 
an average peak signal to noise ratio (S/N) of greater than or equal to 3 (S/N ≥ 3) across three 
repeat calibrant injections. iLOQ was determined as the lowest measured calibrant 
concentration with an average S/N ≥ 10 across three repeat calibrant injections.  
Accuracy was determined at three different concentrations for both chiral and achiral 
analytes. For achiral analytes accuracy was determined at 10, 50 and 200 µg L
-1
, whilst for 
chiral analytes accuracy was determined at 5, 25 and 100 µg L
-1
. Samples were injected in 
triplicate and accuracy at each concentration (x) was calculated using the following equation 
(eq. 1), where x is the theoretical concentration, e.g. 10 µg L
-1
, and x1-3 is the concentration 
measured in each sample. 
𝐴𝑐𝑐𝑢𝑟𝑎𝑐𝑦 (%) =  
𝑥
Average (𝑥1, 𝑥2, 𝑥3)
∗ 100                                𝑒𝑞. 1 
Precision was determined at the same concentrations as those used for the accuracy and 
determined as the relative standard deviation (RSD) between triplicate injections at each 
concentration (eq 2). Interim or interday precision, was calculated by determining precision 
using the triplicate injection of freshly prepared samples on two different, non-sequential 
days. Repeatability was measured as the average RSD of each day’s precision. 
𝐼𝑛𝑡𝑟𝑎𝑑𝑎𝑦 𝑝𝑟𝑒𝑐𝑖𝑠𝑖𝑜𝑛 (%) =
𝜎𝑥1−𝑥3
𝐴𝑣𝑒𝑟𝑎𝑔𝑒(𝑥1, 𝑥2, 𝑥3)
∗ 100                 𝑒𝑞. 2 




Relative retention time (trel) was measured as the difference between the analyte’s peak 
retention time (tA) in mobile phase and the peak retention time of its assigned internal 
standard (tISTD) (eq. 3). 
𝑡𝑟𝑒𝑙 =   
𝑡𝐴
𝑡𝐼𝑆𝑇𝐷
                   𝑒𝑞. 3 
Enantiomeric resolution (Rs) was also calculated (eq. 4). The base peak width (wx S
-1
) for 
each enantiomer was calculated as the difference between the average peak-end and peak-
start times. tn refers to the peak top retention time of the peak, with the subscript referring to 
the order in which the peaks eluted in.  
𝑅𝑠 =   
𝑡2 − 𝑡1
0.5(𝑤2 + 𝑤1)
       𝑒𝑞. 4 
Enantiomeric fraction (EF) was measured as the relative concentration of the first eluting 
enantiomer (E1) relative to the sum of the concentration of both enantiomers (eq. 5) 
𝐸𝐹 =  
[𝐸1]
[𝐸1] + [𝐸2]




Signal suppression (SS) was calculated by comparing analyte peak areas in river water (RW) 
or wastewater (WW) matrix to equivalent peak areas in mobile phase (eq. 6). Samples of 
each matrix underwent filtration and SPE as described above, but without addition of internal 
standards. After matrix elution, 50 ng of each internal standard and 50 ng of each analyte 
were added.  
𝑆𝑖𝑔𝑛𝑎𝑙 𝑆𝑢𝑝𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛 = 1 − (
𝐴𝑛𝑎𝑙𝑦𝑡𝑒 𝑝𝑒𝑎𝑘 𝑎𝑟𝑒𝑎 
𝑅𝑊
𝑊𝑊𝑆𝑆
− 𝐴𝑛𝑎𝑙𝑦𝑡𝑒 𝑝𝑒𝑎𝑘 𝑎𝑟𝑒𝑎 
𝑅𝑊
𝑊𝑊𝐵𝑙𝑎𝑛𝑘
𝐴𝑛𝑎𝑙𝑦𝑡𝑒 𝑝𝑒𝑎𝑘 𝑎𝑟𝑒𝑎 𝑄𝐶100
)  ∗ 100         𝑒𝑞 6 
Absolute and relative recoveries were calculated by comparison of analyte peak areas or 
concentrations in river water (RW) or influent wastewater (WW), to analyte peak areas or 
concentrations in mobile phase (eq. 7). Both recoveries were determined in triplicate at three 
different concentrations, and then averaged. Analyte was spiked into samples of matrix to 
give a concentration of 0, 0.11, 0.5 or 2 µg L
-1
, along with 50 ng of each internal standard, 
before filtration and SPE as described above (2.2.1.4). Analyte concentrations were 
calculated using calibration curves prepared as outlined above (2.2.2.1), and internal 
standards assigned by using a combination of similar retention times (trel ≈ 1) and signal 
suppression (SSanalyte ≈ SSISTD) factors. 







𝐴𝑛𝑎𝑙𝑦𝑡𝑒 𝑝𝑒𝑎𝑘 𝑎𝑟𝑒𝑎 𝑅𝑊/𝑊𝑊𝑥 − 𝐴𝑛𝑎𝑙𝑦𝑡𝑒 𝑝𝑒𝑎𝑘 𝑎𝑟𝑒𝑎 𝑅𝑊/𝑊𝑊0
𝐴𝑛𝑎𝑙𝑦𝑡𝑒 𝑝𝑒𝑎𝑘 𝑎𝑟𝑒𝑎 𝑄𝐶𝑥
∗ 100 𝑒𝑞. 7 
Method accuracy and precision were calculated at 0.05, 0.5 and 2 µg L
-1
 by spiking each 
analyte into either RW or WW at these concentrations. Method accuracy was calculated (eq. 
8) to determine how close the measured concentration (Analyte conc. RW/WWx1-x3) was to 
spiked concentrations (x), whilst method precision (eq. 9) was used to measure how similar 
the measured concentrations values were to each other. For each equation the concentration 
of analyte in the blank RW or WW samples (Analyte conc. RW/WW0)x1-x3 was subtracted 
from the measured concentration, to account for analyte already present in the matrix. The 




𝐴𝑣𝑒𝑟𝑎𝑔𝑒 (𝐴𝑛𝑎𝑙𝑦𝑡𝑒 𝑐𝑜𝑛𝑐. 𝑅𝑊/𝑊𝑊𝑥 − 𝐴𝑛𝑎𝑙𝑦𝑡𝑒 𝑐𝑜𝑛𝑐 𝑅𝑊/𝑊𝑊0)𝑥1−𝑥3
 ∗ 100 𝑒𝑞. 8 
𝑀𝑒𝑡ℎ𝑜𝑑 𝑝𝑟𝑒𝑐𝑖𝑠𝑖𝑜𝑛 (% 𝑅𝑆𝐷)
=  
𝜎(𝐴𝑛𝑎𝑙𝑦𝑡𝑒 𝑐𝑜𝑛𝑐. 𝑅𝑊/𝑊𝑊𝑥 − 𝐴𝑛𝑎𝑙𝑦𝑡𝑒 𝑐𝑜𝑛𝑐 𝑅𝑊/𝑊𝑊0)𝑥1−𝑥3
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 (𝐴𝑛𝑎𝑙𝑦𝑡𝑒 𝑐𝑜𝑛𝑐. 𝑅𝑊/𝑊𝑊𝑥 − 𝐴𝑛𝑎𝑙𝑦𝑡𝑒 𝑐𝑜𝑛𝑐 𝑅𝑊/𝑊𝑊0)𝑥1−𝑥3
∗ 100 𝑒𝑞. 9 
Enantiomeric fraction and chiral peak resolution were calculated at 5, 50 and 200 µg L
-1
 
using eq. 4 and eq. 5 respectively, in both river water and wastewater. 
Method LOD (mLOD) and method LOQ (mLOQ) were calculated using the instrument LOD 
(iLOD) and instrument LOQ (iLOQ) calculated in 2.2.2.2 and the average relative recovery 
(Recaverage) calculated above (2.2.2.8) (eq. 10). mLOQ was also calculated using eq. 10 by 
substituting iLOD for iLOQ. CF is the concentration factor of the SPE method described 
above (2.2.1.4), which is calculated as the initial volume of matrix used (50 mL) divided by 
the final sample volume (0.5 mL). 
𝑚𝐿𝑂𝐷 =  
𝑖𝐿𝑂𝐷 ∗ 100
𝑅𝑒𝑐𝐴𝑣𝑒𝑟𝑎𝑔𝑒 ∗ 𝐶𝐹
     𝑒𝑞. 10  
2.2.4. Analysis of environmental samples 
Samples of influent, effluent and river water were collected by grab sampling to test the 
suitability of the method in the analysis of real samples. Influent and effluent grab samples 
were collected on the same day, at the same time, from a wastewater treatment plant 
(WWTP) serving a city in the South-West of the UK which discharges its effluent into a 
river. River water grab samples were collected mid-stream, upstream and downstream of the 
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WWTP where influent and effluent samples were also collected. All samples were 
transported back to the lab on ice in separate HDPE containers, and prepared as described in 
2.2.1.4. Two samples were prepared for each matrix and each sample was injected and 
analysed in triplicate. Enantiomeric fractions of chiral analytes were calculated using eq. 5. 
Two rounds of samples were collected. The first set of environmental samples were collected 
in early January 2018 and were used for method validation, as detailed above, whilst the 
second set were collected in February 2018 and analysed for as proof of concept (3.3). 
3. Results and discussion 
3.1 Method development 
3.1.1. Initial screening 
Results from the initial screening using conditions described in 2.2.1 can be generalised as 
follows: (1) Amphetamine and MDMA‘s enantiomers were not separated by any of the four 
methods. Ketamine was partially or fully separated by all but the CEL-1 method. (2) CEL-1 
was the only method to partially separate methamphetamine and mephedrone. (3) CEL-2 was 
able to only partially separate venlafaxine and ketamine. (4) No combination of methods was 
able to separate all chiral analytes 
3.1.2. Selection of mobile phase composition 
Table S4 shows the enantioselective separation that was achieved when using the conditions 
described in Tables S2 and S3 to separate a range of chiral pharmaceuticals and drugs of 
abuse. The most consistent and best performing method was method B2, using CEL-1 and the 
following mobile phase composition: mobile phase A: CO2, mobile phase B: 1:1:1 (v/v) 
MeOH:MeCN:IPA at a flow rate of 1.5 mL min
-1
 with a total runtime of 9 minutes. Mass 
chromatograms showing the enantioselective separation are presented in Figure S1. This 
method was considered as performing best and was therefore selected for validation. The 
analytical set-up was altered to allow for coupling the SFC to the triple quadrupole 
instrument. This was achieved by installing a splitter on the SFC instrument, post-dilution 
with make-up solvent, channelling the flow into the switching valve of the adjoining Xevo 
TQD instrument instead of into the QDa module of the UPC
2
. This transition to the new 
instrument also necessitated adaptations to the mobile phase conditions due to higher system 
backpressures. The mobile phase flow rate was therefore decreased to 0.75 mL min
-1
 with all 
other chromatography conditions left unaltered. The MS conditions used were as follows: 
capillary voltage 3.0 kV, desolvation temperature 400.0 
o
C, source temperature 150.0 
o
C, 
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cone gas flow 100.0 L min
-1
. The MRM transitions, cone voltages and collision energies used 
with the TQD instrument are detailed in Table S5. In total 210 compounds were analysed 
using method B2, necessitating their division into multiple MS methods. First the analytes 
and deuterated internal standards ionised under negative ESI conditions were selected for 
inclusion in the NEG method. The remaining analytes were then separated into two groups to 
create a total of three methods, all with a similar number of scan points per analyte peak. The 
methods can be summarised as follows: (i) DAC method: drugs of abuse, antibiotics and 
chiral analytes, and associated deuterated internal standards ionised in ESI+ mode, (ii) 
PHARMA method: pharmaceuticals, pesticides and other analytes, and associated internal 
standards ionised in ESI+, (iii) NEG method: analytes ionised in ESI- (Table S6). 
3.2 Method validation 
3.2.1 UPC
2
-TQD validation  
Instrument linearity, limits of detection and quantification are shown in Table S7. Internal 
standards were assigned using analyte and internal standard retention time, signal suppression 
and absolute recovery factors, which are shown in the supplementary material (Table S8), 
with priority given to (in order) relative retention time and analyte signal suppression in 
wastewater and river water. EMA guidelines were used to determine which compounds were 
fully quantitative, with compounds that did not meet the required specifications being 
described as semi-quantitative or qualitative, using criteria discussed below. 
Linearity results were generally excellent with most analytes showing a calibration R
2
 value 
>0.997, with only fexofenadine, iopromide, O-desmethyl naproxen and triclosan being 
considered as semi-quantitative due to an R
2
 between 0.990 and 0.997. Semi-quantitative 
compounds appear in italics in Table S7. The linearity results were used to create a 
calibration curve to quantify each of the analytes relative to its assigned internal standard. 
Instrument accuracy and precision were then measured on three non-consecutive days over 
the course of a week, with new samples prepared each day. Results of average instrument 
accuracy and precision determinations at three concentrations are shown in Table 9. 
Accuracy at each concentration should be 100 % ± 20 % and where results are outside of this 
limit they were recorded in italics in Table S9. This deviation largely occurred in the 10 µg L
-
1
 samples. Compounds in italics are considered to be semi-quantitative. Precision was 
recorded as required < 20 % RSD for most analytes. Precision of >20 % occurred mostly in 
analytes at 10 µg L
-1
. The instrument’s ability to resolve enantiomers was assessed along with 
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the enantiomeric fraction in mobile phase, which should be close to 0.5. Resolution and EF 
were calculated at 10, 50 and 200 µg L
-1
 and the average results are shown in Table 1. The 
resolutions are all greater than 1.2 and therefore sufficient for quantification [44; 45]. E2-
tramadol was used to calculate resolution but not EF as it could not be successfully validated. 
Figures S2-4 show the extracted ion chromatograms obtained for each analyte in mobile 
phase at a concentration of 100 µg L
-1
 using the MRM1 transitions detailed in Table S5. 
Figures S2-4 were broken down alphabetically by MS method used, as described in Table S6. 
Table 1. Enantiomeric fraction and peak resolution for chiral analytes (n=12) 
Analytes 
Mobile phase 
EF SD Rs SD 
10,11-dihydro-10-
hydroxy-carbamazepine 
0.5 0.02 10.5 0.8 
Alprenolol 0.5 0.01 5.6 0.1 
Atenolol 0.5 0.02 26.3 2.5 
Bisoprolol 0.5 0.02 12.2 3.3 
Metoprolol 0.5 0.01 12.6 2.5 
Mirtazapine 0.5 0.01 8.7 0.2 
Oxazepam 0.5 0.02 15.5 2.1 
Propanolol 0.5 0.07 18.2 3.3 




-TQD validation  
Average relative SPE-UPC
2
-TQD method recovery was determined at three concentrations 
(0.1, 0.5 and 2 µg L
-1
) and presented in Table 2 as averages. Full recoveries at each 
concentration are presented elsewhere (Table S8 and S10). Signal suppression was calculated 
at 1µg L
-1
 only.  
Table 2. Average relative method recovery at three concentrations (n=9) and signal suppression (n=3) in 
river water and wastewater (semiquantitative compounds are presented in italics) 
Analyte 
Average relative recovery Signal Suppression (%) 




% SD % SD % SD % SD 
Aminorex 58 10.2 120 9.4 12 0.07 -23 0.07 
Anhydroecgonine 
methylester 
97 5.9 108 1.1 -17 0.05 -14 0.05 
Benzophenone-1 60 9.3 102 18.6 -42 0.12 -82 0.11 
Benzophenone-4 97 3.6 89 2.3 -51 0.23 -21 0.16 
Benzoylecgonine 101 10.6 88 16.9 -3 0.02 -2 0.02 
Benzylpiperizine 37 8.9 49 2.2 46 0.04 33 0.03 
Bezafibrate 66 12.5 69 7.1 -17 0.05 -17 0.04 
Buprenorphine 53 10.6 61 5.2 1 0.12 30 0.12 
Candesartan Cilexetil 47 19.0 71 16.6 -4 0.04 -82 0.06 
Carbamazepine 90 9.9 89 6.8 -1 0.03 1 0.03 
Carbamazepine 10,11 
epoxide 
86 12.7 90 18.8 -2 0.03 -18 0.04 
Carprofen 62 0.9 47 8.2 -10 0.00 2 0.00 
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Citalopram 83 8.2 57 11.8 4 0.05 18 0.05 
Clothiniadin 79 13.5 104 10.4 -11 0.04 -30 0.03 
Cocaethylene 90 6.6 95 1.6 -9 0.01 -3 0.02 
Cocaine 89 0.8 90 3.1 -3 0.02 4 0.02 
Codeine 118 30.0 68 15.6 -3 0.06 16 0.08 
Cotinine 109 10.9 77 11.7 -2 0.03 10 0.05 
Desmethylcitalopram 76 15.0 125 15.4 35 0.03 -60 0.04 
DHMA 82 4.2 54 7.4 17 0.07 50 0.12 
Diazepam 84 9.1 93 2.9 -4 0.05 -4 0.03 
Diazinon 65 11.5 122 15.1 -10 0.06 -82 0.12 
Diclofenac 82 2.4 75 14.7 -28 0.02 -24 0.04 
Dihydrocodeine 87 2.6 81 3.4 -1 0.02 7 0.08 
Dihydroketoprofen 86 11.7 57 18.1 -16 0.11 -2 0.08 
Dihydromorphine 90 3.4 88 17.5 4 0.04 18 0.03 
Diltiazem 75 6.5 68 30.6 21 0.01 55 0.02 
Duloxetine 24 3.6 49 5.1 48 0.04 11 0.05 
E1-10,11-dihydro-10-
hydroxycarbamazepine 
111 14.3 112 13.7 -12 0.01 1 0.04 
E1-Alprenolol 83 13.8 66 5.0 2 0.05 33 0.05 
E1-Atenolol 93 7.3 95 1.4 -5 0.03 4 0.04 
E1-Bisoprolol 87 10.1 89 18.1 -7 0.03 -7 0.02 
E1-Metoprolol 87 11.3 80 14.7 -6 0.05 1 0.05 
E1-Mirtazapine 80 8.1 78 2.8 2 0.05 15 0.05 
E1-Oxazepam 85 7.0 79 12.8 2 0.06 8 0.04 
E1-Propanolol 89 6.9 85 10.0 -2 0.03 -6 0.04 
E1-Tramadol 89 19.9 37 11.1 3 0.06 55 0.04 
E2-10,11-dihydro-10-
hydroxycarbamazepine 
101 5.6 113 7.2 -8 0.03 -4 0.02 
E2-Alprenolol 69 11.8 72 1.9 5 0.09 19 0.07 
E2-Atenolol 88 9.8 95 1.1 -5 0.03 4 0.03 
E2-Bisoprolol 86 9.5 90 3.5 -1 0.04 -1 0.04 
E2-Metoprolol 82 14.6 93 6.5 5 0.03 2 0.03 
E2-Mirtazapine 80 10.3 80 0.2 1 0.02 9 0.02 
E2-Oxazepam 94 5.0 79 9.4 4 0.06 6 0.05 
E2-Propanolol 93 2.4 87 1.1 2 0.06 2 0.06 
Ethylparaben 91 11.6 87 4.5 -38 0.08 -59 0.07 
Fexofenadine 89 8.4 50 15.1 -1 0.06 21 0.08 
Griseofulvin 88 5.0 84 11.0 4 0.05 22 0.04 
Heroin 88 3.9 87 2.3 -7 0.04 -7 0.06 
HMA 59 5.4 77 3.8 15 0.02 -6 0.02 
HMMA 81 8.8 147 12.1 -3 0.04 -52 0.04 
Hydrocodone 94 6.6 74 8.1 8 0.01 11 0.04 
Imatinib 68 5.8 100 19.1 -9 0.02 -42 0.02 
Imidacloprid 104 2.9 137 17.1 -24 0.03 -63 0.02 
Indoprofen 79 10.9 70 4.9 4 0.01 24 0.03 
Iopromide 88 10.1 163 13.3 15 0.05 -139 0.05 
Ketamine 92 17.3 104 7.2 -15 0.04 -11 0.04 
Ketoprofen 94 29.2 68 19.2 -86 0.17 -85 0.16 
MDA 70 9.5 89 14.0 -9 0.02 3 0.03 
MDMA 81 10.2 82 11.2 -4 0.04 4 0.04 
MDPV 75 9.5 87 4.0 -2 0.04 -1 0.03 
Memantine 95 19.3 161 9.3 -14 0.05 -19 0.04 
Mephedrone 76 14.9 62 8.3 14 0.04 38 0.03 
Metazachlor 96 4.4 83 14.0 14 0.05 13 0.05 
Methadone 79 9.8 78 4.8 -6 0.07 4 0.05 
Methamphetamine 80 0.4 90 5.2 9 0.04 13 0.04 
Methylparaben 99 0.9 102 1.6 -63 0.11 -73 0.11 
Morphine 98 3.1 102 6.9 1 0.06 11 0.08 
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Nordiazepam 84 7.4 96 4.0 -9 0.03 -6 0.03 
Norephedrine 82 6.1 72 9.4 1 0.02 -13 0.03 
Normorphine 51 6.9 66 5.6 32 0.04 29 0.04 
Nortriptyline 62 1.7 71 13.2 7 0.06 3 0.05 
O-Desmethylnaproxen 72 11.0 88 33.9 -23 0.00 -50 0.00 
Omeprazole 95 11.8 132 13.2 1 0.04 -48 0.06 
Oxadiazon 65 16.8 74 18.9 22 0.06 0 0.07 
Oxycodone 91 4.2 104 13.7 -3 0.03 4 0.03 
Oxymorphone 13 3.6 45 6.8 81 0.05 52 0.05 
Pholcodine 90 3.4 109 8.9 -18 0.04 -39 0.12 
Praziquantrel 85 9.9 96 5.5 -3 0.07 -2 0.04 
Propylparaben 73 35.5 88 22.5 -81 0.07 -113 0.06 
Quetiapine 82 4.9 106 23.5 -1 0.03 -2 0.02 
Risperidone 81 5.0 93 5.4 6 0.03 -10 0.04 
Salbutamol 91 9.8 94 8.5 -5 0.02 -48 0.04 
Sotalol 78 9.2 146 3.7 10 0.02 -83 0.04 
Sulphadiazine 57 7.3 70 5.6 12 0.04 13 0.05 
Sulphamethoxazole 119 14.2 119 1.8 17 0.04 -12 0.04 
Sulphapyridine 87 6.8 111 9.9 17 0.04 9 0.04 
Terbutaline 99 0.2 84 1.5 99 0.01 12 0.01 
Terbuthylazine 75 5.0 87 9.6 13 0.06 10 0.07 
Tetramisole 96 6.8 93 0.2 3 0.05 5 0.07 
Thiamethoxam 113 6.3 149 15.4 -40 0.03 -58 0.04 
Triclosan 90 38.6 36 5.1 -59 0.00 -187 0.00 
Valsartan 80 4.2 74 3.5 -16 0.05 -8 0.04 
Vardenafil 83 4.2 103 4.6 10 0.01 -27 0.03 
Zolpidem 87 6.7 112 20.6 -7 0.05 -34 0.07 
                  
Average relative recovery results were considered fully-quantitative if within 80-120 %, 
although compounds with lower accuracies were accepted as fully quantitative provided the 
average SD was <20 %. Semi-quantitative compounds again appear in italics. Briefly, 66 
analytes in river water and 52 analytes in influent wastewater showed relative recovery at 80-
120 %. 29 compounds in river water and 43 compounds in influent wastewater had recoveries 
<80 % or >120 % (Table 2). Signal suppression should ideally be close to zero with a 
negative signal suppression indicating signal enhancement of the analytes in matrix. The 
results are presented in Table 2. Most compounds were observed to have signal suppression 
of <20 % and signal enhancement of <20 %. Exceptions include: oxymorphone and 
terbutaline with high signal suppression exceeding 80 %, and ketoprofen and propylparaben 
with high signal enhancement exceeding 80 % in river water. In influent wastewater no 
analytes had signal suppression exceeding 80 %, but eight analytes (benzophenone-1, 
candesartan cilexetil, diazinon, iopromide, ketoprofen, propylparaben, sotalol and triclosan) 
had high signal enhancement of >80 %.  
Method recovery values were used to calculate method limits of detection and quantification, 
which are presented by matrix in Tables 3 and 4. Most analytes had mLOD of <33 ng L
-1
 and 
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mLOQ of <78 ng L
-1
, exceptions include benzophenone-4, ethylparaben, ketoprofen and 
sotalol. 
Table 3. Method limits of detection, quantification, method accuracy and method precision in river water 














% SD % SD 
Aminorex 0.009 0.02 113.4 34.8 3.5 2.4 
Anhydroecgonine methylester 0.0004 0.0007 130.3 22.4 1.4 0.9 
Benzophenone-1 0.01 0.06 110.8 25.5 9.2 0.6 
Benzophenone-4 0.2 0.4 99.0 9.5 11.7 9.6 
Benzoylecgonine 0.0001 0.0006 110.3 18.1 2.2 2.1 
Benzylpiperizine 0.004 0.02 89.8 2.4 3.6 2.9 
Bezafibrate 0.01 0.06 105.9 18.5 12.6 3.8 
Buprenorphine 0.02 0.09 12.2 3.6 17.4 8.7 
Candesartan Cilexetil 0.0002 0.001 2393.5 1226.7 3.5 0.7 
Carbamazepine 0.001 0.007 119.1 13.4 1.3 0.4 
Carbamazepine 10,11 epoxide 0.001 0.006 106.1 16.6 4.6 3.6 
Carprofen 0.1 0.3 83.5 0.3 4.8 3.5 
Citalopram 0.002 0.008 112.3 42.3 3.1 1.3 
Clothiniadin 0.0007 0.001 135.9 17.4 3.3 1.2 
Cocaethylene 0.0006 0.001 122.8 21.7 3.2 0.6 
Cocaine 0.0007 0.001 111.2 16.2 1.9 0.6 
Codeine 0.0007 0.001 111.6 9.9 5.8 3.0 
Cotinine n/a n/a 97.0 21.4 1.2 1.0 
Desmethylcitalopram 0.02 0.08 1587.2 1012.6 0.7 0.4 
DHMA 0.1 0.2 108.8 1.5 21.2 24.0 
Diazepam 0.01 0.02 123.5 15.3 5.5 5.8 
Diazinon 0.0007 0.001 663.3 226.3 4.4 1.6 
Diclofenac 0.01 0.05 103.3 2.1 12.6 2.6 
Dihydrocodeine 0.01 0.07 111.5 20.0 3.0 1.8 
Dihydroketoprofen 0.1 0.3 81.7 13.6 20.9 2.3 
Dihydromorphine 0.002 0.01 76.2 7.2 3.6 0.7 
Diltiazem 0.003 0.006 642.5 374.1 0.6 0.5 
Duloxetine 0.0006 0.003 810.0 299.2 6.9 3.6 
E1-10,11-dihydro-10-
hydroxycarbamazepine 
0.07 0.2 110.3 19.8 5.8 3.2 
E1-Alprenolol 0.0007 0.003 87.4 18.1 5.7 2.5 
E1-Atenolol 0.003 0.006 115.4 11.0 5.9 2.3 
E1-Bisoprolol 0.0007 0.004 78.9 15.8 3.2 2.4 
E1-Metoprolol 0.003 0.0006 78.8 13.9 3.0 0.3 
E1-Mirtazapine 0.0001 0.007 124.3 19.0 2.6 1.1 
E1-Oxazepam 0.0007 0.003 94.7 8.6 8.0 2.5 
E1-Propanolol 0.007 0.01 87.2 14.2 4.3 2.9 
E1-Tramadol 0.003 0.006 95.1 18.5 5.4 1.5 
E2-10,11-dihydro-10-
hydroxycarbamazepine 
0.006 0.01 122.5 17.6 5.2 4.5 
E2-Alprenolol 0.0006 0.003 107.6 20.4 8.7 7.2 
E2-Atenolol 0.003 0.006 115.6 13.9 5.4 3.1 
E2-Bisoprolol 0.003 0.007 100.9 19.1 2.9 0.8 
E2-Metoprolol 0.01 0.07 84.2 9.9 5.1 4.7 
E2-Mirtazapine 0.0002 0.008 128.7 18.0 3.4 1.1 
E2-Oxazepam 0.0005 0.001 87.5 17.5 6.2 1.5 
E2-Propanolol 0.004 0.07 87.5 17.6 4.7 2.5 
Ethylparaben 0.7 1 101.6 18.8 2.2 0.7 
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Fexofenadine 0.2 0.4 62.8 9.8 9.0 2.6 
Griseofulvin 0.008 0.02 108.1 16.1 5.2 1.5 
Heroin 0.002 0.009 110.8 27.4 4.3 1.1 
HMA 0.02 0.03 110.7 14.6 4.9 3.7 
HMMA 0.0007 0.001 115.0 27.4 4.1 1.2 
Hydrocodone 0.0009 0.002 97.2 36.4 2.2 1.7 
Imatinib 0.007 0.01 1695.3 601.5 1.3 0.4 
Imidacloprid 0.002 0.003 74.3 16.7 2.3 0.8 
Indoprofen 0.001 0.007 88.2 9.9 5.0 2.1 
Iopromide 0.002 0.009 222.9 114.9 3.2 2.5 
Ketamine 0.001 0.006 121.5 20.2 2.7 1.2 
Ketoprofen 0.3 0.7 121.3 41.0 14.5 0.1 
MDA 0.001 0.007 135.8 15.1 2.1 0.3 
MDMA 0.001 0.006 87.1 15.6 2.0 0.3 
MDPV 0.0001 0.0007 84.7 6.3 3.0 0.9 
Memantine 0.007 0.01 184.4 61.2 9.3 7.6 
Mephedrone 0.0001 0.0007 124.2 25.9 4.1 2.2 
Metazachlor 0.01 0.07 107.6 28.6 2.8 1.1 
Methadone 0.0006 0.001 100.1 10.8 1.7 0.3 
Methamphetamine 0.0002 0.0009 150.0 15.7 2.2 0.3 
Methylparaben 0.01 0.05 106.9 12.1 5.0 2.0 
Morphine 0.001 0.005 104.9 16.7 8.1 7.3 
Nordiazepam 0.005 0.03 115.2 15.9 2.0 1.3 
Norephedrine 0.003 0.02 75.5 1.6 2.4 0.4 
Normorphine 0.001 0.002 39.8 9.9 12.1 10.1 
Nortriptyline 0.001 0.006 91.8 6.7 2.4 1.1 
O-Desmethylnaproxen 0.7 2 109.0 2.0 5.1 4.0 
Omeprazole 0.005 0.01 121.9 15.4 1.1 0.6 
Oxadiazon 0.007 0.01 731.2 362.3 2.3 2.7 
Oxycodone 0.06 0.1 106.1 22.3 2.4 0.9 
Oxymorphone 0.0003 0.002 1143.7 597.5 4.8 6.1 
Pholcodine n/a n/a 78.4 18.9 6.5 2.3 
Praziquantrel 0.0001 0.0001 125.1 16.7 4.1 1.1 
Propylparaben 0.05 0.1 111.0 25.6 7.4 0.9 
Quetiapine 0.00004 0.0002 114.2 29.0 2.4 0.9 
Risperidone 0.0008 0.002 426.6 191.5 1.4 0.4 
Salbutamol 0.007 0.01 122.5 33.0 2.2 0.2 
Sotalol 0.1 0.4 649.6 345.1 1.9 1.2 
Sulphadiazine 0.001 0.002 109.8 4.5 4.7 3.1 
Sulphamethoxazole 0.0005 0.001 69.1 11.5 6.0 1.7 
Sulphapyridine 0.001 0.007 87.9 12.7 1.9 0.5 
Terbutaline 0.001 0.002 -15.4 15.3 -0.5 0.2 
Terbuthylazine 0.01 0.05 584.4 173.4 2.7 1.4 
Tetramisole 0.006 0.01 119.1 20.0 4.4 1.6 
Thiamethoxam 0.000004 0.00002 61.8 10.3 3.9 1.7 
Triclosan 0.05 0.1 103.5 2.6 7.6 5.6 
Valsartan 0.06 0.1 87.0 9.9 14.9 8.6 
Vardenafil 0.0007 0.001 510.1 286.9 0.8 0.3 
Zolpidem 0.3 0.8 82.4 12.9 11.8 12.3 
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Table 4. Method limits of detection, quantification, method accuracy and method precision in influent 











Average Accuracy Average Precision 
% SD % SD 
Aminorex 0.005 0.009 105.3 22.6 2.4 2.0 
Anhydroecgonine 
methylester 
0.0001 0.0003 111.6 11.1 2.0 1.6 
Benzophenone-1 0.01 0.07 66.0 9.8 14.2 8.8 
Benzophenone-4 0.2 0.5 107.6 9.0 5.4 2.1 
Benzoylecgonine 0.0001 0.0005 101.2 18.6 1.1 0.4 
Benzylpiperizine 0.002 0.008 74.5 8.5 3.4 3.0 
Bezafibrate 0.01 0.07 99.9 8.9 11.5 6.3 
Buprenorphine 0.006 0.03 10.0 0.7 8.0 5.2 
Candesartan Cilexetil 0.0001 0.0005 1398.0 610.8 4.8 1.6 
Carbamazepine 0.001 0.006 120.6 13.9 0.7 0.2 
Carbamazepine 10,11 
epoxide 
0.001 0.005 104.0 22.3 2.1 1.0 
Carprofen 0.2 0.5 116.9 25.9 9.5 1.7 
Citalopram 0.001 0.006 203.4 63.2 2.5 0.4 
Clothiniadin 0.0006 0.001 101.0 9.9 2.7 0.3 
Cocaethylene 0.0006 0.001 120.4 14.1 1.7 0.8 
Cocaine 0.0006 0.001 118.7 17.5 1.2 0.5 
Codeine 0.0005 0.001 169.9 52.4 3.2 1.6 
Cotinine 0.007 0.04 49.3 146.7 1.6 0.5 
Desmethylcitalopram 0.01 0.06 907.1 554.9 1.6 0.0 
DHMA 0.1 0.2 117.6 17.3 3.9 3.0 
Diazepam 0.006 0.01 110.3 9.8 5.2 1.8 
Diazinon 0.0007 0.001 336.4 80.7 5.2 2.4 
Diclofenac 0.01 0.05 132.3 23.4 7.0 6.3 
Dihydrocodeine 0.02 0.08 128.9 20.4 2.2 1.1 
Dihydroketoprofen 0.2 0.5 135.7 46.8 7.5 2.8 
Dihydromorphine 0.003 0.02 80.4 13.9 4.0 1.9 
Diltiazem 0.001 0.002 1007.7 634.0 1.6 0.5 
Duloxetine 0.0006 0.003 387.4 98.1 5.4 1.8 
E1-10,11-dihydro-10-
hydroxycarbamazepine 
0.04 0.1 109.0 18.8 1.3 0.3 
E1-Alprenolol 0.0008 0.004 107.8 12.7 2.4 1.1 
E1-Atenolol 0.003 0.006 116.2 14.1 1.1 0.2 
E1-Bisoprolol 0.0006 0.003 99.4 20.7 2.3 1.6 
E1-Metoprolol 0.003 0.0006 85.9 11.8 1.3 0.3 
E1-Mirtazapine 0.0001 0.006 220.5 120.8 4.2 2.8 
E1-Oxazepam 0.0006 0.003 103.1 4.1 8.0 2.2 
E1-Propanolol 0.005 0.01 90.7 13.3 2.0 1.2 
E1-Tramadol 0.007 0.01 165.5 64.8 4.6 0.7 
E2-10,11-dihydro-10-
hydroxycarbamazepine 
0.005 0.01 109.0 13.8 3.3 0.7 
E2-Alprenolol 0.0006 0.003 100.7 9.5 3.9 2.4 
E2-Atenolol 0.003 0.006 112.8 9.4 1.2 0.8 
E2-Bisoprolol 0.003 0.005 99.8 20.3 1.3 0.8 
E2-Metoprolol 0.01 0.06 116.1 13.6 4.5 4.5 
E2-Mirtazapine 0.0001 0.007 164.2 36.2 4.6 4.2 
E2-Oxazepam 0.001 0.002 104.0 11.7 5.8 3.0 
E2-Propanolol 0.003 0.05 133.1 16.8 1.4 1.0 
Ethylparaben 0.6 1 122.0 16.3 4.5 2.9 
Fexofenadine 0.3 0.6 133.2 39.8 9.1 1.1 
Griseofulvin 0.008 0.02 91.8 14.8 3.4 1.5 
Heroin 0.001 0.006 125.5 10.5 4.8 0.8 
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HMA 0.008 0.02 83.6 4.4 3.0 1.3 
HMMA 0.0004 0.0008 69.9 7.5 2.3 2.5 
Hydrocodone 0.0008 0.002 105.7 15.7 2.1 0.8 
Imatinib 0.004 0.008 1191.8 445.9 1.2 0.6 
Imidacloprid 0.001 0.003 56.0 7.4 3.2 2.1 
Indoprofen 0.002 0.008 99.1 15.6 3.9 3.4 
Iopromide 0.001 0.006 148.0 20.8 8.7 5.5 
Ketamine 0.001 0.006 104.7 12.0 2.1 0.8 
Ketoprofen 0.4 0.9 110.7 2.9 4.0 3.2 
MDA 0.001 0.006 113.4 34.6 1.5 0.2 
MDMA 0.001 0.006 85.9 16.9 1.2 0.3 
MDPV 0.0001 0.0007 116.1 13.3 2.0 0.6 
Memantine 0.006 0.01 82.9 17.4 4.4 0.5 
Mephedrone 0.0002 0.0009 148.7 21.7 0.8 0.5 
Metazachlor 0.008 0.04 122.9 15.2 5.2 4.1 
Methadone 0.0007 0.001 143.7 25.0 2.6 0.5 
Methamphetamine 0.0001 0.0007 118.7 31.3 2.1 0.5 
Methylparaben 0.01 0.05 103.5 9.2 2.6 0.3 
Morphine 0.001 0.005 31.7 107.8 2.5 1.4 
Nordiazepam 0.002 0.009 100.6 14.4 3.0 1.6 
Norephedrine 0.002 0.009 90.2 2.8 2.6 0.5 
Normorphine 0.0003 0.0006 42.1 14.7 2.1 0.3 
Nortriptyline 0.001 0.006 82.0 10.2 5.3 1.6 
O-Desmethylnaproxen 0.2 0.6 98.7 26.0 6.4 3.0 
Omeprazole 0.01 0.03 89.2 14.5 2.1 0.7 
Oxadiazon 0.007 0.01 633.6 308.4 6.2 0.7 
Oxycodone 0.008 0.02 97.2 32.0 8.6 10.1 
Oxymorphone 0.0002 0.0009 303.9 93.7 5.3 1.2 
Pholcodine 0.006 0.03 50.7 13.3 10.0 7.1 
Praziquantrel 0.0001 0.0001 110.7 15.3 5.6 1.0 
Propylparaben 0.08 0.2 124.9 13.1 2.0 2.3 
Quetiapine 0.00001 0.00006 96.5 36.8 2.3 0.3 
Risperidone 0.0007 0.001 361.9 153.9 1.3 0.4 
Salbutamol 0.007 0.01 96.7 20.3 1.0 0.5 
Sotalol 0.3 0.7 421.5 114.2 2.5 1.6 
Sulphadiazine 0.0007 0.001 88.7 6.9 3.5 0.8 
Sulphamethoxazole 0.0005 0.0009 67.3 3.4 2.1 0.3 
Sulphapyridine 0.0009 0.005 128.4 2.7 1.4 0.2 
Terbutaline 0.001 0.002 -17.9 17.7 -1.0 0.7 
Terbuthylazine 0.01 0.05 506.5 137.4 1.3 0.6 
Tetramisole 0.007 0.01 121.8 11.8 7.1 6.5 
Thiamethoxam 0.000003 0.00001 47.1 8.8 6.7 4.1 
Triclosan 0.08 0.2 170.8 125.2 2.8 3.1 
Valsartan 0.08 0.2 82.1 2.8 5.0 3.9 
Vardenafil 0.0005 0.0009 425.1 166.4 1.8 0.4 
Zolpidem 0.06 0.2 64.2 4.7 13.8 11.2 
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Semi-quantitative compounds again appear in italics. Likewise, precision results should be as 
close to zero as possible and should be < 20 % RSD. Most analytes performed well with 
accuracies between 80-120 % and precision of <20 % (Table 3 and 4).  Exceptions include 
candesartan cilexetil, diltiazem, duloxetine, fexofenadine and thiamethoxam. The only 
analytes with method precision of >20 % were DHMA and dihydroketoprofen in river water 
only, with an average precision of 21%. 
Resolution of chiral compounds and enantiomeric fractions were calculated at three 
concentrations and the average results are presented in Table 7. Resolution was excellent in 
both matrices, although generally better in river water; due to narrower peak widths and 
greater S/N from a “cleaner” matrix. 10,11-dihydro-10-hydroxycarbamazepine had better 
resolution in wastewater than river water as the E1-enantiomer did not always have a 
quantifiable signal to noise (S/N) ratio in the latter matrix. This, coupled with a narrow peak 
width, lead to relatively greater separation of the two enantiomers in wastewater, rather than 
in river water where both were detected with a quantifiable S/N and a broader peak width. 
Table 5. Method resolution of enantiomers and enantiomeric fractions (n=9) 
Analyte 
River water Wastewater 
Rs SD EF SD Rs SD EF SD 
10,11-dihydro-10-
hydroxycarbamazepine 
13.42 2.34 0.45 0.07 28.56 22.11 0.41 0.09 
Alprenolol 21.92 4.73 0.52 0.01 14.90 2.52 0.45 0.05 
Atenolol 20.84 4.26 0.48 0.02 9.48 5.80 0.50 0.02 
Bisoprolol 46.42 30.58 0.53 0.01 24.82 8.03 0.54 0.02 
Metoprolol 50.22 44.11 0.52 0.02 14.58 2.81 0.50 0.01 
Mirtazapine 7.07 2.02 0.51 0.01 6.43 3.17 0.52 0.01 
Oxazepam 6.54 2.01 0.53 0.03 13.89 11.71 0.45 0.13 
Propanolol 46.41 36.90 0.42 0.11 14.32 4.89 0.47 0.04 
Tramadol 3.76 1.30 - - 5.08 1.35 - - 
                  
 
In summary, after validation, out of 140 analytes tested, there were eighty-one compounds 
where fully quantitative information could be determined, and fourteen semi-quantitatively 
analysed compounds: benzylpiperazine, candesartan cilexetil, carprofen, DHMA, diltiazem, 
duloxetine, E1-tramadol, fexofenadine, HMMA, iopromide, memantine, oxymorphone, 
thiamethoxam and triclosan. There was no clear difference between pKa and Log P of the 
fully and semi-quantiative analytes, although the semi-quantitative analytes had a slightly 
higher average log P (3.4 ± 2.5 vs 2.4 ± 1.6 respectively). Likewise, there was no significant 
difference between the Log P and pKa of the 45 qualitative analytes and the 95 quantitative 
or semi-quantitative analytes. Several of these qualitative analytes performed poorly with 
Chapter three: Results and discussion (Section 3.2) 
178 
 
very low or very high average relative recoveries, despite using a deuterated analogue of the 
analyte as the internal standard and good instrument performance results.  
The ninety-five semi- or fully quantitative compounds included analytes from a range of 
environmentally important classes including seven herbicides, insecticides and pesticides, 
which enter the environment directly (without wastewater treatment) as run-off from 
agriculture, as well as five antifungal compounds, that are routinely added to personal care 
products. Additionally, carprofen and sulphapyridine are licensed for veterinary use and may 
also enter the environment directly. Most of the other analytes are primarily classified as 
human pharmaceuticals including, antidepressants, beta-blockers, non-steroidal anti-
inflammatory drugs (NSAIDs) and opioids. In particular, the beta-blockers performed very 
well in this method, and were all fully quantitative, which was expected as the SFC method 
was selected because it effectively separated beta-blockers. Monitoring these pharmaceuticals 
is important for assessing both public health, via influent wastewater, and environmental 
health, via effluent wastewater and river water, particularly considering European directives 
concerning water quality and reducing the environmental impact of human pharmaceutical 
usage (European Parliament & Council, 2002, Commission, 2019). The remaining fourteen 
analytes are primarily classified as drugs of abuse or their metabolites, although ketamine is 
also widely used in veterinary medicine and so may also enter the environment directly. 
Whilst these compounds are primarily of interest for monitoring drug consumption within 
human populations, they are also analogous to other pharmaceuticals as potential compounds 
of environmental concern.  
  




3.3 Environmental analysis 
Environmental samples were analysed using the validated method. Average concentrations in 
each matrix were recorded in Table 6. The average enantiomeric fraction and average peak 
resolution for chiral analytes in each matrix were presented in Table 7.  
Table 6. Analysis of environmental samples in river water, effluent and influent wastewater 
(semiquantitative compounds are presented in italics) 
Analyte 



















Aminorex <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 
Anhydroecgonine 
methylester 
<LOQ <LOQ 2873.3 42.5 2371.7 25.1 
Benzophenone-1 <LOQ <LOQ <LOQ <LOQ 1211.7 24.0 
Benzophenone-4 2101.7 20.7 60825.0 6.5 18363.3 10.9 
Benzoylecgonine 538.3 4.1 7998.3 1.4 22773.3 2.2 
Benzylpiperizine <LOQ <LOQ <LOQ <LOQ 217.5 5.4 
Bezafibrate <LOQ <LOQ 9781.7 42.7 8821.7 21.3 
Buprenorphine 290.8 14.3 295.0 18.8 307.5 17.4 
Candesartan Cilexetil <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 
Carbamazepine 311.7 6.3 5325 1.6 4191.7 1.4 
Carbamazepine 10,11 
epoxide 
<LOQ <LOQ <LOQ <LOQ 237.5 34.9 
Carprofen <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 
Citalopram 826.7 3.6 6176.7 3.6 5083.3 1.8 
Clothiniadin 486.7 5.1 168.3 16.2 150.0 14.4 
Cocaethylene <LOQ <LOQ <LOQ <LOQ 285.0 7.8 
Cocaine <LOQ <LOQ 1698.3 2.5 9338.3 2.7 
Codeine 988.3 6.7 24883.3 3.7 20900.0 3.2 
Cotinine 260.0 4.4 6206.67 0.5 15716.7 2.3 
Desmethyl 
citalopram 
335.0 6.6 1693.3 5.9 1381.7 5.2 
DHMA <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 
Diazepam <LOQ <LOQ 50.0 54.2 20.0 70.7 
Diazinon 242.5 29.7 <LOQ <LOQ 161.7 12.6 
Diclofenac <LOQ <LOQ 8988.3 40.4 1648.4 20.9 
Dihydrocodeine 236.7 7.2 4298.3 11.2 2951.7 4.8 
Dihydro 
ketoprofen 
<LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 
Dihydromorphine <LOQ <LOQ 511.7 4.8 538.3 5.8 
Diltiazem 266.7 1.8 1033.3 3.9 1083.3 3.7 




<LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 
E1-Alprenolol <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 
E1-Atenolol 103.33 40.5 4468.33 2.4 6211.7 5.2 
E1-Bisoprolol <LOQ <LOQ 791.67 9.4 808.33 5.3 
E1-Metoprolol <LOQ <LOQ 61.7 49 65.0 34.1 
E1-Mirtazapine 71.67 9.6 1003.3 3.8 621.7 5.4 
E1-Oxazepam 118.3 37 856.7 18.1 396.7 18.6 
E1-Propanolol <LOQ <LOQ 1170.0 6.2 916.7 9.4 
E1-Tramadol 401.7 6.8 3691.7 9 2348.3 3.1 
E2-10,11-dihydro-10- <LOQ <LOQ 2086.7 11.8 1031.7 8.8 






E2-Alprenolol <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 
E2-Atenolol 193.3 12.2 4583.3 5.4 5925 4.5 
E2-Bisoprolol 113.3 4.2 1086.7 2.2 1003.3 4.6 
E2-Metoprolol <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 
E2-Mirtazapine 96.7 7.7 446.7 5.4 295.0 6.4 
E2-Oxazepam 241.7 12 875.0 18.7 555 18 
E2-Propanolol 245.0 8.7 1970 5.8 1436.7 4.5 
Ethylparaben 511.7 2.6 548.3 6.3 2376.7 9.1 
Fexofenadine <LOQ <LOQ 27843.3 50.7 10281.7 21.8 
Griseofulvin 150.0 19.6 157.5 13.7 205 22.6 
Heroin 305.0 5.3 <LOQ <LOQ 343.33 15.4 
HMA <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 
HMMA <LOQ <LOQ 346.7 16.4 16.7 44.9 
Hydrocodone 791.7 4.7 7540.0 2.3 5551.7 1.8 
Imatinib 183.3 10.3 301.7 14.8 368.3 12.1 
Imidacloprid 446.7 6.2 3091.7 5.8 788.3 7.3 
Indoprofen <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 
Iopromide <LOQ <LOQ 14861.7 35.3 <LOQ <LOQ 
Ketamine 148.3 7.2 3026.7 5.5 2371.7 3.8 
Ketoprofen <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 
MDA 216.7 5.8 870.0 4.3 476.7 3.8 
MDMA 31.7 11.8 2458.3 1.8 3945.0 2.2 
MDPV <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 
Memantine <LOQ <LOQ 391.7 27.7 226.7 9.8 
Mephedrone <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 
Metazachlor 299.7 3.9 278.3 5.3 276.7 1.7 
Methadone 10.0  0.0 431.7 3.4 513.3 2.7 
Methamphetamine 141.7 2.6 263.3 3.6 268.3 5.5 
Methylparaben 371.7 27.9 440 23.2 16301.7 12 
Morphine 328.3 5.4 8661.7 6.3 11210.0 2.7 
Nordiazepam 55.0 9.1 230.0 14.6 171.7 14 
Norephedrine <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 
Normorphine 731.67 2.1 1438.3 18.4 1810.0 9.6 
Nortriptyline 563.3 10.9 923.3 5.1 616.7 7.8 
O-Desmethy 
lnaproxen 
<LOQ <LOQ 25875.0 47.6 35981.7 21.3 
Omeprazole 321.7 2.1 508.3 4.5 1468.3 3.3 
Oxadiazon 536.7 30.6 <LOQ <LOQ <LOQ <LOQ 
Oxycodone <LOQ <LOQ 373.33 20.5 700 0.0 
Oxymorphone <LOQ <LOQ 455.0 19.5 435.0 13.6 
Pholcodine <LOQ <LOQ 44582.5 36.8 26923.3 44.2 
Praziquantrel 15.0 50.9 90.0 9.1 28.3 51.6 
Propylparaben 550.0 1.8 611.7 7.3 3583.3 7.6 
Quetiapine 346.7 1.4 506.7 3.2 751.7 1.8 
Risperidone 3683.3 16.5 4286.7 16.8 2440 13.8 
Salbutamol 238.3 98.0 413.3 60.7 8078.0 215.4 
Sotalol 6198.3 32.6 97220 9.3 44135.0 10.5 
Sulphadiazine <LOQ <LOQ 288.3 38.7 <LOQ <LOQ 
Sulphamethox-azole <LOQ <LOQ 6426.7 9.0 2590.0 11.5 
Sulphapyridine 496.7 5.5 18958.3 13.7 13751.7 4.5 
Terbutaline 106647.0 17.9 136080.0 14.4 206545.0 12.7 
Terbuthylazine 126.7 5.9 <LOQ <LOQ 83.3 6.0 
Tetramisole <LOQ <LOQ 233.3 9.5 256.7 15.0 
Thiamethoxam <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 
Triclosan 1325.0 9.4 1890.0 44.4 6185.0 31.0 
Valsartan <LOQ <LOQ 5481.7 47.0 2325.0 20.9 




Vardenafil 2618.3 27.5 1691.7 33.5 1201.7 46.3 
Zolpidem 190.0 0.4 240.0 10.6 <LOQ <LOQ 
              
 
Table 7. Average enantiomeric fraction and separation of chiral analytes in matrix ± standard deviation 
(n=9). 
Analytes 
River water Effluent Influent 
EF Rs EF Rs EF Rs 
10,11-dihydro-10- 
hydroxycarbamazepine 
<LOQ 18.2 ± 1.4 
0.00 
 ± 0.01 
14.6 ± 1.1 0.0 ± 0.01 14.5 ± 0.9 
Alprenolol <LOQ 5.4 ± 1.1 <LOQ 5.5 ± 0.4 <LOQ 5.3 ± 0.6 
Atenolol 0.30 ± 0.10 30.5 ± 2.4 0.5 ± 0.01 30.3 ± 1.2 0.5 ± 0.01 32.4 ± 1.3 
Bisoprolol 0.00 ± 0.01 10.1 ± 1.8 0.4 ± 0.01 7.9 ± 0.4 0.4 ± 0.01 7.6 ± 0.4 
Metoprolol <LOQ <LOQ 1.0 ± 0.01 12.2 ± 4.7 1.0 ± 0.01 10.5 ± 0.9 
Mirtazapine 0.40 ± 0.01 8.2 ± 0.8 0.7 ± 0.01 6.7 ± 0.2 0.7 ± 0.01 8.6 ± 0.7 
Oxazepam 0.30 ± 0.10 33.2 ± 5.0 0.5 ± 0.10 19.7 ± 2.1 0.4 ± 0.10 25.1 ± 2.7 
Propanolol <LOQ 22.4 ± 2.8 0.4 ± 0.01 23.2 ± 1.3 0.4 ± 0.01 21.8 ± 1.2 
Tramadol - 6.0 ± 0.3 - 6.0 ± 0.1 - 5.9 ± 0.2 
              
 
CECs were quantified in river water at concentrations spanning from <LOQ (aminorex, 
AEME, benzophenone-1, benzylpiperizine, candesartan cilexetil, carbamazepine-10,11- 
epoxide, carprofen, cocaethylene, cocaine, DHMA, diazepam, diclofenac, dihydroketoprofen, 
dihydromorphine, E1 & E2-10,11-hydrodyo-10-hydroxycarbamazepine, E1 & E2-alprenolol, 
E1 & E2-metoprolol, E1-propanolol, fexodenadine, HMA, HMMA, indoprofen, iopromide, 
ketoprofen, MDPV, memantine, mephedrone, norephedrine, O-desmethylnaproxen, 
oxycodone, oxymorphone, pholcodine, sulphadiazine, sulphamethoxazole, tetramisole, 
thiamethoxam and valsartan) through 0-988 ng L
-1
 (benzoylecgonine, buprenorphine, 
carbamazepine, citalopram, clothiniadin, codeine, cotinine, desmethylcitalopram, diazinon, 
dihydrocodeine, diltiazem, duloxetine, E1 & E2-atenolol, E1 & E2-mirtazapine, E1 & E2-
oxazepam, E1-tramadol, E2-bisoprolol, E2-propanolol, ethylparaben, griseofulvin, heroin, 
hydrocodone, imatinib, imidacloprid, ketamine, MDA, MDMA, metazachlor, methadone, 
methamphetamine, methylparaben, morphine, nordiazepam, normorphine, nortriptyline, 
omeprazole, oxadiazon, praziquantrel, propylparaben, quetiapine, salbutamol, sulphapyridine, 
terbuthylazine and zolpidem) to 1-106 µg L
-1
  (benzophenone-4, risperidone, sotalol, 
terbutaline, triclosan and vardenafil). Interestingly, detected concentrations of some CECs 
were lower in wastewater influent (20 – 26,923 µg L
-1
, average concentration 7402 µg L
-1
) 
than in effluent wastewater (50 – 136,080 µg L
-1
, average concentration 8260 µg L
-1
), which 
may reflect influence from microbial metabolic processes during wastewater treatment. For 
example, a metabolite of citalopram (desmethylcitalopram) was found at concentrations of 
1382 µg L
-1
 in wastewater influent and at 1693 µg L
-1
 in wastewater effluent. Likewise, 
oxazepam had greater concentrations in effluent wastewater (1732 µg L
-1
) than in influent 




wastewater (952 µg L
-1
) which could results from it being a common metabolite of several 
other benzodiazepines, such as diazepam. However, as the water used in this experiment was 
collected by grab sampling it was not possible to conclusively say that this observation was 
due to metabolic processes occurring during wastewater treatment. Similarly, some analytes, 
such as oxadiazon and terbuthylazine, had a greater concentration in river water than influent 
or effluent wastewater. This is likely because they are used as pesticides and so are entering 
the environment directly, e.g. through run off from fields and gardens, rather than from 
human consumption.  
Chiral CECs that were enantiomerically separated are presented in Table 7. Most analytes 
showed non racemic EFs, which indicates enantiomer selective processes occurring either 
due to human metabolism or microbial processes.  This in turn highlights the importance of 
understanding chirality for determining biological effects, including toxicity. For example, 
bisoprolol was the only beta-blocker quantified in all three matrices and was also enriched 
with the E2 isomer in river water compared with influent and effluent wastewater. The EF of 
mirtazapine appeared to vary considerably between wastewater influent and effluent, and 
river water, which suggested it was being preferentially metabolised favouring the E1 
enantiomer in humans and the E2 enantiomer in the environment. To the authors knowledge, 
there is no literature data on the ecotoxicity of mirtazapine, although other antidepressants 
have been studied [46; 47]. The EF of oxazepam also varied between the matrices, however 
the difference in EF was much less pronounced.  




The development of new analytical methods for the analysis of environmental 
micropollutants is important, particularly where critical information on chirality can be 
collected. SFC is an excellent technique for combined achiral - chiral analysis as it allows for 
the development of robust methods with shorter run times than would usually be achieved in 
chiral HPLC methods. This is due to the combined use of supercritical CO2, non-biological 
chiral selectors and smaller UHPLC size particles. The method development data shown 
highlighted the range of available SFC column chemistries, and optimised chromatographic 
conditions for the development of new, combined non-chiral and chiral-SFC methods capable 
of separating a range of different chiral and non-chiral analytes. The final method showcases 
the power of SFC for the rapid analysis (within <10min) of chiral and achiral compounds in 
important environmental matrices. Whilst this method was only able to chirally separate nine 
analytes the initial method development showed that under different chromatographic 
conditions the same column could partially or fully separate another five analytes, with others 
separated under the same chromatographic conditions using alternative columns. In summary, 
out of 140 analytes selected for the study, 81 were fully quantifiable and validated, and 14 
were semi-quantitative. mLOQs spanned 10 pg L
-1
 – 2 µg L
-1 
and accuracy and precision 
were maintained at 103 ± 11.1 % and 4 ± 2.1 % respectively. The analysis of environmental 
samples showed omnipresence of selected CECs, some showing enantioselective fate, such as 
mirtazapine. Overall the CEL-1 methods gave excellent separation of chiral enantiomers and 
rapid quantitative analysis of 95 CEC, at the cost of reduced instrument and method 
sensitivity compared to contemporary achiral methodologies. However, these achiral 
methodologies also provide a road map for how to improve sensitivity without sacrificing the 
efficiency of SFC or focusing on only a handful of analytes. 
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Table S1. Supplier information and CAS numbers for all analytes and internal standards used in this paper 
Compound CAS number Supplier 
1,7-dimethylxantine 611-59-6 Sigma Aldrich 
1S,2R-(+)-ephedrine D3 285979-73-9 LGC standards (Middlesex, UK) 
2-Hydroxyibuprofen 51146-55-5 Sigma Aldrich (Gillingham, UK) 
2-Phenylproponic acid 492-37-5 Sigma-Aldrich (Gillingham, UK) 
8-isoF2B 177020-26-7 Cayman Chemicals 
Acetaminophen 103-90-2 Sigma Aldrich 
Acetaminophen D4 64315-36-2 Sigma Aldrich (Gillingham, UK) 
AEME 43021-26-7 Sigma Aldrich (Cerilliant product) 
Aminorex 2207-50-3 Sigma Aldrich (Gillingham, UK) 
Amoxicillin 26787-78-0 Sigma Aldrich 
Amphetamine 300-62-9 LGC (Cerilliant product) 
Amphetamine D5 136765-27-0 LGC standards (Middlesex, UK) 
Ampicillin 69-53-4 Sigma Aldrich 
Azathioprine 446-86-6 Sigma Aldrich 
Azithromycin 83905-01-5 Sigma Aldrich 
Benzophenone-1 131-56-6 Sigma Aldrich 
Benzophenone-2 131-55-5 Sigma Aldrich 
Benzophenone-3 131-57-7 Sigma Aldrich 
Benzophenone-4 4065-45-6 Sigma Aldrich 
Benzoylecgonine 519-09-5 Sigma Aldrich 
Benzoylecgonine D8 205446-21-5 LGC standards (Middlesex, UK) 
Benzylpiperizine 2759-28-6 LGC 
Bezafibrate 41859-67-0 Sigma Aldrich 
Bicalutamide 90357-06-5 Sigma Aldrich 
Buprenorphine 52485-79-7 Sigma Aldrich 
Caffeine 58-08-2 Sigma Aldrich 
Candesartan cilexetil 145040-37-5 Sigma Aldrich 
Capecitabine 154361-50-9 Sigma Aldrich 
Carbamazepine 298-46-4 Sigma Aldrich 
Carbamazepine-10,11-epoxide 36507-30-9 LGC 
Carbamazepine 13C6 298-46-4 Sigma Aldrich (Gillingham, UK) 
Carboxyibuprofen 15935-54-3 Sigma Aldrich (Gillingham, UK) 
Carprofen 53716-49-7 Sigma Aldrich (Gillingham, UK) 
Cetirizine 83881-51-0 LGC 
Chloramphenicol 56-75-7 Sigma Aldrich 
Chlorpyrifos 2921-88-2 LGC (Dr Ehrenstorfer) 
Cimetidine 51481-61-9 Sigma Aldrich 
Citalopram 59729-33-8 Sigma Aldrich (Gillingham, UK) 
Citalopram D6 1190003-26-9 Toronto Research Chemicals Inc. (Ontario, Canada) 
Clarithromycin 81103-11-9 Sigma Aldrich 
Clothiniadin 210880-92-5 Sigma Aldrich (PESTANAL) 
Cocaethylene 529-38-4 Sigma Aldrich (Cerilliant product) 
Cocaethylene D3 136765-30-5 LGC standards (Middlesex, UK) 
Cocaine 50-36-2 LGC (Cerilliant product) 
Cocaine D3 65266-73-1 LGC standards (Middlesex, UK) 
Codeine 76-57-3 Sigma Aldrich 
Codeine D6 1007844-34-9 LGC standards (Middlesex, UK) 
Cotinine 486-56-6 Sigma Aldrich (Cerilliant product) 
Cotinine D3 110952-70-0 LGC standards (Middlesex, UK) 
Creatinine 60-27-5 Sigma Aldrich 
Cytarabine 147-94-4 Sigma Aldrich 
Danofloxacin 112398-08-0 Sigma Aldrich 
Desmethylcitalopram 62498-67-3 Toronto Research Chemicals Inc. (Ontario, Canada) 
Desmethylvenlafaxine 93413-62-8 Sigma Aldrich (Gillingham, UK) 
Desvenlafaxine 300827-87-6 Sigma Aldrich 
DHMA 15398-87-5 Kinesis  
Diazepam 439-14-5 Sigma Aldrich (Cerilliant product) 




Diazepam D5 65854-76-4 Toronto Research Chemicals Inc. (Ontario, Canada) 
Diazinon 333-41-5 Sigma Aldrich (PESTANAL) 
Dichlofluanid 1085-98-9 Sigma Aldrich (PESTANAL) 
Diclofenac 15307-86-5 Sigma Aldrich 
Dihydrocodeine 125-28-0 Sigma Aldrich 
Dihydro ketoprofen 55453-87-7 Toronto Research Chemicals Inc. (Ontario, Canada) 
Dihydromorphine 509-60-4 Sigma Aldrich (Cerilliant product) 
Diltiazem 42399-41-7 Sigma Aldrich 
Donepezil 120014-06-4 LGC 
Duloxetine 116539-59-4 LGC 
E1 & E2-10,11-dihydro-10-
hydroxycarbamazepine 29331-92-8 LGC 
E1 & E2-Alprenolol 13707-88-5 Sigma Aldrich (Gillingham, UK) 
E1 & E2-Atenolol 29122-68-7 Sigma Aldrich (Gillingham, UK) 
E1 & E2-Atenolol D7 1202864-50-3 Sigma Aldrich (Gillingham, UK) 
E1 & E2-Bisoprolol 66722-44-9 Sigma Aldrich 
E1 & E2-Metoprolol 51384-51-1 Sigma Aldrich (Gillingham, UK) 
E1 & E2-Mirtazapine 85650-52-8 Sigma Aldrich 
E1 & E2-Mirtazapine D3 1216678-68-0 Toronto Research Chemicals Inc. (Ontario, Canada) 
E1 & E2-Propanolol 525-66-6 Sigma Aldrich  
E1 & E2-Tramadol 27203-92-5 Sigma Aldrich (Gillingham, UK) 
E1& E2-Metoprolol D7 12929006-91-2 Toronto Research Chemicals Inc. (Ontario, Canada) 
E1& E2-Oxazepam 604-75-1 Sigma Aldrich (Cerilliant product) 
E1& E2-Oxazepam D5 65854-78-6 Sigma Aldrich (Cerilliant product) 
E1& E2-Propanolol D7 344298-99-3 Sigma Aldrich (Gillingham, UK) 
Ecgonine methyl ester D3 136765-34-9 Sigma Aldrich (Cerilliant product) 
EE2 57-63-6 Sigma Aldrich 
Ephedrine 50-98-6 Sigma Aldrich 
Erythromycin 114-07-8 Sigma Aldrich 
Ethylparaben 120-47-8 Sigma Aldrich 
Fexofenadine 83799-24-0 LGC 
Flufenacet 142459-58-3 LGC (Dr Ehrenstorfer) 
Flumequine 42835-25-6 Sigma Aldrich 
Fluoxetine 54910-89-3 LGC (Cerilliant product) 
Fluoxetine D5 1173020-43-3 Toronto Research Chemicals Inc. (Ontario, Canada) 
Furosemide 54-31-9 Sigma Aldrich 
Gabapentin 60142-96-3 LGC (Cerilliant product) 
Gabapentin D4 1185039-20-6 TRC (Toronto Research Chemicals, Toronto, Canada) 
Gemfibrozil 25812-30-0 Sigma Aldrich 
Gliclazide 21187-98-4 LGC 
Griseofulvin 126-07-8 Sigma Aldrich 
Heroin 561-27-3 Sigma Aldrich (Cerilliant product) 
Heroin D9 1338713-49-7 LGC standards (Middlesex, UK) 
HMA 13062-61-8 Kinesis  
HMMA 438625-58-2 Kinesis  
HNE-MA 75899-68-2 Cayman Chemicals 
Hydrocodone 125-29-1 Sigma Aldrich (Cerilliant product) 
Hydrocodone D6 1007844-38-3 Sigma Aldrich (Cerilliant product) 
Ibuprofen 15687-27-1 Sigma Aldrich 
Ibuprofen D3 121662-14-4 Sigma Aldrich (Gillingham, UK) 
Imatinib 152459-95-5 Sigma Aldrich 
Imazalil sulphate 58594-72-2 Sigma Aldrich (Gillingham, UK) 
Imidacloprid 138261-41-3 Sigma Aldrich (PESTANAL) 
Indoprofen 31842-01-0 Sigma Aldrich (Gillingham, UK) 
Iopromide 73334-07-3 LGC 
Irbesartan 138402-11-6 LGC 
Ketamine 1867-66-9 Sigma Aldrich 
Ketamine D4 1246815-97-3 LGC standards (Middlesex, UK) 
Ketoprofen 22071-15-4 Sigma Aldrich 
Lisinopril 76547-98-3 LGC 
Lomefloxacin 98079-52-8 Sigma Aldrich 
MDA 101-77-9 LGC (Cerilliant product) 
MDA D5 136765-42-9 LGC standards (Middlesex, UK) 
MDMA 42542-10-9 LGC  
MDMA D5 136765-43-0 LGC standards (Middlesex, UK) 
MDPV 687603-66-3 Sigma Aldrich 
Memantine 19982-08-2 Sigma Aldrich 
Mephedrone 1189805-46-6 Sigma Aldrich (Cerilliant product) 
Mephedrone D3 1189972-79-9 LGC standards (Middlesex, UK) 
Metazachlor 67129-08-2 LGC (Dr Ehrenstorfer) 
Metazachlor D6 1246816-51-2 Toronto Research Chemicals Inc. (Ontario, Canada) 




Methadone 76-99-3 Sigma Aldrich (Cerilliant product) 
Methadone D9 1435933-74-6 LGC standards (Middlesex, UK) 
Methamphetamine 537-46-2 LGC (Cerilliant product) 
Methamphetamine D5 60124-88-1 LGC standards (Middlesex, UK) 
Methotrexate 59-05-2 LGC 
Methylparaben 99-76-3 Sigma Aldrich 
Methylparaben 13C6 1581694-95-2 LGC standards (Middlesex, UK) 
Morphine 57-27-2 Sigma Aldrich (Cerilliant product) 
Morphine D3 67293-88-3 LGC standards (Middlesex, UK) 
Nalidixic acid 389-08-2 Sigma Aldrich 
Naproxen 22204-53-1 Toronto Research Chemicals Inc. (Ontario, Canada) 
N-desmethyltramadol 75377-45-6  LGC 
N-guanylurea 207300-86-5 Sigma Aldrich 
Nicotine 54-11-5 Sigma Aldrich 
Norcodeine 467-15-2 Sigma Aldrich (Cerilliant product) 
Nordiazepam 1088-11-5 Sigma Aldrich (Cerilliant product) 
Nordiazepam D5 65891-80-7 Sigma Aldrich (Cerilliant product) 
Norephedrine 154-41-6 Sigma Aldrich 
Norfluoxetine 83891-03-6 LGC (Cerilliant product) 
Normorphine 466-97-7 Sigma Aldrich (Cerilliant product) 
Noroxycodone 52446-25-0 LGC 
Nortriptyline 72-69-5 Sigma Aldrich 
Nortriptyline D3 203784-52-5 Toronto Research Chemicals Inc. (Ontario, Canada) 
O-6-MAM 2784-73-8 Sigma Aldrich (Cerilliant product) 
O-desmethyltramadol 185453-02-5 LGC 
O-desmethylnaproxen 52079-10-4 Sigma Aldrich (Gillingham, UK) 
Ofloxacin 82419-36-1 Sigma Aldrich 
Ofloxacin D3 82419-36-1 Toronto Research Chemicals Inc. (Ontario, Canada) 
Omeprazole 73590-58-6 Sigma Aldrich (Gillingham, UK) 
Orlistat 96829-58-2 Sigma Aldrich 
Oxadiazon 19666-30-9 Sigma Aldrich (PESTANAL) 
Oxycodone 76-42-6 Sigma Aldrich (Cerilliant product) 
Oxycodone D6 152477-91-3 Sigma Aldrich (Cerilliant product) 
Oxymorphone 76-41-5 Sigma Aldrich (Cerilliant product) 
Penicillin G 61-33-6 Sigma Aldrich 
Penicillin V 87-08-1 Sigma Aldrich 
Pholcodine 509-67-1 Sigma Aldrich 
PMA 3706-26-1 LGC 
Praziquantrel 55268-74-1 Sigma Aldrich (Gillingham, UK) 
Praziquantrel D11 1246343-36-1 LGC Standards (Teddington, UK) 
Pregabalin 148553-50-8 LGC (Cerilliant product) 
Propylparaben 94-13-3 Sigma Aldrich 
Prulifloxacin 123447-62-1 Sigma Aldrich 
Quetiapine 111974-69-7 LGC 
Quetiapine D8 1185247-12-4 LGC standards (Middlesex, UK) 
Ranitidine 66357-35-5 Sigma Aldrich 
Risperidone 106266-06-2 LGC 
Salbutamol 18559-94-9 Sigma Aldrich (Gillingham, UK) 
Sarafloxacin 98105-99-8 Sigma Aldrich (VETRANAL) 
Sertraline 79617-96-2 LGC 
Sertraline D3 1217741-83-7 Sigma Aldrich (Gillingham, UK) 
Sitagliptin 486460-32-6 TRC 
Sotalol 3930-20-9 Sigma Aldrich (Gillingham, UK) 
Sulphadiazine 68-35-9 Sigma Aldrich (VETRANAL) 
Sulphamethoxazole 723-46-6 Sigma Aldrich 
Sulphapyridine 144-83-2 Sigma Aldrich 
Sulphasalazine 599-79-1 Sigma Aldrich 
Terbutaline 23031-25-6 Sigma Aldrich (Gillingham, UK) 
Terbuthylazine 5915-41-3 Sigma Aldrich 
Tetramisole 5086-74-8 Sigma Aldrich (Gillingham, UK) 
Tetramisole D5 1173021-85-6 LGC Standards (Teddington, UK) 
Thiamethoxam 153719-23-4 LGC (Ultra) 
Triallate 2303-17-5 Sigma Aldrich (PESTANAL) 
Triclosan 3380-34-5 Sigma Aldrich 
Valsartan 137862-53-4 Sigma Aldrich 
Vardenafil 224789-1515-5 Sigma Aldrich (Cerilliant product) 
Venlafaxine 93413-69-5 Sigma Aldrich 
Zolpidem 99294-93-6 Sigma Aldrich (Cerilliant product) 
      













Make-up      
flow   







1990 2 35 
0 min 3 % B,  
4 min 30 % B,  
6 min 30 % B 
 
 (9 minutes) 





w/ 0.1 % 
NH4OH 







1800 1.5 30 
0 min 15 %B, 1 
min 15 % B, 5 
min 60 % B, 7 
min 60 % B 
 
MeOH w/ 0.1 % 
formic acid @ 










with 0.2 % (v/v) 
TFA 
1800 1.5 30 
0 min 5 % B, 
3.5 min 5 % B, 
10 min 60 % B,  
13.5 min  
60 % B 
MeOH w/ 0.2 % 
NH4OH @ 0.3 
mL min-1 





20 mM NH4OAc 
in MeOH 
1500 2 35 
 
0 min 7 % B, 
1 min 7 % B,  
7 min 25 % B,  
9 min 25 % B 
Not given, 
conditions for 
method A used 
(Waters 
2012) 
(10 minutes)     
 
 
Table S3. Matrix of method conditions used to analyse analytes 
SFC method / Column AMY-1 CEL-1 CEL-2 Mobile phase conditions 
A A1 A2 A3 B: IPA:EtOH – 9 minute gradient 
B B1 B2 B3 B: MeOH:MeCN:IPA – 9 minute gradient 
C C1 C2 C3 B: EtOH:MeCN with 0.2 % TFA – 16 minute gradient 
D D1 D2 D3 B: MeOH with 20 mM NH4OAC – 10 minute gradient 
 
 
Table S1. Chiral separation using twelve different methods  
Method / 
column AMY-1 CEl-1 CEL-2 
A 
A1: Temazepam, tramadol (partial) A2: Bisprolol, Metoprolol, propranolol, 
ketamine, Mepehdrone (partial), 
Methamphetamine (partial), MDMA (partial) 
A:3 Temazepam 
B 
B1: Bisoprolol, temazepam, metoprolol, 
propranolol, ketamine, 
desmethylvenlafaxine, PMA (partial), 
Mephedrone (partial) 
B:2 Bisprolol, metoprolol, atenolol, propranolol, 






C1: Metoprolol, propranolol, EDDP C2: Bisoprolol, temazepam, metoprolol 
(partially), atenolol, propranolol, ketamine, 
mephedrone (partially), fluoxetine 
C3: Temazepam, atenolol 
D 
D1: Ketamine, methamphetamine (partial), 
Fluoxetine, betablockers separated but 
carry-over into the next injection 
D2: Mephedrone and methamphetamine, MDMA 
(partial), PMA (partial) 









Figure S1. Enantioselective separation of bisoprolol, temazepam (partial), metoprolol, atenolol and 
propranolol in method B2. N.B. Labetolol elution occurred during column void volume 
  




Table S5. MRM conditions of analytes and isotopically labelled internal standards studied using the 
selected SFC-TQD method  
Analyte MRM 1 transition CV (V) / CE (V) 
MRM 2 
transition 
CV (V) / CE (V) 
1,7 dimethylxantine 181 > 124 54 / 21 - - 
1S,2R-(+)-ephedrine D3 169 > 151 23 / 18 - - 
2-Hydroxyibuprofen 221 > 177 30 /6 221 > 159 30 / 12 
2-Phenylproponic Acid 149 > 105 20 / 5 - - 
8-isoF2B 353 > 309 53 / 18 353 > 247 53 / 22 
Acetaminophen 152 > 110 26 / 16 152 > 93 26 / 24 
Acetaminophen D4 156 > 114 26 / 16 - - 
AEME 182 > 118 39 / 23 182 > 122 39 /21 
Aminorex 163 > 120 20 / 15 163 > 103 20 / 20 
Amoxicillin 366 > 208 22 / 13 366 > 114 22 / 23 
Amphetamine 136 > 119 18 / 8 136 > 91 18 / 16 
Amphetamine D5 141 > 93 20 / 14 - - 
Ampicillin 350 > 160 44 / 10 350 > 107 44 / 28 
Azathioprine 278 > 142 28 / 20 278 > 85 28 / 13 
Azithromycin 750 > 116 60 / 54 750 > 83 60 / 60 
Benzophenone-1 213 > 135 36 / 20 213 > 91 34 / 25 
Benzophenone-2 245 > 109 32 / 20 245 > 135 32 / 13 
Benzophenone-3 229 > 151 35 / 18 229 > 105 35 / 20 
Benzophenone-4 307 > 227 44 / 24 307 > 211 42 / 35 
Benzoylecgonine 290 > 168 38 / 19 290 > 105 38 / 30 
Benzoylecgonine D8 298 > 171 38 / 19 - - 
Benzylpiperizine 177 > 91 35 / 20 177 > 85 35 / 15 
Bezafibrate 360 > 274 30 / 19 360 > 154 30 / 28 
Bicalutamide 431 > 217 40 / 15 431 > 187 40 / 13 
Buprenorphine 468 > 396 66 / 41 468 > 414 66 / 35 
Caffeine 195 > 138 38 / 15 195 > 110 38 / 23 
Candesartan Cilexetil 611 > 567 44 / 7 611 > 467 44 / 7 
Capecitabine 360 > 244 25 / 11 360 > 174 25 / 23 
Carbamazepine 237 > 194 40 / 20 237 > 179 40 / 38 
Carbamazepine-10,11-epoxide 253 > 210 39 / 12 253 > 180 39 / 25 
Carbamazepine 13C6 243 > 200 40 / 20 - - 
Carboxyibuprofen 235 > 191 25 / 8 235 > 73 25 / 15 
Carprofen 272 > 228 39 / 17 272 > 226 39 / 39 
Cetirizine 389 > 201 32 / 21 389 > 166 32 / 40 
Chloramphenicol 321 > 152 27 / 15 321 > 194 35 / 12 
Chlorpyrifos 350 > 198 34 / 16 350 > 125 34 / 19 
Cimetidine 253 > 159 22 / 16 253 > 211 22 / 10 
Citalopram 325 > 262 46 / 18 325 > 110 46 / 26 
Citalopram D6 331 > 109 46 / 28 - - 
Clarithromycin 749 > 590 40 / 20 749 > 158 40 / 31 
Clothiniadin 250 > 132 28 / 15 250 > 113 28 / 25 
Cocaethylene 318 > 196 38 / 20 318 > 82 38 / 30 
Cocaethylene D3 321 > 199 40 / 22 - - 
Cocaine 304 > 182 40 / 20 304 > 82 40 / 31 
Cocaine D3 307 > 185 40 / 20 - - 
Codeine 300 > 215 49 / 25 300 > 152 49 / 57 
Codeine D6 306 > 218 52 / 28 - - 
Cotinine 177 > 80 34 / 21 177 > 98 34 / 22 
Cotinine D3 180 > 80 44 / 24 - - 
Creatinine 114 > 44 30 / 15 114 > 86 31 / 11 
Cytarabine 244 > 112 20 / 14 244 > 133 20 / 15 
Danofloxacin 358 > 340 65 / 20 358 > 255 38 / 38 
Desmethylcitalopram 311 > 109 46 / 27 311 > 262 46 / 18 
Desmethylvenlafaxine 264 > 107 25 / 24 264 > 246 25 / 20 
Desvenlafaxine 264 > 107 25 / 24 264 > 246 25/ 20 
DHMA 182 > 123 6 / 18 182 > 151 6 / 12 
Diazepam 285 > 154 56 / 29 285 > 222 56 / 27 
Diazepam D5 290 > 198 56 / 34 - - 
Diazinon 305 > 169 36 / 22 305 > 153 36 / 22 
Dichlofluanid 335 > 123 29 / 31 335 > 271 29 / 6 
Diclofenac 294 > 250 22 / 13 - - 
Dihydrocodeine 302 > 199 53 / 33 302 > 128 53 / 60 
Dihydroketoprofen 255 > 211 30 / 8 - - 
Dihydromorphine 288 > 185 28 / 42 288 > 213 28 / 32 
Diltiazem 415 > 178 40 / 25 415 > 310 40 / 25 
Donepezil 380 > 288 56 / 24 380 > 262 56 / 23 




Duloxetine 298 > 154 16 / 5 280 > 188 16 / 5 
E1 & E2-10,11-dihydro-10-
hydroxycarbamazepine 
255 > 194 20 / 20 255 > 179 20 / 40 
E1 & E2-Alprenolol 250 > 116 44 / 16 250 > 98 44 / 18 
E1 & E2-Atenolol 267 > 145 38 / 30 267 > 190 38 / 16 
E1 & E2-Atenolol D7 274 > 145 44 / 30 - - 
E1 & E2-Bisoprolol 326 > 116 45 / 18 326 > 204 45 / 19 
E1 & E2-Metoprolol 268 > 116 42 / 20 268 > 121 42 / 22 
E1 & E2-Mirtazapine 266 > 195 44 / 18 266 > 72 44 / 26 
E1 & E2-Mirtazapine D3 269 > 195 35 / 25 - - 
E1 & E2-Propanolol 260 > 116 42 / 16 260 > 183 42 / 18 
E1 & E2-Tramadol 264 > 58 28 / 45 264 > 121 28 / 46 
E1& E2-Metoprolol D7 275 > 123 44 / 20 - - 
E1& E2-Oxazepam 287 > 241 38 / 22 287 > 269 38 /14 
E1& E2-Oxazepam D5 292 > 274 38 / 15 - - 
E1& E2-Propanolol D7 267 > 189 40 / 18 - - 
Ecgonine methylester D3 203 > 85 44 / 22 - - 
EE2 295 > 159 60 / 40 295 > 145 60 / 40 
Ephedrine 166 > 148 23 / 12 166 > 133 23 / 21 
Erythromycin 735 > 159 12 / 32 735 > 576 12 / 20 
Ethylparaben 165 > 92 26 / 20 164 > 137 20 / 14 
Fexofenadine 500 > 456 33 / 14 500 > 378 33 / 19 
Flufenacet 364 > 194 24 / 10 364 > 152 24 / 18 
Flumequine 262 > 202 28 / 34 262 > 245 28 / 26 
Fluoxetine 310 > 44 34 / 10 310 > 148 34 / 10 
Fluoxetine D5 315 > 153 26 / 8 - - 
Furosemide 331 > 313 31 / 8 331 > 239 31 / 10 
Gabapentin 172 > 154 30 / 12 172 > 95 30 / 22 
Gabapentin D4 176 > 158 33 / 16 - - 
Gemfibrozil 251 > 205 21 / 9 251 > 123 21 / 14 
Gliclazide 324 > 127 41 / 20 324 > 110 41 / 20 
Griseofulvin 353 > 69 45 / 25 353 > 165 45 / 23 
Heroin 370 > 165 51 / 50 370 > 268 51 / 29 
Heroin D9 379 > 166 51 / 50 - - 
HMA 182 > 123 6 / 18 182 > 165 6 / 14 
HMMA 196 > 165 16 / 12 196 > 133 16 / 22 
HNE-MA 318 > 171 32 / 22 318 > 162 32 / 14 
Hydrocodone 300 > 199 24 / 34 300 > 171 24 / 46 
Hydrocodone D6 306 > 202 64 / 32 - - 
Ibuprofen 205 > 161 19 / 8 - - 
Ibuprofen D3 208 > 164 20 / 6 - - 
Imatinib 494 > 394 57 / 27 494 > 378 57 / 48 
Imazalil sulphate 297 > 159 40 / 20 297 > 201 40 / 18 
Imidacloprid 256 > 209 34 / 15 256 > 175 34 / 19 
Indoprofen 282 > 236 45 / 20 282 > 77 45 / 15 
Iopromide 792 > 573 46 / 25 792 > 559 46 / 32 
Irbesartan 427 > 193 50 / 28 427 > 121 50 / 65 
Ketamine 238 > 125 31 / 27 238 > 220 31 / 15 
Ketamine D4 242 > 129 31 / 27 - - 
Ketoprofen 253 > 209 15 / 7 253 > 212 15 / 7 
Lisinopril 406 > 84 38 / 27 406 > 246 38 / 22 
Lomefloxacin 352 > 265 22 / 24 352 > 308 22 / 22 
MDA 180 > 163 21 / 11 180 > 105 21 / 22 
MDA D5 185 > 168 21 / 11 - - 
MDMA 194 > 163 24 / 13 194 > 105 24 / 24 
MDMA D5 199 > 165 26 /13 - - 
MDPV 276 > 126 40 / 28 276 > 135 40 / 25 
Memantine 180 > 107 36 / 24 180 > 121 36 / 24 
Mephedrone 178 > 145 10 / 22 178 > 160 10 / 12 
Mephedrone D3 181 > 148 30 / 22 - - 
Metazachlor 278 > 210 21 / 21 278 > 134 21 / 10 
Metazachlor D6 284 > 216 21 / 10 - - 
Methadone 310 > 265 31 / 15 310 > 105 31 /28 
Methadone D7 319 > 268 31 / 15 - - 
Methamphetamine 150 > 91 24 / 19 150 > 119 24 / 10 
Methamphetamine D5 155 > 92 28 / 18 - - 
Methotrexate 455 > 175 40 / 35 455 > 308 40 / 20 
Methylparaben 151 > 92 34 / 20 151 > 136 20 / 14 
Methylparaben 13C6 157 > 98 30 / 20 - - 
Morphine 286 > 165 53 / 38 286 > 152 53 / 56 
Morphine D3 289 > 152 53 / 56 - - 
Nalidixic acid 233 > 187 30 / 28 233 > 131 30 / 36 




Naproxen 229 > 169 20 / 8 229 > 185 20 / 8 
N-desmethyl tramadol 250 > 44 25 / 12 250 > 232 25 / 8 
N-Guanylurea 103 > 60 24 / 10 103 > 86 24 / 8 
Nicotine 163 > 130 37 / 20 163 > 117 37 / 24 
Norcodeine 286 > 165 46 / 40 286 > 268 46 / 20 
Nordiazepam 271 > 140 51 / 29 271 > 165 51 / 29 
Nordiazepam D5 276 > 140 48 / 36 - - 
Norephedrine 152 > 134 23 / 10 152 > 117 23 / 16 
Norfluoxetine 296 > 134 18 / 6 - - 
Normorphine 272 > 165 45 / 43 272 > 152 45 / 49 
Noroxycodone 302 > 227 22 / 36 302 > 187 22 /38 
Nortriptyline 264 > 91 33 / 23 264 > 233 33 / 16 
Nortriptyline D3 267 > 191 40 / 20 267 > 233 40 / 8 
O-6-MAM 328 > 165 52 / 39 328 > 211 52 / 26 
O-desmethyl tramadol 250 > 58 30 > 18 250 > 232 30 / 10 
O-Desmethylnaproxen 215 > 170 20 / 10 - - 
Ofloxacin 362 > 261 43 / 28 362 > 318 43 / 19 
Ofloxacin D3 365 > 261 47 / 28 365 > 322 47 / 23 
Omeprazole 346 > 198 20 / 10 - - 
Orlistat 496 > 319 40 / 13 496 > 160 40 / 12 
Orlistat 496 > 319 40 / 13 496 > 160 40 / 12 
Oxadiazon 345 > 303 43 / 14 344.9 > 302.8 43 / 20 
Oxycodone 316 > 241 36 / 29 316 > 256 36 / 26 
Oxycodone D6 322 > 247 36 / 29 - - 
Oxymorphone 302 > 284 40 / 19 302 > 227 40 / 28 
Penicillin G 335 > 176 48 / 20 335 > 160 48 / 20 
Penicillin V 316 > 114 54 / 40 316 > 160 54 / 40 
Pholcodine 399 > 381 55 / 25 399 > 100 55 / 35 
PMA 166 > 121 20 / 20 166 > 149 20 / 20 
Praziquantrel 313 > 203 40 / 15 313 > 83 40 / 35 
Praziquantrel D11 325 > 204 40 / 20 - - 
Pregabalin 160 > 142 32 / 11 160 > 125 32 / 14 
Propylparaben 179 > 92 34 / 25 179 > 136 20 / 16 
Prulifloxacin 462 > 444 42 / 22 462 > 360 42 / 32 
Quetiapine 384 > 253 50 / 21 384 > 221 50 / 40 
Quetiapine D8 392 > 258 50 / 23 - - 
Ranitidine 316 > 176 26 / 17 316 > 124 26 / 14 
Risperidone 411 > 191 49 / 30 411 > 110 49 / 51 
Salbutamol 240 > 148 30 / 18 240 > 166 30 / 14 
Sarafloxacin 386 > 368 49 / 23 386 > 299 49 / 28 
Sertraline 306 > 159 23 / 27 306 > 275 23 / 10 
Sertraline D3 309 > 159 23 / 27 - - 
Sitagliptin 408 > 235 46 / 19 408 > 193 46 / 26 
Sotalol 273 > 133 30 / 28 273 > 213 30 / 16 
Sulphadiazine 251 > 108 30 / 26 251 > 158 30 / 15 
Sulphamethoxazole 254 > 92 36 / 30 254 > 156 36 / 20 
Sulphapyridine 250 > 156 42 / 16 250 > 92 42 / 30 
Sulphasalazine 397 > 197 45 / 25 397 > 240 45 / 25 
Terbutaline 226 > 105 66 / 22 - - 
Terbuthylazine 230 > 174 35 / 17 230 > 132 35 / 24 
Tetramisole 205 > 91 45 / 35 205 > 123 45 / 30 
Tetramisole D5 211 > 183 30 / 15 - - 
Thiamethoxam 292 > 211 44 / 12 292 > 132 44 / 22 
Triallate 306 > 145 34 / 26 306 > 128 34 / 13 
Triclosan 289 > 35 18 / 10 289 > 37 18 / 10 
Valsartan 434 > 350 35 / 20 434 > 179 35 / 25 
Vardenafil 489 > 151 74 / 68 489 > 312 74 / 48 
Venlafaxine 278 > 58 27 / 40 278 > 260 27 / 12 
Zolpidem 308 > 221 8 / 44 - - 
          
  









SD DAC method analyte 
tR 
(min) 




1,7-DMX 0.8 0.01 
AEME 
0.3 0.0 2-Hydroxy-ibuprofen 1.1 0.04 
Ecgoninemethylester D3 
Acetaminophen 
0.8 0.02 Aminorex 1.3 0.03 2-Phenylproponic acid N/A 0.03 
Acetaminophen D4 
Azathioprine 2.5 0.02 
Amoxicillin 3.4 0.05 
8-IsoF2B 2.7 0.02 
Amphetamine 
0.8 0.00 
Benzophenone-3 0.4 0.01 Amphetamine D5 Benzophenone-1 0.6 0.01 
Bicalutamide 0.7 0.02 Ampicillin 2.9 0.05 Benzophenone-2 N/A N/A 
Buprenorphine 0.9 0.01 Azithromycin 1.2 0.05 Benzophenone-4 4.5 0.01 
Caffeine 0.6 0.00 
Benzoylecgonine 
2.4 0.01 Bezafibrate 3.8 0.01 
Benzoylecgonine D8 
Candesartan Cilexetil 3.4 0.01 Benzylpiperizine 1.0 0.01 Carboxyibuprofen 4.0 0.04 
Capecitabine 1.4 0.02 
Carbamazepine 
1.6 0.00 Carprofen 3.1 0.02 
Carbamazepine 13C6 
Chlorpyrifos 0.4 0.01 
Carbamazepine-10,11-
epoxide 
2.1 0.01 Chloramphenicol 1.0 0.01 
Cimetidine 2.2 0.03 Cetirizine 3.2 0.05 Diclofenac 2.4 0.01 
Citalopram 
0.7 0.01 Clarithromycin 1.2 0.05 Dihydro-ketoprofen 2.5 0.02 
Citalopram D6 
Clothiniadin 1.5 0.02 
Cocaethylene 





0.4 0.00 Ethylparaben 0.4 0.01 




Danofloxacin 3.0 0.05 Fexofenadine 4.2 0.02 
Cotinine D3   
Creatinine 2.0 0.04 DHMA 0.4 0.01 HNE-MA 3.9 0.02 







Desmethyl-citalopram 1.2 0.01 E1-Alprenolol 0.8 0.01 Irebsartan 3.4 0.00 
Desmethyl-venlafaxine 1.1 0.01 
E1-Atenolol 
3.1 0.01 Ketoprofen 1.2 0.02 
E1-Atenolol D7 







1.0 0.02 Naproxen N/A N/A 
Diazepam D5 E1-Metoprolol D7 
Diazinon 0.3 0.00 
E1-Propanolol 
2.3 0.01 O-desmethyl-naproxen 2.9 0.01 
E1-Propanolol D7 
Dichlofluanid 0.4 0.01 E1-Tramadol 0.6 0.00 Propylparaben 0.4 0.01 
Dihydrocodeine 1.2 0.01 
E2-10,11-dihydro- 
10-hydroxy-carbamazepine 
1.8 0.01 Sulphasalazine 5.5 0.02 
Dihydromorphine 2.6 0.02 E2-Alprenolol 1.1 0.01 Triclosan 0.6 0.01 
Diltiazem 0.6 0.00 
E2-Atenolol 
3.4 0.00 Valsartan 7.1 0.04 
E2-Atenolol D7 











E1-Oxazepam D5  E2-Propanolol D7 
E2-Mirtazapine 
0.8 0.01 E2-Tramadol 1.1 0.00 
E2-Mirtazapine D3 
E2-Oxazepam 
2.4 0.01 Ephedrine 1.0 0.02 
E2-Oxazepam D5 
Flufenacet 0.4 0.01 Erythromycin 0.9 0.05 
Fluoxetine 
0.6 0.01 Flumequine 1.5 0.05 
Fluoxetine D5 





Gabapentin D4 Heroin D9 
Gemfibrozil 0.4 0.02 HMA 2.1 0.01 
Gliclazide 1.0 0.02 HMMA 1.7 0.01 
Hydrocodone 
1.1 0.02 Imazalil sulphate 0.6 0.02 
Hydrocodone D6 
Imatinib 3.8 0.01 Indoprofen 2.7 0.01 




Iopromide 3.9 0.03 Lomefloxacin 3.2 0.05 









2.2 0.02 MDPV 0.4 0.01 
Morphine D3 

















1.5 0.01 Nalidixic acid 1.0 0.05 
Nordiazepam D5 
Norfluoxetine 1.0 0.01 N-desmethyl-tramadol 1.2 0.03 
Normorphine 3.5 0.02 Norephedrine 1.4 0.01 
Noroxycodone 2.7 0.03 O-6-MAM 1.0 0.02 
Nortriptyline 
1.3 0.02 O-desmethyl-tramadol 1.1 
0.01 
Nortryptyline D3 0.01 




Orlistat 0.4 0.01 Orlistat 0.5 0.02 
Oxadiazon 0.3 0.01 Penicillin G 3.4 0.05 
Oxycodone 
0.7 0.01 Penicillin V 3.0 0.05 
Oxycodone D6 
Oxymorphone 2.7 0.02 PMA 0.9 0.02 




Pregabalin 3.6 0.02 Prulifloxacin 3.4 0.05 
Quetiapine 
1.3 0.01 Sarafloxacin 3.2 0.05 
Quetiapine D8 
Ranitidine 2.6 0.01 Sulphadiazine 2.4 0.00 
Risperidone 1.9 0.01 Sulphamethoxazole 1.8 0.01 





Sertraline D3 Tetramisole D5 
Sitagliptin 1.4 0.03 Tylosin N/A N/A 
Sotalol 2.5 0.01 
 
 
Terbutaline 0.6 0.00 
 
Terbuthylazine 0.4 0.00 
 
Thiamethoxam 1.4 0.02 
 
Triallate 0.4 0.02 
 
Vardenafil 3.2 0.02 
 
Venlafaxine 0.5 0.00 
 
Zolpidem 1.0 0.01   
                  
 
  









Figure S2. Extracted mass chromatograms for analytes in the PHARMA method using their MRM 1 
transitions 









Figure S3. Extracted mass chromatograms for analytes in the DAC method using their MRM 1 transitions 





Figure S4. Mass chromatograms for analytes in the NEG method using their MRM1 transitions 
  




Table S7. Instrument linearity, range, instruments limits of detection and quantification and average 














Aminorex 1.6±0.02 1.5-600 0.997 0.50 1.50 Tetramisole D5 
Anhydroecgonine methylester 1.0±0.02 0.1-600 0.999 0.05 0.10 
Ecgonine methylester 
D3 
Benzophenone-1 1.1±0.03 5-1000 0.998 1.00 5.00 Ibuprofen D3 
Benzophenone-4 11.1±0.02 15-800 0.994 5.00 15.00 Methylparaben 13C6 
Benzoylecgonine 1.0±0.003 0.05-600 0.998 0.01 0.05 Benzoylecgonine D8 
Benzylpiperizine 7.5±0.02 0.5-800 0.999 0.10 0.50 Amphetamine D5 
Bezafibrate 1.1±0.02 5-1000 0.997 1.00 5.00 Ibuprofen D3 
Buprenorphine 1.2±0.01 5-400 0.999 1.00 5.00 E2-Mirtazapine D3 
Candesartan Cilexetil 0.9±0.01 5-400 0.999 1.00 5.00 Gabapentin D4 
Carbamazepine 1.0±0.004 0.5-600 0.999 0.10 0.50 Carbamazepine 13C6 
Carbamazepine 10,11 epoxide 1.3±0.01 0.5-600 0.998 0.10 0.50 Carbamazepine 13C6 
Carprofen 6.1±0.03 25-600 0.997 10.00 25.00 Ibuprofen D3 
Citalopram 0.9±0.02 1.5-400 0.998 0.50 1.50 Citalopram D6 
Clothiniadin 1.7±0.01 0.5-400 0.998 0.10 0.50 Diazepam D5 
Cocaethylene 1.0±0.01 0.15-600 0.999 0.05 0.15 Cocaethylene D3 
Cocaine 1.0±0.02 0.15-600 0.998 0.05 0.15 Cocaine D3 
Codeine 1.0±0.01 0.15-400 0.998 0.05 0.15 Codeine D6 
Cotinine 1.0±0.01 0.15-200 0.999 0.05 0.15 Cotinine D3 
Desmethylcitalopram 1.0±0.01 0.5-400 0.998 0.10 0.50 Codeine D6 
DHMA 0.5±0.03 25-600 0.993 10.00 25.00 MDMA D5 
Diazepam 1.0±0.01 0.15-200 0.999 0.05 0.15 Diazepam D5 
Diazinon 0.2±0.01 1.5-600 0.999 0.50 1.50 E1-Oxazepam D5 
Diclofenac 4.7±0.03 5-600 0.997 1.00 5.00 Ibuprofen D3 
Dihydrocodeine 1.0±0.01 0.15-200 0.997 0.05 0.15 Codeine D6 
Dihydroketoprofen 4.9±0.03 25-1000 0.995 10.00 25.00 Ibuprofen D3 
Dihydromorphine 1.2±0.01 5-400 0.998 1.00 5.00 Morphine D3 
Diltiazem 0.8±0.01 0.5-800 0.999 0.10 0.50 Oxycodone D6 
Duloxetine 4.5±0.01 0.15-600 0.997 0.05 0.15 Metazachlor D6 
E1-10,11-dihydro-10-
hydroxycarbamazepine 
0.8±0.01 0.5-200 0.998 0.10 0.5 Carbamazepine 13C6 
E1-Alprenolol 0.3±0.01 0.25-200 0.997 0.05 0.25 E1-Atenolol D7 
E1-Atenolol 1.0±0.003 0.75-600 0.998 0.25 0.75 E1-Atenolol D7 
E1-Bisoprolol 1.1±0.01 0.25-200 0.999 0.05 0.25 E1-Metoprolol D7 
E1-Metoprolol 1.0±0.02 0.5-200 0.999 0.25 0.5 E1-Metoprolol D7 
E1-Mirtazapine 1.0±0.01 0.25-100 0.998 0.05 0.25 E1-Mirtazapine D3 
E1-Oxazepam 1.0±0.01 0.5-200 0.998 0.01 0.50 E1-Oxazepam D5 
E1-Propanolol 1.0±0.004 1.5-600 0.998 0.50 1.50 E1-Propanolol D7 
E1-Tramadol 0.7±0.01 0.25-200 0.997 0.05 0.25 MDMA D5 
E2-10,11-dihydro-10-
hydroxycarbamazepine 
1.1±0.01 1.5-800 0.998 0.50 1.50 Carbamazepine 13C6 
E2-Alprenolol 0.3±0.01 0.25-500 0.998 0.05 0.25 E2-Attenolol D7 
E2-Atenolol 1.0±0.002 0.75-600 0.999 0.25 0.75 E2-Atenolol D7 
E2-Bisoprolol 1.0±0.01 0.75-400 1.000 0.25 0.75 E2-Metoprolol D7 
E2-Metoprolol 1.0±0.01 2.5-200 0.999 1.00 2.5 E2-Metoprolol D7 
E2-Mirtazapine 1.0±0.01 0.25-200 0.999 0.05 0.25 E2-Mirtazapine D3 
E2-Oxazepam 1.0±0.004 0.5-400 0.998 0.01 0.50 E2-Oxazepam D5 
E2-Propanolol 1.0±0.003 0.75-400 0.997 0.25 0.75 E2-Propanolol D7 
Ethylparaben 1.0±0.03 5-600 0.998 1.00 5.00 Methylparaben 13C6 
Fexofenadine 8.5±0.03 25-1000 0.993 10.00 25.00 Ibuprofen D3 
Griseofulvin 0.8±0.01 1-400 0.997 0.50 1.00 Praziquantrel D11 
Heroin 1.0±0.02 0.5-800 0.999 0.10 0.50 Heroin D9 
HMA 2.7±0.01 1-600 0.997 0.50 1.00 MDMA D5 
HMMA 2.1±0.01 0.1-200 0.999 0.05 0.10 MDMA D5 
Hydrocodone 1.0±0.02 5-400 0.997 1.00 5.00 Hydrocodone D6 
Imatinib 1.7±0.01 0.1-200 0.999 0.05 0.10 Morphine D3 
Imidacloprid 3.8±0.01 1-200 0.997 0.50 1.00 Metazachlor D6 
Indoprofen 1.7±0.004 0.5-600 0.999 0.10 0.50 Carbamazepine 13C6 
Iopromide 1.1±0.01 10-400 0.994 5.00 10.00 Gabapentin D4 




Ketamine 1.0±0.01 0.5-600 0.998 0.10 0.50 Ketamine D4 
Ketoprofen 2.3±0.03 10-1000 0.997 5.00 10.00 Ibuprofen D3 
MDA 1.0±0.03 0.5-600 0.999 0.10 0.50 MDA D5 
MDMA 1.0±0.01 0.5-400 0.998 0.10 0.50 MDMA D5 
MDPV 0.5±0.01 0.05-200 0.998 0.01 0.05 MDMA D5 
Memantine 0.8±0.01 0.5-400 0.998 0.10 0.50 Codeine D6 
Mephedrone 1.0±0.03 0.05-400 0.998 0.01 0.05 Mephedrone D3 
Metazachlor 1.0±0.02 1.5-400 0.998 0.50 1.50 Metazachlor D6 
Methadone 1.0±0.01 0.1-600 0.998 0.05 0.10 Methadone D9 
Methamphetamine 1.0±0.01 0.05-800 0.999 0.01 0.05 Methamphetamine D5 
Methylparaben 1.0±0.03 5-600 0.997 1.00 5.00 Methylparaben 13C6 
Morphine 1.0±0.01 5-400 0.998 1.00 5.00 Morphine D3 
Nordiazepam 1.0±0.01 0.5-200 0.999 0.10 0.50 Nordiazepam D5 
Norephedrine 1.4±0.01 0.5-600 0.997 0.10 0.50 Flumequine 13C3 
Normorphine 8.7±0.01 5-800 1.000 1.00 5.00 Metazachlor D6 
Nortriptyline 1.0±0.01 5-400 0.998 1.00 5.00 Nortryptyline D3 
O-Desmethylnaproxen 5.6±0.03 75-1000 0.991 25.00 75.00 Ibuprofen D3 
Omeprazole 0.9±0.01 0.5-400 1.000 0.10 0.50 Quetiapine D8 
Oxadiazon 0.2±0.03 1.5-400 0.998 0.50 1.50 E1-Oxazepam D5 
Oxycodone 1.0±0.02 1.5-400 0.998 0.50 1.50 Oxycodone D6 
Oxymorphone 6.8±0.01 1.5-600 1.000 0.50 1.50 Metazachlor D6 
Pholcodine 0.6±0.01 5-200 0.998 1.00 5.00 Gabapentin D4 
Praziquantrel 1.0±0.01 0.05-400 0.998 0.01 0.05 Praziquantrel D11 
Propylparaben 1.0±0.03 5-800 0.999 1.00 5.00 Methylparaben 13C6 
Quetiapine 1.0±0.02 0.1-400 0.998 0.05 0.10 Quetiapine D8 
Risperidone 0.5±0.01 0.05-400 0.998 0.01 0.05 Gabapentin D4 
Salbutamol 3.2±0.01 1-200 0.997 0.05 0.10 Diazepam D5 
Sotalol 0.7±0.01 0.5-400 0.999 0.10 0.50 Gabapentin D4 
Sulphadiazine 0.9±0.003 0.1-400 0.999 0.05 0.10 E2-Propanolol D7 
Sulphamethoxazole 0.7±0.02 0.1-1000 0.998 0.05 0.10 Ofloxacin D3 
Sulphapyridine 0.9±0.003 0.5-200 0.998 0.10 0.50 Benzoylecgonine D8 
Terbutaline 1.0±0.02 25-800 0.997 10.00 25.00 Fluoxetine D5 
Terbuthylazine 0.2±0.01 0.15-400 0.999 0.05 0.15 E1-Oxazepam D5 
Tetramisole 1.0±0.01 1.5-600 0.999 0.50 1.50 Tetramisole D5 
Thiamethoxam 1.1±0.02 5-200 0.999 1.00 5.00 Quetiapine D8 
Triclosan 1.1±0.04 15-1000 0.991 5.00 15.00 Ibuprofen D3 
Valsartan 14.2±0.03 15-1000 0.998 5.00 15.00 Ibuprofen D3 
Vardenafil 0.9±0.01 0.05-400 0.998 0.01 0.05 Gabapentin D4 
Zolpidem 0.9±0.01 0.5-600 0.999 0.10 0.50 Hydrocodone D6 








Table S8. Average absolute recoveries (%) for all analytes analysed in the method, even if not developed 
further (n=3)  
Analyte 
River water Wastewater 
10 µg L-1 50 µg L-1 200 µg L-1 10 µg L-1 50 µg L-1 200 µg L-1 
1,7 dimethylxantine 130.38 51.33 59.65 7320.58 2303.42 318.38 
2-Hydroxyibuprofen 18.88 42.19 27.30 16890.07 1991.20 226.19 
8-isoF2B 0.00 0.00 101.45 0.00 258.28 95.79 
Acetaminophen 106.09 57.33 87.86 8642.40 1522.31 -118.34 
Anhydroecgonine methylester 22.99 41.17 48.74 27.85 42.26 45.70 
Aminorex 18.02 29.83 32.12 26.73 36.02 41.64 
Amphetamine 30.76 59.35 60.77 22.22 28.40 32.16 
Azathioprine 0.00 59.68 61.18 30.63 51.60 55.33 
Benzophenone-1 29.48 67.94 59.97 75.64 113.44 85.44 
Benzophenone-3 9.99 46.16 56.54 -187.79 33.62 54.26 
Benzophenone-4 180.31 101.10 79.60 -201.52 145.17 85.40 
Benzoylecgonine 50.58 83.03 82.57 47.53 67.41 52.26 
Benzylpiperizine 9.12 11.89 23.56 17.58 23.59 32.26 
Bezafibrate 57.66 69.82 66.44 67.27 95.59 77.57 
Bicalutamide 110.59 72.76 80.32 68.74 13.20 36.45 
Buprenorphine 27.70 39.47 56.19 7.11 34.39 40.00 
Caffeine 53.67 63.29 85.61 349.13 -34.88 -33.04 
Candesartan Cilexetil 20.02 22.92 24.91 4.29 22.82 20.79 
Capecitabine 43.75 58.78 63.93 39.60 52.68 55.40 
Carbamazepine 48.48 75.00 75.99 50.15 60.47 53.33 
Carbamazepine 10,11 epoxide 51.92 75.83 75.37 44.51 65.34 60.60 
Carprofen 23.20 68.68 53.29 32.20 61.04 55.09 
Chlorpyrifos -272.63 17.16 21.34 -127.30 16.89 16.63 
Cimetidine 21.22 53.14 53.14 62.67 76.14 54.92 
Citalopram 34.36 55.57 73.66 11.26 27.94 31.51 
Clothiniadin 46.84 69.70 74.66 41.18 49.96 52.04 
Cocaethylene 44.81 64.54 71.64 22.24 34.79 38.40 
Cocaine 38.96 64.34 69.73 20.35 33.69 37.12 
Codeine 31.17 67.54 90.62 166.17 56.83 48.69 
Cotinine 26.76 56.98 78.36 34.53 22.55 26.09 
Creatinine -2.85 0.18 0.25 509.83 137.81 -0.38 
Cytarabine -1.58 -0.10 0.52 -1.35 1.73 0.42 
Desmethylcitalopram 26.23 39.21 57.52 24.39 46.05 49.95 
Desmethylvenlafaxine 23.23 70.99 81.25 73.41 62.60 49.78 
Desvenlafaxine 29.49 71.30 79.91 68.06 63.47 47.64 
DHMA 11.98 57.91 52.65 95.89 30.14 30.52 
Diazepam 56.15 73.41 82.00 41.31 45.23 42.35 
Diazinon 35.90 47.89 42.83 40.18 58.87 53.56 
Diclofenac 49.80 77.11 67.47 53.64 90.57 75.64 
Dihydrocodeine 52.79 70.88 85.94 47.77 56.35 57.27 
Dihydroketoprofen 104.48 89.07 69.86 89.69 62.65 71.85 
Dihydromorphine 60.70 69.61 75.13 63.09 53.68 48.70 
Diltiazem 35.50 54.61 60.67 7.31 18.30 19.58 
Duloxetine 9.58 14.48 22.21 0.83 25.53 27.02 
E1-10,11-dihydro-10-hydroxycarbamazepine 53.52 79.18 90.76 34.85 59.09 65.89 
E1-Alprenolol 48.53 49.23 70.17 19.40 35.84 38.73 
E1-Atenolol 46.60 65.81 69.80 -9.66 59.69 53.21 
E1-Bisoprolol 38.92 59.11 77.48 34.95 55.82 57.23 
E1-Metoprolol 45.99 64.10 77.30 30.54 47.92 51.58 
E1-Mirtazapine 42.94 70.68 85.65 17.04 30.42 35.68 
E1-Oxazepam 55.45 68.32 67.12 51.25 54.68 51.09 
E1-Propanolol 35.49 51.80 62.29 53.72 67.84 63.91 
E1-Tramadol 32.06 73.71 78.75 3.51 21.80 25.21 
E2-10,11-dihydro-10-hydroxycarbamazepine 50.83 79.73 80.88 47.71 66.05 62.26 
E2-Alprenolol 47.04 49.31 64.76 43.13 51.43 48.38 
E2-Atenolol 55.74 67.86 75.00 56.15 74.97 61.10 
E2-Bisoprolol 40.08 58.74 68.24 55.38 81.21 71.12 
E2-Metoprolol 39.85 58.00 69.15 65.86 75.87 69.59 
E2-Mirtazapine 54.58 70.00 88.17 27.54 41.84 44.32 
E2-Oxazepam 61.50 69.90 67.28 39.36 45.81 44.21 
E2-Propanolol 37.05 51.71 65.77 27.51 51.65 53.63 
E2-Tramadol 38.70 73.92 75.55 14.33 48.27 42.98 
Ephedrine 6.70 8.08 17.89 -23.58 23.67 29.30 
Ethylparaben 59.78 87.00 78.39 0.00 127.87 93.85 
Fexofenadine 97.97 74.04 67.01 75.84 72.29 68.28 
Flufenacet 32.58 46.04 56.01 24.01 31.12 33.15 
Fluoxetine 10.94 17.39 29.63 1.70 11.01 12.81 




Furosemide 3.53 1.85 1.12 4.84 13.23 5.93 
Gabapentin 15.31 0.96 1.40 56.91 9.93 2.54 
Gemfibrozil 448.09 68.28 69.93 -519.74 -33.21 15.32 
Gliclazide 30.89 59.29 66.52 42.76 51.47 50.69 
Griseofulvin 62.76 75.18 95.44 42.34 38.45 49.48 
Heroin 28.87 41.02 44.01 14.62 18.22 19.55 
HMA 19.75 37.29 44.48 13.54 35.33 36.28 
HMMA 45.31 65.03 70.37 44.54 59.97 57.87 
HNE-MA 0.00 98.95 64.79 0.00 66.50 79.25 
Hydrocodone 42.33 68.62 90.08 85.42 56.98 59.50 
Ibuprofen 0.00 116.96 102.88 6291.11 2364.50 562.20 
Imatinib 42.45 50.63 55.69 35.65 55.29 49.51 
Imazalil sulphate 22.87 48.64 65.00 2.88 12.00 16.60 
Imidacloprid 50.06 79.46 87.27 61.58 70.02 66.97 
Indoprofen 50.88 68.24 68.29 32.94 44.57 43.67 
Iopromide 43.82 71.14 77.87 107.35 87.92 60.68 
Irbesartan 47.04 66.20 65.94 44.94 57.07 51.62 
Ketamine 49.23 73.70 74.37 28.93 35.63 34.75 
Ketoprofen 30.29 87.24 79.39 0.00 83.54 82.07 
MDA 22.63 47.14 49.70 29.07 44.36 57.03 
MDMA 37.05 64.01 71.57 29.25 38.11 40.49 
MDPV 40.48 54.45 68.77 25.76 37.23 37.18 
Memantine 38.50 66.94 56.87 43.38 60.00 71.88 
Mephedrone 16.15 33.76 41.91 8.52 15.42 21.19 
Metazachlor 61.03 74.27 77.81 15.22 39.11 45.58 
Methadone 52.35 59.04 68.91 13.90 34.98 36.81 
Methamphetamine 20.61 52.81 40.76 14.68 19.52 24.49 
Methylparaben 0.00 92.80 76.52 201.09 158.44 97.57 
Morphine 49.04 73.39 81.15 150.38 94.67 68.89 
N-desmethyl tramadol 19.62 31.91 45.39 37.13 53.31 48.49 
N-Guanylurea -20.70 -3.03 0.11 -6.66 0.04 1.00 
Nicotine -3.60 35.06 40.05 113.06 42.10 28.70 
Norcodeine 22.85 21.93 57.17 47.32 30.54 41.45 
Nordiazepam 57.15 73.94 81.20 47.52 59.81 56.70 
Norephedrine 13.18 16.22 27.49 25.63 30.38 29.36 
Norfluoxetine 4.15 7.81 11.92 4.02 13.61 18.90 
Normorphine 2.57 31.17 52.07 36.88 51.19 43.43 
Noroxycodone 9.93 6.56 17.04 14.64 23.32 26.07 
Nortriptyline 21.02 26.26 33.56 13.42 36.69 38.99 
O-6-MAM 48.89 83.27 117.30 30.24 55.98 64.73 
O-desmethyl tramadol 42.29 73.16 79.00 28.73 48.39 45.60 
O-Desmethylnaproxen 0.00 62.40 66.56 0.00 95.71 96.27 
Omeprazole 72.68 86.54 75.22 80.08 73.43 54.70 
Orlistat 5.60 7.72 11.04 1.73 1.41 1.46 
Orlistat 5.18 7.29 10.79 -1.65 1.07 1.41 
Oxadiazon 40.26 37.82 39.99 17.69 26.20 25.26 
Oxycodone 64.42 74.69 94.18 43.24 41.02 50.38 
Oxymorphone 0.00 6.28 17.37 15.14 23.61 28.13 
Pholcodine 56.25 76.65 83.27 91.65 72.15 70.54 
PMA 30.95 36.10 49.82 0.00 106.43 69.58 
Praziquantrel 50.65 78.00 97.41 39.75 51.81 60.21 
Pregabalin 0.00 0.00 0.00 7.79 2.51 0.96 
Propylparaben 102.92 102.23 86.18 370.29 157.29 106.81 
Quetiapine 53.54 67.78 76.65 47.64 55.11 51.89 
Ranitidine 28.09 56.33 66.60 240.41 111.69 53.71 
Risperidone 50.32 60.62 68.23 43.74 62.09 56.19 
Salbutamol 49.45 70.32 76.68 15.78 35.59 37.86 
Sertraline 16.33 21.90 31.69 9.63 17.69 17.43 
Sitagliptin -3.95 15.47 24.62 34.13 36.23 32.69 
Sotalol 40.86 53.02 68.76 51.81 59.03 52.03 
Sulfasalazine -52.84 12.12 19.67 -13.91 60.34 55.25 
Sulphadiazine 35.36 40.65 35.99 40.49 42.05 36.80 
Sulphamethoxazole 40.36 59.42 66.30 31.32 51.83 49.21 
Sulphapyridine 44.29 62.24 69.41 119.96 78.46 50.55 
Terbutaline 12.92 13.09 6.78 10.59 9.46 3.46 
Terbuthylazine 40.37 54.88 59.43 30.56 37.61 37.34 
Tetramisole 48.29 64.11 74.83 28.05 33.49 33.62 
Thiamethoxam 68.36 84.84 102.92 42.42 67.96 74.71 
Triclosan 4.71 225.85 45.81 222.34 211.87 46.72 
Valsartan 17.95 82.36 72.78 45.83 85.68 72.56 
Vardenafil 52.77 67.45 69.07 44.94 71.44 70.32 




Venlafaxine 49.69 69.54 73.31 11.59 29.03 29.10 
Zolpidem 55.60 76.28 81.95 36.63 63.45 54.91 
        
 
 
Table S9. Instrument accuracy and precision assessed over a period of one week (semiquantitative 







(% RSD) (Average % RSD) 
Average 
(n = 9) 
SD 
Average 
(n = 9) 
SD 
Average 
(n = 3) 
SD 
Aminorex 99 7.4 4 0.7 3 1.5 
Anhydroecgonine 
methylester 
101 3.8 2 1.3 2 0.9 
Benzophenone-1 107 6.9 6 3.8 19 3.4 
Benzophenone-4 106 26.0 7 1.1 14 7.7 
Benzoylecgonine 102 5.2 1 1.0 1 0.6 
Benzylpiperizine 99 7.2 2 0.1 2 0.2 
Bezafibrate 123 11.6 7 3.0 16 0.2 
Buprenorphine 100 8.8 5 1.3 6 1.5 
Candesartan Cilexetil 99 9.7 5 4.3 5 4.2 
Carbamazepine 101 5.9 2 1.0 2 0.6 
Carbamazepine 10,11 
epoxide 
97 6.7 3 1.6 3 2.2 
Carprofen 98 0.3 6 2.1 15 1.6 
Citalopram 98 18.0 3 0.4 2 0.4 
Clothiniadin 97 10.9 2 0.6 2 0.9 
Cocaethylene 105 7.3 1 0.3 2 0.7 
Cocaine 103 6.3 3 1.7 3 1.0 
Codeine 99 13.6 4 0.1 5 1.2 
Cotinine 99 6.9 3 1.2 2 0.2 
Desmethylcitalopram 99 13.0 3 1.6 3 0.4 
DHMA 107 4.9 12 9.1 7 2.8 
Diazepam 98 3.2 2 1.2 2 0.7 
Diazinon 103 4.8 5 3.0 5 2.5 
Diclofenac 116 0.7 9 6.7 17 0.2 
Dihydrocodeine 103 9.3 4 1.1 4 0.6 
Dihydroketoprofen 112 18.3 5 0.8 15 0.4 
Dihydromorphine 100 13.5 3 1.5 3 2.3 
Diltiazem 106 15.8 4 0.9 3 0.6 
Duloxetine 106 15.7 4 1.6 4 1.6 
E1-10,11-dihydro-10-
hydroxycarbamazepine 
92 5.7 4 0.8 4 3.1 
E1-Alprenolol 105 8.4 2 1.0 3 0.7 
E1-Atenolol 96 6.4 1 0.8 2 0.8 
E1-Bisoprolol 95 4.1 2 1.0 3 1.0 
E1-Metoprolol 95 3.0 2 0.8 4 1.2 
E1-Mirtazapine 93 3.4 2 0.0 2 0.3 
E1-Oxazepam 100 9.1 3 0.8 4 0.3 
E1-Propanolol 95 9.6 2 1.4 3 0.1 
E1-Tramadol 90 6.3 3 0.1 3 0.3 
E2-10,11-dihydro-10-
hydroxycarbamazepine 
95 5.0 3 0.5 2 0.4 
E2-Alprenolol 109 5.9 2 1.2 2 0.8 
E2-Atenolol 95 4.7 2 1.1 2 0.9 
E2-Bisoprolol 94 5.7 2 0.6 2 0.5 
E2-Metoprolol 99 12.4 2 0.1 3 1.8 




E2-Mirtazapine 97 3.1 2 0.6 2 0.1 
E2-Oxazepam 101 13.4 2 1.2 2 0.7 
E2-Propanolol 91 3.5 3 0.6 3 0.1 
Ethylparaben 103 8.6 8 0.7 11 3.9 
Fexofenadine 104 2.8 2 0.7 14 12.4 
Griseofulvin 97 7.1 4 0.7 4 0.8 
Heroin 98 14.5 3 0.8 4 0.6 
HMA 96 12.6 3 1.9 3 1.0 
HMMA 108 12.0 3 2.0 2 0.9 
Hydrocodone 93 18.1 5 1.9 3 0.8 
Imatinib 105 5.8 3 0.6 3 0.5 
Imidacloprid 96 10.4 2 1.5 2 0.8 
Indoprofen 86 6.4 5 4.2 4 3.0 
Iopromide 98 17.2 4 2.4 5 1.4 
Ketamine 103 7.9 1 1.0 3 0.1 
Ketoprofen 127 9.7 7 5.9 17 3.4 
MDA 99 10.4 1 0.1 1 0.1 
MDMA 101 8.5 1 0.6 1 0.4 
MDPV 104 9.4 3 0.8 3 0.4 
Memantine 100 7.6 5 1.5 4 1.8 
Mephedrone 105 4.1 2 0.5 3 0.2 
Metazachlor 95 11.6 5 1.9 4 2.0 
Methadone 104 7.7 3 0.6 2 0.6 
Methamphetamine 94 10.6 2 0.2 3 0.4 
Methylparaben 99 8.3 6 0.7 9 5.4 
Morphine 103 11.0 5 1.6 4 0.3 
Nordiazepam 102 5.9 2 0.6 2 0.2 
Norephedrine 102 17.8 7 6.4 3 2.4 
Normorphine 93 16.6 5 3.4 5 1.8 
Nortriptyline 97 12.5 3 1.8 4 0.5 
O-Desmethylnaproxen 142 58.3 12 8.1 11 4.6 
Omeprazole 106 8.9 1 1.4 2 0.4 
Oxadiazon 119 11.6 6 2.2 6 2.3 
Oxycodone 99 12.6 3 1.5 3 1.3 
Oxymorphone 96 8.8 3 2.2 3 1.1 
Pholcodine 100 9.3 4 3.9 4 2.1 
Praziquantrel 101 5.7 3 0.4 3 0.5 
Propylparaben 108 12.4 6 1.8 10 1.6 
Quetiapine 101 15.9 1 0.3 2 0.7 
Risperidone 102 15.2 2 0.7 2 0.5 
Salbutamol 103 9.7 1 0.2 1 0.2 
Sotalol 100 15.4 2 0.3 2 0.4 
Sulphadiazine 96 4.6 5 1.3 4 0.2 
Sulphamethoxazole 105 5.1 5 2.4 4 0.1 
Sulphapyridine 98 5.2 3 1.2 2 1.0 
Terbutaline 91 55.1 35 38.8 8 7.3 
Terbuthylazine 106 10.7 5 3.7 4 0.9 
Tetramisole 96 5.3 4 1.4 4 1.0 
Thiamethoxam 97 1.3 2 1.4 4 2.0 
Triclosan 231 113 10 6.5 24 8.2 
Valsartan 105 7.8 8 2.3 15 0.7 
Vardenafil 96 10.4 2 0.2 2 0.7 
Zolpidem 104 6.3 8 5.8 5 3.5 
    
 
        
 
Table S10. Average relative recoveries for all analytes analysed in the method, even if not developed further (n=3) 
Analyte 
River water Wastewater 
10 µg L-1 50 µg L-1 200 µg L-1 10 µg L-1 50 µg L-1 200 µg L-1 




1,7 dimethylxantine 0.00 110.56 88.46 61862.73 7155.72 1111.20 
2-Hydroxyibuprofen 10.39 53.75 32.63 4039.25 1099.68 159.46 
8-isoF2B 0.00 0.00 145.67 0.00 234.65 111.65 
Acetaminophen 0.00 39.34 81.64 -135882.32 -30190.06 -7853.75 
Anhydroecgonine methylester 0.00 47.85 68.24 0.00 110.92 129.70 
Aminorex 0.00 61.76 67.19 0.00 30.59 61.38 
Amphetamine 0.00 90.65 102.36 0.00 108.83 106.64 
Azathioprine 106.73 101.85 143.43 -1.19 -150.11 690.10 
Benzophenone-1 0.00 51.02 69.57 128.18 90.18 87.55 
Benzophenone-3 -31.17 -742.53 117.79 147.69 -543.44 218.70 
Benzophenone-4 0.00 93.04 100.29 0.00 86.48 91.08 
Benzoylecgonine 86.46 102.96 112.09 65.07 95.11 104.86 
Benzylpiperizine 36.26 26.75 48.54 50.68 46.16 51.13 
Bezafibrate 0.00 53.94 78.97 0.00 61.67 75.90 
Bicalutamide 136.54 56.24 94.07 173.08 12.35 57.55 
Buprenorphine 39.34 53.10 65.38 68.01 56.16 57.79 
Caffeine 103.80 94.05 105.17 -4020.34 -1532.72 -125.69 
Candesartan Cilexetil 72.91 40.60 27.88 89.90 72.68 49.45 
Capecitabine 35.50 23.22 19.76 8.89 61.75 80.55 
Carbamazepine 76.65 93.82 99.92 80.14 89.22 96.79 
Carbamazepine 10,11 epoxide 68.68 92.43 98.12 64.14 99.44 107.35 
Carprofen 0.00 63.14 61.33 49.19 36.74 56.48 
Chlorpyrifos 0.00 22.56 16.56 -220.00 42.68 38.43 
Cimetidine 102.77 122.56 57.50 2.43 -190.70 290.87 
Citalopram 94.56 76.60 78.02 0.00 45.23 68.85 
Clothiniadin 59.56 89.64 86.44 92.75 117.81 101.84 
Cocaethylene 0.00 83.07 96.29 93.51 93.36 96.83 
Cocaine 0.00 88.43 89.94 0.00 86.68 92.82 
Codeine 160.55 96.79 97.11 0.00 52.91 84.02 
Cotinine 123.95 102.48 99.31 0.00 65.66 89.11 
Creatinine 0.82 0.41 0.09 -42.97 140.16 -3.23 
Cytarabine -333.81 -57.39 -10.08 -1336.61 -226.00 -43.16 
Desmethylcitalopram 94.75 76.71 58.03 138.63 133.54 103.76 
Desmethylvenlafaxine 111.68 109.38 77.72 -351.42 -139.77 65.46 
Desvenlafaxine 124.62 111.71 80.87 -744.51 -203.87 69.80 
DHMA 0.00 85.75 77.30 0.00 46.58 61.28 
Diazepam 71.10 87.78 92.16 91.03 96.84 90.29 
Diazinon 77.71 67.32 49.94 120.15 141.31 104.41 
Diclofenac 0.00 84.73 79.95 87.30 54.06 82.71 
Dihydrocodeine 87.90 82.89 88.82 0.00 77.22 83.97 
Dihydroketoprofen 0.00 74.47 97.87 0.00 38.87 75.01 
Dihydromorphine 91.75 93.84 85.74 111.26 85.26 68.65 
Diltiazem 84.26 72.69 69.02 109.47 58.05 36.55 
Duloxetine 27.17 19.07 26.29 55.86 46.38 44.05 
E1-10,11-dihydro-10-hydroxycarbamazepine 0.00 96.78 125.36 0.00 98.52 125.92 
E1-Alprenolol 0.00 69.32 96.88 0.00 60.72 70.67 
E1-Atenolol 82.72 98.37 98.16 0.00 93.08 95.97 
E1-Bisoprolol 77.17 83.75 101.15 65.40 92.01 109.38 
E1-Metoprolol 72.74 88.67 100.40 61.93 81.10 97.81 
E1-Mirtazapine 70.48 80.13 90.37 0.00 75.60 81.29 
E1-Oxazepam 75.63 91.42 89.28 63.80 95.14 78.04 
E1-Propanolol 79.59 89.97 96.46 72.60 86.76 96.99 
E1-Tramadol 60.43 103.27 101.81 0.00 26.29 48.46 
E2-10,11-dihydro-10-hydroxycarbamazepine 94.08 101.80 107.65 122.08 104.43 113.97 
E2-Alprenolol 58.45 63.54 85.62 0.00 70.21 73.95 
E2-Atenolol 75.10 89.05 98.99 0.00 96.51 94.27 
E2-Bisoprolol 76.18 83.58 99.03 0.00 86.88 93.79 
E2-Metoprolol 64.96 79.82 100.46 100.44 84.47 93.59 
E2-Mirtazapine 66.29 83.89 90.74 0.00 80.17 80.51 
E2-Oxazepam 95.12 100.06 87.86 69.27 91.51 75.21 
E2-Propanolol 96.41 91.41 91.35 0.00 86.05 88.21 
E2-Tramadol 80.74 107.43 110.59 0.00 31.50 54.53 
Ephedrine 37.40 40.14 48.09 -100.62 36.96 60.39 
Ethylparaben 78.00 89.67 106.35 0.00 82.98 91.94 
Fexofenadine 0.00 97.51 80.65 0.00 34.79 64.93 
Flufenacet 325.72 54.85 66.33 179.85 73.90 66.89 
Fluoxetine 58.20 51.17 51.08 -54.15 29.26 40.06 
Furosemide 132.16 116.42 0.00 133.15 114.80 0.00 
Gabapentin 92.70 20.31 6.49 -14983.04 -3829.28 -851.19 
Gemfibrozil 525.36 -467.06 53.79 1561.83 -1579.26 -116.71 
Gliclazide -2.29 -51.17 -2459.15 -3.65 -57.30 -2526.93 




Griseofulvin 88.37 82.35 94.53 96.58 69.61 84.48 
Heroin 84.28 86.55 93.54 0.00 89.56 84.95 
HMA 66.00 53.80 55.72 80.22 78.37 71.47 
HMMA 69.25 83.71 90.31 159.22 150.74 130.34 
HNE-MA 0.00 37.60 100.26 0.00 79.46 150.77 
Hydrocodone 103.31 88.79 89.88 0.00 65.79 81.97 
Ibuprofen 0.00 138.19 149.28 0.00 699.53 130.70 
Imatinib 76.30 63.24 64.91 125.66 96.07 79.54 
Imazalil sulphate 0.00 70.40 93.45 0.00 30.49 47.19 
Imidacloprid 103.26 108.38 101.51 120.74 160.62 129.84 
Indoprofen 63.68 84.53 88.63 66.73 66.47 76.99 
Iopromide 95.99 95.23 74.24 0.00 175.85 149.24 
Irbesartan 0.00 47.86 72.17 21.78 42.36 49.64 
Ketamine 68.73 95.64 110.65 93.57 109.17 108.44 
Ketoprofen 0.00 64.57 122.99 0.00 48.64 86.97 
MDA 62.42 83.74 64.83 108.12 82.64 75.40 
MDMA 67.35 83.44 91.82 66.68 89.17 91.51 
MDPV 66.38 70.30 88.26 83.99 92.22 83.60 
Memantine 69.26 115.51 101.28 0.00 151.50 170.19 
Mephedrone 0.00 61.23 90.98 0.00 53.90 70.42 
Metazachlor 99.19 99.20 89.86 63.17 95.55 89.13 
Methadone 0.00 69.36 88.92 0.00 73.43 83.11 
Methamphetamine 0.00 79.09 79.98 96.86 84.54 87.58 
Methylparaben 0.00 98.28 100.15 0.00 103.82 100.58 
Morphine 99.32 100.70 93.59 0.00 108.61 94.87 
N-desmethyl tramadol 46.87 64.34 97.27 95.26 263.88 215.37 
N-Guanylurea -95790.65 -1016.78 -230.66 -34802.26 -366.18 -81.29 
Nicotine -2.74 -21555.17 75.52 -178.01 -56282.76 146.11 
Norcodeine 21.20 24.01 58.83 -31.70 43.53 60.32 
Nordiazepam 75.55 83.52 93.57 101.73 94.51 92.24 
Norephedrine 88.42 83.33 73.82 84.76 69.04 62.40 
Norfluoxetine 7.81 21.26 20.54 -106.22 39.69 60.90 
Normorphine 45.79 46.77 60.91 0.00 71.90 60.60 
Noroxycodone -12.32 5.09 16.85 -13.43 49.76 47.73 
Nortriptyline 63.23 62.55 59.25 88.77 65.00 57.94 
O-6-MAM 0.00 193.32 272.59 -686.70 379.84 320.14 
O-desmethyl tramadol 110.24 148.92 170.38 2.61 235.49 203.46 
O-Desmethylnaproxen 0.00 60.71 82.75 0.00 54.04 121.92 
Omeprazole 100.52 105.24 78.25 0.00 145.58 119.15 
Orlistat 0.00 0.57 12.48 -197.37 -7.50 0.00 
Orlistat 17.62 13.13 13.56 0.00 7.65 5.33 
Oxadiazon 87.36 60.95 46.89 96.81 75.82 50.67 
Oxycodone 84.82 93.36 93.98 123.41 95.08 93.49 
Oxymorphone 13.75 8.97 17.67 55.07 41.19 40.08 
Pholcodine 93.94 89.51 85.71 121.07 103.92 100.87 
PMA 270.74 191.36 139.39 0.00 225.09 150.46 
Praziquantrel 72.68 85.39 96.94 90.38 93.18 103.15 
Pregabalin 0.00 0.00 0.00 -11.51 -4.66 0.58 
Propylparaben 24.53 86.55 108.29 56.37 100.95 106.58 
Quetiapine 77.32 79.95 88.81 138.45 95.59 83.75 
Ranitidine 0.00 117.09 118.99 -249112.12 -38521.13 -7552.42 
Risperidone 87.66 76.86 77.12 96.91 97.51 85.67 
Salbutamol 99.98 95.80 77.40 0.00 85.99 102.89 
Sertraline 14.52 36.32 46.60 -218.14 -15.59 22.58 
Sitagliptin 57.64 28.14 30.13 214.43 87.00 57.79 
Sotalol 90.97 74.04 69.74 0.00 149.67 142.30 
Sulfasalazine 0.00 0.00 20.86 0.00 39.54 49.62 
Sulphadiazine 53.63 66.77 49.83 73.20 74.72 62.25 
Sulphamethoxazole 114.69 104.15 138.23 0.00 120.45 116.93 
Sulphapyridine 87.66 78.41 95.06 0.00 121.17 101.46 
Terbutaline 98.55 98.93 0.00 82.53 85.55 0.00 
Terbuthylazine 81.22 75.56 68.91 94.24 92.72 73.26 
Tetramisole 0.00 89.42 103.01 0.00 93.17 92.79 
Thiamethoxam 105.91 112.66 121.21 130.31 168.11 149.41 
Triclosan 0.00 129.08 51.90 0.00 40.80 30.57 
Valsartan 0.00 75.95 84.27 69.78 75.52 78.20 
Vardenafil 88.49 83.54 78.09 97.10 107.83 105.12 
Venlafaxine 124.94 97.53 75.43 -1022.94 -43.87 67.67 
Zolpidem 77.51 91.88 91.53 85.35 135.28 116.15 
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Chapter four introduction 
Chapter four marks a change in direction for the thesis by being both a literature review and a 
discussion of a new potential source of public health biomarkers. In this manner chapter four directly 
explores the third aim of the thesis “the exploration of proteins as potential new biomarkers of public 
health”, although it does include an in-depth discussion of current WBE biomarkers. 
The narrative of the chapter begins by discussing how public health is currently measured, from 
clinical assessments that are used to build up a picture of public health from the assessment of 
individuals, to techniques like WBE that look at wastewater as equivalent to a pooled, population-
wide urine sample. The narrative then merges the two concepts to suggest that proteins should be 
considered as biomarkers of public health. 
The discussion throughout the chapter is focussed on urinary biomarkers of individual health as an 
under developed area of interest, with most FDA qualified biomarkers being found or analysed only 
in blood, either plasma or serum. In table 1, designed to show the breadth of analytes available from 
small molecules to proteins to genes, only KIM-1, albumin and cystatin C are FDA qualified 
biomarkers and are all biomarkers of kidney or renal injury in rats or humans, excluding albumin, and 
are all analysed via immunoassays. The chapter then discusses current WBE practise and how widely 
wastewater analysis has been used, and the range of biomarkers that have been identified. The 
possibility of linking urinary proteomics and WBE is then discussed, highlighting their shared usage 
of LC-MS/MS for biomarker analysis. In order to facilitate this, a range of selection criteria for 
urinary protein biomarkers is then outlined before presenting an initial series of biomarker candidates, 
including their urinary concentrations in healthy individuals. 
An addendum of additional considerations and a more in-depth discussion of protein analysis, which 
was not appropriate for inclusion in the publication, is included at the end of the chapter on page 232. 
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Abstract 
Public health monitoring cannot currently provide real time and comprehensive information 
about the health of a community as it depends on individual data collection (e.g. surveys) and 
is limited by the cost of biomonitoring campaigns. To allow for better monitoring of public 
health the burden of accuracy must move from the participant, whose accuracy cannot always 
be determined, to an assay or model whose accuracy can be determined either mathematically 
or scientifically. Additionally, new techniques should reduce overall costs in data collection 
and collation, whilst also expanding the number of individuals included in a study. Water 
fingerprinting that originated from wastewater based epidemiology (WBE) has a strong 
potential to revolutionise public health monitoring. WBE is a tool used for the analysis of 
drugs of abuse in populations worldwide, and future developments in this field are currently 
focussed on an expanding range of molecular biomarkers such as pharmaceuticals. However 
there also exists the possibility to adapt this approach for the analysis of proteins, which are 
currently clinically limited to the analysis of individual patients. By combing the techniques 
of WBE and clinical proteomics there exists the possibility for near-real time, population 
wide, human biomonitoring of disease. This manuscript details the considerations and 
stepping stones needed to allow for water proteome fingerprinting, as well as giving an 
overview of WBE and its applications; including the range of biomarkers, methods and 
populations currently examined. 
Keywords: water fingerprinting, wastewater-based epidemiology, public health, protein 
markers 
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Introduction - Public health monitoring and its limitations 
Public health monitoring cannot currently provide real time and comprehensive information 
about the health of a community, limiting its ability for prediction and tracking of health 
events resulting from seasonal infections, environmental contamination (e.g. respiratory 
diseases resulting from air pollution), or long term monitoring of public health. This 
limitation is brought about by a reliance of current public health studies, such as NHS 
England’s health survey for England [1], using methodologies based on individual data 
collection. These sources of data rely on practitioners and participants to have accurate 
knowledge of their health to collect accurate information, or rely on collecting biological 
samples from every participant. This limits their ability to provide information in real time as 
each individual piece of patient data must be collected and collated before any conclusions 
can be drawn. To allow for better monitoring of public health the burden of accuracy must 
move from the participant, whose accuracy cannot always be determined, to an assay or 
model whose accuracy can be determined either mathematically or scientifically. 
Additionally, new techniques should reduce overall costs in data collection and collation, 
whilst also expanding the number of individuals included in a study. 
Molecular epidemiology in public health assessment 
 Molecular epidemiology provides a better tool for understanding public health by targeting 
specific health biomarkers. The burden of accuracy can then be moved from the individual to 
the methodology, whose accuracy can be verified. Clinical biomarkers range from (i) non-
molecular markers such as blood pressure as a biomarker of heart disease, (ii) genetic 
biomarkers, (iii) small molecule metabolic biomarkers, and (iv) large molecules like proteins. 
The range of possible urinary biomarkers is summarised in Table 1 and highlights that urine 
can also be a source of biomarkers for non-urogenital diseases [2]. 
  




Table 1. Examples of urinary biomarkers. 






Bladder cancer [2] 
[3] 
Nucleosides Small molecule Colorectal cancer [4] 
PCA3 
GSTP1, RASSF2, HIST1H4K, TFAP2E, 9P21 




Prostate cancer [5] 
[6] 
[7] 
Lipocalin 2 Protein Breast cancer [8] 
1,4-dihydroxynonane mercapturic acid,  
8-hydroxy-2-deoxguanosine, 8-isoprostane-
F2alpha;  
Small molecule Oxidative stress [9-11] 
Porphobilinogen, 5-aminolevulinic acid Small molecule Acute intermittent 
porphyria 
[12] 
Adiponectin Protein Systemic lupus 
erythematosus 
[13] 
Pyridinolines Small molecule Osteoporosis [14] 
NGAL, KIM-1, IL-18, cystatin C, a1-
microglobulin, fetuin-A, Gro-alpha, meprin 
Protein Acute Kidney Injury [15] 
Immunoglobulin G, transferrin, ceruloplasmin, 
albumin 
Protein Diabetic neuropathy [16] 
Nitric oxide Small molecule Acute respiratory distress 
syndrome 
[17] 
VEGF, PlGF, sFlt-1 Protein Pre-eclampsia [18] 
AD7C-NTP Protein Alzheimer’s disease [19] 
 
Clinical proteomics for individual health 
Despite the wide range of biomarkers listed in Table 1 there is a perceived bottleneck in 
confirming the validity of protein biomarkers, which is broadly attributed to the time and 
expense required to take these biomarkers through clinical trials [20-22]. When compared to 
the cost of researching potential new biomarkers this leads to a range of potential biomarkers 
being identified, but very few of them being confirmed or used clinically. A proposed 
solution to this bottleneck is the introduction of liquid chromatography coupled with mass 
spectrometry techniques (LC-MS) for protein analysis as opposed to antibody based methods 
such as ELISA [22; 23]. The advantages of mass spectrometry over ELISA are that it enables 
greater multiplexing of samples at a lower cost per sample, despite an initial larger capital 
investment in equipment. Other advantages include the ability to multiplex analysis, either by 
analysing multiple biomarkers in a single run [24] or multiple different samples in a single 
run through isotopic labelling [25; 26].  
Protein biomarkers are particularly ubiquitous within oncology, as the majority of FDA 
approved protein biomarkers are biomarkers of cancer [27]. Despite a current bias for blood 
serum or plasma biomarkers, only 2 of the FDA approved biomarkers are found in urine, 




there is a growing interest in urinary biomarkers for clinical analysis as it can be more easily 
collected in large quantities and more willing given for repeat analysis, meaning an 
individual’s health can more easily be tracked over time, such as when tracking disease 
progression [28]. As an example prostate specific antigen (PSA) is an FDA recognised 
biomarker of prostate cancer [27], which is analysed every 6-12 months in serum from men at 
risk of developing or with early stage prostate cancer, a process known as watchful waiting, 
[29; 30] to identify when intervention or treatment is necessary. Analysis of PSA in urine 
would potentially allow for this process to be carried out more frequently, or for a panel of 
biomarkers to be used for more accurate characterisation of disease state [31]. 
However the current clinical biomarker approach is still limited to the collection of data on 
individual health through analysis of blood or urine. Analysis of individual health can simply 
be scaled up for public health analysis but this presents its own challenges due to the large 
number of samples that would require collection and analysis [1; 32]. The largest of these 
studies [32] took place on a city-wide scale collected and analysed roughly 58,000 urine and 
8600 blood samples, including controls, whilst also relying on questionnaires to screen 
participants into or out of the study. This approach allowed researchers [32] to collect data on 
the urinary concentration of one protein (C-reactive protein). Positive association between 
elevated levels of C-reactive protein and cardiovascular and renal risk factors was observed. 
However with this approach, only 10% of a population or approximately 8600 individuals 
were included in the study. New approaches are therefore urgently needed to provide more 
comprehensive datasets covering whole population and accounting for spatial and temporal 
variability.  
Urban water fingerprinting for public health assessment: the role of mass spectrometry 
in water fingerprinting for small molecules. 
Molecular epidemiology can be expanded to provide information on the health of a 
community through the use of urban water fingerprinting (UWF), where wastewater influent 
acts as a surrogate pooled urine sample for the entire population; meaning one representative 
sample can be collected for an entire population (Figure 1). For the study above [32]  the city 
surveyed was served by one WWTP, meaning the whole population could have been 
examined using only one composite sample.  





Figure 1. Water fingerprinting for public health assessment (note: the image of the protein: 
KLK3_HUMAN (PSA) [33] 
This cutting-edge approach of extracting epidemiological information from urban water is 
also known as Wastewater-Based Epidemiology (WBE). The concept was introduced by [34] 
and followed by researchers worldwide [35-39]. In Europe WBE was developed in a strong  
transdisciplinary collaborative ethos within SCORE (www.score-cost.eu) and SEWPROF 
teams (www.sewprofitn.eu). WBE is currently used to report on world-wide illicit drug use 
trends [39] and feeds into the Europe-wide evidence based EWS managed by the European 
Agency for Drugs & Drug Addiction (EMCDDA, www.emcdda.europa.eu). In practice WBE 
can be divided into three stages: sample collection, sample analysis and back calculation, 
which are explained in detail in a guide published by the EMCDDA [40]. Sample collection 
typically involves the collection of time or flow proportional composite samples of influent 
wastewater from a wastewater treatment plant, over a 24h period. The composite sample is 
then transported back to the laboratory for analysis. Sample preparation often includes a 
sample concentration step, typically solid-phase extraction, before analysis using 
chromatography coupled to mass spectrometry to determine the analyte concentration. This 
measured concentration represents the amount of analyte in the sample and cannot be directly 
compared to other samples and needs normalisation. The back calculation step takes this 
measured concentration and normalises it using parameters such as flow and population size 
to generate a value that can be compared between treatment works and beyond to cities and 
countries. 




Currently WBE is applied to the analysis of small molecules, such as pharmaceuticals, drugs 
of abuse and their metabolites [41]. Emerging analysis focuses on the importance of 
stereoselective human metabolism [42; 43], or endogenous chemicals formed in humans, i.e. 
biomarkers of oxidative stress [44], or on estimating the population contributing to the 
wastewater [36; 41; 45-47], or in matching wastewater and prescription or consumption data 
[48-51]. Powerful European sampling campaigns proved WBE’s potential for comprehensive 
spatial and temporal community-wide (i) drug use assessment [52-59], (ii) pharmaceuticals 
and population biomarkers [48; 60], (iii) alcohol and tobacco use [61; 62], (iv) caffeine [63], 
(iii) pesticide and EDCs’ exposure [64-66], (iv) air pollution and asthma [67] and (v) levels 
of oxidative stress [48]. The list of available biomarkers is presented below (Table 2). 
Table. 2 Available biomarkers and studies undertaken so far. 






















































 HMMA and HMA are 
metabolites of MDMA 
 O-6-MAM is a specific 
metabolite of Heroin 
 BEG is the major 
metabolite of cocaine 
and the BEG/Cocaine 
ratio is used for back 
calculation. 
Cocaethylene is a 
specific metabolite of 























































Sweetener Acesulphame 33,280,000  [36] 















































JWH-XYZ is a generic 
placeholder for over 450 
synthetic cannabinoids 
identified by Clemens 
University. Examples 
include the cannabinoid 






















































Methadone, EDDP, Morphine, 
















 EDDP is a metabolite 
of Methadone 
 Oxazepam, Temazepam 
and Nordiazepam are 




 Salicylic acid is 
analysed as a 






































































Public health:     
Biomarkers of 
oxidative stress 
8-isoPGF2Alpha 5,274,075 . All prostaglandins are 











The advantages of wastewater analysis are that the sample collected is more representative of 
the population (as the whole population continuously contributes to its wastewater in real 
time), is collected non-invasively, has low collection costs and is effectively anonymous due 
to contribution of material from many individuals. Participant anonymity is an important 
ethical consideration, and an advantage of WBE is that data gets easier to anonymise as larger 
populations are investigated. However, limitations include WBE’s inability to identify the 
demographics of the population, meaning researchers would need to rely on censuses to 
collect data about the population contributing to the wastewater (Table 3). 
Table 3. Advantages and limitations of WBE 
Advantages Disadvantages 
Representative samples 
Non-invasive sample collection 
Low sample collection costs 
Contributor anonymity 
Applicable to large populations 
No demographic information 
Specialised equipment required 
High-skilled staff required 
Ethically unsuitable for small 
populations 
Relatively small pool of biomarkers 
available 
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Urinary proteins as public health biomarkers:  the role of mass spectrometry in water 
fingerprinting for proteins. 
By coupling the individual focussed approaches of clinical proteomics with the non-invasive 
and representative sample collecting of WBE there exists the potential to achieve population 
wide proteomic monitoring. Whilst the analysis of proteins within wastewater has, to the 
authors’ knowledge, never been attempted before it can share a lot of the same techniques 
and advances as other molecular epidemiological approaches. First amongst these is the use 
of mass spectrometry (MS) as a tool for screening for biomarkers followed by quantitative 
analysis [93], allowing for the development of robust methods whose accuracy and precision 
can be validated. MS is already used within proteomics both for the analysis of intact proteins 
(top-down) [94] and in the analysis of peptides (bottom-up) [95]. The use of bottom-up 
proteomics is of greater interest as the same range of spectrometers can be used in both WBE 
and peptide analysis. 
Bottom-up LC-MS/MS analysis is increasingly used within clinical proteomics as a means of 
increasing sample through-put, reducing analysis cost per samples and decreasing manual 
sample preparation as compared to traditional immunoassays. The population study discussed 
earlier analysed C-reactive protein (CRP) using nephelometry [32], a light scattering 
technique from the formation of antibody-antigen particles in solution, whilst several papers 
published at the same period measure CRP in serum using LC-MS/MS. The use of 
nephelometry only allowed quantification down to 0.18mg/L of intact CRP, whilst MS based 
approaches were able to achieve quantify CRP between 1-1000 fmol/µL or 25-25000µg/L in 
a more complex matrix [96]. MS based approaches have been developed that achieve similar 
sensitivity to that of ELISA [97; 98] and avoid the issue of non-specific antibody binding 
[99] that could result from using as complex a matrix as wastewater. The use of isotopically 
labelled internal standards is common in MS-based analysis for both small molecules and 
proteins, with a range of protein quantifications strategies available including labelled 
peptides (AQUA) [23; 96; 100], labelled proteins (PSAQ) [101] and concatomers formed by 
linking several peptides of interest together like a synthetic protein (QConCat) [102]. Label 
free methods that do not use isotopically labelled standards are also available [103; 104], 
instead adding an exogenous protein such as adding bovine serum albumin to samples of 
lupin seeds[104]. Label free methods are likely unsuitable for public health purposes due to 
the complexity and highly variable nature of wastewater, as without a more thorough 




understanding of the wastewater proteome it is impossible to say that any protein added as a 
standard would not be naturally present in wastewater.  
Taken together current proteomic analysis techniques could be adapted for analysis of 
wastewater but where new ground must be broken is in the selection of biomarker targets. 
The following five criteria are suggested to be important for biomarker selection: (1) Urinary 
excretion – Wastewater analysis requires that the biomarker be excreted in urine; (2) Known 
biomarker-disease relationship – Specifically how excretion and wastewater concentrations 
change with disease state and progression; (3) Disease specificity – Important for targeted 
disease monitoring, although more general biomarkers should also be considered; (4) 
Biomarker stability – The biomarker must be stable both in-vivo and after excretion and 
sample collection and (5) High urinary concentration – To allow for quantification in 
wastewater 
The use of non-specific biomarkers, such as biomarkers of inflammation like C-reactive 
protein [32] and interleukins [28], can potentially be used to monitor the overall health of a 
population. This can allow for better targeting of healthcare services and interventions to 
specific communities, whilst also allowing for the long term monitoring of community health 
across different populations. Further work is needed to assess biomarker stability in 
wastewater, but their storage within the bladder, for a period of hours, prior to excretion 
suggests good stability [21]. Using the criteria above the following biomarkers are suggested 
as being initial targets of interest (Table 4): prostate specific antigen (PSA), C-reactive 
protein (CRP), interleuekin-6 (IL-6), interleukin-8 (IL-8), podocin (PDC), anterior gradient 
protein 2 (AGR2) and uromodulin (URM). They are all excreted in urine and have been 
targeted in clinical studies that focussed on the relationship between a single biomarker and 
disease. All the biomarkers have a known biomarker disease relationship in urine, with the 
presence of disease generally increasing the biomarker concentration, although 
concentrations of URM have been observed to increase or decrease depending on the specific 
kidney disease [105].  
  




Table 4. Proteins as potential biomarkers in WBE  
Biomarker Function Healthy urinary 
concentration 
Reference 





(average age 30) 
Women (not using 
contraception): 1-35 



















Urinary tract infections 
1.6-5.28 pg/mL [28; 109] 
Interleukin-8 (IL-8) 7-12 pg/mL [110] 
Podocin (PDC) Acute kidney injury 
Pre-eclampsia 
4.05 ng/mL [111] 
[112] 







Uromodulin (URM) Chronic Kidney Disease (CKD) 
Hypertension, CVD 
21-1344 ng/mL [105; 113] 
 
Prostate specific antigen is a well-studied biomarker for prostate cancer diagnosis and is used 
to complement more invasive methods of diagnosis [30; 114], including biopsies, as well as 
for monitoring changes in prostate health, known as watchful waiting. The analysis of urinary 
CRP for measuring renal function in a healthy population has already been discussed [32], 
but urinary-CRP is not as well studied as a serum/plasma CRP, which is used as a biomarker 
for cardiovascular disease, rheumatoid arthritis and other inflammation related diseases [96; 
115; 116]. Similarly IL-6 and IL-8 are also biomarkers of inflammation and have been 
individually quantified in urine as biomarkers of urinary tract infections [28; 109; 110; 117; 
118] as well as potential biomarkers of Lupus nephritis [119]. IL-8 has also been examined as 
a biomarker of diabetic nephropathy [120]. Podocin is a protein that originates from podocyte 
cells in the kidneys, which act like a molecular sieve for proteins, and has been examined as a 
biomarker of both kidney health [111] and for determination of pre-eclampsia [112]. 
Uromodulin is the most abundant protein in urine and is touted as a biomarker for accessing 
renal health [113], CKD and hypertension [105]. Uromodulin is also interesting as its 
expression can be both up and down regulated by disease [105], with uromodulin-associated 
kidney disease reducing the excreted concentration, whilst individuals with greater risk of 
CKD, hypertension or CVD could produce more uromodulin than those with a lower risk. 




Quantification of expected protein levels in wastewater might prove challenging but not 
impossible. Protein levels vary from ng to mg L
-1
 in urine (Table 4). Assuming 100 times 
dilution of urine in wastewater, one should expect estimated levels to range between pg and 
µg L
-1
. Whilst these very low concentrations seemed daunting, current proteomic 
methodologies were able to quantify proteins within the upper portion of this range.  A recent 
publication [111] was able to quantify podocin at 0.5 µg/L by making use of solid phase 
extraction (SPE), which is also used within WBE, to increase the podocin concentration and 
remove unwanted interferences from the urinary matrix. For analysis in wastewater it is not 
unusual to use the same SPE methodology to concentrate samples up to 200 times [42; 121], 
meaning quantification in the low ng/L range would theoretically be possible by using current 
proteomic methods to analyse wastewater. More research is therefore needed to determine the 
best approaches for the detection and quantification of proteins in wastewater. Antibody 
based method have been used to help separate proteins in complex matrices, like serum and 
plasma, and lead to an increase sensitivity [99; 122; 123], such as a 1000x fold increase in the 
quantification of PSA after depletion of more abundant proteins in serum [122]. However, 
and as previously discussed, antibody based methods are designed to assist in the analysis of 
only one or two proteins at a time, whilst the strength of WBE lies in its ability to analyse 
potentially hundreds of different compounds at a time.   
The combination of proteomics and WBE has the potential to allow for long term monitoring 
of public health, as well as identification of disease hot spots or the prediction of epidemics. 
Advances in the related field of WBE can easily be incorporated for the analysis of proteins, 
giving rise to the possibility of monitoring both overall public health and specific health 
concerns in near real time, as well as to verify the effectiveness of interventions or 
government policy. The differences in the broad physical and chemical properties of proteins, 
peptides and small molecules should be exploited to aid in their analysis. One such example 
is the presence of carboxylic acid and amine containing side groups within peptides can allow 
for their selective enrichment using ionic SPE stationary phases or separation using ion 
chromatography or HILIC [111; 122; 124], both of which can be readily adapted for use with 
wastewater matrices. The larger mass and size of proteins and peptides compared to small 
molecules also makes the use of techniques like size-exclusion chromatography and ion 
mobility mass spectrometry promising, but this requires a shift away from the techniques 
already used within WBE analysis [40] and those proposed for clinical proteomics [22; 23],
Chapter four: Conclusion 
226 
 
 namely reverse-phase liquid chromatography and either triple quadrupole, quadrupole-time 
of flight or orbitrap mass spectrometers. 
Further development of WBE will be driven by advances in the analytical approaches 
utilised, both from the point of selective and sensitive measurement of known markers, as 
well as the discovery of new biomarkers. Breakthrough in protein analysis is yet to be 
realised by advancements in high resolution mass spectrometry utilising both Orbitrap and 
TOF technology, which enable both sensitive and selective quantitative analysis as well as 
retrospective data mining. 
Conclusions 
Clinical proteomics is currently limited to analysis of individual health, with attempts being 
made to expand this to cover a population. In this way proteins are comparable to illicit drug 
and other smaller molecule analysis prior to the introduction of WBE. Clinical proteomics 
already shares many of WBE’s methods of analysis, namely liquid chromatography and mass 
spectrometry, with WBE providing many advantages for population proteomics, including 
contributor anonymity and easier applicability to analysing large populations. As wastewater 
analysis advances to encompass a broader range of health biomarkers new developments can 
be applied to the analysis of proteins, which will allow for the monitoring of public health 
using an entirely new class of health biomarkers.  
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When writing this paper for publication the decision was made to focus solely on WBE for collecting 
data on public health. Whilst WBE is a very powerful technique it cannot and should not stand alone. 
As was discussed in chapter one, non-wastewater sources of data, such as local prescription data, are 
important for giving context to the results of WBE investigations and for the important 
epidemiological work that takes place after wastewater analysis. For example, without local 
prescription data the calculation of heroin in chapter one would have to rely on using either only 
morphine or only O-6-MAM loads in wastewater, both of which are problematic [70; 125]. This 
epidemiological work can include determining correction factors for better analysis [126; 127] but 
also modelling drug usage with the community  [128; 129]. This type of work is essential for the 
development of WBE going forwards, particularly for biomarkers of human health, like proteins and 
biomarkers of oxidative stress, in determining when public health intervention is necessary. 
Likewise there was not the opportunity to discuss protein analysis in depth, particularly how it differs 
from proteomics and the specifics of protein analysis by LC-MS/MS. In brief, proteomics is the study 
of all proteins in a system, like a cell, humans or wastewater, whilst protein analysis refers simply to 
the analysis of one or more proteins. Within literature there are a variety of different methods used for 
the analysis of proteins in clinical samples and is not as cut and dry as outlined in the chapter, which 
briefly outlined a move from analysis using ELISA to analysis using LC-MS/MS. Firstly, there are 
physical methods of analysing proteins via techniques like nephelometry, which measures the amount 
of light scattered by an antibody-antigen complex to determine the concentration of either the antigen 
or antibody by comparison to a calibration curve of known concentrations [130]. Nephelometry was 
used to quantify urinary serum albumin and urinary CRP in the city-wide public health study 
discussed in the chapter [32]. The popularity of the technique comes from its reliability and the ability 
for automation, making it an essential workhorse for clinical analysis, however it is not as sensitive as 
other antibody based techniques such as ELISA, which is regarded as the gold standard for clinical 
analysis [24]. ELISA differs from nephelometry by using an antibody or antigen that is attached to a 
surface and adding a reagent that measures the formation of the antibody-antigen complex [131; 132]. 
The analysis of interleukins IL-6 and IL-8 in literature has almost exclusively been performed by 
ELISA [28; 109; 110; 120]. The advantages of ELISA include its ability to generate sensitive, 
quantitative results in only a few hours, which is very important for ensuring rapid disease diagnosis 
[131; 132], particularly where it can be used to assess disease outcomes as well [109]. Additionally, 
the use of multi-well plates makes it possible to analyse several clinical samples at once, which 
increasing sample throughput compared to nephelometry.  
Other non-MS, non-antibody based methods of analysis do also exist, such as gel electrophoresis 
combined with staining [133] but these methods have largely been supplanted by more sensitive 




methods of protein/peptide detection, although examples of gel electrophoresis coupled with mass 
spectrometry do appear in literature [134; 135]. The advantages of using liquid chromatography over 
electrophoresis, aside from its ability to be directly coupled to MS, come from the ability to mix 
different stationary and mobile phases together in order to create a wide variety of separation 
conditions to aid analyte detection. In contrast gel electrophoresis can struggle to detect low 
abundance proteins due to a limited dynamic range [134] that leads to overlapping peaks, essentially 
biasing the technique towards the most abundant proteins in the sample. The most common form of 
LC method described in literature is one that uses reverse-phase (RP) chromatography with a 
water/methanol or water/acetonitrile mobile phase and a C18 stationary phase [136]. However, 
alternatives like hydrophilic interaction liquid chromatrography (HILIC) [124; 137] or ion 
chromatography [124] can be used to selective separate different peptides. Multiple or different 
stationary phases can also be linked together to provide two-dimensional separation. For example, by 
using two reverse-phase columns and two different pH gradients it was possible to selectively 
separate phosphopeptides from other peptides, in a similar manner to the electrophoresis technique of 
isoelectric focussing that separates analytes by pH [138]. Likewise, RP and HILIC are often combined 
together to give greater analytical sensitivity by selectively trapping analytes, separating them from 
matrix, in the first dimension and then separating them from each other in the second [122; 137; 139]. 
HILIC is particularly suited for use as the second dimension when coupled to MS [122], as the mobile 
phase by necessity contains a large percentage of organic solvents, which can make it easier to ionise 
analytes in the MS source. 
Despite the supposed ascendency of MS over ELISA for protein and peptide analysis, a lot of method 
LC-MS/MS method development is focused on trying to develop methods as sensitive or as rapid as 
ELISA [24; 98]. Despite this, the advantages of LC-MS/MS lie in its ability to more easily allow for 
multi-biomarker assays through a combination of easier sample multiplexing and lower method 
development costs [22; 23; 99; 140], due to a lack of need for antibody development, which has been 
estimated to cost >$100,000 per antibody [22]. LC-MS/MS was used to quantify the following 
biomarkers proposed earlier in the chapter: podocin [112], uromodulin [113] and PSA [95; 99; 141]. 
However, whilst LC-MS/MS may be used to move away from antibody based methods of detection 
this does not mean that antibodies are not still used, with several papers making use of antibody based 
affinity columns to either deplete (i.e. remove matrix) or enrich (i.e. concentrate an analyte) samples 
prior to detection [99; 140].  
For public health analysis the main advantage of using LC-MS/MS for protein analysis is that the 
same range of instrumentation can be used to analyse smaller molecules and peptides, with many 
WBE biomarkers, CEC and peptides analysed using the same range of RP columns coupled with 
triple quadrupole or hybrid time of flight instrumentation and ESI. However, others types of detector 
and ionisation are also common within protein analysis including ion traps, Orbitrap type instruments 




and the use MALDI. MALDI can often be seen coupled to gel based and offline LC methods of 
separation [23; 134-136; 142] as well as being used for the analysis of intact proteins [94]. Likewise, 
whilst affinity columns may be commonly used in clinical analysis they are likely to be less important 
for public health analysis. Firstly, the low protein concentration of wastewater makes 
immunodepletion unnecessary and secondly, the use of affinity columns to enrich samples removes 
the main advantage of LC-MS/MS over antibody based methods of detection; namely its ability to 
analyse multiple biomarkers at once. 




Chapter five introduction 
The previous chapter laid out the foundation of why urinary proteins should be considered for analysis 
in wastewater, particularly for their ability to measure public health using currently utilised methods 
of analysis. This formed the initial discussion of the third thesis aim of exploring proteins as potential 
new biomarkers of public health. 
This chapter continues to explore this aim by practically examining the steps required to analyse 
proteins in wastewater, including the selection of potential biomarkers and the development of a 
digestion and analytical methodology for use in wastewater. 
Initially, the chapter outlines enzyme digest conditions used in literature in order to identify what 
makes an effective and robust digestion method, which is crucial for reproducibly producing predicted 
peptides in wastewater. This is then followed by an assessment of which biomarkers from the 
previous chapter are most likely to be detected in wastewater, and should therefore be investigated 
first. This included the identification of human specific peptides from in-silico digestion and the 
estimation of wastewater protein concentrations. The bulk of the paper focuses on the step by step 
development of an enzyme digestion methodology for use in buffer and then wastewater and its 
subsequent use to identify human proteins via LC-MS/MS. 
  




Development of an enzymatic digestion method for use in wastewater for the 
analysis of proteins of disease by hydrophilic interaction liquid chromatography 
coupled to triple quadrupole mass spectrometry 
Abstract 
Proteins were identified in the previous chapter as potential biomarkers of public health as by 
measuring urinary proteins that are biomarkers for human disease it would be possible to directly 
measure public health. Additionally, by using bottom-up proteomics to measure peptides it would be 
possible to use the same techniques currently used to analyse other public health biomarkers in 
wastewater-based epidemiology (WBE), which would make analysis of urinary proteins more readily 
accessible to the wider analytical community.  However, wastewater is a challenging analytical 
matrix, combining the low protein concentration of urine, which is further reduced by dilution in the 
sewer system, the high matrix complexity of blood, and the contribution of non-human proteins to the 
wastewater proteome. This chapter details the development of a methodology that allowed for the 
detection of a human specific protein biomarker in wastewater using hydrophilic interaction liquid 
chromatography (HILIC) coupled to a triple quadrupole (QQQ) mass spectrometer. Additionally, the 
chapter explored the considerations that must be made when selecting biomarkers to ensure human 
specificity. An analysis of literature was used to identify the most common reagents used during 
enzyme digestion and was used to develop a simplified digestion method that did not use expensive 
reagents or difficult to remove surfactants. In-silico digests of five potential protein biomarkers were 
used to identify human specific peptides, as well as pseudo-specific peptides shared with non-native 
primates.  Data from previous chapters was used to estimate the wastewater concentration of each of 
the five biomarkers and showed that the most abundant peptides should be detectable using current 
WBE techniques. The final method digested used 100 mL of wastewater and led to the potential 
detection of one peptide of C-Reactive Protein (CRP) in wastewater, which would require the use of a 
synthetic analogue to confirm. This represented the first tentative steps required for the development 
of a robust WBE-compatible protein analysis method. The in-silico digestion and wastewater 
concentration estimation carried out here should provide an excellent resource for other researchers 
interested in the wastewater proteome, allowing for the identification of species-specific biomarkers 
that are accessible to current analytical techniques.  
  





1.1 Public health monitoring 
The use of analytical science for monitoring individual health is well established, with its utility and 
general purpose outlined in chapter four [1]. In brief, molecular diagnostics of human health has long 
been used for the analysis of individual health but techniques like wastewater-based epidemiology 
(WBE) seek to apply these methods to analysing public health. Currently, most WBE biomarkers are 
biomarkers of drugs of abuse or pharmaceuticals, although it should be noted that some endogenous 
human biomarkers have been considered [2-5]. It can be argued that this largely consumption-based 
approach gives only a limited understanding of public health, as it focuses on only the population that 
is consuming a biomarker and not the wider population. Whilst it is understandable that a less healthy 
population will consume more pharmaceuticals, drugs of abuse or other WBE biomarkers, this is still 
a passive approach to monitoring human health as it cannot say how what was consumed yesterday 
will affect public health tomorrow. However, by analysing proteins of disease it would be possible to 
link the excretion of disease biomarkers with future human health, potentially allowing the 
development of an early warning system for public health. 
The primary challenge in analysing proteins for public health monitoring is one of scale. Attempts 
have been made before to analyse the health of a city by collection and analysis of thousands of 
individual urine samples [6]. Such invasive attempts to analyse public health are inefficient but have 
the advantage that the analytical techniques used to quantify protein biomarkers did not need to re-
validated or adapted to work on this larger scale. WBE’s greatest strength is that it replaces mass 
sample collection with collection of just a single representative wastewater sample. This approach has 
worked well for analysing a wide range of small molecular analytes [chapter four] , even those with 
very low excretion percentages like metabolites of heroin [7]. The difficulty for proteomic analysis of 
wastewater is that movement from urinary analysis to wastewater analysis brings about a big decrease 
in analyte concentration and a big increase in the complexity of the matrix. The concentration of 
current small molecule biomarkers in wastewater ranges from ng/L-g/L [8], depending on the 
substances. Whereas, the concentration of proteins in wastewater is currently unknown, although 
excretion varies from ng/L-mg/L in urine of health individuals [1]. The overall lower abundance of 
proteins is complicated by a lack of studies examining their stability in wastewater, meaning that 
actual protein concentrations may be even lower. However, this still puts the more abundant proteins 
into the same concentration range as other WBE suitable small molecule analytes. Solid phase 
extraction (SPE) has been used in both urinary proteomics [9; 10] as well as WBE [11-13] to increase 
sample concentration and reduce matrix interference. By applying the techniques of WBE to protein 
analysis it may be possible to analyse proteins in the same way as small molecules.  




Liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) is routinely used in 
both proteomics [9; 10; 14; 15] and WBE [11-13] for analyte quantification and identification. 
Additionally, by converting protein biomarkers into peptides, using an enzyme, it is possible to use 
the same range of LC and MS techniques for both proteomic [9; 16] and WBE [11; 13] applications. 
However, enzyme digestion necessitates a departure from established WBE protocols, which dictates 
that samples should be left unaltered and undergo sample preparation and SPE as soon as possible 
after collection. Additionally, a lack of understanding around the wastewater stability of proteins 
makes the addition of an enzyme digestion procedure an extra hurdle for analysts to overcome; 
although the stability of urinary biomarkers in the bladder suggests that proteins may be stable in 
wastewater for long periods [17].  
The final considerations therefore surround the actual analysis of the protein/peptide biomarkers using 
LC-MS/MS. In literature the most commonly used type of chromatography is reverse phase liquid 
chromatography [14; 16; 18-20], often using the same type of silica based C18 end-capped columns 
used in WBE analysis [2; 3; 11; 21-23]. However, other chromatographic techniques are also used 
such as: ion-exchange chromatography (IEC) [24] or hydrophilic liquid chromatography (HILIC)  
[25; 26], particularly as second dimensions for analysis of peptides in complex mixtures [10; 27]. 
These other chromatographic methods seek to exploit the different combinations of polarity and 
hydrophobicity present within peptides, which is caused by their amino acid building blocks. HILIC 
has also been used within WBE but its usage is far less common and mostly restricted to very 
hydrophilic amphetamine-like drugs of abuse and drug metabolites [28-31]. For WBE the most 
common forms of MS detector are either quadrupole-time of flight (Q-ToF) or triple quadrupole 
(QQQ) type instruments, which are widely available in commercial and research labs worldwide. 
However, in proteomic analysis more advanced ion trap/triple quadrupole hybrid instruments are 
commonly used [14; 32-34], particularly in applications seeking to identify low abundance proteins in 
complex protein mixtures, although triple quadrupole type instruments are still used [16; 18]. Whilst 
proteins with a low predicted wastewater concentration could benefit from the additional sensitivity 
that more advance instrument can bring, for proteins with a similar abundance to small molecule 
biomarkers, the more routine QQQ and Q-ToF instrument may still be viable.  
  




1.2 Literature analysis 
The analysis of protein derived peptides, known as bottom-up proteomics, using mass spectrometry 
has several advantages compared to the analysis of intact proteins, known as top-down proteomics, 
including more developed analytical and quantification methodologies [35; 36]. The drawbacks of 
analysing proteins in this way are primarily an increase in the complexity of sample preparation and 
sample preparation time, as peptides are produced by incubating the protein with an enzyme for a 
period ranging from hours to days [37-39]. In addition to this, the majority of methods include extra 
pre-enzyme digestion steps aimed at increasing enzymatic efficiency by reducing protein structural 
complexity, usually through either disrupting hydrogen bonding, or reducing covalent bonds within 
the protein [40] as depicted in figure 1.  
 
Figure 1. An overview of the peptide production process  
Hydrogen bonding is important in determining the 3D structure of a protein, as the 2D amino acid 
sequence folds to allow for hydrophilic sections to interact with the aqueous intracellular environment 
whilst sheltering hydrophobic regions. Chaotropic reagents such as urea and guanidinium chloride 
(GuHCl), or surfactants including sodium dodecyl sulphate (SDS) or sodium deoxycholate (SDC) are 
commonly used within literature to disrupt hydrogen bonding in proteins [41]. However, this is not a 
requirement for bottom-up proteomics [37] and is almost always followed by the addition of other 
reagents before the addition of any enzyme. Additionally, many chaotropes will also interfere with the 
enzyme itself so their concentrations need to be considered carefully [40]. Likewise, urea can react 
with primary amines in amino acids in a process known as carbamylation [41]. Carbamylation is 
catalysed by both heat and time, which are both important for insuring efficient enzyme activity. 
Lastly, the use of surfactants can interfere with separation and ionisation in downstream LC-MS 
analysis [42] and so they should be removed, usually by either buffer exchange or by precipitation 
[43]. 
The strongest bonds holding a protein’s 3D structure together are covalent disulphide bonds between 
cysteine amino acids. As the strongest intra-protein bond they play a key role in determining a 
protein’s structure and their reduction increases the accessibility of the protein to the enzyme [40]. 















most commonly used regent is dithiothreitol (DTT) [9]. A stronger reagent that can be used is tris  
(2-carboxyethyl) phosphine (TCEP), which has the advantage of being irreversibly oxidised after 
reduction, soluble in water and odourless compared to DTT [32; 44]. However, when either reagent is 
used in isolation the disulphide bond would reform, so after reduction an alkylating agent is generally 
added to prevent re-formation of the disulphide bond with the most common reagents being 
iodoacetamide (IAM) [32] and iodoacetic acid (IAA) [45]. 
The most important consideration in an enzymatic digestion is the choice of enzyme, as this directly 
determines the peptides that are produced.  The most common protease reported in literature is trypsin 
[40], which cleaves the amide bond directly after arginine and lysine. Digestion times can vary widely 
from a few hours to days but the most common is the 16 hour digest (or overnight) which allows 
sufficient time for protein digestion [40; 41; 46]. If the enzyme digestion is quenched too soon, by 
addition of acid to the reaction, or if digest efficiency is low then there is a risk of producing peptides 
with missed cleavage sites, which complicates interpretation of the analysis. 

























[48] SDS TCEP IAM Trypsin 5 hours 
Immunodepletion 
before digestion 
was used to 
improve 
detection of some 
proteins 
[45] GuHCl DTT IAA Trypsin 8 hours 
Assessed the 
effect of trypsin 
quality on digest 
efficiency 
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[50] Urea DTT (x2) IAM Trypsin 14 hours 
Extra DTT was 
added to quench 
excess IAM 

















[53] Urea DTT IAM Trypsin Overnight 
The paper 
examined the use 








[39] Rapigest DTT (x2) IAM Trypsin (x2) 45-48 hours 
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second aliquot of 
trypsin was 
added after 24 
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before digestion 
[54] Urea DTT IAM Trypsin Overnight 
Serum 
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was carried out 
before digestion 
[32] SDC TCEP IAM Trypsin 16 hours 























[56] GuHCl DTT IAA Trypsin 22 hours 










[57] SDC DTT IAM Trypsin 16 hours 
Optimisation of 
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[20] Urea DTT IAM Trypsin 3 hours 
Different length 
LC gradients 
were used to try 







[64] Urea DTT IAM Trypsin Overnight 
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[33] Urea, thiourea 
Not 
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mTRAQ Trypsin 16 hours 
mTRAQ is a 
labelling agent 
and was used to 
isotopically label 
cysteines and for 
differential 
labelling of 
samples for MS 
analysis 
[67] n/a n/a n/a Trypsin Unspecified 
In-gel digestion 
of pooled urine 




From this snapshot a good starting point for a theoretical digestion protocol would be to use urea as a 
denaturant, followed by reduction with DTT, alkylation with IAM and finally a 16-hour trypsin 
digest. From the sources referenced above, this average method was only reported in 11% of sources, 
although if overnight digestion  is considered the same as 16-hour digestion [66] then this rises to 
19% of sources.  An overnight or 16 hour digest is perhaps most commonly used due to its 
convenience, as well as ensuring sufficient time for peptide concentration to reach an end-point or 
steady state [41; 46]. Where the digestion was monitored by collecting samples over the duration of 
the digest, the concentration of peptides produced always reached its maximum before the end of the 
16 hour [41] or 23 hour [46] digest, but the concentration of some peptides would then decrease as the 
digestion continued until quenching. Whilst the use of trypsin was fairly ubiquitous, other enzymes 
could be used including endoproteinase lys-C [47; 49] that cleaves after lysine, and chymotrypsin [49] 
that cleaved after tryptophan, tyrosine and phenylalanine. Trypsin was observed to be the best 
performing enzyme in a direct comparison of trypsin, chymotrypsin and lys-C [49] in terms of the 




number of peptides produced without missing any cleavage sites. Despite an observed bias for 
missing lysine cleavages in trypsin digests, the use of lys-C followed by trypsin did not reduce the 
number of peptides with missed cleavages. Chymotrypsin was the worst performing enzyme 
compared in this study due to its slower rate of reaction, and the presence of peptides with missed or 
incorrect cleavages in the final solution. 
The biggest variability in the literature is regarding the use of denaturants, which was reflected by 
several method development papers that assessed the effects of different chaotropes and surfactants on 
digest efficiency. Despite being the most commonly used, (47%) urea did not compare favourably to 
other reagents. This was particularly true when compared to surfactants, such as SDS, sodium 
deoxycholate (SDC), Rapigest (Waters), Invitrosol (Thermofisher) and PPS silent (Expedeon) that 
produced better digest efficiency than urea under identical conditions [41; 42] without the risk of 
carbamylation. Rapigest, Invitrosol and PPS silent are all commercially available, proprietary 
surfactants marketed for use in enzyme digestion. However, SDS, SDC and Rapigest needed to be 
removed before LC-MS/MS analysis to prevent interference [42], whilst Invitrosol and PPS silent 
were non-interfering surfactants and did not need removing. SDS was the hardest to remove in this 
regard with buffer exchange proving to be the best method for its removal [43], whilst Rapigest was 
the easiest as it is acid labile and could be made non-interfering by addition of acid after digestion. 
SDC was harder to remove than Rapigest but would precipitate under acidic conditions where it could 
be removed [41; 43] or alternatively it was removed via phase-transfer or liquid-liquid extraction 
(LLE) with ethyl acetate under acidic conditions [41; 43; 57]. As acid precipitation could cause 
unwanted peptide co-precipitation, LLE was reported as being more efficient at removing the 
surfactant without removing analyte [41; 43]. Where direct comparisons were possible SDC was 
reported as outperforming urea, Rapigest and SDS [41; 43; 57] and so it should be considered as a 
replacement for urea in enzyme digestion.  
Another interesting technique was the use of organic solvents, such as methanol (MeOH), acetonitrile 
(MeCN) and isopropyl alcohol (IPA) to denature proteins, either used independently or in 
combination with surfactants [41; 42]. However, whilst a combination of MeCN and Rapigest was 
observed to give the best digest efficiency for analysis of cancer cell lysates [42], the use of MeOH 
was observed to decrease digest efficiency. Conversely, the use of MeOH and MeCN without 
surfactant was observed to increase digest efficiency for analysis of human plasma proteins [41] and, 
although not as much as when using SDC, they could be mixed together or with trifluoroethanol 
(TFE) to achieve comparable digest efficiencies. The use of common organic solvents to increase 
digest efficiency is intriguing due to its simplicity, but their benefits seem to be related to the proteins 
being studied with the potential to decrease digest efficiency as well as increase it. For this reason, 
when developing a new enzyme digestion method, surfactants are preferably to urea and other 




chaotropes as they have been observed to only increase digest efficiency for a broad range of different 
proteins and matrices. 
The final stage of all enzymatic digestion was the quenching of the digest with acid [49], usually 
using formic acid or TFA, and was generally followed by an extraction or similar process to prepare 
the sample for analysis. The most commonly extraction technique was solid-phase extraction (SPE) 
using either Oasis HLB (Waters) [9; 19; 41; 52; 62] or reverse-phase C18 [20; 43; 45; 50; 56; 58] 
stationary phases. Other methods were performed using molecular weight cut-off (MWCO) filters 
[37; 43; 46; 65] that allowed for protein concentration before digestion, or C18 spin filters that allowed 
for peptide concentration and surfactant removal after digestion [38]. The use of both kinds of filters 
simplified the digestion and extraction process but sample volumes were limited by the volume of the 
filter, whereas SPE is able to extract and concentration larger digestion volumes, which would be 
beneficial for analysing less abundant proteins. 
1.3 Human proteins in wastewater 
1.3.1 Human specific biomarkers 
The use of WBE for understanding any public health question raises the issue of where the analyte 
originates. In studies of drugs of abuse or human pharmaceuticals the source of an analyte is expected 
to be consumption [68], disposal [69; 70] or metabolism [71]. When investigating the wastewater 
proteome, the source of a protein must be determined as human in origin if it is to be used for 
interpreting human health. Consequently, in bottom-up proteomics the focus must be on analysing 
human specific peptides originating from digestion of human proteins, as human and non-human 
proteins may share much of their amino acid sequences. In chapter four [1] seven potential WBE 
protein biomarkers were proposed: Prostate Specific Antigen (PSA), C-Reactive Protein (CRP), 
Interleukin-6 (IL-6), Interleukin-8 (IL-8), Podocin (PDC), Anterior Gradient Protein 2 (AGR2) and 
Uromodulin (URM). The peptides produced from digestion are dependent on the enzyme used to 
digest. Table 1 shows the human specific and non-specific peptides from an in-silico enzymatic digest 
using trypsin for each of the seven proteins listed above. In-silico digestion and monoisotopic peptide 
masses were performed using ExPASy online peptide mass programme. The search parameters left 
cysteines in their reduced form and assumed no missed cleavages. Peptides are presented in table 2 in 
a shortened format consisting of the first three amino acids of the sequence, a hyphen, and the last 
amino acid of the sequence, usually K or R. For example, the PSA peptide WTGGK is shortened to 
WTG-K. Human specificity was determined by searching for the sequence using Uniprot’s online 
peptide search, treating leucine and isoleucine as the same to help identify isobaric peptides and only 
considering reviewed results.  




Table 2. Specificity of tryptic peptides from biomarkers of disease, non-human specific peptides with asterisks 
(
*
) could be considered pseudo-specific, as discussed below the table.  
Protein 
Peptide (Molecular weight (Da)) 
Comments 
Human specific Non-human specific 
Prostate specific antigen 
(PSA) 
DTI-P (729.4)  
FML-R (796.4)  
LSE-K (1271.7)  
FLR-R (1870.9)  
LQC-K (2345.2)  




 (547.3)  
VVH-R
†
 (672.4)  
SVI-R
*
 (728.5)  
IVG-K
*†
 (1019.5)  
HSQ-R
*




*= shared with Macaca 
mulatta and/or Macaca 
fascicularis 
 
† = shared with another 
human protein (KLK2) 
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* = Shared with 
infraorder Simiiformes of 
the order primates, 
including macaques  
 
ETC-K and EAL-K are 
very non-specific  
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All the protein biomarkers, except IL-8, had at least one human specific peptide biomarker. 
Fortunately, many of the IL-8 biomarkers are only shared with other primates, as is the case for many 
of non-specific peptides of other proteins, meaning they could still be used in countries without a 
large primate population; such as the UK. More problematic peptides are those shared with common 
European animals such as Mus musculus (house mouse), Rattus norvegius (brown rat) and Canis 
lupus familiaris (domestic dog), as these species may also contribute urine to wastewater, as well as 
those held in common with bacteria, fungi and yeasts that may colonise the inside of sewers or 
otherwise be discharged into them by natural or anthropogenic activity.  
The selection of human specific peptides has not been a concern in previous clinical proteomic 
publications. As such, a variety of non-human specific peptides have become routinely used for 
analysis of the protein biomarkers listed above. For example, the analysis of URM via LC-MS/MS 
[72] used the peptides STE-R, shared with Pongo abelli (Sumatran orangutan), and DWV-R, shared 
with Pongo abelli and Canis lupus familiaris. Likewise the peptides IVG-K and LSE-K are 
ubiquitously used for analysing PSA [18; 73; 74] but IVG-K is shared by the related human 
kallikrein-related peptidase 2 protein and LSE-K has a single nucleotide polymorph (SNP) in humans 
causing the PSA protein to be expressed as LSE(I)-K, LSE(L)-K or a mixture of the two [75]. Podocin 




and CRP meanwhile are largely analysed in bottom-up proteomics using human unique peptides, with 
separate studies of podocin using APA-R (Simon) and QEA-R [16] respectively.  
1.3.2 Estimating human protein concentrations in wastewater 
In WBE the last step after analysis is known as back-calculation [1; 76] and comprises all of the 
mathematical manipulation and interpretation required to take a result from a measurement of a 
sample in a vial through to a reliable estimation of the average amount consumed by a given 




) [76]. A more thorough accounting of 
how this process takes place can be found in chapter one. In brief, the concentration of analyte in a 
sample is multiplied to account for any increases in concentration that occurred from sample 
preparation, such as SPE. I.e. a 50 mL wastewater sample is concentrated down to 0.5 mL, so when 
back calculating the concentration in the sample is first multiplied by 0.1. Next, the concentration is 
multiplied by the daily wastewater flow (L day
-1
) and then multiplied by 1000 divided by the 
population (1000 inh
-1
) to normalise the results. This produces a value that can be compared with 
others taken in a different place and/or at a different time. For the purposes of estimating the protein 
concentration in wastewater, known as the load, this process can be reversed as shown below in 
equation 1 (eq. 1). 
𝑊𝑎𝑠𝑡𝑒𝑤𝑎𝑡𝑒𝑟 𝑙𝑜𝑎𝑑 (𝑔 𝐿−1) =  
𝑉𝑢𝑟𝑖𝑛𝑒 ∗ 𝐶𝑏𝑖𝑜𝑚𝑎𝑟𝑘𝑒𝑟 ∗ 𝑃𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛
𝑉𝑤𝑎𝑠𝑡𝑒𝑤𝑎𝑡𝑒𝑟
 𝑒𝑞. 1 
Vurine (L day
-1
) is the volume of urine that an average person excretes each day and is multiplied by the 
average urinary biomarker concentration of a healthy individual, Cbiomarker (g L
-1
), to calculate the 
amount of biomarker one healthy individual would excrete each day (g day
-1
). This is then multiplied 
by the population served by the wastewater treatment works to calculate the total amount of 
biomarker excreted by the whole population each day. Finally, to account for dilution in wastewater 
caused by the presence of non-urinary water, such as rainfall, the result is divided by Vwastewater (L day
-
1
). Vurine can be calculated using clinical estimates for a healthy individual [77], which suggest a 




 of urine. Therefore, the average adult weight in the studied 
country, in this case the UK, is needed. The Office for National Statistics (ONS) [78] estimated in 
2010 that the average UK adult male weighed 83.6 kg, whilst the average UK adult woman weighed 
70.2 kg, for an average weight of 77 kg (assuming equal gender balance). VU can be calculated using 
equation 2.   
𝑉𝑈 = 1 ∗ 77 ∗ 24 ∗ 10
−3 = 1.848 𝐿 𝑑𝑎𝑦−1 𝑒𝑞. 2 
Using the healthy urinary biomarker concentrations presented in chapter four [1], the population of 
the chapter 1 UK study city [76] and the average wastewater volume for 2014-2018 from chapter 1 SI 








) the wastewater load of each biomarker can be calculated. An example 
for C-reactive protein is shown below in equation 3 (eq. 3). 
𝐶𝑅𝑃 𝑙𝑜𝑎𝑑 (𝑔 𝐿−1) =  
1.848 ∗ 0.0012 ∗ 886650
229,804,840
= 8.5 𝜇𝑔 𝐿−1 𝑒𝑞 3.  
Uromodulin: 0.15 µg L
-1
 
Podocin: 28.9 ng L
-1
 
Interleukin-6: 11.4 pg L
-1
 
Interleukin-8: 49.9 pg L
-1
The difference between men and women in average, healthy, urinary concentrations of PSA meant 
each gender’s contribution had to be calculated separately and then averaged. This was performed 
again assuming equal division of gender in the population, i.e. each gender’s calculated used a 
population of 443,325 and calculated Vurine using the average weight of their gender.  
PSA (Male): (Vurine = 2.006 L day
-1
) 87.0 ng L
-1
 
PSA (Female): (Vurine = 1.685 L day
-1
) 0.23 ng L
-1
 
PSA (Average): 43.6 ng L
-1 
These estimated wastewater concentrations are subject to a number of assumptions, the biggest of 
which are that it assumes all of the population are adults and that all of the population is healthy. As 
such they should be used as a benchmark for assessing the analytical challenges of detecting and 
quantifying the biomarkers rather than for determining health interventions or as a measurement of 
population health. The concentration range of these biomarkers extends from pg-µg L
-1
, which fits 
largely with the concentration range of other WBE analytes [8] although the interleukins would be 
just outside of this range.  





2.1 Analytical instrumentation and materials 
The development of a successful digestion method required two interconnected aspects to be working 
alongside each other, firstly there needed to be a validated method for analysing the results of a 
prospective digestion method and secondly there needed to be a reproducible digestion method to 
create samples for analytical method development. This chicken and egg scenario required the use of 
an already validated LC-MS/MS method, and this was provided by the Chemical Characterisation and 
Analysis Facility (now the material and chemical characterisation facility (MC2)) of the University of 
Bath. 
The first analytical method used an HPLC-Chip cube system that was directly coupled to an Agilent 
6520 quadrupole-ToF (Q-ToF) mass spectrometer (Agilent Technologies, Santa Clara, CA) fitted with 
an electrospray ionisation (ESI) source and operated in positive ionisation mode. Liquid 
chromatography separation and sample enrichment was performed on the chip using a 40 nL 
enrichment column and 43 mm x 75 μm analytical column packed with 5 μm, Zorbax 300SB-C8 
particles (G4240-63001, Agilent, Santa Clara, CA). An injection volume of 2 μL was used for 
samples with a total protein concentration 30nM, an injection volume of 1 μL was used for samples 
with a total protein concentration 60 nM and above this concentration either a 0.1 μL or 0.3 μL 
injection volume was used. Samples were first loaded onto the enrichment column at a rate of 
4μL/min using the initial conditions shown below (Table 2). After 1 minute the samples were 
transferred onto the analytical column at a flow rate of 6 μL min
-1
 and the linear gradient was started. 
The solvents used were A: water with 0.1% formic acid (FA) and B: 90:10 acetonitrile: water, with 
0.1% formic acid.  
Table 3. Chip LC gradient with enrichment prior to analytical separation 
Time (minutes) 
% mobile phase A:  
H2O + 0.1% FA 
% mobile phase B:  
90:10 MeCN: H2O + 0.1% FA 
0.0 97 3 
1.0 97 3 
28.0 50 50 
30.0 0 100 
31.0 0 100 
32.0 97 3 
 
The MS ChipCube source was interfaced with an Agilent 1260/1200 series HPLC system consisting 
of a 1260 capillary pump, a 1200 Nano pump, a 1200 Micro WPS and a 1290 infinity thermostat 
(Agilent, Santa Clara, CA). The ChipCube source operated at a temperature of 365 
o
C, with a N2 




drying gas flow rate of 5 L min
-1
 and a capillary voltage of 2.1 kV. Data acquisition was carried out in 
a data dependant manner, with initial ToF only MS acquisition between 300-1700 m/z, with a scan 
rate of 4 spectra S
-1
. Once a precursor was detected at or above an intensity threshold of 2000 counts 
the spectrometry conditions changed to MS/MS mode, with a collision energy proportional to the 
detected m/z, a scan rate of 3 spectra S
-1
 and data acquisition between the range of 50-1700 m/z.  
Peptides were identified using Matrix science’s Mascot peptide database, which takes imported 
MS/MS data and information about the digest, such as the enzyme used, and generates a list of 
detected peptides and the proteins that they could belong to. An added benefit was that the software 
identified peptide sequences that were unique to a particular protein and which were shared between 
related species or related proteins. The software was set up to allow for up to 2 missed cleavages and 
both methionine oxidation and cysteine labelling with iodoacetamide. Where urea was used in digests 
carbamylation was also selected as a possible peptide modification.  
All other experiments were performed using a Waters Acquity UPLC coupled to a Waters Xevo TQD 
triple quadrupole instrument with the following MS instrument conditions: Capillary voltage: 2.5 kV, 
Source temperature: 150.0 
o
C, Cone gas flow: 100.0 mL min
-1
. The HILIC method used 100% H2O 
with 0.1% formic acid as mobile phase A and 100% MeCN with 0.1% formic acid as mobile phase B. 
The flow rate used was 0.3 mL min
-1
 and a mobile phase gradient was developed as detailed below in 
table 4. HILIC separations were performed using a Waters Acquity UPLC BEH column, 1.7 µm, 1.0 
x 100 mm. 
Table 4. HILIC method gradient 
Time (minutes) 
% mobile phase A: 
H2O + 0.1% FA 
% mobile phase B:  
MeCN + 0.1% FA 
0.0 5 95 
2.0 5 95 
22.0 50 50 
27.0 50 50 
27.1 5 95 
40.0 5 95 
 
Acetonitrile (MS grade), methanol (MS grade) and ethyl acetate (>95%) were purchased from VWR. 
Formic acid (>98%), ammonium bicarbonate (>99.5%), hydrochloric acid (≥32% purity), sodium 
deoxycholate (>98%), dithiothreitol (>98%), iodoacetamide (>99%), trypsin (porcine, di-methylated) 
and Whatman GF/F filter paper were purchased from Sigma Aldrich, UK. Prostate specific antigen 




(Human), Bovine serum albumin (Fraction V), C-reactive protein (Human), Interleukin-6 (Human) 
and Interleukin-8 (Human) were all purchased from Merck. Oasis HLB SPE cartridges (3 CC, 60 mg) 
and 300 µL PPE vials were purchased from Waters UK. 4 mm, 0.2 µM Titan
3
 PVDF syringe filters 
were purchased from Thermo scientific. 
2.2 Enzyme digestion development 
The goal of digest development was to create a method that reproducibly produced protein unique 
peptides from several different biomarkers, and that could be adapted to work with more complex 
matrices like wastewater. The proteins used to develop the digest were prostate specific antigen (PSA) 
and bovine serum albumin (BSA). PSA is a well-studied biomarker of human health that is excreted 
in urine and used as a diagnostic biomarker for prostate cancer in men, as discussed in chapter four 
[1]. BSA was included as it is a relatively cheap protein that could be used as an internal control in 
future digests with real samples to ensure that the digest procedure worked and to assess digest 
efficiency. Samples were extracted using Oasis HLB cartridges and eluted and reconstituted to a 
specified final protein concentration. Before extraction cartridges were conditioned using 2 mL of 
MeOH followed by 2 mL of H2O with 0.1% v/v formic acid. Oasis HLB cartridges were selected as 
they have a broad selective that would allow for the simultaneous extraction of as many peptides as 
possible. After loading samples were eluted in 4 mL of 80:20 MeOH: H2O with 0.1% formic acid and 
placed in a water bath at 40 
o
C before evaporating to dryness under a steady stream of N2. Samples 
were then reconstituted to a specified final volume in a specified mobile phase. Figure 2 (below 2.2.4) 
shows a summary of all the digest conditions trialled. 
2.2.1 Enzyme only method 
The enzyme only digest protocol was performed in duplicate and had 10 pmoles of BSA and PSA in 
individual samples 1 mL containing 100 mM NH4HCO3 buffer at pH 8.4. Trypsin was then added, 
and the proteins were left to digest for 16 hours before quenching with 0.5% v/v formic acid. Samples 
were extracted using Oasis HLB cartridges and loaded under gravity for 5 minutes before being 
washed with 3 mL of 0.1% v/v formic acid solution. After drying, samples were eluted and 
reconstituted as described above (2.2) to a final protein concentration of 30 nM in 300 µL of 95:5 
H2O: MeOH for analysis via the Chip cube method.  
The method was repeated in duplicated with a greater initial concentration of both PSA and BSA to 
give a final protein concentration of 303 nM and 606 nM respectively.  
2.2.2 No surfactant methodology  
A more comprehensive methodology was then developed using DTT and IAM solutions to reduce and 
alkylate the two proteins prior to digestion with trypsin, with the goal of increasing digest efficiency 




by increasing trypsin’s ability to access cleavage sites in the proteins. This was expected to be 
particularly beneficial for BSA which contains seventeen disulphide bonds, whereas PSA contains 
only five. The final protein concentration of BSA and PSA was reduced back to 30 nM in a final 
volume of 300 µL.  
2.2.3 Use of sodium deoxycholate (SDC) 
To assess the benefits of using a surfactant to denature the proteins before digestion 100 µL of 7% 
(m/v) aqueous sodium deoxycholate (SDC) solution was added to samples containing either BSA or 
PSA before addition of DTT. As a denaturant SDC was expected to increase digest efficiency and was 
shown to be more beneficial than urea. However, SDC required removal before analysis, which was 
performed by precipitating SDC when quenching the digest, using 0.5% v/v formic acid, with the rest 
of the digest was carried out as detailed in the no surfactant methodology (2.2.2) until after the digest 
was quenched. After quenching the samples were left to precipitate for 15 minutes and then 
centrifuged at 1000 RPM for 1 minute to help pellet the precipitated SDC and the supernatant was 
then loaded onto cartridge as normal. SPE and sample preparation then continued as before with 
samples reconstituted to a volume of 300 µL giving a final protein concentration of 30 nM.  
An alternative SDC removal method using liquid-liquid extraction with ethyl acetate was also trialled 
to compare against acid precipitation. The digest was carried out as above but before the digest was 
quenched 1 mL of ethyl acetate (1:1 v/v) was added to each sample and 0.5% v/v formic acid was 
then added to quench the digest. The digests were then shaken, and the two phases were allowed to 
separate before the ethyl acetate was removed by pipetting. This process was repeated twice more, 
without addition of more formic acid, before the aqueous fraction was loaded onto cartridge as before. 
SPE and sample preparation then continued as before with samples reconstituted to a volume of 300 
µL giving a final protein concentration of 30 nM.  
2.2.4 Use of urea 
Whilst less efficient and more likely to carbamylate peptides urea was trialled as an alternative to 
SDC, as urea had the advantage of being removed by SPE without the need for extra sample 
preparation. The digest procedure was carried out as described in 2.2.2 but before addition of DTT 
100 µL of 6 M urea was added. From addition of DTT, IAM and additional buffer solution the 
concentration of urea was reduced to <0.6 M to prevent urea from interfering with trypsin activity. 
SPE and sample preparation were carried out as before with samples reconstituted to a volume of 300 
µL giving a final protein concentration of 30 nM.  
 




Figure 2. Summary of digestion experiments with colour coding to show the steps that were used by each 
method.  
2.3 Assessing digest robustness 
2.3.1 Co-digestion of BSA and PSA 
Further work was then carried out using the best performing digest from section 2.2 to assess the 
impact on digest efficiency of combing multiple proteins into one digest, in this instance BSA and 
PSA, each at an individual concentration of 30 nM. 
2.3.2 Digestion of new biomarkers 
New protein biomarkers were selected and digested alongside BSA, at an increased individual 
concentration of 500 nM, using the method described above. The final concentration was increased so 
that they could more easily be used with the HILIC-MS method described in section 2.4. The selected 
biomarkers were C-reactive protein (CRP), interleukin-6 (IL-6) and interleukin-8 (IL-8), all of which 
are biomarkers of inflammation, with CRP also being a biomarker of cardiovascular disease and the 
two interleukins as biomarkers of urinary tract infection. The proteins also show a large discrepancy 




in mass range and were selected to check if protein size impacted digest efficiency. IL-8 has a mass of 
8.4 kDa and was the small protein examined here, IL-6, CRP and PSA all have relatively similar 
masses (21 kDa, 24 kDa and 26 kDa respectively), whilst BSA is the largest protein with a mass of 66 
kDa.  
2.4 Quantotypic peptides 
The peptides produced from all the digest experiments carried out in 2.2 and 2.3 were recorded and 
compared to the list of human unique peptides contained in table 2 in order to identify quantotypic 
peptides for each of the biomarkers. For this purpose, peptides with missed cleavages were also 
considered quantotypic but were only used to determine sequence coverage if the fully cleaved 
peptide was not detected. For example: DTI-P is a human unique peptide of PSA, WIK-P is a related 
peptide where the bond between K and D was not cleaved. As such WIK-P is still a human unique 
peptide of PSA but only counted towards sequence coverage if DTI-P was not detected. 
2.5 HILIC-MS method development 
Method development focused on the use of HILIC for the separation of quantotypic peptides 
identified in the previous sections (2.2 and 2.3). In section 1.3 a complete range of tryptic peptides for 
several potential biomarkers was produced from their in-silico digestion via trypsin. These peptides 
encompass a wide range of physical properties resulting from the differences in their constituent 
amino acids. HILIC was chosen instead of the more commonly utilised place reverse phase 
chromatography to take advantage of the fact that almost all digested peptides would have a charged, 
hydrophilic C-terminal peptide giving the peptide some HILIC retention. Additionally, the presence 
of polar amino acid side chains allowed for a secondary mode of interaction with the stationary phase.  
Binary two proteins digests containing 5 µM of bovine serum albumin (BSA) and either CRP or PSA 
were prepared using the method developed in section 2.2. PSA and CRP were selected above other 
biomarkers discussed in section 1.3 due to their relatively high urinary concentration and clear 
disease-biomarker relationships, i.e. a disease state progresses the amount of biomarker excreted 
increases. Samples for HILIC analysis were reconstituted in 50:30:20 (% v/v) MeCN: MeOH: H2O 
with 0.1% formic acid. This diluent was used for reconstitution of HILIC samples after reconstitution 
in mobile phase (95:5 (% v/v) MeCN: H2O with 0.1% formic acid) was unable to fully dissolve the 
sample.   
The use of a triple quadrupole instrument necessitated the selection of MRM transitions for the 
peptides. MRM transitions were selected by infusing 5 µM digests of each biomarker into the 
instrument at a flow rate of 20 µL min
-1
. Ionisation conditions were then altered to determine optimal 
conditions for the ionisation of the precursor peptides at a collision energy of 0 V in full scan MS 
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mode. Next the collision energy was increased so that the precursor peak intensity was reduced by 
half and peptide daughter ions were then identified. The collision energy was then altered to find the 
optimal energy to produce the greatest daughter ion peak intensity possible. The three most intense 
peptides and their most intense transitions were recorded and confirmed by injection and analysis of 
the remaining 5 µM digests using the HILIC method outlined above (section 2.1). The HILIC method 
was kept deliberately broad by starting at a low percentage of mobile phase A and slowly increasing 
to 50% in order to provide some separation for all the potential biomarkers. The flow rate selected 
was the fastest possible whilst keeping the maximum column pressure below 80% of its maximum 
operating pressure, which occurred at a 50:50 mixture of the two mobile phases. 
Full instrument and method validation were not possible at this stage of development, so a 
preliminary method performance experiment was performed to examine the instrument’s response to 
BSA and to gain an understanding of digest intraday reproducibility. Method performance was 
performed using BSA only digests at a range of concentrations. BSA linearity was determined for 
each of three BSA peptides, identified as quantotypic in sections 2.2 and 2.3, using a twelve-point 
calibration curve ranging from an initial BSA concentration of 0-1000 µg mL
-1
. The calibration curve 
was created by spiking in differing initial amounts of a 1 mg mL
-1
 BSA solution into digests prepared 
according to the best performing method developed in section 2.2. The final concentrations selected 
were 0, 1, 2.5, 5, 10, 18, 32, 63, 125, 250, 250, 500 and 1000 µg mL
-1
. Each sample was analysed 
twice using the HILIC method developed above and integrated using MassLynx (V4.1) with analyte 
peak areas used to generate a calibration curve.  The linearity of this calibration curve was a measure 
both of analyte response and digest reproducibility. Accuracy was determined by comparing the 
concentration of each sample, as determined by the calibration curve, to the known initial BSA 
concentration (x) using equation two (eq. 2).  
𝐴𝑐𝑐𝑢𝑟𝑎𝑐𝑦 (%) =  
𝑇ℎ𝑒𝑜𝑟𝑒𝑡𝑖𝑐𝑎𝑙 𝐵𝑆𝐴 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛𝑥
𝑀𝑒𝑎𝑠𝑢𝑟𝑒𝑑 𝐵𝑆𝐴 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛𝑥
∗ 100 𝑒𝑞. 2 
Reproducibility was determined by injecting the same sample twice and comparing the difference in 
integrated peptide areas. Reproducibility was calculated as % RSD using equation three (eq. 3). 
𝑃𝑟𝑒𝑐𝑖𝑠𝑖𝑜𝑛 (% 𝑅𝑆𝐷) =  
𝜎 𝑃𝑒𝑎𝑘 𝑎𝑟𝑒𝑎𝑠𝑋1𝑋2
𝐴𝑣𝑒𝑟𝑎𝑔𝑒(𝑃𝑒𝑎𝑘 𝑎𝑟𝑒𝑎𝑥1, 𝑃𝑒𝑎𝑘 𝑎𝑟𝑒𝑎𝑥2)
∗ 100 𝑒𝑞. 3 
The goal of this work was to establish an effective linear range for BSA so that it could be considered 
as a potential marker for determination of digest efficiency in real samples, via the addition method 
[79]. 
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Limits of detection and quantification were calculated using the slope (m) and standard deviation of 
the intercept (σC) of the linear concentration line of best fit, rather than the more traditional signal to 
noise approach. The standard deviation of the intercept was calculated using Microsoft Excel’s 
regression function and LOD and LOQ were calculated using equation three (eq. 3) where x = 3.3 for 
LOD and x = 10 for LOQ. N was the number of points in the calibration.  
𝐿𝑂𝐷 𝑜𝑟 𝐿𝑂𝑄 = 𝑥 ∗ 
𝜎𝐶 ∗  √𝑁
𝑚
 𝑒𝑞. 3 
2.6 Analysis of wastewater samples 
From predicted wastewater concentrations of PSA and CRP (section 1.3) it was possible to estimate 
how much wastewater would be required to achieve a protein concentration of 500 nM. For PSA the 
required volume was several litres and so not currently feasible but for CRP this was equivalent to 
300 mL of influent wastewater. Whilst more reasonable this is still a larger volume than was used for 
most WBE applications, so initially a volume of 100 mL was used. 100 mL was selected as a starting 
volume because the estimate wastewater concentrations for both CRP and PSA assumed a 100% 
healthy population, which suggests that their actual wastewater concentration may be higher. Influent 
wastewater was collected from a treatment works in the South-West of the UK by grab sampling. As 
the reagents used for protein reduction and alkylation were already added in excess the volumes used 
were unchanged, as was the amount of trypsin added. Before digests were loaded on SPE cartridges, 
as discussed in section 2.2, they were first filtered through 0.2 µM Whatman GF/F filter paper under 
vacuum. The digest efficiency of trypsin is known to be determined by pH, so the pH of wastewater 
samples was measured after addition of each reagent and before and after acidification to ensure pH 
stability. Initial digests using wastewater compared three sets of conditions, which were prepared and 
analysed in duplicate, as follows:  
1) A standard digest with 500 nM each of BSA, CRP and PSA in buffer 
2) A 100 mL of wastewater digest with 500 nM each of BSA, CRP and PSA added 
3) A 100 mL wastewater digest with 500 nM of BSA added 
Each of the three digests tested a specific parameter of the methodology. Firstly, if the digestion and 
reagents were working (digest one), if proteins could be detected when spiked into wastewater (digest 
two) and if proteins endogenous to wastewater could be detected (digest three). BSA was added to all 
digests as a digestion control, i.e. if BSA peptides were present then the digestion worked.  
Follow up digests tried adding different amounts of protein to wastewater digests to allow for better 
detection of analytes. This time four digests were prepared: 
1) A buffer digest containing 500 nM each of BSA, CRP and PSA 




2) A 100 mL wastewater digest with 500 nM of BSA added 
3) A 100 mL wastewater digest with 500 nM each of BSA, CRP and PSA added 
4) A 100 mL wastewater digest with 5 µM each of BSA, CRP and PSA added 
In the same vain three more digests were prepared to examine the effects of adding more trypsin to 
digests, 1 mL of 20 ng mL
-1
 trypsin instead of 25 µL of 20 ng mL
-1
 trypsin and increasing the amount 
of wastewater used for the digests from 100 mL to 500 mL. As before three digests were prepared, but 
this time no buffer digest was prepared and the only protein added was BSA, which was added to a 
final concentration of 500 nM in each digest. 
1) 100 mL of wastewater with 500 nM of BSA, digested with 25 µL of 20 ng mL-1 trypsin 
2) 100 mL of wastewater with 500 nM of BSA, digested with 1 mL of 20 ng mL-1 trypsin 
3) 500 mL of wastewater with 500 nM of BSA, digested with 25 µL of 20 ng mL-1 trypsin 
The purpose of each of the three sets of digests was to examine the feasibility of using wastewater as a 
source of proteins of human health and to investigate the effects of different conditions on the 
developed digest methodology (section 2.2) to convert proteins of disease into their respective 
quantotypic peptides. 





3.1 Enzyme digestion development 
Section 2.2 trialled a number of different digest methodologies with varying complexities as 
summarised in figure 2. All detected peptides were detected as the [M+2H]
2+
 ion unless otherwise 
specified. 
3.1.1 Enzyme only digests 
The result of using only trypsin was that no BSA peptides were detected, whilst only one peptide of 
PSA was detected at low intensity (SI figure 1). As the final digest concentration (30 nM) was 
relatively close to the instrument’s detection limit of 10 nM the final concentration of each biomarker 
was increased to 303 nM for PSA and 606 nM for BSA. This increased concentration resulted in 
better digest efficiency with more peptides detected for each biomarker (SI figures 2-5). Sequence 
coverage is a measure of how many peptides were produced relative to the number of peptides 
produced from an in-silico digestion of the protein and is a good way of assessing digest efficiency. 
The high concentration, trypsin only method managed to achieve an average BSA sequence coverage 
of 46.7% or 28.5 peptides, and an average PSA sequence coverage of 33.6% or 4 peptides (SI figures 
2-5). This was an encouraging start but the concentration of proteins required to get this sequence 
coverage is very high when compared to urinary concentrations in healthy men (525 ng/L or 20.19 
pM) [80]. The PSA peptides detected were SVI-R, WIK-P, LSE-K and HSQ-R, where WIK-P is the 
incomplete digest form of the DTI-P peptide reported in table 2, resulting from a missed cleavage 
between the K and D amino acids. Likewise, KWI-P was also detected. KWI-P, WIK-P and DTI-P 
were considered equivalent for determining sequence coverage and are all human unique peptides of 




 ions. LSE-K is also human unique 
peptide whilst SVI-R and HSQ-R are pseudo-unique for the purpose of wastewater analysis in the 
UK, as they are shared with primate species that should not be present in the UK. 
3.1.2 No surfactant digests 
A more comprehensive methodology was then developed using DTT and IAM solutions to reduce and 
alkylate the two proteins prior to digestion with trypsin, with the goal of increasing digest efficiency 
by increasing trypsin’s ability to access cleavage sites in the proteins. The final concentration of BSA 
and PSA was reduced back to 30 nM for comparison with the initial trypsin only digest and for a 
better comparison of digest efficiency between BSA and PSA. For BSA the average sequence 
coverage was 86.7% with an average of 52 peptides detected, and for PSA the average sequence 
coverage was  
40.3% with 6 peptides detected (SI figures 6-9). This was a marked improvement in digest efficiency 
and showed that reduction and alkylation of disulphide bonds was very important for ensuring high 




digest efficiency. The PSA peptides detected included SVI-R, WIK-P, LSE and HSQ-R, which were 
also detected in the high concentration enzyme only digest, as well as FM
*
L-R and IVG-K. IVG-K is 
shared with human kallikrein protein 2 and is therefore not human PSA unique. FM
*
L-R is the 
methionine oxidised form of FML-R, which is a human PSA unique peptide and an example of a 
post-translation modification (PTM).  
3.1.3 SDC containing digests 
SDC was shown to be more beneficial than urea but required removal before analysis, which was 
performed by either precipitation SDC when quenching the digest using 0.5% v/v formic acid or 
liquid-liquid extraction (LLE) using ethyl acetate. After quenching with acid and the visible 
precipitation of SDC a clear, colourless gel formed that could only be re-dissolved by reducing the pH 
below pH 2, which was below the recommended pH for extraction using Oasis HLB SPE cartridges. 
If the gel was dissolved and then the pH increased to between pH 2 and pH 4 then the gel reformed. If 
the samples were loaded immediately after quenching, without waiting for SDC to precipitate, then 
this gel formed in the SPE cartridge and prevented analysis of the digest. A more pH tolerant 
stationary phase material could have been selected, such as a cation exchanging phases, but this would 
restrict the selectivity of the stationary phase and could have unfavourably biased the types of 
peptides that were detected.  
With the LLE method of extraction no precipitate was visible during this process but there was also 
no gel formation and the samples could be extracted and eluted as normal. However, the final digests 
only contained peptides originating from porcine trypsin above LOQ, no peptides of BSA or PSA 
were detected.  
3.1.4 Urea contain digests 
Urea was used as an alternative to SDC, which had the advantage of being removed by SPE without 
the need for extra sample preparation. The concentration of urea was reduced to <0.6 M before 
addition of trypsin due to the addition of other reagents and buffer and should not have interfered with 
trypsin activity. However, this still led to no peptides of BSA or PSA being detected at a final 
concentration of 30 nM, showing it to be worse than the previous methods without any denaturants. 
For these digests the Mascot search parameters were expanded to include carbamylation as a potential 
peptide modification.  
  




3.2 Assessing digest robustness 
As none of the commonly used denaturants seemed to benefit the digest they were removed, and the 
digest described in sections 2.2 and 3.1.2 (no surfactant digest) was used for assessing digest 
robustness. 
3.2.1 Co-digestion of BSA and PSA 
The co-digestion of BSA and PSA was performed using the method described above with a protein 
concentration of 30 nM for each protein. (SI figures 10 and 11) Overall this caused a reduction in total 
sequence coverage for both proteins with 64.7% sequence coverage for BSA with 13 unique peptides, 
whilst PSA had an average of 26.9% sequence coverage with 4 unique peptides. Whilst disappointing 
this reduction in unique peptide coverage was still acceptable as the detection of any of these peptides 
indicated that the protein was present in the digest, and for both proteins this reduction represented the 
loss of only two unique peptide sequences. For PSA the four detected peptides were SVI-R, IVG-K, 
WIK-P and LSE-K representing one pseudo-unique, one non unique and two unique peptides of PSA 
respectively. This was particularly encouraging as SVI-R, IVG-K and LSE-K are the most commonly 
reported peptides of PSA in bottom up digests in literature. 
3.2.2 Digestion of new biomarkers 
New protein biomarkers were then selected and digested alongside BSA, at an increased individual 
concentration of 500 nM, using the method described above. The selected biomarkers were C-reactive 
protein (CRP), interleukin-6 (IL-6) and interleukin-8 (IL-8). The summary for all biomarker digests is 
shown below in table 5. CRP and IL-8 were injected twice at different injection volumes (0.1 µL or 
0.3 µL) to try and maximise the number of peptides detected. IL-6 was not reinjected as eight peptides 
were determined to be sufficient.  
  

































BSA only 500 0.1 n/a n/a n/a 70.4 43 8 
CRP 
500 0.1 65.9 5 1 63.9 39 3 
500 0.3 94.2 6 0 91.7 56 3 
IL-6 500 0.1 58.7 8 0 62.3 38 4 
IL-8 
500 0.1 39.8 4 0 50.8 31 2 
500 0.3 49.7 4 0 81.9 50 3 
 
There were five CRP peptides detected in the 0.1 µL injection volume analysis (SI figure 12): AFV-
K, ESD-K, GYS-K, RQD-K and YEV-P. AFV-K and an alternate form with a missed cleave, KAF-K, 
were the only human non-unique peptides detected. In addition to YEV-P the missed cleavage form 
ALK-P [M+3H]
3+
 was also detected. RQD-K is the missed cleavage form of the unique peptide QDN-
K. In total seven peptides were detected. By increasing the injection volume to 0.3 µL the following 
peptides were detected (SI figure 13) in addition to those reported in the 0.1 µL analysis: QDN-K, 
APL-K and ESD-K, as well as missed cleavage forms of several peptides. In total eleven peptides 
were detected. 
With a final injection volume of 0.1 µL there were eight IL-6 peptides detected (SI figure 14): EFL-R, 
VLI-Q, YIL-R, EAL-K, DGC-K, NLD-K, LQA-R and IIT-R. NLD-K and LQA-R were the only 
human unique peptides detected, whilst EAL-K is non-specific and all others are pseudo-specific; 
being shared only with primates that are not expected to be found in the UK. Several missed cleavage 
forms of peptides were also detected so that in total, thirteen peptides were detected. 
The first analysis of the IL-8+BSA digest with an injection volume of 0.1 µL contained only four 
peptides (SI figure 15): ENW-R, ELC-K, TYS-K and VIE-K, all of which are pseudo-unique as they 
are only shared with non-UK native primates. It is important to note that TYS-K and VIE-K were 
detected as [M+3H]
3+





 ions of TYS-K and VIE-K peptides were detected, as 
well as a missed cleavage form of ELC-K, LSD-K.  




Unique peptides of BSA have not been discussed as its role in the digests is to act as a control for 
digest efficiency. Instead what was needed was to identify peptides that were produced reproducibly 
regardless of their uniqueness. In total BSA was included in a total of twelve analysed digests from 
experiments 2.2.1-2.2.4 and 38 peptides were detected in at least half the digests. Of these 38 peptides 
fourteen were detected in ten or more digests: LVT-K, AEF-K, LVV-A, QNC-K , LVN-K, YIC-K, 
TCV-K, LGE-R, EYE-K, DDP-K, DAF-R, LKP-K, RPC-K and GLV-K. Additionally, LFT-K was 
detected in eight digests.  
Overall, the final digestion method showed robustness in producing a range of peptides for each of the 
assessed biomarkers. Size did not appear to have a significant impact on digest efficiency, as assessed 
by percent sequence coverage. However, BSA sequence coverage across these digests was observed 
to fluctuate. The BSA+CRP, BSA+IL-6 and BSA+IL-8 digests were all performed at the same time 
and whilst the number of BSA peptides and the number of missed cleavages did vary between digests 
there were fourteen peptides, which corresponds to 21.3% sequence coverage, that were detected in 
every one of these digests. These peptides can be described as quantotypic, meaning they are 
produced reproducibly and can be thought of as being typical of that protein. The identification of 
quantotypic peptides is important for protein detection and quantification in real samples. At this stage 
the goal was only to show that the digest protocol could successfully digest a range of different 
proteins with a range of different masses and assessing how digest efficiency was impacted by having 
them all together was thought of as more application than development. 
The analytical method used here was beneficial for achieving high sensitivity without the need for 
large sample volumes. However, the chip LC-MS/MS system used is relatively niche in proteomics 
[50; 61] compared to more common standard flow chromatography. The goal of the project was to 
create a digestion procedure that could be used to prepare protein samples for analysis using the same 
instrumentation and methodologies as those currently used to analyse other WBE biomarkers. As such 
this required a move away from the Chip-LC method to more conventional UHPLC. Additionally, 
whilst using SPE to concentrate peptides was not really required for these samples it would need 
when working with more dilute protein solutions and more complex matrices, such as wastewater. 
  




3.3 HILIC-MS method development  
5 µM digests of BSA+CRP and BSA+PSA were prepared in accordance with the procedure detailed 
in 2.2 and used to tune the Xevo TQD MS and identify peptide ionisation conditions and MRM 
transitions. During infusion of analytes it became necessary to switch to a combined flow where 
mobile phase was used to assist analyte ionisation. 100% of mobile phase B (100% MeCN with 0.1% 
(v/v) formic acid) was flowed into the MS at a rate of 0.1 mL min
-1
. Into this flow of mobile phase 
analytes were infused from the MS module at a rate of 20 µL min
-1
. Using these conditions, the most 





 were as abundant as each other and so both were included as they were both related to the 
same CRP unique peptide. Fragmentation of the parent peptides then lead to the detection of at least 
two daughter ions for each parent, with the most intense two selected for future use. The MRM 
conditions used are shown below (Table 6) and source conditions are listed below: 
Capillary voltage: 2.5 kV, Source temperature: 150.0 
o
C, Cone gas flow: 100.0 mL/min,  
Table 6. Peptide MRM conditions for the triple quadrupole method 
Protein Peptide MRM 1 
CV (V) / CE 
(V) 
MRM 2 CV (V) / CE (V) 
BSA 
LGE-R 740.5 > 171.1 50 / 45 740.5 > 300.1 50 / 30 
LVN-K 582.3 > 213.2 35 / 20 582.3 > 951.5 35 / 21 
LVT-K 395.2 > 213.2 30 / 11 395.2 > 74.1 30 / 45 
CRP 
YEV-P 911.0 > 622.8 60 / 34 911.0 > 703.9 60 / 34 
ALK-P 711.7 > 715.4 35 / 35 711.7 > 559.3 35 / 35 
GYS-K 568.8 > 124.6 30 / 18 568.8 > 221.1 30 / 12 
APL-K 434.3 > 398.8 40 / 5 434.3 > 147.1 40 / 5 
PSA 
LSE-K 636.8 > 943.5 40 / 25 636.8 > 646.4 40 / 25 
IVG-K 539.2 > 213.0 25 / 20 539.2 > 283.5 25 / 12 
SVI-R 379.2 > 458.3 25 / 11 379.2 > 232.14 25 / 11 
 
Peptide retention times are shown below in table 7 and chromatograms from injection of the tuned 
samples are shown in figures 6-13. The CRP peptide GYS-K had a very unusual peak pattern of five 
peaks, which was not observed in the chip-LC experiments. At this stage no reason could be 
suggested for why this occurred, other than an insufficient number of points per peak (ppp) causing a 
broad peak to appear chopped into several smaller peaks. However, the method had >30 ppp, which 
was regarded as sufficient for quantification previously on this instrument (Chapter 3, [81]) and no 
other peptide was affected by this apparent peak chopping. 




Table 7. Average retention times of tuned peptides using average peak top retention time for each 
daughter (MRM) ion 
Protein Peptide Average retention time (min) ± deviation (min) 
BSA 
LGE-R 9.31 ± 0.00 
LVN-K 9.46 ± 0.02 
LVT-K 8.96 ± 0.05 
CRP 
YEV-K 8.02 ± 0.02 
ALK-P 8.00 ± 0.00 
GYS-K 
14.43 ± 0.02  
16.80 ± 0.02  
18.80± 0.02  
20.57 ± 0.02 
 22.89 ± 0.08 
APL-K 8.13 ± 0.01 
PSA 
LSE-K 10.38 ± 0.07 
IVG-K 9.14 ± 0.00 
SVI-R 7.97 ± 0.06 
 
 Figure 6. Two MRM transitions for the BSA peptide [LVT-K]
2+
 from infusion of 5 µM tuning solution 





 Figure 7. Three MRM transitions for the BSA peptide [LVN-K]
2+
 from infusion of 5 µM tuning solution 
 Figure 8. Two MRM transitions for the BSA peptide [LGE-R]
2+
 from infusion of 5 µM tuning solution 





Figure 9. Two MRM transitions for the CRP peptide [APL-K]
2+
 from infusion of 5 µM tuning solution 
 Figure 10. Three MRM transitions for the CRP peptide [GYS-K]
2+
 from infusion of 5 µM tuning solution 





Figure 11. Two MRM transitions for the CRP peptide [ALK-P]
3+
 from infusion of 5 µM tuning solution 
 Figure 12. Two MRM transitions for the CRP peptide [YEV-P]
2+
 from infusion of 5 µM tuning solution 






Figure 13. Three MRM transitions for the PSA peptide [SVI-R]
2+
 from infusion of 5 µM tuning solution 
 Figure 14. One MRM transitions for the PSA peptide [IVG-K]
2+
 from infusion of 5 µM tuning solution 





Figure 15. Four MRM transitions for the PSA peptide [LSE-K]
2+
 from infusion of 5 µM tuning solution 




3.4 Preliminary method performance 
The preliminary method performance was designed to test the instrument’s accuracy, precision and 
linearity for a range of BSA peptides. The results of the calibration curves prepared to test linearity 
for the three BSA peptides are shown below in table 8 and figure 16. LOD and LOQ were calculated 
using the slope of the intercept instead of the more common signal to noise method because the 
concentration range did not include samples with a low enough concentration to reach S/N = 3.3 or 
10. 







(%) ± SD 
Average 
precision 





LVT-K 1-500 0.999 101.6 ± 15.7 1.1 ± 0.8 25.4 77.0 
LVN-K 5-250 0.998 102.7± 15.5 1.2 ± 0.9 19.8 59.9 
LGE-R 18-500 0.999 97.6 ± 6.9 1.7 ± 1.9 4.2 12.8 
 
 
Figure 16. Calibration curves for BSA peptides 
All peptides gave excellent linearity, accuracy and precision although this would be expected to as the 
same sample was being injected twice, and the digest was being carried out at high concentration in 
buffered solution. However, this was still encouraging and showed that the HILIC-QQQ method was 

























method development this would potentially allow for BSA to be used as both a digest control, or as an 
internal standard for correcting peptide recovery from wastewater and SPE. 
3.5 Analysis of wastewater samples 
Wastewater pH was measured using five samples, prepared in section 2.6, by measuring the initial pH 
and pH after the addition of all reagents. The results are shown below in Table 9. 














Initial 7.5 7.5 7.3 7.3 7.3 7.4 ± 0.1 
Reduction 8.1 8.0 7.3 7.3 7.4 7.6 ± 0.4 
Incubation 7.9 7.9 7.3 7.3 7.3 7.5 ± 0.3 
Alkylation 8.0 7.8 7.1 7.1 7.2 7.4 ± 0.4 
Incubation 7.9 7.9 6.9 6.8 6.8 7.3 ± 0.5 
Enzyme 
addition 
- - 6.9 6.8 6.8 6.8 ± 0.0 
Digest 7.8 7.8 6.9 6.8 6.8 7.2 ± 0.5 
Acidification 3.3 3.2 2.6 2.5 2.5 2.8 ± 0.4 
 
The results of the pH stability experiment showed that the pH of wastewater was stable throughout the 
digestion procedure but was of a lower pH than that of the buffered solution used normally (pH 8.4). 
However, trypsin is known to be active around pH 7 [40] and because the pH was stable until 
acidification, where of 0.5% (v/v) of formic acid was still sufficient to reduce the pH to < 4, digest 
efficiency was not expected to be altered sufficiently to invalidate the procedure.  
However, from the first set of digestions it became clear that wastewater would still pose a significant 
challenge for the digestion method. No BSA or PSA was detected in either of the digests containing 
wastewater, although the presence of BSA, PSA and CRP in the control digest (without wastewater) 
showed that the reagents and trypsin were working. There were a series of peaks detected for the CRP 
peptide GYS-K, which matched was observed in buffer samples both at the time and in method 
development (section 3.2). The retention times of the GYS-K peak pattern did vary, as did the relative 
abundance of each peak, but this appeared to be due to a shift in retention time due to matrix effects. 
Additionally, there did not appear to be a clear difference in GYS-K peptide peak intensity between 
digest samples 2 and 3, where it would be expected that the addition of 500 nM of CRP would make a 
difference to peak intensity. Due to the relative similarities in peak shapes and retention times and the 




presence of BSA and CRP in the buffer control samples it seemed plausible that CRP was detected in 
the wastewater samples. 
 
Figure 17. Two MRM transitions for the BSA peptide [LVT-K]
2+
 in a standard 500 nM buffer digest 





Figure 18. Three MRM transitions for the BSA peptide [LVN-K]
2+
 in a standard 500 nM buffer digest 
Figure 19. Two MRM transitions for the BSA peptide [LGE-R]
2+
 in a standard 500 nM buffer digest 




Figure 20. Three MRM transitions for the PSA peptide [SVI-R]
2+
 in a standard 500 nM buffer digest
Figure 21. Three MRM transitions for the CRP peptide [GYS-K]
2+
 in a standard 500 nM buffer digest




Figure 22. Three MRM transitions for the CRP peptide [GYS-K]
2+
 in a 100 mL wastewater digest without 
addition of any proteins
Figure 23. Three MRM transitions for the CRP peptide [GYS-K]
2+
 in a 100 mL wastewater digest with addition 
of BSA, CRP and PSA each to a final concentration of 500 nM 




The next set of digests prepared used differing concentrations of BSA, CRP and PSA added to 
samples of wastewater. These digests were prepared to see if BSA or PSA could be detected in 
wastewater if the concentration at which they were added was increased, as well as looking for 
repeated detection of the CRP peptide GYS-K in wastewater. The results of these digests are shown in 
figures 22-27. The increase in BSA concentration from 500 nM to 5 µM was sufficient for it to be 
detected when added to wastewater (figure 23). This increased the possibility of using BSA as a 
qualitative measure of whether digestion occurred. PSA remained undetected in wastewater samples 
despite the increase in concentration. The CRP peptide GYS-K was detected in all wastewater 
samples, even the wastewater control sample that only added BSA (figure 25), as well as in buffer 
(figure 24). As with the previous digests there was a shift in retention time for the GYS-K between 
buffer and wastewater samples, but the same pattern of peaks was observed in both. Once again, the 
relative abundance of the detected GYS-K peaks varied between buffer and wastewater samples. 
Likewise, the concentration of CRP added did not appear to change the relative intensity of peak 
shape of the detected GYS-K peaks. This suggested that either the digest was not working and that the 
detected peaks were a systematic artefact produced during digestion, or that the amount of CRP is in a 
large excess relative to the amount of trypsin; meaning that the rate limiting step was the amount of 
trypsin not the amount of CRP. As BSA is a larger protein with many more disulphide bonds, 
requiring more extensive reduction and alkylation than CRP, this suggested that there was insufficient 
trypsin in the digests, rather than insufficient reduction and alkylating reagents.




Figure 24. Two MRM transitions for the BSA peptide [LVT-K]
2+
 in a standard 500 nM buffer digest 
 
Figure 25. Two MRM transitions for the BSA peptide [LVT-K]
2+
 in a 100 mL wastewater digest with addition 




of BSA, CRP and PSA each to a final concentration of 5 µM
Figure 26. Three MRM transitions for the CRP peptide [GYS-K]
2+
 in a standard 500 nM buffer digest 
Figure 27. Three MRM transitions for the CRP peptide [GYS-K]
2+
 in a 100 mL wastewater digest with addition 
of BSA only to a final concentration of 500 nM




Figure 28. Three MRM transitions for the CRP peptide [GYS-K]
2+
 in a 100 mL wastewater digest with addition 
of BSA, CRP and PSA each to a final concentration of 500 nM
 Figure 29. Three MRM transitions for the CRP peptide [GYS-K]
2+
 in a 100 mL wastewater digest with 
addition of BSA, CRP and PSA each to a final concentration of 5 µM 




From the previous digests the amount of trypsin was suspected to be insufficient to effectively digest 
all the proteins present in wastewater, so the next three digests sought to compare the current 
methodology with two alternative methodologies. The most obvious was to increase the amount of 
trypsin added to digests from 25 µL to 1 mL, which would have led to increase CRP concentrations if 
there had been insufficient trypsin previously. The second digest increased the amount of wastewater 
used from 100 mL to 500 mL. The rationale was that if increasing the amount of spiked protein did 
not lead to an observable increase in the amount of GYS-K detected then perhaps the signal 
suppression is too great, or the SPE recoveries too low for this amount of peptide to make a 
difference. The final concentration of CRP was therefore increased by increasing the volume of 
wastewater used instead of the concentration of protein added. However, if trypsin was the limiting 
factor for digestion then this increase in wastewater volume would not lead to an increase in the 
amount of GYS-K detected relative to the control digest. For the 500 mL digest the amount of each 
reagent added was kept the same as for the 100 mL control digest, performed with 25 µL of 20 ng mL
-
1
 trypsin. Each digest was performed in duplicate and the results of these digests are shown in figure 
28-30. 




Figure 30. Spectra showing the presence of the CRP peptide [GYS-K]
2+
 in duplicate 100 mL wastewater digests 
under standard digest conditions 




Figure 31. Spectra showing the presence of the CRP peptide [GYS-K]
2+
 in 100 mL duplicate wastewater digests 
using 1 mL of 25 µg mL
-1 trypsin 




Figure 32. Spectra showing the presence of the CRP peptide GYS-K in 500 mL duplicate wastewater digests, 
under standard digest conditions 
The results of these digests showed that increasing both the amount of wastewater and the amount of 
trypsin used lead to an increase in the intensity of the GYS-K peaks detected relative to the control. 
However, this complicated the investigation into how to best detect proteins in wastewater as it 
suggested that both trypsin and CRP concentration were limiting the amount of GYS-K produced. 
This can perhaps be explained by the presence of trypsin in wastewater from urinary sources [82], but 
in humans this is only associated with certain diseases and would not be expected to make up a 
significant part of the urinary proteome. However, the amount of trypsin used increased 40 times 




whereas the amount of wastewater increased only 5 times yet lead to greater peak intensity of GYS-K. 
Instead, the reason for a lack of sensitivity in response when changing the concentration of CRP 
added to samples may be due to high signal suppression or poor SPE recoveries. This should be 
investigated further with a synthetic GYS-K peptide by directly infusing the peptide into the MS post-
column during analysis. Alternatively, SPE strategies using charged stationary phases could also be 
considered and would be expected to give greater selectivity for peptides during extraction, due to the 
presence of charged lysine or arginine residues after quenching the digest, and reduce matrix effects 
from wastewater [9].  
4. Conclusion 
An enzyme digestion method was successfully developed and was able to produce an array of 
peptides for five different proteins in binary digest of BSA plus one biomarker. The final digestion 
method made use of commonly available reagents for protein reduction, alkylation and enzyme 
digestion without the need for either expensive acid-labile surfactants or potentially disruptive 
reagents like urea. The success of this method allowed for the subsequent development of new 
methods of analysis, including a digestion method for the analysis of peptides in wastewater and a 
HILIC-QqQ method for their detection. Analysis of wastewater proved challenging but did result in 
the repeated detection of CRP in wastewater samples, although PSA and BSA proved elusive even 
when spiked into samples. The CRP peptide GYS-K was potentially detected in several wastewater 
digests, although a synthetic peptide reference standard would be needed to confirm this. The 
detection of a protein of human health in wastewater has not be reported in literature before and 
would represent an important step forwards for developing new methods to monitor human health. 
Future innovations should build towards the development and integration of proteomics into the 
established WBE workflow to enable a deeper understanding of public health.  
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Supplementary information (SI) figure 1. 30 nM concentration, enzyme only, PSA only digest 




 Supplementary information (SI) figure 2. 606 nM concentration, enzyme only, BSA only digest 1 





Supplementary information (SI) figure 3. 606 nM concentration, enzyme only, BSA only digest 2 





Supplementary information (SI) figure 4. 303 nM concentration, enzyme only, PSA only digest 1 
 
 Supplementary information (SI) figure 5. 303 nM concentration, enzyme only, PSA only digest 2 








 Supplementary information (SI) figure 6. 30 nM concentration, no surfactant, BSA only digest 1 








 Supplementary information (SI) figure 7. 30 nM concentration, no surfactant, BSA only digest 2 




 Supplementary information (SI) figure 8. 30 nM concentration, no surfactant, PSA only digest 1 




 Supplementary information (SI) figure 9. 30 nM concentration, no surfactant, PSA only digest 2 









Supplementary information (SI) figure 10. 30 nM concentration, combined BSA & PSA digest 1 








 Supplementary information (SI) figure 11. 30 nM concentration, combined BSA & PSA digest 2 











Supplementary information (SI) figure 12. 500 nM concentration, combined BSA & CRP digest 0.1 µL 
injection volume 








 Supplementary information (SI) figure 13. 500 nM concentration, combined BSA & CRP digest 0.3 µL 
injection volume 








 Supplementary information (SI) figure 14. 500 nM concentration, combined BSA & IL-6 digest 0.1µL 
injection volume 





Supplementary information (SI) figure 15. 500 nM concentration, combined BSA & IL-8 digest 0.1 µL 
injection volume 








 Supplementary information (SI) figure 16. 500 nM concentration, combined BSA & IL-8 digest 0.3µL 
injection volume 





Supplementary information (SI) figure 17. 500 nM concentration, BSA only digest 0.1µL injection volume





The aims of the research were broadly focused on how to use LC-MS/MS to expand our 
understanding of human and environmental health through the analysis of molecular biomarkers in 
river and wastewater. There were three primary themes to the research:  
Aim one: To explore the uses of chirality in determining analyte origin and its impact on assessments 
of public and environmental health 
Aim two: To develop new methodologies to maximise the information obtainable from currently 
utilised health biomarkers 
Aim three: The exploration of proteins as potential new biomarkers of public health  
Objective 1: To develop new methodologies to maximise the information obtainable from currently 
utilised health biomarkers and to explore the uses of chirality in determining analyte origin and its 
impact on assessments of public health by using Wastewater-based epidemiology combined with local 
prescription analysis as a tool for temporal monitoring of drug trends – a UK perspective 
WBE was popularised by its ability to measure large populations quickly and relatively easily 
compared to more traditional survey-based approaches [1; 2]. However, governments and other large 
public health organisations have been slow to adopt WBE for use as anything more than a yearly snap 
shot of drug use in Europe. WBE can generate vast amounts of data about what is being consumed in 
a community and this can then be used to feedback to inform policy about the state of public health, 
which is difficult to estimate via traditional means. Five weekly periods of monitoring across five 
years in one city in the UK was examined to find trends in consumption that can provide information 
about the long-term state of DoA and pharmaceutical use in the UK. Trends in the consumption of 
other drugs of abuse was examined and placed into the wider context of European drug consumption, 
which showed that despite rising consumption of cocaine across Europe consumption in the UK was 
happening significantly faster. Meanwhile, MDMA consumption remained steady despite rising use 
across Europe. Chirality was also important here, as the detected EF of methamphetamine appeared to 
vary by year, suggesting a change in how it was being manufactured, which can directly support 
actions aimed at reducing the supply of methamphetamine.  The backdrop to this research was 
initially the continued detection of mephedrone after being regulated, with the eventually reduction in 
use to < LOQ showing that UK drug policy can be effective. After 2016 the focus shifted to how the 
introduction of sweeping drug reform, courtesy of the 2016 psychoactive substance bill, changed drug 
consumption in the UK. This contextualisation of UK drug can then allow for decisions on drug 
policy to be taken in the appropriate context, which would then allow for appropriate response to 
tackle drug abuse in the UK. 




The use of pharmaceuticals, particularly opioids and benzodiazepines, and a comparison to rates of 
prescription were also explored. Of particular interest was the relationship of prescription rates to 
wastewater concentration, which did not always agree. For compounds with low potential for abuse, 
like venlafaxine, there was good agreement between trends in wastewater and prescription. However 
prescription analysis could not fully explain use of drugs available without a prescription, like 
pseudoephedrine, or with potential for abuse or illicit supply like opioids.  
Objective 2: To explore the uses of chirality in determining analyte origin and its impact on 
assessments of environmental health by determination of the Stereochemistry of ephedrine and its 
environmental significance: Exposure and effects direct approach. 
The importance of chiral analysis was shown in chapter two by the changes in ephedrine 
stereochemistry observed and the impact this has on ephedrine ecotoxicity. In river water microcosms 
mimicking environmental conditions significant degradation only took place under biotic conditions, 
which showed that ephedrine degradation was primarily biological meaning it will be persistent in the 
environment until metabolised. The microcosms also showed how the synthetic ephedrines (1S,2R-
(+)-ephedrine and 1R,2R-(-)-pseudoephedrine) were not degraded under any conditions, making them 
persistent in the environment and therefore a more potent micropollutant. Whereas under achiral 
chromatography all that would be observed was that the half-life of ephedrine was about two weeks.  
Even when using single isomers chiral chromatography was crucial for detecting the formation of 
1S,2R-(+)-ephedrine in river water microcosms containing only 1R,2S-(-)-ephedrine. This double 
chiral inversion was observed to take place after two weeks with the presence of any other isomer, 
which would be expected if it were formed via a non-enzymatic mechanism like elimination and 
nucleophilic addition.  
Assessments of ephedrine toxicity using D. magna, P. subcapitata and T. thermophile showed that the 
synthetic ephedrines, generally, had much lower EC50 than their naturally occurring enantiomers. This 
combined with microcosm results showing the stability of the synthetic ephedrines, and the formation 
of 1S,2R-(+)-ephedrine from less toxic 1R,2S-(-)-ephedrine allowed for a better assessment of the 
ecotoxicity of ephedrine, by showing that a more toxic isomer could form under environmental 
conditions.  
Objective 3: To develop new methodologies to maximise the information obtainable from currently 
utilised health biomarkers via A multi-residue method by supercritical fluid chromatography coupled 
with tandem mass spectrometry method for the analysis of chiral and non-chiral chemicals of 
emerging concern in environmental samples 




The work presented so far has demonstrated that there was still a lot of roam for growth in how 
analytical analysis was undertaken and how data was used when trying to understand public and 
environmental health. To this end environmental analysis has fundamentally limited itself by not fully 
considering the importance micropollutant chirality has on environmental impact. SFC was shown to 
be an excellent technique for developing chiral methodologies that can track the progress of potential 
micropollutants through wastewater treatment and into the environment. SFC achieves this whilst 
maintaining still retaining the high sample throughput offered by reverse phase chromatography and 
required for routine analysis. In total 48-analytes, including five fully separated chiral molecules, 
were separated and analysed in only ten minutes. In comparison the same analytes were analysed 
using the same instrument in 35 minutes for achiral analysis [3] or 80 minutes for chiral analysis [4]. 
The method had excellent average limits of detecting and quantification, which were 16.7 and 
46.7ng/L in river water and 20 and 52.3 ng/L in wastewater respectively. Whilst not quite at the fg L
-1
 
level reported for some already regulated environmental pollutants [5] six analytes achieved a mLOQ 
≤ 1.0 ng L
-1
.  This sensitivity is still sufficient to quantify 86% of analytes in at least one matrix with 
50% being quantified in river water, effluent and influent including three chiral analytes. This is 
important as it would allow the method to monitor changes in EF as compounds pass through 
wastewater treatment in larger scale studies. 
Whilst only five chirally separated analytes were successfully validated, the method demonstrated that 
for all its speed SFC was still able to give excellent separation of enantiomers. A range of alternative 
columns and mobile phases were trialled during method development and conditions were found to at 
least partially separate thirteen different chiral compounds, although the most separated fully by one 
method was five.  
Objective 4: The exploration of proteins as potential new biomarkers of public health via A new 
paradigm on public health assessment: water finger printing for protein markers of public health 
using mass spectrometry and Development of an enzymatic digestion method for use in wastewater for 
the analysis of proteins of disease by hydrophilic interaction liquid chromatography coupled to triple 
quadrupole mass spectrometry 
The rise of WBE for monitoring public health has been accompanied by a rise in the number of small 
molecule human health biomarkers examined, which now range from pharmaceuticals and drugs of 
abuse to NPS and biomarkers of oxidative stress as highlighted in chapter one. However, despite 
tentative steps towards monitoring human health using biomarkers of oxidative stress many current 
WBE biomarkers are primarily biomarkers of human consumption rather than human health. Urinary 
proteomics has the potential to revolutionise the field of UWF and WBE by introducing a huge range 
of potential human health biomarkers that are directly related to human health. Chapter five 
encompassed the development of a methodology for analysing proteins in wastewater using widely 




available techniques and instrumentation with the goal of fitting proteomics into the established WBE 
workflow. The digestion procedure developed could be incorporated easily into current sample 
preparation procedures, taking only an additional two hours of analyst time to prepare samples with 
the majority of the preparation taking place overnight. The five proteins digested encompassed a wide 
range of molecular weights, from 8.4 kDa for IL-8 up to 66 kDa for BSA, which demonstrated that it 
was applicable to a wide range of proteins with varying amounts of cysteine-cysteine bonding to 
overcome. Whilst this diversity was beneficial in design the digest procedure the interleukins were not 
suitable first choice candidates for method development due to their low wastewater concentrations. 
The choice of limiting method development using the triple quadrupole to CRP and PSA was 
designed to help increase the methods ability to detect proteins in wastewater by focussing on only 
those most likely to be present at quantifiable concentrations. The observation of a protein of disease 
in wastewater is perhaps the most important outcome of this thesis as it opens up a whole new area of 
exploration in the quest for biomarkers of disease. In turn this method can be used as a baseline to 
help further refine the digestion method and increase its suitability for analysis in wastewater. In this 
way the process of digestion and analysis can be refined to create a method suitable for analysing 
proteins of disease for the purpose of monitoring public health. 
Novelty and contribution statement 
In order to effectively direct resources and guide policymakers there is an increasing need for accurate 
data on public and environmental health. Molecular diagnostics using LC-MS/MS is used in a number 
of ways to help gather such data, often through measurements of urban water. However, what was 
once an emerging field of research is becoming increasingly important in understanding and 
predicting public and environmental health, so it is vital that the data that is collected be of sufficient 
scope and quality for this purpose. This thesis has presented several novel approaches to highlight the 
need for better data and suggested ways it can be collected. Firstly, the innovative use of local 
prescription data for assessing drug consumption used in chapter one, which helped to give context to 
observed trends in wastewater concentrations and provided a means for assessing consumption of 
heroin. In chapter two, ephedrine was observed to both degrade and undergo chiral inversion under 
environmental conditions, which was important for confirming prior observations from wastewater 
treatment and for identifying the potential of CECs to convert into more toxic compounds in-situ. 
Chapter three addressed the lack of chiral methods of analysis for use in urban water by developing a 
method that could quantitatively analyse 95 CECs in less than 30 minutes using SFC. Chapter four’s 
novelty came from the proposition that proteins could be used as a non-invasive method to measure 
public health through wastewater analysis. The chapter also identified several potential protein 
biomarkers, using a set of criteria that can be adapted by other researchers to identify other 
biomarkers. Finally, chapter five followed this by using established WBE procedures to estimate the 




wastewater concentration of urinary biomarkers. Additionally, chapter five detailed the steps required 
to develop a bottom-up protein analysis method for use in wastewater and was able tentatively 
identify a peptide of C-reactive protein in wastewater for the first time.  
Future work 
Often during a PhD it feels as if no project is ever truly complete and this feeling extends even to 
published work. Chapter one contained a wealth of information and so there is likely a lot of future 
work around mining this data for further insights into public health, particularly examining the effect 
that prescription rates may have on pharmaceutical consumption beyond the simple links made in the 
chapter. The observation of increasing  drug consumption from 2016 onwards should be followed up 
with more monitoring to see if this trend continues. In terms of whether this information can be used 
to inform policy future work could also be to investigate how to present data like this in a way that it 
can be digested by policy makers. Similarly, methods by which this data could be presented to the 
public could also be examined, with the goal of informing the public about how they can reduce the 
environmental impact of pharmaceuticals by curbing their own usage. Ultimately long term 
information about trends in drug use should be used to measure the efficacy of regulation on a broader 
scale than just country to country. The UK and Irish governments are in the fortunate position of 
being island nations, so drug policy that targets the supply of drugs can be simplified and limited to 
monitoring ports and shipping as their only land borders are with each other. Although in the wake of 
the UK’s departure from the European Union the porosity of this border and the willingness of 
governments to cooperate on border policy and enforcement is currently up for debate.  However, for 
continental Europe disrupting drug supply becomes much harder due to the presence of land borders 
and, mostly, free movement of people all over the continent, as well as land and sea borders to non-
EU countries that sit astride important drug trafficking routes, such as Turkey and North Africa [6]. 
Long term data on drug use by country is useful for examining regional trends but this should be 
considered on a broader scale by organisations like the EMCDDA to look for broader geographic 
trends. This can then be used to propose drug policies on both a union and country level to reduce 
drug addiction. This already takes place to a degree but is focussed on changes in the type of cannabis 
used by region [7]. Ultimately legislation affecting the drug policy of individual countries is taken by 
that country’s government, but if drug abuse is only considered on a local level then action taken may 
be misdirected or inadequate. The modular nature of drug policy within the EU also leads to country 
specific trends, such as the observed trend of cocaine usage in the UK increasing by more than the 
European average, which shows that whilst European wide action on cocaine may be required  there 
are other UK specific reasons driving the increase within the country. Whether the UK and EU can 
cooperate on drug policy after Brexit is currently doubtful, with the UK at time of writing preparing to 
also leave Europol. Brexit will undoubtable affect the supply of drugs manufactured in Europe, both 




licit and illicit, into the UK, particularly MDMA, which is mainly produced in the Netherlands and 
Belgium [7] and increasingly consumed in the UK and across continental Europe. 
Similarly, the stereochemical fate of ephedrines in the environment could benefit from further 
research. The obvious first choice would be to repeat the microcosm experiment again and run them 
for a period longer than two weeks to observe how 1S,2R-(+)-ephedrine is formed and if given 
enough time 1R,2R-(-)-pseudoephedrine might also be produced, which would have a serious impact 
on the perceived ecotoxicity of  ephedrine. Likewise, the ecotoxicity of mixtures of ephedrines could 
be trialled using other organisms like D. Magna, where only individual isomers have been studied, to 
look for synergistic effects, particularly at a ratio of ephedrine: pseudoephedrine that matches normal 
environmental conditions. This could then be expanded to examine a range of other CECs in order to 
understand their ecotoxicity with the ultimate goal of proving that environmental monitoring needs to 
consider chirality. With a more detailed appreciation of environmental toxicity researchers would be 
able to support the ability of governments and regulatory organisations to prioritise their resources 
towards tackling the most problematic CEC. The first WFD in 2000 [8] did a good job of identifying 
the most dangerous environmental pollutants and future work should look at either expanding this list 
of compounds or developing a further classification system for their environmental risk; similar to 
how drugs in the UK are categorised (nominally) by risk. It is discussed in chapter four that 
diclofenac and synthetic oestrogens were considered as additions to the WFD list of banned 
substances [5] due to their environmental toxicity but were not added. Ultimately this can be seen as a 
compromise between protecting future environmental and current human health. If compounds like 
synthetic oestrogens, or painkillers like ibuprofen that are present in high concentration in the 
environment already, cannot be banned under a tiered system they could at least be controlled 
appropriately. To achieve this tiered system of risk environmental risk assessments that consider 
chirality would need to be implemented for all currently registered active pharmaceutical ingredients 
(APIs) and excipients/additives. For many APIs this process would require government action as 
where generic formulations exist trying to decide who does the testing would be difficult, although for 
patented formulations the burden would lie with the manufacturer within the current regulatory 
framework. Additionally illicit drugs are generally poorly studied by ecotoxicity, despite being 
present in wastewater at concentrations greater than some licit pharmaceuticals. Despite many of 
these substances once being used as APIs the burden of testing them would likely fall on the state 
rather than their initial manufacturer’s. Finally, unlike the current ERA system where ERAs cannot be 
used to deny regulation of an API a new system should be able to deny regulation of particularly 
environmentally dangerous APIs or formulations from entering the market and hence the 
environment.  
Chapter three has perhaps the most to gain from future work, although the method itself was 
successfully validated. Once it no longer became possible to analyse all compounds via the same MS 




method the SFC method should have been altered to allow for better separation and analysis of more 
biomarkers, instead of creating a one size fits all SFC method for three MS methods. By separating 
the betablockers from the drugs of abuse it may be possible to create a method for chirally separating 
each of them using the CEL-1 and AMY-1 column’s respectively. However, recoveries were a large 
source of problems during method validation and an alternative approach could be considered to help 
determine why this was so problematic. Whilst the normal approach to poor recoveries is to select a 
new internal standard, many analytes that used a deuterated or 
13
C version of the analyte as their 
internal standard still exhibited poor recoveries. Instead of comparing analyte concentrations spiked 
into matrix before SPE, to analyte concentrations in mobile phase it would maybe be fairer to 
compare them to analyte concentration in samples where analytes are added after SPE, which are 
currently used to calculate signal suppression. However the ultimate goal is not to create one method 
or three methods to analyse CEC but to inspire other researchers to create their own chiral SFC 
methods. The scale of the problem of analysing what is going into the environment is too big to be 
performed by any individual country or organisation and this means that researchers need to band 
together and analyse environment samples in the same way that drugs of abuse are analysed in chapter 
three by the SCORE network. The advantage of using SFC instead of chiral LC or, worse, achiral LC 
is that it is not currently very widely used and so standards can be set early in adoption. Meanwhile 
for SCORE each contributor performs analysis using their own instruments and methodologies, 
despite a common protocol on how samples should be collected [9], although a strict inter-lab 
validation procedure takes place each year to assess the suitability of these methods. This could 
complement the wide spreading environmental toxicity testing suggested earlier and can help guide 
prioritisation of CEC by observing changes in enantiomeric fraction occurring during wastewater, 
which suggests stereospecific metabolism. 
Whilst chapter four is largely exempt from future work given its purpose was to be an introduction to 
the concept of combining WBE and urinary proteomics there are some areas where it could be further 
developed. A more in-depth discussion surrounding the estimation of wastewater concentrations of 
urinary proteins, as was discussed in chapter five, would allow for other researchers to consider 
whether to explore other potential biomarkers of disease and not just those discussed. It would also 
allow for a dialogue surrounding whether such estimations are appropriate, given that the assumption 
of a completely health population is obviously false but served to hopefully provide a baseline for 
future analysis.  
Chapter five presented a streamlined version of enzyme method development and future work could 
explore other avenues that were ignored during initial development, such as the use of surfactants. 
Whilst sodium deoxycholate (SDC) was trialled it proved difficult to remove from digests without 
filtering. At the time this was problematic as relatively low volumes (<2 mL) were being used and it 
was hoped SPE would be sufficient to remove SDC from digests. Now that larger volumes of 




wastewater are being digested filtration has become a necessity so SDC may be viable once again. 
Likewise, with a method developed in chapter six it would be possible to more easily refine the 
digestion process quickly without waiting for samples to be analysed by third parties. An alternative 
to the digestion procedure that could help increase sensitivity in wastewater would be to extract 
proteins from wastewater first and then digest them second. This would remove the need to scale up 
digests for larger volumes and would allow for the use of extraction techniques that focus on the 
unique properties of proteins. If the volume of reagents used was further scaled down to less than 1 
mL it would also be possible for samples to be analysed immediately after digestion. The initial step 
towards trying to validate a method for the detection of proteins of disease in wastewater and as such 
there are several areas of future work that should be explored. The first is the introduction of an 
internal standard, such as a deuterated form of the CRP peptide GYS-K that was repeatedly detected 
in both buffer and wastewater with several peaks where only one would be expected. The introduction 
of an internal standard would also allow for recovery and other required pieces of method validation 
to be carried out. BSA should still be considered as a measure of digest efficiency and this can then be 
quantified against an internal standard rather than against an external calibration curve. The ultimate 
goal of this research would be to analyse proteins of infectious disease to provide an early warning 
system for epidemics and other seasonal outbreaks like influenza. The first step to achieving this 
would be to identify proteins of infectious disease, or proteins excreted in response to infectious 
disease, in urine. This would require large scale testing of infectious populations and would be 
extremely challenging, particularly for viruses like influenza that vary from strain to strain as this 
would require the identification of biomarkers that are common to each strain. Once identified 
proteins of infectious disease would need to be detected in wastewater and quantified. This would 
require a more refined version of the currently developed method to facilitate the detection of 
infectious disease at low concentrations to maximise its utility as an early warning system. For non-
infectious disease future developments should focus either on non-specific biomarkers of public 
health, like CRP, rather than specific diseases like PSA and prostate cancer. A more general health 
marker can serve as its own measure of community health and can help direct interventions to the 
most needy areas instead of taking a once size fits all approach. This would allow for proteomics to be 
used to measure qualitatively or quantitatively the efficacy of measures undertaken to improve public 
health i.e. if measures to reduce cardiovascular disease were introduced their efficacy could be 
measured by a long term decline in the concentration of CRP [10]. The most pressing limitation in the 
quest for biomarkers of disease is a validated method to analyse them in wastewater. Once this has 
been achieved then the only limiting factor is deciding what proteins to analyse and how best to use 
the information obtained to inform and interpret public health.  
One option would be to try and directly link protein biomarkers with small molecule WBE, similar to 
how biomarkers of oxidative stress (a relatively new class of biomarker in WBE) were linked to 




smoking through analysis of well-established biomarkers such as nicotine and cotinine. For example, 
the concentration of CRP could be linked to wastewater concentrations of beta-blockers and other 
drugs of cardiovascular health, perhaps incorporating the prescription analysis detailed in chapter one. 
However, for this technology to be useful it must be applicable, and the difficulty of any public health 
monitoring is knowing how the data relates to what is being measured and when to intervene. Whilst 
simplistically we may want disease biomarker concentrations to go down, although as uromodulin 
shows this may not always be because of decreasing rates of disease [11; 12], what this means in 
reality can be difficult to quantify. Concentrations of heroin were observed to decrease in chapter one, 
which agreed with other epidemiological data [13] but does this mean that current UK drug policy is a 
success? Does it mean the UK is right to not have a needle exchange programme like other European 
countries? And what does it tell us about those continuing to use heroin? Likewise, if wastewater 
concentrations of CRP did not correlate with wastewater and prescribed concentrations of beta-
blockers or with hospital data on cardiovascular disease does this mean intervention is necessary? The 
answer to all these questions is sadly that more research is needed to quantify if, when and where 
intervention is necessary. Despite this WBE is still a useful tool for increasing our understanding of 
human and public health even if we perhaps do not fully understand how to use what we now know. 
Research outputs 
During my PhD I had the opportunity to speak and present at a number of conferences and be 
involved with the organisation of others. I also contributed to several published articles not submitted 
as part of my thesis.  
 Conferences and symposia: 
SCORE second training school: April 2015, Castellon, Spain – Attendee 
Chemistry department symposia: May 2015 – Poster presentation 
Testing the waters 2015: Second international conference on wastewater-based drug epidemiology: 
October 2015, Ascona, Switzerland – Oral presentation 
Presentation to department: Spring 2016 – Oral presentation 
Chemistry department symposia: May 2016 - Attendee 
Emerging Analytical Professionals 2016: Analytical alchemy – Tablets, toxins and tonics: 
 May 2016, Fareham, UK - Poster and oral presentation  
- Best poster pitch prize winner “Quantitative proteomics for molecular diagnostics of public 
health” 




Bright Spark Symposium 2016: September 2016, University of Warwick, UK – Poster presentation 
Wetskills Water Challenge programme: April 2017, University of Bath, UK – Organising committee  
18
th
 Young Water Professionals conference: April 2017, University of Bath, UK – Organising 
committee and workshop facilitator 
Bolland symposium (department event) 2017: May 2017 – Oral presentation 
Emerging Analytical Professionals 2017: The theory of everything – Launching the careers of 
analytical scientists: May 2017, Kettering, UK – Organising committee, session chair and technical 
presentation  
SETAC UK annual meeting: August 2017, Oxford, UK – Poster presentation 
Bright Spark Symposium 2017: September 2017, University of Bath, UK – Conference Chair and 
organiser 
Testing the waters 2017: 3
rd
 international conference on wastewater-based epidemiology: October 
2017, Lisbon, Portugal – Oral presentation “Quantitative proteomics for molecular diagnostics of 
public health” 
- Best oral presentation prize winner 
Hyphenated techniques in chromatography (HTC-15): January 2018, Cardiff, UK – Oral presentation 
Emerging Analytical Professionals 2018: The circle of life – Analysing the world around us:  
May 2018. Knutsford, UK – Organising committee, session chair 
Bright Spark Symposium 2018: September 2018, University of Manchester, UK – Organising 
committee and session chair 
Emerging Analytical Professionals 2019: Exploring the analytical sciences: May 2019, Leeds, UK – 
Organising committee and session chair 
Emerging Analytical Professionals 2020: May 2020, Kettering, UK – Organising committee and 
conference vice-chair 
 Publications: 
Sims, N., J. Rice, and B. Kasprzyk-Hordern. An ultra-high-performance liquid chromatography 
tandem mass spectrometry method for oxidative stress biomarker analysis in wastewater (2019) Anal. 
Bioanal. Chem. Volume 411, issue 11, pp 2261-2271  




Camacho-Munoz, D., B. Petrie, L. Lopardo, K. Proctor, J. Rice, J. Youdan, R. Barden and B. 
Kasprzyk-Hordern. Stereoisomeric profiling of chiral pharmaceutically active compounds in 
wastewaters and the receiving environment – A catchment-scale and a laboratory study (2019) 
Environ. Int. Volume 127, pp 558-572 
 Other activities: 
Associate member of the royal society of chemistry (RSC): 2015- 
Alan Tetlow bursary winner – 2015: Funding to attend testing the waters 2017 conference. Article 
published in Water Science Forum (WSF) newsletter volume 16 issue 2. 
Member of the analytical science network (ASN): 2016- 
SETAC member: 2017-2018 
ASN website coordinator: 2017- 
ASN representative to the analytical division council of the RSC: 2018- 
  





[1] Daughton, C.G., 2001. Emerging pollutants, and communicating the science of environmental 
chemistry and mass spectrometry: Pharmaceuticals in the environment. Journal of the American 
Society for Mass Spectrometry, 12(10), pp. 1067-1076. 
[2] Zuccato, E., Chiabrando, C., Castiglioni, S., Calamari, D., Bagnati, R., Schiarea, S. and Fanelli, R., 
2005. Cocaine in surface waters: a new evidence-based tool to monitor community drug abuse. 
Environmental health : a global access science source, 4, pp. 14-14. 
[3] Petrie, B., Youdan, J., Barden, R. and Kasprzyk-Hordern, B., 2016. Multi-residue analysis of 90 
emerging contaminants in liquid and solid environmental matrices by ultra-high-performance liquid 
chromatography tandem mass spectrometry. Journal of Chromatography A, 1431, pp. 64-78. 
[4] Evans, S.E., Davies, P., Lubben, A., and Kasprzyk-Hordern, B., 2015. Determination of chiral 
pharmaceuticals and illicit drugs in wastewater and sludge using microwave assisted extraction, 
solid-phase extraction and chiral liquid chromatography coupled with tandem mass spectrometry. 
Analytica Chimica Acta, 882, pp. 112-126. 
[5] Loos, R., 2012. Analytical methods relevant to the European Commission's 2012 proposal on 
Priority Substances under the Water Framework Directive. JRC scientific and policy reports: 
Luxembourg: Publications office of the European Union, 2012. 
[6] European Monitoring Centre for Drugs and Drug Addiction and Europol, 2019. EU drug markets 
report 2019. Luxembourg: Publications office of the European Union. 
[7] EMCDDA, E.M.C.f.D.a.D.A., 2019. European Drug report 2019: Trends and developments. 
Luxembourg: Publications Office of the European Union. 
[8] European Commission, 2002. Implementing Council Directive 96/23/EC concerning the 
performance of analytical methods and the interpretation of results. Official Journal of the European 
Communities. 
[9] Castiglioni, S., Bijlsma, L., Covaci, A., Emke, E., Harman, C., Hernandez, F., Kasprzyk-Hordern, B., 
Ort, C., van Nujis, A.L.N., de Voogt, P. and Zuccato, E., 2016. Estimating community drug use through 
wastewater-based epidemiology. Assessing illict drugs in wastewater: advances in wastewaster-
based epidemiology. Publications office of the European Union, Luxembourg, pp. 17-34. 
[10] Kuhn, E., Wu, J., Karl, J., Liao, H., Zolg, W. and Guild, B., 2004. Quantification of C-reactive 
protein in the serum of patients with rheumatoid arthritis using multiple reaction monitoring mass 
spectrometry and C-13-labeled peptide standards. Proteomics, 4(4), pp. 1175-1186. 
[11] Hammond, T.G., Moes, S., Youhanna, S., Jennings, P., Devuyst, O., Odermatt, A. and Jeno, P., 
2016. Development and characterization of a pseudo multiple reaction monitoring method for the 
quantification of human uromodulin in urine. Bioanalysis, 8(12), pp. 1279-1296. 
[12] Rampoldi, L., Scolari, F., Amoroso, A., Ghiggeri, G. and Devuyst, O., 2011. The rediscovery of 
uromodulin (Tamm-Horsfall protein): from tubulointerstitial nephropathy to chronic kidney disease. 
Kidney International, 80(4), pp. 338-347. 
[13] EMCDDA, 2018. United Kingdom Country Drug Report 2018. Available from: 
www.emcdda.europa.eu/countries/drug-reports/2018/united-kingdom. 
 
 
